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IN VIVO BREAKING STRENGTH RETENTION

The dawn of a new era in
synthetic absorbable technology
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The first and only monofilament
synthetic absorbable suture for
prolonged wound support

Data on file ETHICON Research Foundation

□ Twice the breaking strength retention in vivo of any
other synthetic absorbable suture.
□ Minimal tissue reaction— similar to monofilament
nonabsorbable sutures.
□ Won’t wick or harbor bacteria.
□ Better knot security than monofilament nylonequivalent to surgical gut.
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Innovators in wound closure
A monument to strength and endurance on the
Salisbury plains of England, Stonehenge has withstood
time for over 5,000 years.
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Activity comparable to doxorubicin
Effective as first and second line therapy
in ®
Responses at all major sites of metastases
Long duration of response

■ ■

SB ■

. .a

Less than 6% severe alopecia
Little or no severe nausea and vomiting
No tissue necrosis on extravasation reported
Low potential for cardiotoxicity

NOVANTRONE*
m ito x a n tr o n e h y d r o c h l o r id e
in tr a v e n o u s in je c tio n

>
ANTINEOPLASTIC
AGENT
►
!►

CAUTION

JOVANTRONE* IS A POTENT DRUG AND SHOULD BE USED ONLY
iY PHYSICIANS EXPERIENCED WITH CANCER CHEMO'HF.R4PEUTIC DRUGS (SEE WARNINGS AND PRECAUTIONS).
JLOGD COUNTS SHOULD BE TAKEN AT FREQUENT INTER/ALS PRIOR. DURING AND POST THERAPY. CARDIAC MONIrORtl.NG IS ADVISED IN THOSE PATIENTS W HO HAVE R E 
CEIVED PRIOR ANTHRACYCLINES. PRIOR M EDIASTINAL
RADIOTHERAPY OR WITH PRE-EXISTING CARDIAC DISEASE.

'

PHARMACOLOGICAL ACTION

lIthough

its mechanism of action has not been determined, mitoxantrone
a DNA-reactive agent. It induces nuclear aberrations with chromo,r^c mattering in cell cultures (human colon carcinoma line) and is a
(tent inhibitor of RNA and DNA synthesis. Compared on an equimor basis, mitoxantrone is seven times more potent than doxorubicin in
ihibitif# the uptake of 3H-uridine and four times more potent in inhibiting
te uptake o f ’H-thymidine by mouse lymphoma L5178 Y cells in vitro.

.

INDICATIONS

'OVA^JTRONE* is indicated for chemotherapy in patients with carcioma o f the breast, including locally advanced and metastatic disease.

CONTRAINDICATIONS
CJVANI RONE is contraindicated in patients who have demonstrated
ior hyper- sensitivity to anthracyclines.

t

WARNINGS

ncc NOVANTRONE* produces m yelosuppression (see ADVERSE
FFF.CTS). it should be used with caution in patients in poor general
nnditi^n or with pre-existing myelosuppression.
ases of functional cardiac changes, including congestive heart failure
nd decreases in left ventricular ejection fraction have been reported,
heseicardiac events have occurred almost exclusively in patients who
ave had prior treatment with anthracyclines, prior mediastinal radioicrapy or w ith pre-existing heart disease. Cardiac monitoring is advisable
>such patients. It is suggested that cardiac monitoring also be per(rmedjn other patients during therapy exceeding 12 courses of NOVAN!i^ T b riM cX
.pCricncc during prolonged treatment is limited.
UWANTRONE* may impart a blue-green colouration to the urine for 24
>urs after administration, and patients should be advised to expect this
jring active therapy. Sate use of NOVANTRONE* in pregnancy has not
-cn established. No information is available concerning the presence
[ NOVANTRONE* in the milk of nursing mothers.

|

PRECAUTIONS

ull blood counts should be undertaken serially during a course of
fatment. Dosage adjustments may be necessary based on these counts
ee DOSAGE section).
It ithecommended (hat NOVANTRONE’ not be mixed in the same infuon with other drugs.

ADVERSE EFFECTS

suggest that NOVANTRONE* is comparable in efficacy with doxorubicin
in the treatment of advanced breast cancer. Myelosuppression with 2 1-day
treatment intervals is comparable with that observed with doxorubicin.
Multiple courses o f single-agent NOVANTRONE* therapy, in some cases
for longer than twelve cycles, have been administered with excellent
tolerance and a good response. NOVANTRONE* showed incomplete crossresistance with doxorubicin since responses have been observed in pa
tients in whom doxorubicin had failed or who relapsed after response to
that drug. A continuing large-scale clinical trials program with com bi
nation therapy also demonstrated early positive results for efficacy and
safety. In seven studies, over 100 cycles o f combination therapy have
been given to 77 patients.
Safety
Data on the overall safety profile of NOVANTRONE* (based on 989 patients)
demonstrated advantages o f NOVANTRONE* compared to the anthracyc Imcs with respect to both the quality o f life and the long-term safety of
patients. The majority o f side effects with NOVANTRONE* are mild in
nature. Removal of patients from NOVANTRONE* treatment for reasons
o f toxicity has been rare in clinical studies. A num ber of patients have
reported no side effects at all. In addition, the relatively low risk of
serious side effects has permitted treatment o f patients on an out-patient
basis. The most common acute effects were nausea and/or vomiting
(only 3.5% severe or very severe with NOVANTRONE*. compared to
10-15% reported with doxorubicin), stomatitis/mucositis (only 0.3%
severe or very severe with NOVANTRONE*) and alopecia (only 0.9%
severe or very severe, and 15% overall with NOVANTRONE* compared
with 85% severe or very severe and 100% overall reported with
doxorubicin). Serious local reactions have not been reported following
extravasation o f NOVANTRONE* at the infusion site.
With respect to myelosuppression. initial NOVANTRONE* doses o f 14
mg/m2 every three weeks are well-tolerated in good-risk patients. Se
vere degrees o f myelosuppression have been rare. The median white
cell nadir in a European second-line study was 2 .5 x l0 3; in a European
first-line study only 4.8% (2/42) o f patients experienced a nadir o f less
than 1.000. The nadir usually occurs around day lO or 11 and returns to
normal baseline value by day 2 1, in time for the next course of treatment
After multiple courses o f NOVANTRONE*. white blood cell and platelet
nadirs show no further decrease beyond those observed in the first few
cycles, indicating no cumulative or permanent effects o f NOVANTRONE*
on marrow reserves.
Cardiotoxicity
Adverse cardiac experiences have been infrequent. In contrast, doxoru
bicin has been reported to produce chronic cardiomyopathy and irre
versible congestive heart failure in up to 11 % of patients given nine or
more courses of that drug at the usual dose schedule (60 mg/m2 every
three weeks). Whether or not related to NOVANTRONE*. only 119 cardiacrelated episodes have been reported from a total data-base of more than
3.200 treated patients, including only 29 (0.9%) reports o f cl inical con
gestive heart failure, o f which only one had no other known predispos
ing factors. The risk o f cardiotoxicity is increased with prior antineoplastic drug or radiation therapy. In patients without predisposing
factors, development of congestive heart failure with NOVANTRONE5
therapy is rare.
Clinical experience suggests there is no need to lower the dose for p a
tients with existing renal or hepatic disease.
In summary, NuVANTRONE* is well tolerated and provides a better
quality of life for patients with breast cancer, compared with doxorubicin
and yet shows comparable efficacy.
NOVANTRONE* has been used alone or in combination in patients with
or without prior chemotherapy, as well as in those who have received
prior adjuvant therapy. It is less cardiotoxic than anthracyclines such as
doxorubicin and thus represents a clear therapeutic advance over cu r
rently available compounds.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

y B ^ ^ O N E is clinically well tolerated, demonstrating a low overall
pF ciice of adverse events, particularly those of a severe, irreversible
ife-threatening nature.
>me degree of leukopenia is to be expected following recommended
•ses of NOVANTRONE*. However, suppression o f WBC counts below
^00/mtjv1is infrequent. With dosing every 21 days, leukopenia is usu'V transient, reaching its nadir at about 10 days after dosing, with
overs usually occurring by the 2 1st day. Thrombocytopenia can occur,
J anaemia occurs less frequently. Myelosuppression may be more
vere and prolonged in patients having had extensive prior chemother/ or radiotherapy or in debilitated patients.
The mqst commonly encountered side effects are nausea and vomiting,
fiough in the majority of cases these are mild (WHO Grade I) and
nsient. Alopecia may occur, but is most frequently of minimal sever
e d reversible on cessation of therapy.
W ' side effects which have occasionally been reported include
’a. diarrhoea, dyspnoea, fatigue and weakness, fever, gastroin“Meeding, stomatitis/ mucositis, and non-specific neurological

There is no known specific antidote for NOVANTRONE. As would be
expected from the pharmacological actions of the drug, haematopoietic,
gastrointestinal, hepatic and renal toxicity may be seen, depending on
the dosage given and the physical condition o f the patient. The manage
ment of overdosage is symptomatic and supportive and patients should
be monitored closely. (See also the sections ‘-W ARNINGS''. "P R E 
CAUTIONS" and "ADVERSE REACTIONS")

DOSAGE
The recommended initial dosage for use as a single agent is 14 mg/m2o f
body surface area, given as a single intravenous dose, which may be
repeated at 2 1-day intervals. A lower initial dose (12 m g/m 2 or less) is
recommended in patients with inadequate marrow reserves due to prior
therapy or poor general condition.
Dosage modification and timing o f subsequent dosing should be deter
mined by clinical judgement depending on the degree and duration of
myelosuppression. If 2 1 -day white blood cell and platelet counts have
returned to adequate levels, prior doses can usually be repeated. The
following Table indicates a guide to dosing based on myelosuppression.

iges in laboratory test values have been observed infrequently, e.g..
rea^d liver enzyme levels, elevated serum creatinine and blood urea
rogen levels.
rdiovascular effects, which have only occasionally been of clinical
.mficuijpe. include decreased left ventricular ejection fraction (de
mined by ECHO or MUGA scan). EKG changes and acute arrhythmia,
ngestive heart failure has been reported. Such cases generally re
nted well to treatment with digitalis and/or diuretics.

W BC AND
P L A T E L E T N A D IR
IF W B C N A D IR
> 1 500
AND
P LA T E L E T N A D IR
> 50 000
IF W B C N A D IR
> 1 500
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P L A T E L E T N A D IR
> 5 0 000
IF W B C N A D IR
< 1 500
OR
P LA T E L E T N A D IR
< 5 0 000
IF W B C N A D IR
< 1 000
OR
P L A T E L E T N A D IR
< 2 5 000

CLINICAL RESULTS
reduction
inical trials experience has established the dosage range, efficacy and
ety profile of NOVANTRONE*
single dose can be given intermittently every three or four weeks,
e refcommended initial treatment dose in good risk patients is 14
•/m2.
Tcacy data are available on 349 patients with locally advanced or
tastatic breast carcinoma. Results are dependent on many predisposfactors including prior chemotherapy and/or radiotherapy, the health
he patients, sites of metastases. and dose of the agent employed. In a
ropean multi-centre first- line single-agent trial using an initial dose
14 m&'m2. the overall response rate was 39% . which compared
(urably to doxorubicin therapy at a dose o f60-75 nig/m2when given
salients with similar stage disease. In an ongoing study o f a direct
nparison with doxorubicin, given as second-line therapy to breast
icerpatients who failed a standard first-line combination, response
:s arc 27% for NOVANTRONE* and 23% for doxorubicin. The mean
ytion jff response observed after NOVANTRONE* was greater than
reported after doxorubicin. Responses have been seen in all major
;s of metastases including lymph nodes, lung. bone, skin and viscera, in
ients both with and without prior hormonal therapy. Available data

T IM E T O
RECOVERY

SUBSEQ UENT
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RECOVERY
< 2 1 DAYS

R E P E A T P R IO R D O S E OR
IN C R E A S E B Y 2 m a / m ! IF
M Y E L O S U P P R E S S IO N NOT
C O N S ID E R E D A D E Q U A T E .

RECOVERY
> 2 1 DAYS

W IT H H O L D U N T IL
RECOVERY THEN
R E P E A T P R IO R D O S E .

A N Y D U R A T IO N

D E C R E A SE B Y 2 m q /m 2
F R O M P R IO R D O S E A FTE R
RECOVERY.

A N Y D U R A T IO N

DEC R EASE B Y 4 m g /m 2
F R O M P R IO R D O S E A FTE R
RECOVERY

While no unforeseen problems have been encountered when NOVAN
TRONE* is used in combination with other antineoplastic therapy, data
are limited; therefore. NOVANTRONE* in combination therapy should
be used with caution until wider experience is obtained.
As a guide, when used in combination chem otherapy with another
myelosuppressive agent, the initial dose o f NOVANTRONE* should be
reduced by 2-4 m g/m 2 below the doses recommended above for single
agent usage; subsequent dosing, as outlined above, depends on the de
gree and duration o f myelosuppression.

ADMINISTRATION O F SOLUTION
NOVANTRONE* solution should be diluted to at least 50 mL w ith either
Sodium Chloride for Injection (U.S.P.) or 5% Dextrose for Injection
(U.S.P.). This solution should be introduced slowly into the tubing o f a
freely-running intravenous infusion o f Sodium Chloride for Injection
(U.S.P.) or 5% Dextrose for Injection (U.S.P.) adm inistered over not
less than three to five minutes intravenously. If extravasation occurs,
the administration should be stopped immediately and restarted in an
other vein. However, serious local reactions have not been reported
following extravasation.
NOVANTRONE* should be administered by individuals experienced in
the use o f antineoplastic therapy.
Caution in the handling and preparation o f NOVANTRONE* solutions
must be exercised and the use o f protective eyeglasses, gloves and other
protective clothing is recommended. (See "S A F E HA ND LING BY
HOSPITAL PERSONNEL" section).

STORAGE DIRECTIONS
NOVANTRONE* should be stored at room tem perature — DO NOT
FREEZE. With recommended storage, NOVANTRONE* rem ains stable
for two (2) years.
Following preparation of the infusion, the diluted solution should be
stored at room temperature and used within 24 hours. Any original
solution which remains in the vial should be discarded. NOTE: LIKE
THE ORIGINAL SOLUTIONS, THE D ILU TIONS SH OULD ALSO
NOT BE FROZEN.

DRUG COMPATIBILITY
Until specific compatibility data are available, it is recom mended that
NOVANTRONE* not be mixed in the same infusion with other drugs.

GUIDELINES FOR SAFE USE BY HOSPITAL PERSONNEL
Handling:
1. Preparation o f antineoplastic solutions should be done in a vertical
laminar flow hood (Biological Safety Cabinet — Class II).
2. Personnel preparing NOVANTRONE* solutions should w ear PVC
gloves, safety glasses and protective clothing such as disposable
gowns and masks.
3. Personnel regularly involved in the p rep aratio n and handling of
antineoplastics should have bi-annual blood examinations.
Disposal:
1. Avoid contact with skin and inhalation o f airborne particles by use
o f PVC gloves and disposable gowns and masks.
2. All needles, syringes, vials, ampoules and other m aterials which
have come in contact with NOVANTRONE* should be segregated in
plastic bags, scaled and marked as hazardous waste. Incinerate at
!000°C or higher. Sealed containers may explode if a tight seal
exists.
3. If incineration is not available, mitoxantrone hydrochloride may be
detoxified by adding 5.5 parts by weight o f calcium hypochlorite to
each I part by weight of mitoxantrone hydrochloride in 13 parts by
weight o f water.t The calcium hypochlorite should be added G R A 
DUALLY and the procedure carried out with adequate ventilation
since chlorine gas is liberated.
Vials:
Prepare an adequate quantity o f calcium hypochlorite solution (eg; Add
43.5 g calcium hypochlorite to 100 mL o f w a te rt). W ithdraw any
NOVANTRONE* remaining in the vial with the aid o f a hypodermic syringe.
Add to the prepared calcium hypochlorite solution slowly, preferably in
chemical fume hood or biological safety cabinet — Class II. Add an
appropriate quantity o f the calcium hypochlorite solution to the vial to
detoxify any remaining drug. W ithdraw the solution and discard in the
sewer system with running water. Dispose o f the detoxified vials in a
safe manner.
Needles, syringes, disposable and non-disposable equipment:
Rinse equipment with an appropriate quantity o f calcium hypochlorite
solution (43.5 g per 100 mL o f water+). Discard the solution in the
sewer system with running water and discard disposable equipm ent in a
safe manner. Thoroughly wash non-disposable equipm ent in soap and
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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Congenital Disease of the Liver
and Biliary Tract in Adults
r
^The surgery and complications of
gallstones constitute a large and growing
4 part of the general surgeon’s practice. A
congenital cause for symptomatic biliary
> ‘tract disease in adults is rarely considered,
although congenital cystic fibrosis of the
* pancreas and congenital polycystic disease
of the kidney are well-recognized condi
tions not infrequently presenting in adult
^J.ife. In this issue (pages 271 to 273), La
pointe and his colleagues report a case of
y cystic dilatation of the intra- and extrahepatic ducts in a 60-year-old woman.
A recent review1 reported that 25% of
patients with biliary cysts were over 21
years of age. With increasing use of en
doscopic retrograde cholangiopan
creatography (ERCP), this type of con
genital abnormality will be recognized
r more frequently. The general surgeon will
,also make the diagnosis at laparotomy
and by operative cholangiography, and
-r must be prepared to deal with it
appropriately.
7 There is a wide spectrum of congenital
fibrocystic disorders of the liver and
* biliary tract. At one end of the spectrum
is adult polycystic disease, consisting en
tirely of intrahepatic cysts, and at the
y other end there is congenital hepatic
fibrosis in which fibrosis may be the onv!y abnormality. Many patients have
associated disease of the kidney and this
►may be the dominant clinical feature.
Congenital polycystic disease of the
“ liver is of two types — childhood and
adult; the former is an autosomal
K recessive disorder. Polycystic disease of
*the kidney is a prominent feature; all pa
tients have renal failure and inevitably die
a before reaching adulthood. By contrast,
,
the adult form is inherited as an
jh ^autosomal dominant condition. The cysts
do not communicate with the bile ducts
f and therefore never contain bile. About
half the patients with this condition also

have mildly polycystic kidneys (the disease
is compatible with long life), and other
congenital abnormalities are common.
Characteristically, the cysts are large and
the patient presents with a nodular,
enlarged liver and excellent liver function.
This is most likely to be confused with
metastases because of the similar ap
p earance on liver scanning and
ultrasonography.
Congenital hepatic fibrosis is also in
herited (autosomal recessive) but may pre
sent either in childhood or in adult life.
Although fibrosis is the predominant
pathologic feature, many patients also
have dilated intrahepatic ducts. Portal
hypertension, probably from fibrous com
pression of portovenous radicals, is com
mon. This disease is associated with
a cystic condition called medullary sponge
kidney in the majority of patients. It may
also be associated with cysts of the extrahepatic biliary tree. Congenital hepatic
fibrosis usually presents as portal
hypertension with or without cholangitis
and for this reason is often misdiagnos
ed as cirrhosis. Hepatic function,
however, is well preserved and tests of
liver function usually give normal results
apart from an elevated serum alkaline
phosphatase level. Liver biopsy is essen
tial for diagnosis, and because of exten
sive fibrosis, an operative wedge biopsy
is usually necessary. These patients are ex
cellent candidates for surgical treatment
of the portal hypertension should their
esophageal varices bleed.
Caroli’s disease is cystic dilatation of
the intrahepatic biliary tree.2 The cysts
are in free communication with the en
tire duct system, are prone to cause
cholangitis and often contain stones. This
is not an inherited abnormality and renal
lesions are rare. The condition presents
usually in early adult life with recurring
abdominal pain and cholangitis. Mild

jaundice may occur during episodes of
cholangitis which may be complicated by
septicemia. Surgical treatment is rarely
indicated.
Cystic dilatation of the extrahepatic
biliary tree has been termed choledochal
cyst and perhaps this is the best name
when it is a solitary lesion. The cysts,
however, may be multiple and may then
affect the extrahepatic biliary tree alone,
both intra- and extrahepatic biliary tree
or the intrahepatic biliary tree alone
(C aro li’s disease). In c o n tra st to
polycystic liver disease, the cystic renal le
sion associated with this congenital ab
normality is usually not clinically impor
tant. The solitary cyst may be a typical
choledochal cyst, a diverticulum arising
from the choledochus, or a choledochocele, depending on its anatomical posi
tion. The cyst may merely form a mild
dilatation of the entire extrahepatic biliary
tree but has been known to reach a gallon
in capacity. Large cysts have burst.3 The
“ typical” triad of symptoms — inter
mittent jaundice, pain and abdominal
tumour — in fact is unusual in the adult
as the cyst is often not palpable.
No convincing unifying theory has been
proposed to explain the developmental
abnormality in those conditions that are
not inherited. The earliest explanation
was that cysts developed as a result of
unequal epithelial proliferation o f the
duct.4 Other suggestions were that the
cysts formed as a result of congenital
weakness of the duct wall5 or that they
represented a Hirschsprung-like lesion6
or that the cysts were merely dilatations
between areas of segmental fibrosis.7
The latest theory is that of Babbitt8 who
proposed that the dilatation was due to
regurgitation of pancreatic juice into the
biliary tree as a result of a common chan
nel. None of these theories explains all of
the findings. It appears that a number of
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different developmental abnormalities
can produce cystic dilatation of the biliary
tract.
U ntil recently, the conventional
surgical approach to patients with these
cysts was to achieve decompression by in
ternal drainage into either the duodenum
or a defunctioned Roux-en-Y limb of je
junum. Japanese surgeons, who have
more experience with this condition, have
championed a more radical approach.
They recommend total excision of the
cystic dilatation followed by Roux-en-Y
hepaticojejunostomy 9 or hepatoportojejunostom y . 10 This approach is now
gaining fav o u r am ong w estern
surgeons, 11,12 mainly because it has been
shown 13 that internal drainage is follow
ed by recurring cholangitis in 30% to 40%
of patients and closure of anastomoses in
10%. There is also the risk of cancer
developing in the residual cyst . 14’15
Radical excision of the cyst is not as dif
ficult as it appears. If there is extensive
fibrosis, Lilly 16 has suggested a way of
excising the cyst by confining the major
part of the dissection to the inside of the
cyst, thus minimizing the danger of
vascular injury. The long-term results of

excisional surgery have been remarkably
good even when intrahepatic cystic dilata
tion remains. Surgical excision thus ap
pears to be the treatment of choice par
ticularly in young patients, and drainage
should be considered only if conditions
are very unfavourable. The surgeon must
have the knowledge to recognize the con
dition and the courage and skill to em
bark on resection on the basis of his find
ings at operative cholangiography.
M a x M . C o h e n , m b , c h b , fr cs (Ed in ),
FRCS[C], FACS
Member,
Editorial Board.
Professor of Surgery,
University of Toronto,
Ste. 440,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont. M5G 1X5
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If My Son Had a Spinal Cord Injury
Therapeutic advances may come from
several sources such as new treatments,
more precise use of those that exist due
to a better understanding of patho
physiology, and a more consistent ap
plication of established methods due to
programmatic health care delivery. The
article by Tator and associates in this issue
(pages 289 to 296) falls into the last
category.
Ever since Sir Ludwig Guttmann in
troduced programmatic management for
patients with spinal cord injuries and
dramatically changed the prognosis, it has
been generally accepted that these patients
are best managed in specialized centres.
On the other hand, experience gained
from the Korean and Vietnamese wars
showed that any delay in actively treating
acute traum a appreciably worsens out
come. In Canada, the Sunnybrook Hos
pital in Toronto is privileged because it
is designated as a major trauma centre,
serving a population of several million,
and is the hub of a helicopter ambulance
system. At this centre Tator and his col
leagues have been able to incorporate ag
gressive trauma management and pro
grammatic spinal cord care with minimal
212

delay. Since the spinal cord has an impor
tant coordinating role, its injury caus
ing disturbances in many organ systems,
the expertise of several disciplines is re
quired. Episodic and inconsistent care in
vites trouble; therefore, by having defin
ed care protocols, it is possible to prevent
common complications. Staff who deal
regularly with a condition collect ex
perience, and regular rounds and good
communication between specialists reduce
the risk of missing a diagnosis or
neglecting necessary intervention.
This ideal setting should lead to better
care and outcomes. The authors try to
establish the advantages of their health
care delivery model by describing the
results obtained in the first 144 patients
treated at the Acute Spinal Cord Injury
Unit at the Sunnybrook Hospital since
its opening in 1974 and comparing them
with the results obtained in 358 patients
with spinal cord injuries admitted to two
Toronto hospitals between 1948 and
1973. Also, a comparison is made be
tween a group of 49 patients treated at the
acute injury unit from 1978 to 1979 and
a matched group of 49 patients treated in
other hospitals in Ontario; all 98 patients

were eventually referred to Lyndhurst*
,
Hospital in Toronto for rehabilitation.
The authors use two outcome measures 1
— length of stay in the acute care unit and(
degree of neurologic deficit. Unfortuna1
tely, historical controls are not valid, since ,
many other components of care apart
from organization have changed in the,
past 30 years. Today, newer antibiotics
are more effective in treating urinary tract *
infections; a better understanding of
venous thrombosis and its prevention has
all but eliminated pulmonary embolism
as a cause of death; an improved
knowledge of pulmonary physiology has^
reduced early mortality; and a trend
towards more aggressive management of ,
spinal fractures has reduced the length of
patient immobilization. The list could go*
on. Similarly, comparing the 49 Sunny
brook patients with those managed in ■*
other hospitals and referred to Lyndhurst
Hospital will provide no better evidence.
For example, hospitals could keep those A
patients who are easier to treat in their
own rehabilitation facilities, and it may* 4
be more complicated to admit patients to
Lyndhurst from another hospital.
<
This methodologic problem is not uni-
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que to Tator’s paper. Proving the
superiority of one method of health care
delivery over another requires strict ex^ perimental design, which, for practical
^ reasons, is usually difficult, timeconsuming and costly. But does that mat, } ter? Can’t we just take pride in the out
comes that Tator and his colleagues have
shown? It does matter, since the implied
conclusion is that patients with spinal
►cord injuries should be cared for in
specialized centres. Some of us believe'
this and others do not. Unless studies
looking at the effectiveness of treatment

are methodologically sound, proof will
not be incontrovertible.
The article of Tator and colleagues is
important as a descriptive study that sets
a standard to be emulated. Other centres
can look at the data and compare them
to their own. Differences do not neces
sarily indicate that one approach is bet
ter than another but do suggest a need to
search for explanations. If we pursue this
honestly, care can only improve.
As for myself, I would pack my son in
to a helicopter and fly him to the Acute
Spinal Cord Injury Unit at Sunnybrook.

The reason is not in the body o f T ator’s
paper but in the byline. The fact that
neurologic, orthopedic and urologic
surgeons join hands with a physiatrist and
a nurse in organizing care and reviewing
outcomes gives me confidence.
R a lph F. B l o c h ,

m d , frcs [C]

Department of Rehabilitation Medicine,
Chedoke-McMaster Rehabilitation Centre,
Hamilton, Ont.
L8N 3Z5
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Symposium on Morbid Obesity: Part II

Y
«

\
The abstracts that appear on pages 227
* to 238 constitute the second of two parts
of the First Canadian Symposium on the
* Surgical Treatment of Morbid Obesity
held at the University of Ottawa in May
1983. In the March issue of this Journal
^ all of the papers dealing with the medical

»

r

aspects of morbid obesity were published.
The current issue contains the surgical
abstracts.
The second symposium will be held at
the same location on May 17-19, 1984.
Please contact my office at (613) 737-8537
for further information.
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Surgical Complications of Endoscopic Sphincterotomy
V
►

Endoscopic s p h in ctero to m y (pa p illoto m y)
r w a s perfo rm e d in 2 8 9 pa tie nts fo r
I
ch o le d och o lith ia sis (25 0 , o f w h o m 2 2 3
had undergone c h o le cyste cto m y
p re vio u sly), papillary stenosis or spasm
* (32) and am pullary neoplasm (7).
The co m p licatio n s encountered in 39
p a tie nts w ere hemorrhage (15 patients),
4 p e rfo ra tio n (4), hem orrhage and p e rfo ra 
i
tio n (1), ch o la n gitis (5), pa n cre a titis (11),
im p actio n (1) and others (2). Laparotom y
k
w a s required in seven o f these patients
fo r hem orrhage (tw o ), p e rfo ra tion (tw o ),
hem orrhage and perforation (one),
► p a n cre a titis (one) and im paction
(one). Bleeding required duode* n o to m y w ith an extension o f the
L t s p h in c te ro to m y incision to co n tro l
hem orrhage, and a form al sutured
s p h in c te ro p la s ty . Perforation occurred at
►
th e ju n c tio n o f the distal bile d u c t and
t duodenum and w as m anaged by
m ob iliza tion o f the duodenum , w ith Ttu b e drainage through th e p e rfo ra tion ,
and s u tu re d closure. A pancreatic
y abscess fo llo w in g pancreatitis required
f
surgical drainage. An im pacted Dormia
i
r
basket w ith entrapped stone in the bile
^ d u c t required duodenotom y fo r its
rem oval.
There w a s a high risk o f p e rfo ra tion in
th o se p a tie n ts w h o did n o t have
’ ch o le d och o lith ia sis or w h o had had a
previous B illroth II g a stre cto m y. There
w ere tw o deaths but th e overall co m 
p lic a tio n rate o f 2 .4 % is considered lo w ,
because m any o f the pa tie nts w ere
elderly or debilitated.

I

f From the divisions o f *general surgery and
tgastroenterology, The Wellesley Hospital,
University o f Toronto, Toronto, Ont.
y
Presented at the 6th annual meeting o f the
* Canadian Association o f General Surgeons,
Calgary, Alta., Sept. 20, 1983
Accepted fo r publication Oct. 13, 1983
A

Reprint requests to: Dr. C. Jamieson,
Ste. 322, E.K. Jones Building, The
Wellesley Hospital, 160 Wellesley St. E,
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Des sp h in ctero to m ie s endoscopiques
(papillotom ies) o n t 6te pratiquees chez
2 8 9 p a tie n ts dans des cas de choledoch o lith ia se (2 5 0 , d o n t 2 2 3 a va ie n t deja
eu une ch o le cystecto m ie ), de stenose ou
de spasm e papillaire (32) ou de neoplasm e am pullaire (7).
Des co m p licatio n s o n t ete rencontrees
chez 3 9 patients; il s 'a g issa it d'hem orragie (1 5 pa tie nts), de p e rfo ra tio n (4),
d 'he m o rra g ie avec p e rfo ra tio n (1), de
ch o la n gite (5), de p a ncreatite (1 1 ), d'ertcla ve m e n t (1) et d 'a u tre s (2). S ept de
ces p a tie n ts o n t necessite une laparotom ie p o u r une hem orragie (deux), une
p e rfo ra tio n (deux), une hem orragie avec
p e rfo ra tio n (un), une p a n cre a tite (un) et
un encla ve m e n t (un). Les saignem ents
o n t necessite une d u o d e n o to m ie avec
e xte nsion de I'in cisio n de sp h incterotomie p o u r arreter I’ hem orragie, puis une
sp h in ctero p la stie . La p e rfo ra tio n est survenue a la jo n c tio n de la partie distale du
choledoque e t du duodenum ; elle fu t traitee par m ob ilisa tion du duodenum a
I'aide d 'u n tu b e de drainage en T passe a
tra ve rs la pe rfo ra tion e t fe rm e tu re par
su tu re . Un abc6s du pancreas consS cutif
a la p a n cre a tite a necessite un drainage
ch irurg ica l. Un pannier Dorm ia renferm a n t un calcul qui s 'e s t tro u ve bloque
dans le choledoque a necessite une
duode n o to m ie.
Un risque eieve de p e rfo ra tio n a ete
tro u v e chez les pa tie nts qui n 'a va ie n t
pas de ch o ie d och o lith ia se et chez ceux
qui a va ie n t deje subi une gastrectom ie
de ty p e B illro th II. On a e n re g istre deux
deces m ais le ta u x de c o m p lica tio n de
2 .4 % e st c o n s id e r fa ib le p u isq u 'o n
c o m p ta it plusieurs p a tie nts ages ou
p h ysiq u e m e n t a ffa iblis.

The in trodu ction o f en d oscop ic
retrograde cholangiopancreatography
(ERCP) has presented new opportunities
for n onop erative intervention in
choledocholithiasis or biliary obstruction.
Bile-duct calculi can be removed endoscopically with a wire basket or balloon

catheter after the sphincter o f Oddi has
been cut. However, such procedures are
not without risk and we present our ex
perience with complications o f this tech
nique that led to subsequent surgical in
tervention.
Between August 1977 and March 1982,
289 endoscopic sphincterotomies were
performed by one o f us (GBH), for a
variety of indications (Table I). The com
plications encountered were hemorrhage
(requiring transfusion of two units o f
blood or more), perforation, pancreatitis
(with hyperamylasemia and typical
clinical features), cholangitis and impac
tion (Table II). The seven patients who
required laparotomy are described below.

Case Reports
Case 1
A 55-year-old woman underwent ERCP for
investigation of biliary colic, 9 years after a
cholecystectomy. There was a tight ampullary
orifice but a normal-sized common bile duct
without stones. Injection of contrast material
into the duct reproduced her pain. She was
thought to have papillary stenosis, so an en
doscopic sphincterotomy 1.2 cm long was per
formed. Within 12 hours, generalized perito
nitis developed.
At laparotomy, she was found to have bilestained fluid in the peritoneal cavity, with bile
and gas in the retroperitoneal tissues about the
duodenum. When the duodenum was mobiliz
ed, a 5-mm perforation was seen at the junc
tion of the common bile duct and duodenum.
A T tube was inserted through the perforation
and the tissues were loosely sutured about it.
An omental patch was placed over the site and
a large drain placed near by. A gastrostomy
was created and a tube duodenostomy was
fashioned at the second part of the duodenum.
Postoperatively, her recovery was smooth and
she has had no further problems in the subse
quent 3 years.

Case 2
A 45-year-old woman with acute pancreatitis
and jaundice was found to have cholelithiasis
and therefore underwent cholecystectomy.
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Three years and again 4 years later she had fur
ther attacks of pancreatitis. She denied drink
ing large amounts of alcohol. Endoscopic
retrograde cholangiopancreatography did not
demonstrate a stone or stricture, but because
of the tightness of the papillary orifice and
delayed drainage, we thought papillary spasm
was the probable cause of her pancreatitis. She
underwent endoscopic sphincterotomy. Bleed
ing from the site of the sphincterotomy was
noticed endoscopically. She rapidly became
hypotensive despite vigorous infusion of blood
a n d plasm a a n d she req u ired im m ediate
laparotomy, which revealed a perforation of
the posterior wall of the duodenum at the site
o f entry of the common bile duct. The edges
o f the perforation were bleeding profusely. A
duodenotomy and sutured sphincteroplasty
control’ed the bleeding. The perforation was
closed primarily, the site of the duodenotomy
was drained, and tube gastrostomy and jejunostomy were performed. The patient did
well postoperatively and had no further prob
lems in the subsequent 2 years.

Case 3
A 77-year-old woman became jaundiced
while in hospital for investigation of a rectal
carcinoma. Ultrasonography revealed extrahepatic biliary obstruction and ERCP
demonstrated a single filling defect obstructing
the distal common bile duct but no stones in
the gallbladder. An endoscopic sphincterotomy
1 cm long was performed but several passes of
the Dormia basket failed to retrieve the stone.
A t the end of the procedure she was noted to
have a grossly protruberant abdomen as well
as massive subcutaneous emphysema. Retro
peritoneal perforation of the duodenum was
diagnosed and im m ediate lap aro to m y
performed.
A perforation 1 cm long was found at the
junction of the distal common bile duct and
duodenum. There was no evidence of
metastatic disease from her rectal carcinoma.
The gallbladder was normal. A T tube was
placed through the perforation with one arm
passing into the duodenum. The perforation
was loosely closed around the T tube with in
terrupted sutures and a sump drain placed near
the site of the perforation. Twelve days after
the laparotomy, the patient had severe upper
gastrointestinal bleeding, which was found at
endoscopy to originate in the second part of
the duodenum. Laparotomy and duodenotomy
revealed that the T tube had eroded a small
blood vessel at the site of the sphincterotomy.
The vessel was cauterized and the limb o f the
T tube shortened. The duodenum was closed
and patched with omentum and the sump
drainage was continued. Her recovery was

smooth until her sudden death of pulmonary
embolism 8 days postoperatively.

Case 4
An 81-year-old man was admitted to hospital
for investigation of jaundice. He had previous
ly had a cholecystectomy. A percutaneous transhepatic cholangiogram demonstrated a dilated
common bile duct with a distal stricture of
unknown cause. On ERCP, ampullary stenosis
was noted but there was no malignant lesion
and he underwent a 1-cm sphincterotomy;
moderate bleeding was seen endoscopically.
Over the next 4 days he required 10 units of
blood, so a laparotomy was done. A small
bleeding artery was found at the site of the
sphincterotomy. The artery was cauterized and
a formal sutured sphincteroplasty was perform
ed. No cause could be found for the ampullary
stenosis. Nine days later he had profuse
gastrointestinal bleeding, which was found at
reoperation to come from the sphincteroplas
ty incision. This was oversewn. The patient
died of multiple organ failure 10 days after his
second operation.

Case 5
A 45-year-old woman underwent ERCP and
a 1-cm endoscopic sphincterotomy because she
had two residual common duct stones 4 months
after cholecystectomy. One stone was identified
and removed but no other stones were seen.
Twenty-four hours later, acute pancreatitis
developed and her serum amylase level was
elevated. Computerized tomography confirmed
pancreatic inflammation with extension of the
inflammatory process to the right anterior
pararenal space.
She failed to respond to conservative treat
ment and 1 month after sphincterotomy under
went laparotomy, which revealed necrosis of
the pancreas, retroperitoneal tissues and the
transverse and ascending mesocolon. A com
munication between the colon and the necrotic
cavity was encountered. Necrotic tissue was
debrided, the colonic fistula was controlled by
a tube colostomy and the retroperitoneal space
was lavaged with a closed irrigation system.
Sinograms later demonstrated free communica
tion between the abscess cavity and the pan
creatic duct. She had spontaneous closure of
all fistulous tracts and was well 18 months
later.

Case 6
Four years after cholecystectomy, following
an episode of cholangitis, a 51-year-old man
was found to have a stone in the common bile

duct on ERCP. He had had a Billroth II
gastrectomy for peptic ulcer disease. He under
went endoscopic sphincterotomy but stone ex
traction was made difficult by excessive A
bleeding. Intravenous administration of
vasopressin slowed the bleeding for a short time A
but after transfusion of 10 units of blood,
laparotomy was deemed necessary. A retroperi- A '
toneal hematoma and perforation of the
duodenum at the junction with the common
A
bile duct was found. Duodenotomy and
choledochotomy were performed and a single ■*
large stone was removed from a dilated bile
duct. A T tube was placed in the bile duct and
the duodenal perforation sutured in such a way
as to convert the endoscopic sphincterotomy"
into a sutured sphincteroplasty. The patient
had no further complications and was well 16
A
months later.
-i

Case 7

i

A 74-year-old woman required endoscopic
removal of a stone in the common bile d u ct 1
that remained after a difficult cholecystectomy.
She underwent endoscopic papillotomy; the
^
stone was grasped with the Dormia basket but
could not be pulled through the ampulla in
spite of the papillotomy. The endoscope was
removed, leaving the basket in place. A
laparotomy was performed. After opening the k
duodenum, the basket catheter was grasped
and with direct pressure and traction the stone
,
with the basket was pulled through the am*
pulla. The patient had no further problems.
,

Discussion

-*

Endoscopic sphincterotomy for the
removal of bile-duct stones is well
established.1-5 It has been used to in- <
troduce indwelling endobiliary prostheses
for palliative drainage o f malignant
-4|
obstruction of the biliary tract and in
chronic cholestasis associated with *
sclerosing cholangitis. The major com
plications are hemorrhage, perforation, *
cholangitis and pancreatitis.
,
Bleeding at the site o f endoscopic
sphincterotomy is common and usually
^
stops promptly. Occasionally, profuse
bleeding requires urgent resuscitation and <
immediate laparotomy. Less often,
operation i3 required for slow but unre- "
mitting bleeding. Surgical management of ^
the bleeding patient is straightforward. At
operation, a duodenotomy is necessary to
4
inspect the sphincterotomy site. Surgical

T a b le I I - C o m p lic a tio n s o f 2 8 9 E ndosco pic S p h in c te ro to m ies
T a b le 1— In d ic a tio n s fo r
E nd o s co p ic S p h in c te ro to m y

In d ic atio n

C o m p lic a tio n
No. of
p a tie n ts

C o m m o n -d u c t sto n es
G allbladder in
G allb lad d e r o u t
P ap illary s te n o s is or s pasm
A m p u lla ry n e o p la s m

223
32
7

T o ta l

289

216

27

H e m o rrh a g e
P e rfo ra tio n
H e m o rrh a g e and p e rfo ra tio n
C h o lan g itis
P a n c re a titis
Im p a c tio n
O th e r
% o f to ta l
s p h in c te ro to m ie s

No.

N o. requiring
la p a ro to m y

N o . of
d e a th s

15
4
1
5
11
1

2
2
1
0
1
1

2

0

1
1
0
0
0
0
0

2 .4

0 .7

1 3 .5
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extension of the sphincterotomy incision
may be required in order to obtain access
^.to the bleeding vessel. Following control
of the bleeding, the site should be in^ spected for an associated perforation. The
occurrence o f m ajor bleeding is
^unpredictable despite an appropriate mix
ture of cutting and coagulating current us^ ed for the endoscopic sphincterotomy.
► Retroperitoneal perforation of the
common bile duct occurs at the junction
►of the distal bile duct and the duodenum.
The risk of perforation depends on
Several factors: the length of the sphinc
terotomy incision, the length of the in*" tramural portion of the common bile duct
^and the degree of dilatation of the bile
duct. In our experience a dilated duct impinging on the duodenal wall above the
ampulla allows for a longer sphinc
terotom y incision with minimal risk of
perforation. This may be due to the
Y fibrosis and inflammation induced by a
stone in the distal duct. On the other
*hand, the duct without stones that is not
dilated is a greater risk for perforation,
i especially when a stronger current is re•iquired to cut a hypertrophic sphincter. In
our series, only 4 (cases 3, 5, 6 and 7) of
4 289 (1.4%) patients with stones required
laparotomy compared with 3 (cases 1, 2
and 4) of 32 (9.4%) in the stenosis with
spasm group. Patients with a Billroth II
^anastomosis, requiring an endoscopic ap
proach through the afferent loop, are also
from a group recognized as high risk
y because of the difficulty in orienting the
papillotomy and controlling the length of
>- the cut. In our series, 1 (case 6) of 12 pa
tients (8.3%) required laparotomy.
* The diagnosis of perforation may be
obvious if there are signs of peritonitis,
y but more often the perforation is confined
>to the retroperitoneum. The more subtle
signs of retroperitoneal perforation may
r be localized pain, low-grade fever, sub
cutaneous emphysema or retroperitoneal
>gas seen radiologically. Our impression is
that small perforations often occur but
f are not clinically important. One author6
has recommended a trial of medical
management consisting of bowel rest and
administration of antibiotics and fluids
intravenously. Two patients in our series
►were suspected of having a minor localiz
ed perforation on the basis of pain, per► sistent leukocytosis and a low-grade fever.
They were managed, successfully, with a
course of antibiotics orally for 6 weeks.
Patients with extensive retroperitoneal
*" gas, peritonitis or appreciable sepsis
„ should undergo laparotomy. When possi
ble, the duodenum should be mobilized,
the perforation sutured and a T tube
introduced through either the perforation
1 A or a proximal choledochotomy. If access
is difficult or bleeding remains uncontrolt
led, we recommend duodenotomy and a
sutured sphincteroplasty.

Cholangitis following endoscopic
sphincterotomy is a complication that
usually occurs because a stone is impacted
in the common bile duct. If a large
residual stone cannot be recovered with
a Dormia basket, it is important to
establish drainage from above the ob
structing stone. This can be done by
inserting an indwelling nasobiliary can
nula; the distal end is placed above the
stone and the proximal end brought out
through the nose and allowed to drain
freely. If adequate drainage is not achiev
ed, the patient requires operation to pre
vent sepsis.
Acute pancreatitis may follow endo
scopic sphincterotomy. Although this
condition is well seen following injection
of contrast material into the pancreatic
duct, the exact etiology following sphinc
terotomy is unclear. We suspect that it is
caused by a thermal injury to the adja
cent pancreas that can occur as the biliqry
sphincter is cut. It is mandatory to verify
fluoroscopically the correct position of
the papillotome in the common bile duct
to avoid inadvertently cutting the pan
creatic duct. Pancreatitis in these patients
is managed by conventional methods.
Impaction of the wire basket with an
entrapped stone is a rare complication.
When surgical removal is required, it may
be achieved by simple manipulation of the
stone and basket or it may be necessary
to open the duodenum in order to extend
the papillotomy or to increase the trac
tion on the basket. The stone in the basket
may pass spontaneously if the catheter is

left in place for 2 or 3 days provided sep
sis does not intervene.
Summary
Of 289 patients who underwent endo
scopic sphincterotomy, 7 had complica
tions that required surgery. The complica
tions were hemorrhage, perforation, pan
creatitis, cholangitis and impaction of the
retrieval basket. There appears to be a
higher risk of complications in those who
do not have choledocholithiasis or have
had a previous Billroth II gastrectomy.
Early recognition of complications with
immediate surgical intervention should
reduce the mortality associated with
serious complications. Hemorrhage and
perforation usually required duodeno
tomy and a sutured sphincteroplasty;
pancreatitis was managed conservatively
initially but later required operation for
abscess and fistula; impaction required
duodenotomy to remove the stone and
basket. The overall complication rate of
2.4% was low, especially as many of the
patients were elderly and debilitated.
References
1. C lassen M, OSSENBERG FW: Non-surgical removal of
common bile duct stones. Gut 1977; 18: 760-9
2. SAFRANY L: Endoscopic treatment o f biliary-tract
diseases; an international study. Lancet 1978; 2: 983-5
3. Idem: Duodenoscopic sphincterotomy and gallstone
removal. Gastroenterology 1977; 72: 338-43
4. KOCH H, ROSCH W, SCHAFFNER O, DEMLING L: En
doscopic papillotomy. Gastroenterology 1977; 73: 1393-6
5. COTTON PB: Non-operative removal o f bile duct stones
by duodenoscopic sphincterotomy. B rJS u rg 1980; 67: 1-5
6. LlGUORY C: Endoscopic sphincterotomy. In KUNE GA,
Sali A (eds): The Practice o f Biliary Surgery, 2nd ed,
Blackwell Sci Pub, Oxford, 1980: 361-75

SESAP IV Question
16. The most serious of the complications accompanying gastric bypass for
morbid obesity is

(A)
(B)
(C)
(D)
(E)

hepatic failure
anastomotic leakage
urolithiasis
intestinal pseudo-obstruction
hypocalcemia

For the incomplete statement above select the one answer that is best of the
five given. For the critique of Item 16 see page 236.

(Reproduced by permission from SE SA P I V Syllabus: Surgical Education and
Self-Assessment Program No. 4. For enrolment in the Surgical Education and
Self-Assessment Program No. 4, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Measurement of Liver Blood Flow by Galactose Clearance "
Low-dose galactose clearance is a new
method for measuring functional
(nutrient) liver blood flow. In 22 healthy
beagle dogs, the mean ( ± SD) blood
galactose clearance rate of 311 ± 93
mL/min was not significantly different
from the mean measurement obtained
using electromagnetic flow probes (322
± 37 mL/min). This shows that galac
tose clearance can be used to measure
liver blood flow in healthy dogs. The 22
dogs were divided into two groups of
11.
The first group underwent portacaval
shunting and weekly galactose clearance
rates were measured until death an
average of 6 weeks later. The an
ticipated fall in liver blood flow was suc
cessfully detected by the second week
after shunting. This suggests that long
term (week-to-week) changes in liver
blood flow can be detected by this
method.
In the second group, ligation of the
common bile duct was used to induce
secondary biliary cirrhosis. Galactose
clearance was measured weekly for 6
weeks and showed a significant
decrease by 6 weeks. At 7 weeks,
laparotomy was performed in order to
take flow-probe measurements; the
galactose clearance rate was also
measured. Whereas the two methods
were similar at the time of the original
operation, 7 weeks after ligation there
was a significant difference (p = 0.02)
with the rate of liver blood flow as
measured by galactose clearance being
much lower than the flow rate measured
by the electromagnetic flow probes.
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These findings suggest that in cirrhotic
dogs, galactose clearance measures
functional or effective (nutrient) liver
blood flow whereas the electromagnetic
flow probe measures anatomic flow. The
effective flow gives a more accurate
reflection of perfusion of the hepatocyte
by blood.
La clairance du galactose a faible dose
represente une nouvelle mdthode de
mesurer la circulation hgpatique fonction
nelle (nutritive). Chez 22 chiens beagles
normaux, le d6bit moyen (± E.T.) de
311 ± 93 mL/min mesure par la
methode de la clairance du galactose n'a
pas 6t6 significativement different de la
valeur obtenue a I'aide d'une sonde elec
tromagnetique (322 ± 37 mL/min). Ceci
montre que la clairance du galactose
peut etre utilisee pour mesurer la circula
tion hepatique chez le chien normal. Ces
22 chiens ont ete repartis en deux groupes de 11.
Le premier groupe a subi une anasto
mose porto-cave, aprfes quoi la clairance
du galactose a ete mesuree chaque
semaine, jusqu'au deces des animaux,
en moyenne 6 semaines plus tard. La
chute anticipde de la circulation h£patique a ete decelee des la deuxieme
semaine qui suivit I'anastomose. Ceci
indique que sur une base hebdomadaire,
les changements a long terme de la cir
culation hepatique peuvent etre deceles
par cette methode.
Dans le deuxi&me groupe, les chiens
ont subi une ligature du choledoque destinee a provoquer une cirrhose biliaire
secondaire. La clairance du galactose
mesuree chaque semaine pendant 6
semaines a revele une baisse significa
tive aprds 6 semaines. Apres 7 semai
nes, une laparotomie a ete pratiquee afin
de mesurer le d6bit a I'aide d'un cathe
ter; la clairance du galactose a aussi ete
mesuree. Alors que les deux m^thodes
donnaient des resultats similaires au
moment de I'anastomose, elles diff£raient significativement (p = 0.02) 7
semaines apr&s la ligature, alors que la
clairance du galactose indiquait un debit
beaucoup plus faible que celui qui etait

mesure a I'aide de sondes electromagnetiques. Ces resultats indiquent que, chez
le chien cirrhotique, la clairance du galac
tose mesure la circulation hepatique
fonctionnelle ou efficace (nutritive) alors ,
que la sonde electromagnetique mesure
le ddbit anatomique. Le debit efficace
traduit de fagon plus exacte la perfusion
des hepatocytes par le sang.
*

In 1974 Bradley1 stated, “ The measure
ment of liver blood flow has been a highly k
desirable if somewhat elusive goal in the
establishment of hepatic physiopathol- *
ogy.” Numerous methods for measuring
liver blood flow have been tried, each
with its pros and cons1 (Table I). The^
ideal technique should be:
• Able to measure nutrient perfusion, *
total hepatic blood flow and the shunt
fraction.
4
• U sable in the presence of
hepatocellular disease.
"*
• Noninvasive.
• Safe and repeatable.
• Simple in concept and procedure.
• Widely available.
• Validated against the most objective, .<
current methods.
We can now measure liver blood flow <
noninvasively with the galactose clearance
method, which approaches the r e - <
quirements for the ideal technique.

Table 1-Measurement of Liver Blood Flow
Physical techniques
Electromagnetic flow probes
Lipoid velocity
Heat transfer
Clearance techniques
Hepatocyte uptake
Hepatocyte excretory clearance measured
by bromsulfalein, indocyanine green,
131 l-rose bengal
Hepatocyte metabolic clearance measured
by ethanol, galactose, sorbitol
Kupffer-cell uptake (RES) measured
by 198Au, 9®mTc-sulfur colloid
Inert-gas washout measured by 85Kr, 133Xe
Indicator dilution techniques
131 l-labelled serum albumin
51 Cr-labelled erythrocytes
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liver blood flow, using electromagnetic
flow probes, in healthy dogs; to follow
the effect of portacaval shunting on liver
blood flow, using galactose clearance
measurements; to see if they could detect
the expected decrease in liver blood flow
and finally to follow the effect o f com
mon-bile-duct ligation on liver blood
flow, using galactose clearance
measurements, and to compare liver
blood flow by galactose clearance and
electromagnetic flow-probe measure
ments in cirrhosis induced by ligation of
the common bile duct.

Tygstrup and Winkler2 and Waldstein
and Arcilla3 showed independently, in
^1958, that the liver is able to clear galac
tose substantially from the blood,
y especially at low blood concentrations
(high first-pass clearance). This ability
kstems from several facts: (a) galactose is
actively transported into the hepatocyte,
► (b) it has its own metabolic pathway, con
verting it to glucose, (c) it is water solu
ble and (d) it has no protein-binding ability. Clearance of galactose from blood can
be studied as both zero-order and firstorder kinetic phases. At blood concentra
tions above 2.22 mmol/L (40 mg/dL), the
v metabolic pathway is saturated and the
liver removes a maximum amount of
'galactose, depending on the functional
hepatocyte mass. This observation has
y been substantiated and used by some as
a true test o f q u an titativ e liver
function.4'5 In contrast, galactose
y clearance from blood at concentrations
below 2.22 mmol/L shows an exponen
t i a l decline, the pathway is no longer
saturated and liver blood flow is rate4 limiting in clearance.
Before 1980, no technique was
available to measure low concentrations
, of galactose in the blood. Then, Hender
son and Fales6 published a landmark
paper outlining a refined method that
enabled low concentrations of galactose
*4o be measured. The main refinements in
this assay were removal of interfering
► substances, use of fluorometry and phydroxyphenylacetic acid as the fluoro*metric substrate and providing the op
timal concentration of galactose oxidase.
Since then, galactose clearance has been
rused to measure liver blood flow in man
and dogs.7' 11
h The experiments reported here were
undertaken to compare nutrient liver
blood flow, using low-dose galactose
clearance measurements, with anatomic

Results
A ll Dogs
The mean (± standard deviation)
preoperative galactose clearance in the 22
dogs was 375 ± 61 m L/m in and mean
operative value was 311 ± 93 m L/m in.
The mean operative flow-probe measure
ment was 322 ± 37 m L/m in.
There was no statistically significant
difference between operative galactose
clearance and flow-probe measurements
(p = 0.675).
Portacaval Shunting

Methods
Twenty-two conditioned beagle dogs,
weighing 10.7 ± 1.4 kg, were studied.
Galactose clearance was measured two
to six times preoperatively in each dog.
At laparotomy, liver blood flow was
measured by galactose clearance. Separ
ately, the hepatic artery and portal vein
blood flows were measured with Statham
Gould electromagnetic flow probes
(Dynetech Ltd., Toronto, Ont.) and the
total compared in all 22 dogs with the
galactose clearance values.
Eleven dogs then underwent portacaval
shunting and galactose clearance was
measured weekly until the dogs died, an
average of 6 weeks later.
The remaining 11 dogs underwent liga
tion of the common bile duct and their
galactose clearance was measured week
ly for 6 weeks. Because measurement us
ing electromagnetic flow probes is in
vasive and requires a laparotomy, the
dogs were operated upon again at 7 weeks
and liver blood flow was measured by
galactose clearance and electromagnetic
flow probes. The dogs were then killed.
Statistical analysis of the results was by
the paired t-test.

Ta b le II - L i v e r Blood F lo w M e a s u r e d b y Blood G a l a c t o s e C le a r a n c e and E le c t r o m a g n e t i c
F lo w Pr ob es in th e P o r t a c a v a l S h u n t Gro up o f Dogs

The mean ( ± SD) preoperative blood
galactose clearance rate in these 11 dogs
was 341 ± 49 m L/m in, while the
operative clearance value was 279 ± 64
m L/m in and the operative flow-probe
measurement was 304 ± 44 m L/m in
(Table II). The difference between the last
two values was not significant; the coef
ficient of variation between them was
12.5%. At 2, 3 and 4 weeks following
portacaval shunting, the mean blood
galactose clearance rates were 197 ± 44
m L/m in, 177 ± 61 m L /m in and 146 ±
12 mL/min respectively (Table II). The
difference between the preoperative galac
tose clearance and the value 2 weeks after
portacaval shunting was statistically
significant (p < 0.01) (Fig. 1). Four of
the 11 dogs died immediately after opera
tion due to technical or metabolic com
plications related to the procedure.
Ligation o f the Common Bile Duct
The mean preoperative galactose
clearance value for the 11 dogs that
underwent ligation of the common bile
duct was 374 ± 55 m L /m in. The
operative mean galactose clearance value
(360 ± 115 mL/min) was not significant
ly different from the mean flow-probe
value (340 ± 14 m L/m in).

O p e r a t iv e
Pr e op e ra tiv e ga la c to s e

G a la c t o s e c le a ra n c e ( w k
a f t e r shuntin g), m L /m in

m e a s u r e m e n t s , m L/m in

cle a ra nc e , mL/min
Dog
no.
5
6
7
8
9
10
11
13
14
15
16

G a la c t o s e

F lo w

1

2

3

c le a ra n c e

prob e

2

3

4

363
305
322
395
157

323
258
293
507
379

360

192
177

209

—

—

—

145
249

134

140

151

-

—

—

—

—

—

-

391
416
347
557

401
344
324
342
442

255
335
278
321
360
318
303
345
331
295

163
230
199

148
283
169

143
132
170*

428
520

509

—
-

421
355
401
389
-

335
371
507

368
253
326
353
319
266
226
264
327

—

-

-

-

—

—

-

-

-

Mean
± SD

341 ± 49

‘ M e a s u re d a t 5 w k .

279 ± 64

304 ± 44

197 ± 44

177 ± 6 1

146 ±

12

FIG. 1—Sequential galactose clearance rates
in dogs before and after portacaval shunt
ing. Decrease in galactose clearance (*) before
and 2 weeks after shunting is significant
(p < 0.01).
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Following ligation of the common bile
duct, at weeks 1, 2, 3, 4, 5 and 6, the
mean blood galactose clearance rates were
286 ± 97 m L/m in, 295 ± 134mL/min,
269 ± 135 m L/m in, 243 ± 94 m L/m in,
213 ± 47 m L/m in and 207 ± 70 mL/min
respectively. The clearance at 6 weeks
postoperatively was significantly lower
than the operative rate (p = 0.008, Fig.
2).
At reoperation 7 weeks after the first
procedure, the mean blood galactose
clearance rate was 146 ± 55 mL/min and
mean flow-probe rate was 286 ± 36
mL/min. There was no statistically
significant difference between flow-probe
measurements before and after ligation
(p = 0.90). Although there was no dif
ference in galactose clearance and flowprobe rates before ligation, there was a
statistically significant difference after
wards (p = 0.02, Fig. 3).
Discussion
In the first part of the operative pro
cedure, liver blood flows measured by
galactose clearance and by flow probes
were compared in all 22 dogs. The mean
operative rates of 311 ± 93 mL/min ver
sus 322 ± 37 mL/min respectively were
not significantly different (p = 0.675).
We previously reported that the coeffi
cient of variation between galactose
clearance and flow-probe measurements
intraoperatively for the 11 dogs that
subsequently had portacaval shunts was
12.5%.8 This shows that in healthy dogs,
anatomic liver blood flow measured by
flow probes approximates physiologic
(nutrient or effective) flow measured by
galactose clearance. By extrapolation we
can assume that this is true in healthy
humans also. This is in keeping with the
findings o f other investigators that in
healthy hum an livers there is virtually no
intrahepatic shunting. Galactose clear-

FIG. 2—Sequential galactose clearance rates
following ligation of common bile duct (CBD).
Significant decrease (p = 0.008) in clearance
is noted 6 weeks (*) after ligation compared
with operative rate.
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ance can therefore be used to measure
liver blood flow in healthy humans. In
fact, this has been successfully done by
Henderson and associates9,10 and by our
group.11
Portacaval shunting will divert all por
tal blood away from the liver and hence
will result in decreased liver blood flow.
This anticipated decrease in flow was easi
ly observed on weekly galactose clearance
determinations. Two weeks after por
tacaval shunting, the rate of galactose
clearance was significantly (p < 0.01)
lower than the preoperative rate. This
demonstrates that long-term (week-toweek) changes in liver blood flow can
readily be measured using galactose
clearance.
One of the requirements of the ideal
method for measuring liver blood flow is
its ability to measure nutrient flow in cir
rhotic livers.1 In an attempt to see how
measurements of liver blood flow would
change after the development of cirrhosis,
11 dogs were subjected to ligation of the
common bile duct to cause secondary
biliary cirrhosis. Galactose clearance and
flow-probe values were determined before
and after ligation. Measurements of
galactose clearance were made weekly,
but, because liver blood flow measure
ment by flow probes requires laparotomy,
it could not be done every week. By 6
weeks, liver blood flow as measured by
the g alactose clearance rate was
significantly decreased from preoperative
values (p = 0.008). At 7 weeks, the dogs
were operated upon again and flow was
measured by galactose clearance and flow
probes. Flow-probe values before and
after ligation were not significantly
changed, suggesting that anatomic liver
blood flow is basically unchanged by
biliary cirrhosis. On the other hand,
galactose clearance rates were significant

FIG. 3—Before ligation of common bile
duct there is no difference between galactose
clearance (broken line) and flow-probe (solid
line) rates; but at reoperation 7 weeks after liga
tion (*), flow-probe value was unchanged,
whereas, galactose clearance rate was markedly
reduced (p = 0.02).

ly decreased after ligation of the common
bile duct, indicating that cirrhosis
significantly decreases nutrient flow even
though the anatomic flow remains*
basically unchanged. This can be readily .
explained by the presence of intrahepatic *
shunting in cirrhosis. This phenomenon^
has been well described in people with
cirrhosis.12 In them, not all the blood 4
entering the liver perfuses hepatocytes;
some blood leaves the liver directly"
through the hepatic veins without perfus
ing hepatocytes. This is known as the *
shunt fraction. Of course, in cirrhosis,
there are also spontaneous extrahepatic
shunts around the liver. This explains the v
concept of nutrient versus anatomic liver
blood flow. Thus, in cirrhotics, nutrient*
liver blood flow is more important than
anatomic flow and galactose clearance is "
a more physiologic measurement and
more valid than flow-probe measure-'
ments. We are currently using galactose
clearance measurements before and after *
distal splenorenal (Warren) shunts as well,,
as in the research evaluation of other pa
tients with various liver diseases. With this *
new method by which to measure liver
blood flow, liver hemodynamics can be*
evaluated and followed over time to see
how different liver diseases or shunts af- *
feet or are affected by changes in liver
blood flow. This can only increase our
understanding of the basic pathophysio
logy and hemodynamics of liver disease.
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Treatment of Intra-abdominal Sepsis
Twenty-three surgeons at three McGill
University hospitals were interviewed
about their treatment of intra-abdominal
sepsis. They described their use of anti
biotics, operative practices and other
treatment of generalized peritonitis and
intra-abdominal abscesses. If more than
7 5 % of respondents used a given
method, its use was considered “ uni
form " unless substantial interhospital
variation existed for that method.
Treatment was variable in 18 situa
tions. Only four of these involved
systemic antibiotic use — drug regimens
in appendicitis and intra-abdominal
abscess, and duration of antibiotic
therapy following appendicitis and per
forated duodenal ulcer. The other 14 ex
amples of variation were in operative
management. In generalized peritonitis,
they were: use of diagnostic paracen
tesis; abdominal lavage with saline alone
versus saline plus antibiotic use; whether
the peritoneum should ever be left open;
the use or avoidance of drains; primary
versus delayed wound closure in appen
dicitis, bowel perforation and trauma
with gastrointestinal perforation and,
finally, wound lavage with saline alone
or with antibiotics. Treatment of intra
abdominal abscesses varied in regard to
the diagnostic and therapeutic roles of
percutaneous needle aspiration, the
preferred route of drainage of a pelvic
abscess, the use of an extra- or transserosal approach to a subphrenic

abscess, local versus full abdominal ex
ploration for a single abscess and the
type of drain used.
The authors conclude that operative
management of intra-abdominal sepsis
varies widely among surgeons. This fact
invalidates many "controlled" trials of
antibiotics and should focus attention
less on drugs and more on surgical treat
ment.
Vingt-trois chirurgiens de trois hopitaux
affilies a I'Universite McGill ont repondu
a un questionnaire portant sur leur facon
de traiter les infections intraabdominales. ils ont decrit leur utilisation
des antibiotiques, leur pratique operatoire
et les autres moyens de traiter les peritonites generalises et les abces intraabdominaux. Quand plus de 75% des
participants utilisaient une meme
mdthode, celle-ci etait consideree comme
"standard", d moins qu'il n'ait existe
des variations inter-hopitaux importantes
pour cette methode.
Les traitements ont varie dans 18
situations cliniques dont 4 seulement
necessitaient ('administration d'antibiotiques par voie generate: les regimes thdrapeutiques utilises dans les cas d'appendicite et d'abc&s intra-abdominale et la
duree de I'antibiotherapie apres une
appendicite ou un ulc&re duodenal perfore. Les 14 autres exemples de varia
tions avaient trait au mode operatoire.
Dans les cas de peritonite generalisee, il
s'agissait de ('utilisation de la paracentese a visee diagnostique, du lavage
abdominal 3 I'aide de solute physiologique par opposition au solute physiologique additionne d'antibiotique. de la deci
sion de laisser ou non le peritoine ouvert
et d'utiliser ou non un drain, de la fermeture de la plaie par premiere ou deuxifeme
intention dans les cas d'appendicite, de
perforation intestinale et de traumatisme
avec perforation gastro-intestinale, et,
finalement du lavage de la plaie avec du
solute physiologique seul ou additionn£
d'antibiotique. Le traitement des abc&s
intra-abdominaux variait par rapport aux
roles diagnostique et th^rapeutique de la
ponction-biopsie, a la meilleure voie de

drainage des abcds pelviens, a I'abord
extra- ou trans-sereux des abces sousdiaphragmatiques a I'eploration abdomi1
nale locale ou complete en presence d'un
absces unique, et au type de drain
*
utilise.
Les auteurs concluent que le traite^
ment chirurgical des sepsies intraabdominales varie considerablement d'un
chirurgien a I'autre. Ce fait rend nulles
,
plusieurs etudes controlees d'antibiotiques et devrait faire porter I'attention
*
davantage sur le traitement chirurgical
que sur les medicaments utilises.
t

General surgeons commonly deal with
intra-abdominal sepsis; they expound the
principles of management, but do they ;
agree on what those principles are?
,,
The purpose of this survey is to iden
tify methods of management of intra- *
abdominal sepsis that differ among
surgeons. Awareness of such variability "*
should influence the design of future
clinical research studies and should alert"
us to issues that are still unresolved ^
despite much collective experience.
Methods

Twenty-three general surgeons at three
McGill University teaching hospitals were '
interviewed, either by telephone or in per
son, by the same author (J.M.A.B.). For *
a variety of clinical situations, each
surgeon was asked to state the frequency
(on a 0 to 5 scale) with which he or she +
used certain diagnostic and therapeutic
From the Department of Surgery,
measures. Some questions were hypotheRoyal Victoria Hospital,
tical in that they involved clinical situa
McGill University, Montreal, PQ
tions never before encountered by the -<
Presented at the 6th annual meeting o f the
surgeon. In such cases, “What do you
Canadian Association o f General Surgeons,
do?” was replaced by “What would you A
Calgary, Alta., Sept. 22, 1983
do?” .
Accepted for publication Nov. 7, 1983
The question referred to either intra
abdominal
abscesses or generalized peri- t
*St. Joseph’s Health Centre,
tonitis (defined as the presence of free pus
University o f Toronto, Toronto, Ont.
or gastrointestinal content in the perito- >
t Royal Victoria Hospital,
neal cavity). Each respondent answered
McGill University, Montreal, PQ
all questions, except for two who decli- * <
ned to discuss trauma because they did
Reprint requests to: Dr. John Bohnen,
not deal with it clinically.
A
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ly considered to be “ variable” or “ not
uniform” if less than 75*% of the surgeons
l_used a similar method in a given situation.
This usually meant that if fewer than 18
^ of 23 surgeons agreed on a certain prac
tice, it was considered not uniform. In
►one case, although 18 surgeons agreed on
a method, the 5 dissenters were from the
A same hospital; treatment in this case was
considered not uniform because of varia
tio n between hospitals.
Questions Related to
Generalized Peritonitis
Surgeons were asked the following
►questions:
• How many and which antibiotics do
r you administer systemically for generaliz
e d peritonitis, secondary to each of per
forated duodenal ulcer, perforated appeny dix and peritonitis secondary to all other
causes; are antibiotics given before, dur* ing or after the operation, and for how
long are they continued postoperatively?
T
• Is paracentesis used to establish a
diagnosis of peritonitis in uncertain cases?
In cases with an obvious clinical diagnosis
^ of generalized peritonitis, what ab
dominal incision is used?
• Are cultures of peritoneal fluid
taken, and how often do reports of
►cultures and sensitivities influence
treatment?
• Do you lavage the peritoneal cavity
before closure and, if so, with what solution? In severe cases is continuous
postoperative lavage ever used or is the
peritoneal cavity ever intentionally left
„ open? What types of drains are left in the
peritoneal cavity, if any?
• In generalized peritonitis associated
with each of perforated duodenal ulcer,
*■perforated appendicitis, trauma with
gastrointestinal perforation and all other
causes, is the wound (skin and subcuta^ neous tissue) left open? Is a drain left in

wounds that are closed? Are wounds
lavaged and, if so, with what solution?
Questions Related to
Intra-abdominal Abscesses
• Which, if any, systemic antibiotics
are administered before, during or after
operative or percutaneous drainage of
intra-abdominal abscesses?
• Is percutaneous aspiration used to
establish a diagnosis of intra-abdominal
abscess? How frequently is percutaneous
drainage the treatment of intra-abdom
inal abscesses, considering all types of
abscesses? Which of the following four
situations are relative indications for per
cutaneous drainage of abscesses: (1)
“ anything the needle can reach” , (2) a pa
tient “ too sick for surgery” , (3) multiple
system organ failure and (4) proximity to
a body wall? Which of the following four
settings are relative contraindications to
percutaneous drainage: (1) multiple
abscesses, (2) abscess between loops of in
testine, (3) need to enter a hollow viscus
with the needle and (4) pelvic abscess?
• What is the best route for operative
drainage of a pelvic abscess in a female,
if the abscess is as accessible through the
rectum as through the vagina? Is an extraserosal route used for operative
drainage of a subphrenic abscess? For a
single abscess seen on computerized ax
ial tomography or ultrasonography, is a
long incision and full exploration used,
or a local incision and drainage? What
type of drain is left in an abscess cavity?
Results
All examples of variation in manage
ment are listed in Table I. When use of
a single antibiotic was stated as a regimen,
it was a cephalosporin in all but one in
stance (ampicillin); when multiple drugs
were mentioned they included an amino

r

Table 1-Aspects of Management that Vary among Surgeons
Description
Duration of administration postoperatively for perforated ulcer,
perforated appendix
►
Regimen for perforated appendix, intra-abdominal abscess
Invasive and operative measures
r
Use of diagnostic paracentesis
Generalized peritonitis
Intraoperative peritoneal lavage solution
r
Delayed closure of peritoneum
Use and type of drains
Delayed wound closure: trauma with gastrointestinal perfora
tion, perforated appendix, other causes of peritonitis
A
Wound lavage solution
Diagnostic percutaneous needle aspiration
Intra abdominal abscesses
Therapeutic percutaneous needle aspiration
Route of drainage for pelvic abscess in a female
A
Operative approach to subphrenic abscess, solitary abdominal
abscess
Type of drain
Aspect
Antibiotics

glycoside and an antianaerobe (clinda
mycin or metronidazole), with the occa
sional addition of ampicillin or penicillin.
Generalized Peritonitis
For peritonitis secondary to perforated
duodenal ulcer, 18 surgeons used a single
antibiotic agent and 5 a multiple-drug
regimen. All but one clinician gave the
drug(s) before making the incision; two
added a dose intraoperatively. The dura
tion of postoperative administration was
variable: 9 surgeons stated that they gave
antibiotics for more than 3 days, 10
surgeons for less than 1 day, and 4 that
they did not use antibiotics postoperative
ly. For perforated appendicitis, 8 re
sponded that they used a single-drug and
15 a multiple-drug regimen. Twenty-two
surgeons gave antibiotics before opera
tion and 2 added a dose during the pro
cedure; 15 said they gave antibiotics post
operatively for more than 3 days and the
rest for less than 1 day. For peritonitis
secondary to all other causes, antibiotic
use was consistent. All but one surgeon
used a multiple-drug regimen, given preoperatively; 2 gave antibiotics during
operation and 18 continued the drugs
more than 3 days postoperatively.
It was the practice of 11 respondents
occasionally to use paracentesis to
establish a diagnosis of peritonitis; the
other 12 did not use the technique. A
midline abdominal incision was favoured
by 18, other approaches by 5. Each
surgeon obtained bacterial cultures of
peritoneal fluid and claimed that treat
ment is influenced in some cases by cul
ture reports.
All 23 surgeons lavaged the peritoneum
— 12 with saline alone, 9 with saline and
a cephalosporin and 2 with saline and
povidone-iodine. Four surgeons said they
used continuous peritoneal lavage post
operatively in severe cases; 19 never used
it. Thirteen respondents did or would
leave the peritoneal cavity open in severe
cases and 10 never did so. Ten surgeons
avoided drains altogether, 6 used Penrose
drains, 5 favoured sump drains and 2
other types.
Delayed primary wound closure was
used by 4 surgeons for perforated
duodenal ulcer; the other 19 generally
closed the wound. Delayed closure was
employed by 14 surgeons dealing with
trauma and gastrointestinal tract perfora
tion, whereas 7 said they closed the
wound. In cases of perforated appendix
and generalized peritonitis due to all other
causes, 18 surgeons left the wound open;
however, all 5 “ closers” were from the
same hospital. This is an example of
nonuniformity in treatment because of
variation between hospitals. Only one
surgeon ever left drains in wounds that
were closed. Nineteen surgeons lavaged
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Intra-abdominal Abscesses
Antibiotics were given as an adjunct to
operative drainage of an abscess by all but
one surgeon; multiple drugs were used by
17 and a single drug by 5. They were ad
ministered pre- and postoperatively in the
great majority.
Percutaneous aspiration of an abscess
for diagnosis was used liberally by 9 sur
geons and never or rarely by 13. Opinions
on the therapeutic use of percutaneous
drainage were quite variable: 11 surgeons
said they would use it for the majority of
abscesses encountered, whereas the rest
would use it rarely or never. For per
cutaneous drainage, only five respondents
accepted the broad indication, “ anything
the needle can reach” . Multiple system
organ failure and “ patient too sick” were
considered to be indications for per
cutaneous drainage in the majority, but
by less than 75% of the surgeons; some
surgeons thought these were the very
situations in which laparotom y is
necessary to avoid overlooking abscesses.
Proximity to a body wall was considered
an indication by 17 of 22 surgeons ask
ed. Multiple abscesses, an interloop
abscess and the need to traverse a hollow
viscus were all seen as contraindications
by more than 75% of the surgeons. Opi
nion was divided on the use of percuta
neous drainage of a pelvic abscess.
Pelvic abscesses were stated to be
operatively drained per rectum by almost
half the surgeons; the rest (13 surgeons)
were divided between a vaginal approach
(6), no preference (5) and abdominal ex
ploration (2). Opinion was divided on
operative management of a subphrenic
abscess: eight said they took great care to
stay outside the peritoneum; six made no
attempt at all and nine used an extraserosal approach only if it was
technically very simple to do so. When
confronted with a single abscess seen on
computerized tomography (and assuming
percutaneous drainage was not performed),
nine surgeons used a full midline incision
and abdominal exploration, nine used a
local incision and drainage and five used
either. Fifteen surgeons preferred to leave
a sump drain in an abscess; the rest were
divided among Penrose (4), sump and
Penrose drains (3) and closed suction (1).

to miss the point. It is evident from the
results that the management of intra
abdominal sepsis differs widely among
surgeons.
Instances of variation, listed in Table
I, can be divided into those concerned
with antibiotic use and those related to
operative or other invasive techniques.
Differences of opinion about antibiotics
concern the importance of those effective
against anaerobes, and the duration of
drug administration. These issues, espe
cially the former, are of great controversy
in the literature.1’2 It is interesting that
there are more instances of differences in
operative measures than in antibiotic use.
Variations in operative management in
volve four broad categories: peritoneal
toilet in generalized peritonitis, wound
lavage and closure, the role of per
cutaneous abscess drainage and the
operative approach to abscesses.
When one realizes that no systemic
antibiotic regimen has ever been proven
superior to another in reducing m ortali
ty in intra-abdominal sepsis, the finding
that operative treatment is more variable
than antibiotic use becomes im portant.
There is too much emphasis on clinical
trials of antibiotics. Although such studies
are easily funded, they have been simply
adding to the long list of acceptable alter
natives in antibiotic therapy. There are
numerous issues related to operative in
tervention that need to be studied and
have been relatively ignored.
Furthermore, the results of this survey
demonstrate that most clinical trials of
antibiotic therapy are scientifically un
sound. Although they are invariably con
trolled in that there is a group receiving
an accepted form of antibiotic therapy,
they are rarely controlled for the
operative procedure. Clinicians would
agree that operation is more im portant
than antibiotics in the treatment of
generalized peritonitis. Therefore, the
trials that abound in the literature are
seldom controlled for the most important
aspect of treatment and thus are of
dubious value.
Let us hope that in future a more
rigorous approach will be applied to the
management of intra-abdominal sepsis.
As for antibiotics, perhaps some drug
regimens are in fact more effective than
others. If this is so, it will be demon
strated by more carefully designed clinical
trials.

Discussion
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15. Roux-en-Y Gastric Bypass
*

y

Thirty patients who underwent Roux-enY gastric bypass operations were followed
A up for 18 to 24 months. All had the
generally accepted preoperative evalua1 tion for morbid obesity, including
psychiatric assessment.
* The volume of the proximal stomach
, pouch, created by the single application
of the TA-90 stapler, did not exceed 50
mL; 4.8-mm staples were used. The con
struction of the stoma was standardized
y-by using the EE A Autostapler (Auto
Suture Co., Div. of United States Surgical
► Corp., Norwalk, Conn.) with the no. 25
head for the gastrojejunal anastomosis,
giving a stomal diameter of 12 mm. The
distal jejunal limb was positioned in front
of the transverse mesocolon.
Heparin was not used routinely, but a
miniheparin regimen was given to patients
y with marked varicose veins or who had
used the birth control pill for a long time.
• Postoperatively, a nasogastric tube
draining both stomach pouch and distal
r jejunal limb was left in position for 3
days. Then the patients were given clear
r fluids up to 60 m L/h by mouth and by
^ postoperative day 6 the patients were tak
ing four high-protein feedings daily of up

From the Department o f Surgery, Victoria
Genera! Hospital, Winnipeg, Man.
Correspondence to: Dr. R.A. James, 203
Edmonton St., Winnipeg, Man. R3C IR5

*

to 90 mL of egg, cheese, fish or minced
chicken, in addition to an hourly fluid in
take of 90 mL of milk or soup, coffee or
tea, during the waking hours. They were
usually discharged 7 days after operation.
Operative and postoperative complica
tions were reviewed. They included blood
loss of more than 500 mL (in four cases),
incidental splenectomy (one), proven
anastomotic leak (one), intra-abdominal
sepsis, including subphrenic abscess
(three), postoperative atelectasis (one),
vomiting (three), epigastric pain (three),
gastric pouch ulcer (two), iron deficien
cy anemia (two), psychological problems
(two), wound dehiscence and late ventral
hernia (one). There were no cases of
thrombophlebitis or pulmonary em
bolism, dumping syndrome or disruption
of the staple line.
Only one of the patients with sepsis
could be shown to have a definite
anastomotic leak on roentgen studies. The
other two had continued pyrexia; one had
a positive culture from the tip of the
drainage tube and the other a positive
blood culture. In all three cases, the in
fecting organism was Bacteroides fragilis,
which was controlled with metronidazole
given intravenously. Of importance was
the occurrence of the positive blood
culture because this patient had received
cefoxitin prophylactically. Metronidazole
was subsequently used prophylactically in
all cases and no further sepsis occurred.
The presence of small symptomatic

gastric pouch ulcers in two patients, pro
ven gastro sco p ically , was a new
phenomenon. These were not anas
tomotic ulcers. They could be due to
relative avascularity of the pouch after
division of the short gastric arteries, but
one has responded to ranitidine, sug
gesting an acid peptic etiology in this case.
The two patients who had psychologic
problems, despite preoperative psychiatric
evaluation, show that psychiatrists are not
necessarily in the best position to give a
meaningful assessment of a patient’s
ability to withstand stressful situations.
An analysis o f weight losses showed
that the initial weight loss was rapid but
slowed markedly at 9 months and virtual
ly levelled off at 12 months, ceasing com
pletely at 18 months. During the period
of the study, the percentage of excess
weight lost ranged from 85% to 61%; no
patient lost more than 50 kg.
It was concluded that the Roux-en-Y
gastric bypass operation is a difficult pro
cedure, accompanied by an appreciable
number of postoperative complications.
It does not appear to be a good opera
tion for those patients who are more than
68 kg over their ideal weight. However,
the operation does not unduly restrict the
quality of life and patients learn to eat
and drink slowly, do not experience recur
rent episodes o f severe vomiting and have
no diarrhea. Long-term deficiency dis
orders appear to be minimal and easily
controlled.

A
A

A
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16. Gastric Bypass in Nova Scotia: an Analysis of 100 Patients <
One hundred patients, ranging in age
from 20 to 61 years, underwent a gastric
bypass procedure for morbid obesity. The
male to female ratio was 1 to 7. Preopera
tive investigations included a complete
biochemical profile, cholecystography,
intravenous pyelography, pulmonary
function tests and electrocardiography.
The operation conformed to the stan
dards set out by M ason.1 Gastric parti
tioning was performed with two rows of
TA-90 staples (4.8 mm) placed across the
stomach from a point 1 cm distal to the
esophagogastric junction on the lesser
curvature to a point on the greater cur
vature that would produce a proximal
gastric pouch of 50-mL volume; the
stoma was no more than 1.2 cm wide.
Prolene, 4-0, was used to reinforce the
stoma in the last 50 patients. The paten
cy of the anastomosis was tested by in
jection of methylene blue dye through a
Levin tube placed close to the stoma. The
distal anastomosis between the horizon
tal and vertical limbs was 40 cm from the
proximal anastomosis. Patients walked
on the day after operation and the
nasogastric tube was removed within 24
hours. Four days after operation, roent
genography with Gastrografin contrast
medium was done before the patient was
started on fluids orally. The average
hospital stay was 9.1 days.

Results
Gallbladder Disease
It has been suggested that with rapid
weight loss bile becomes lithogenic.
Thirty-three patients who had pre-existing
gallbladder disease had cholecystectomy
before (23) or during (10) the gastric
bypass procedure. During the period of

weight loss, symptomatic gallstones
developed in only five patients. Two of
the five were offered medical dissolution
therapy of the gallstones with chenodeoxycholic acid. The gallstones in both
dissolved completely within 3 months and
have not recurred in the succeeding 3
years.

Complications (Table I)
Splenectomy had to be performed dur
ing the bypass procedure in three patients,
early in the study, because of bleeding
from tears of the splenic capsule that
could not be controlled. In the last 75 pa
tients, splenectomy was not necessary.
Anastomotic leakage was not a major
problem. Partial volvulus of the stomach
was seen in one patient and led to the
disruption of staples. She was operated
upon again and the stomach was re
stapled. Four patients with acute in
testinal obstruction were admitted several
months after the operation. The reopera
tion rate was 8%. There were no deaths.
Hypoproteinemia and Anemia
Severe hypoproteinemia and malnutri
tion were present in one patient, who re
quired total parenteral nutrition to bring
the protein levels to normal. One patient
in whom the staple line became disrupted
twice in 6 months had gastritis. Complete
gastric transition and revision of the
Roux-en-Y anastomosis was followed by
full recovery.

T a b le 1— C o m p lic a t io n s
C o m p lic a tio n

t Head, Division o f Gastroenterology,
Dalhousie University, Halifax, N S
Reprint requests to: Dr. S. V. Anand,
Clinical Research Centre, 5849 University
A ve., Halifax, N S B3H 1W2
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Patients were seen every month after
!
the operation for the first 3 months; at +
6 months and 1 year they were contacted
\
by phone, letter or by their family doc- 5
tor. A questionnaire was mailed to every
j
patient; 86 replied. Ninety-two percent of ^
the responders replied positively to the
question, “ Are you satisfied with the K j
operation and your weight loss?” . The
negative responses o f seven patients did *
not correlate with their weight loss. The v
average weight loss is noted in Table II.
The weight loss is most notable in the
^
first 12 months following the operation
j
and then levels off at 2 years. Substan
tial weight loss continued up to 2 years
because of frequent follow-up, which inj
creased compliance with dietary and ex- ^
ercise programs. Body mass index, which
is a mathematical expression of ideal body ■»
weight, was used to assess the result in
each patient. In the analysis of the first
4
25 patients more than 2 years after opera|
tion, only 5 showed a decrease of body 1 l
mass index of less than 25%. They were
\
older patients; all were women. These are
regarded as failures, although some of the ,
medical problems have been alleviated by
the operation.
t
Weight loss can be predicted if patients
]
are properly selected. It is difficult to '
;
achieve ideal body weight following
!
operation, but if the criterion for a good "*
result is a 25% decrease in body mass ini
dex, then 94% could be classified as hav
ing achieved a good result from gastric <
bypass in our series.
Adaptation to an entirely new life-style
following weight loss is difficult; gastric
operations for morbid obesity should be -«

No.

O p e r a tiv e
S p le n e c t o m y

T a b le I I — A v e r a g e W e ig h t Loss

3

E a rly p o s t o p e r a tiv e

*Surgeon, Valley Health Services,
Kentville, N S

Follow-up

Leakage

1

T im e a f t e r

N o . of

W e ig h t

o p e r a t io n , m o

p a t ie n t s

lo s s , %

O b s t r u c t io n

1

1 -3

9

1 1 .9

R e a d m is s io n f o r v o m itin g

6

3 -6

11

2 4 .1

S u b p h re n ic a b s c e s s

1

6 -1 2

11

3 4 .0

W o u n d in f e c tio n

4

1 2 -2 4

38

3 7 .0

P n e u m o n ia a n d a te le c t a s is

2

2 4 -3 6

21

3 1 .4

V o lv u lu s o f s to m a c h

1

10

4 1 .3
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only a part of an integrated program.
Moen (unpublished data, 1983) followed
►up 650 patients and stressed the impor
tance of preoperative evaluation, postoperative follow-up and counselling on bi
-monthly visits for the first year. Total
rehabilitation requires nutritional gui-

dance, a properly directed exercise pro
gram, and family support while the
patient is making mental, emotional and
sexual adjustments. Reconstructive sur
gery, namely panniculectomy, and thigh,
arm and hip reduction are needed in the
long-term management.

We thank Drs. R.H. Burnett and D.A.
Pyne, Kentville, for assisting in the operations
and care of the patients and Professor Bernard
Perey for help in preparing the material.
R eferen ce
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17. Recent Gastroplasty Experience in Saskatchewan

»■

The purpose of this review was to assess
two gastroplasty procedures used in
Saskatoon and Regina over 2 years. The
* patients were initially assessed by a
multidisciplinary team. The selection
^ criteria were those commonly used (i.e.,
*the patient was 45 kg or more over ideal
weight, with endogenous obesity, no conj traindications to operation and a satisfac
tory result from psychiatric assessment).
The patient had to understand the opera
tion and show a willingness to cooperate
'-fully.
Psychosocial assessment was done to
y eliminate severely disturbed patients. The
psychosocial outcome may be improved
by maintaining postoperative contact. A
w questionnaire, using the Hopkins Symp
tom Checklist1 as well as a self-concept
y
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and self-rating scale, was used. The ideal
patient had stable home relationships, a
high-school education or better, a history
of juvenile obesity, a reasonable selfimage, was reasonably adjusted psychosocially and had no history of serious
psychiatric problems.
The dietitian made a 7-day food record
preoperatively and during the postopera
tive phase. Stage I feedings were com
posed of Sustacal (Mead Johnson Can
ada, Candiac, PQ), providing 4000 kJ
and 57 g of protein plus vitamins, given
through the gastrostomy. The patient
then progressed until at 3 to 4 weeks
postoperatively the diet was a pureed one
supplying 3360 kJ and 57 g protein. The
final stage III diet comprised a variety of
foods, providing 3360 to 4200 kJ and 60
g of protein depending on the patient’s
needs. Patients tolerated fish and chicken
but could not ingest other meats for some
time. There were many idiosyncratic
deviations from the diet, including denial
of food and such oddities as drinking 1.5
L of wine to acquire an adequate iron in
take and eating 2 kg of peanut butter in
10 days to replenish potassium lost in

FIG. 1—Outcome of double-stapled horizontal gastroplasties in
Regina (squares = type I, circles = type II, equivalent to Saskatoon
type IV).

vomiting! It was not uncommon for pa
tients to modify their dietary regimen by
eating once a day. Continuing review of
the patient by the dietitian is essential for
long-term success.
Preoperative work-up was routine and
included measurement of serum trigly
ceride levels, pulmonary function studies
and ultrasonography of the gallbladder.
Respiratory insufficiency was not a con
traindication; several patients showed
marked improvement of respiratory func
tion following substantial weight loss.
Two operations were performed. One
was the double-stapled horizontal gas
troplasty with an opening towards the
lesser curvature, produced by removing
three staples and reinforcing the stoma
with nonabsorbable sutures using the
technique suggested by Gomez.1 The
other was the Mason2 vertical banded
gastroplasty with a Marlex circumferen
tial band.
The demographic data regarding the
two gastroplasty groups in Regina and
Saskatoon were essentially the same
(Table I).

FIG. 2 —Outcome o f double-stapled horizontal (squares = type IV)
and vertical banded (circles) gastroplasties in Saskatoon,
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Complications

tion. Secondary closure did not work
well. In the Regina group, where anti
biotics were routinely given prophylacti
cally, there were only two wound infec
tions (6.2%).

Two cases o f thromboembolism occur
red among the 44 patients in whom
heparin was not given prophylactically.
These were not serious and heparin pro
phylaxis was not used without definite
indications.
There was a high wound infection rate
in the Saskatoon group despite the use of
Jackson P ratt drains and wound irriga

Results
Several patients in the Regina group
had considerable weight loss. All under
went a standard double-staple-line

Tab le 1- Dem ographic Dat a
Group
Characteristic
Men
Women
Age, yr
Mean
Range
Preoperative w ei gh t, kg
Mean
Range
Operative procedure
Mason vert ical banded
Horizontal gastroplasty

Sas katoon,
n - 28

Regina,
n - 32

6
22

5
27

36
18 -5 5

38
1 9 -5 5

144
8 5 -1 9 1

125
90 -1 8 0
2*
31

16
12

* 1 patient reoperated on.

Table II— Results of Gastroplasty at 6 and 1 2 M o n t h s *
Weight, kg
Weight at
Patient
no.
1

2
3
4
5
6
7
8
9
10
11
12

Age,
Sex

yr

Preop

Ideal

+ 30%
ideal

M
F
M
F
F
F
F
F
F
F
F
F

40
34
32
28
34
51
31
33
34
30
34
33

175
85
183
166
136
131
179
125
172
125
128
185

85
55
80
65
57
70
70
67
54
50
65
65

11 0.5
71 .5
10 4.0
84 .5
74 .0
9 1 .0
91 .0
87 .0
70 .0
6 5 .0
8 4 .5
8 4 .5

“ Excellent result * within 3 0 % of ideal weight.

6 mo
134
56
112
94
93
—

142
86
122
89
95
125

12 mo
(% of ideal)
10 2(1 20.0)
-(1 0 1 .8 )
81 ( 1 0 1 . 2 )
84(12 9.2)
91 ( 1 5 9 . 6 )
10 4(1 48.5)
13 0(1 85.7)
83 (1 2 3 .8 )
10 5(1 94.4)
8 3 (16 6.0)
87 (1 3 3 .8 )
11 4(1 75.4)

gastroplasty with a reinforced stoma. By
12 months, the mean weight loss was 26%
of preoperative weight (Fig. 1). This ^
operation has been abandoned in favour
of the Mason vertical banded gastroplas- ^
ty. In the Saskatoon group, where the ver
tical banded gastroplasty and the double- ^
stapled horizontal gastroplasty were
assessed, there was a more consistent
weight loss of 35% of body weight at 12
months (Fig. 2). The details of each p a - 1
tient are important in assessing the overall „
effect of the gastroplasty. A weight loss
to within 30% of ideal weight at 1 years
is considered an excellent result. As seen
in Table II, five patients were within this A
range and a sixth very close to it. Never
theless, it should be noted that patient no.
9, weighing 172 kg preoperatively, had
lost 67 kg in 1 year and, although still
weighing 194% of ideal weight, had subjectively attained a satisfactory result.
Late complications included a readmis- ^
sion for vomiting (nine patients), reopera
tion for stomal obstruction (three pa- *
tients) and esophageal stricture (one pa
tient), which was treated with bougienage. ^
Two patients became pregnant; it is im- k
portant to remind women that, during
weight loss, menstruation may be ir- ^
regular and contraceptive precautions
must be taken in order to avoid pregnan
cy. Six patients had abdominoplasty. One
patient committed suicide; in retrospect,
this was due to a lack of appreciation of
the depth of her previous psychiatric *
problems.
Of 60 cases from Saskatchewan, both
the horizontal double-stapled and the vertical banded gastroplasty performed well
and provided satisfactory weight loss at
1 year. Currently, both centres are using
the vertical banded gastroplasty. A stand- *
ardized form of reporting results is nec
essary in order to compile comparable"'
data on a national basis.
References
1. GOMEZ CA: Gastroplasty in morbid obesity. Surg Clin
North A m 1979; 59: 1113-20
2. Mason EE: Vertical banded gastroplasty for obesity. Arch
Surg 1982; 117: 701-6
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18. Use of Marlex in Horizontal G astroplasty

►

Between September 1979 and October
^1982, 162 obese patients were operated
on. All had a transverse gastroplasty pro> viding a gastric pouch volume of less than
100 mL and a stoma on the greater cur
v a tu r e wrapped by a 2 x 6-cm strip of
polypropylene mesh (Marlex; Bard Im*■ plants, Billerica, Mass.). Two staple lines
^ were used in 152 patients. The mean pa
tient weight preoperatively was 134 kg
y
and the mean age was 36 years. The mean
weight loss at 6 months for all patients
; was 32 kg or 24% of body weight. At 1
year, weight loss for 113 patients was
4 33% of body weight (44 kg). Weight loss
at 18 months for 75 patients was 35% of
"'body weight (47 kg) and at 24 months for
^ 51 patients was 33% of body weight.
Although the average weight loss was
quite good, the failure rate did increase
with time. If one regards failure as a loss
*_of less than 25% of body weight, then the
From the Department o f Surgery,
University o f Western Ontario,
YLondon, Ont.

v
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failure rates at 1 and 2 years were 14%
and 30%, respectively. If failure is re
garded as weight loss less than 15% of
body weight, then the failure rate at 1 year
was 4% and at 2 years 20%.
There were no deaths attributable to
the operation for obesity. There was on
ly one leak, successfully treated by
removal of the Marlex mesh and
drainage. Other major complications in
cluded liver abscess, which was drained,
and arterial embolism that required embolectomy. Ten patients had cholecystec
tomy and 5 splenectomy. The major
postoperative problem related to Marlex
mesh is obstruction. Five had early
obstruction requiring reoperation by gastrogastrostomy. In one patient, this led
to a return to preoperative weight. The
others have been followed up for 1 year
and have maintained their weight loss,
although it is likely that they will regain
their weight. Possible causes of obstruc
tion include fibrosis under the Marlex
mesh, erosion of the Marlex mesh, tor
sion of the stomach with adherence of the
mesh to pancreas behind or liver in front
and stomal ulceration. Men seemed more
prone to early obstruction than women.
Four patients had late obstruction 1 to 3

years after operation. All required
gastrogastrostomy. In one case, the
Marlex mesh eroded into the lumen of the
stomach after 3 years. Two of the four
have maintained the weight loss but the
other two have begun to gain weight slow
ly. I would now recommend revision by
Roux-en-Y gastroenterostomy rather than
gastrogastrostomy. In many cases, post
operative upper gastrointestinal films
showed marked enlargement of the fundal pouch and this may be a factor in late
weight gain.
Transverse gastroplasty with Marlex
mesh can be done quickly and safely. In
itial weight loss is gratifying. Careful
follow-up with encouragement is essen
tial and may contribute to good early
results. The findings on long-term follow
up reveal pouch enlargement and a return
to old eating habits with late weight gain.
There is also a low but notable frequen
cy of obstruction of the greater curvature
stoma related to the use of Marlex mesh.
This risk may persist over many years.
The Roux-en-Y type of gastric bypass and
the vertical banded gastroplasty of Mason
may be better operative procedures for
obesity.

v
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19. Vertical Banded G astroplasty
y
Forty vertical banded gastroplasties with
_ feeding jejunostomies were performed in
13 months. This procedure is technically
► easier than gastric bypass and other par
titioning procedures. The operating time
Gs shorter, early postoperative morbidity
is minimal and the patient is usually
> discharged 5 days after operation. Weight
, loss of 23 patients followed up for 6

A From the Department o f Surgery,
University o f Ottawa, Ottawa, Ont.
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months was 33.8 kg (range from 17.3 to
51.0 kg) or 26.6% of preoperative body
weight (range from 7.5% to 37.7%). At
12 months, mean weight loss was 39.9 kg
(range from 31.4 to 57.0 kg) or 31.8% of
preoperative body weight (range from
24.0% to 46.1%). Contrast films of the
pouch were obtained in all patients before
discharge and at 6 months. Nine patients
had transient stomal obstruction due to
edema or impacted food. All were
managed conservatively by endoscopic
dilatation and total parenteral nutrition
or home enteral feeding; no operative
revisions were required. The value of
routine feeding jejunostomy cannot be

overemphasized. Weight loss in three pa
tients levelled off at 1 year. The staple line
was disrupted in three patients but
without an adverse effect on weight loss.
Roentgenograms at 6 months suggested
that the stoma or pouch had dilated in at
least three patients.
Weight loss with vertical banded
gastroplasty is greater than with other
gastric partitioning procedures but even
at 1 year there are suggestions that the
operation is less than perfect and longer
follow-up is required. Of note is the ab
sence o f any early (i.e., less than 12
months) failures in contrast to other gas
troplasty techniques.
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20. Preventing Dilatation of the Gastroplasty Stoma:
a Canine Model
Current gastric partitioning procedures
are based on the creation of a small,
proximal gastric pouch that limits the
amount of food that can be ingested at
any time. The rationale is early satiety
combined with slow gastric emptying.
The commonest cause of technical failure
in gastroplasty is dilatation of the gastrogastrostomy.
The purpose of the present study was
to determine which of two methods of ex
ternal reinforcement might safely and ef
fectively prevent dilatation of the
gastroplasty stoma.
Eighteen gastroplasties were performed
in dogs. The following steps were carried
out in all animals: general anesthesia with
endotracheal intubation, midline incision,
mobilization of the esophagogastric junc
tion, a proximal horizontal pouch of
30-mL volume, calibration of the greater
curve gastrogastrostomy with a no. 14
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French Levin tube, application of a dou
ble row of staples with the TA-55 stapl
ing instrument, using 4.8-mm cartridges,
dividing the proximal reservoir from the
distal pouch, and a feeding jejunostomy.
Group 1 (nine dogs) had a 4 x 1-cm
long strip of Marlex mesh wrapped
around the greater curvature of the
stomach at the gastrogastrostomy and in
corporated into the staple lines. In group
2 (nine dogs), the Marlex mesh was not
stapled, but held in place with throughand-through horizontal mattress sutures
placed as closely as possible to the naso
gastric tube.
All animals were weighed preoperatively and daily thereafter. Food intake (oral
ly or by feeding tube) was measured and
controlled daily. Morbidity and mortali
ty were monitored, and autopsies were
done in animals dying during the 6-month
observation period. At 6 months, all sur
viving animals were killed. The proximal
reservoir was examined and the stoma
was calibrated and compared with
operative values.
Two group 1 and six group 2 dogs sur
vived 6 months. Autopsy showed that the
Marlex lay free but embedded on the
anterior or posterior aspects of the
gastrogastrostomy stoma, the stoma

Z.Y. A l -H a l e e s ,

m d , fr c sic j ;

width varied from three to five no. 14i
French nasogastric tube diameters, the
staple lines were disrupted with loose
staples on the exterior of the stomach or
lying clumped together on the inside of'*
the dilated stoma. No difference could be
detected between the stoma size and the
reinforcement procedure used. In spite of -*
this, there was a mean weight loss of 4 kg.
Deaths were divided into immediate,
early and late. Three immediate deaths •
occurred in the operating room and were
related to unrecognized pneumothorax.
In group 1, three dogs died of anasto
motic leaks within the first 9 days. This k
accounts for the smaller number of dogs
that survived in this group. The three late
deaths were unexpected, occurring at 4,
6 and 12 weeks. Autopsy revealed that the
stoma was intact in all cases and minimal- ^
ly dilated to the diameter of two
nasogastric tubes.
Both forms of external reinforcement ,
proved unsatisfactory: the sutured mesh
because of disrupted staples and a dilated
stoma, and the stapled mesh for the same
reasons and because of anastomotic leaks. «
The long-term control of the size of the
gastric outlet is an unresolved problem
and requires further research.

J.B . F r e e m a n , m d , c m , frcsicj

21. Nonoperative Management of Stomal Stenosis after
Gastric Partitioning
Over a 4-year period, 157 patients under
went gastric partitioning procedures for
morbid obesity. Stomal stenosis, defined
From the Division o f Genera! Surgery,
University o f Ottawa, Ottawa General
Hospital, Ottawa, Ont.
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as an inability to drink fluids or to
swallow saliva, or both, developed in 10
patients (6.4%). All were managed con
servatively in hospital or as outpatients.
Management consisted of endoscopy to
evaluate the stoma, with or without
dilatation using Eder-Puestow dilators,
and long-term enteral nutrition through
a feeding jejunostomy. Seven patients had
the stoma dilated, for a total of 18 dilata
tions. Three patients required three to six

dilatations each, up to the maximum size -*
(no. 45 French). All dilatations were done
under fluoroscopic control with local
anesthesia and intravenous ValiumDemerol sedation, followed by contrast *
studies. There were no complications.
Three m alnourished patients were
repleted by a combination of parenteral *
and enteral nutrition. They required
reinsertion of the jejunostomy as a
separate procedure. This permitted
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discharge from hospital and enteral nutri
tion at home.
Patients were followed up from 4 to 24
months. Nine patients did well and re
quired no further treatment. Two patients

J.A . P a l m e r ,

actually returned to weights 20% over
ideal. Our data indicate that reoperation
is seldom needed no matter how severe
the stenosis. Long-term outpatient enteral
feeding is valuable, since the temptation

to operate is much greater if the patient
is in hospital. Insertion of a feeding jejunostomy, even as a separate procedure,
permits treatment at home and temporization of reoperation.
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22. Treatm ent of Morbid Obesity by G astric Partitioning
We carried out a retrospective study of
251 patients (208 women, 43 men), who
underwent transverse gastric partitioning
from 1978 to 1982, in an attempt to deter
mine the risks and benefits of this pro
cedure in the treatment of morbid obesi
ty. The median age was 36 years (range
from 16 to 62 years). The operation perFrom the *Department o f Surgery and
tDivision o f Endocrinology-Metabolism,
Toronto General Hospital, Toronto, Ont.
Reprint requests to: Dr. L.E. Rotstein,
Mulock-Larkin Wing, First Floor,
Rm. 0-50, Toronto General Hospital, 101
College St., Toronto, Ont. MSG 1L7

formed on the first 51 patients (1978 to
1979) was evolving, but it consisted
basically of the placement of a single row
of staples and various treatments of the
stoma (group 1). Complications in all pa
tients are listed in Table I. Follow-up for
this group was 3 to 4 years. There were
two late deaths, 3 patients were lost to
follow-up and 10 underwent reoperation.
Only 13 patients lost 30% of their
preoperative weight and only 8 have been
able to maintain a loss of 15% to 25%
(mean 18%) at 3 to 4 years. The remain
ing 200 patients (1979 to 1982) had a stan
d ard m odification o f the Gomez
transverse gastroplasty with a double row

Table 1—Complications in 251 Patients Who Underwent 298 Operations*
Type of
No. requiring
reoperation (no.)
reoperation
No. (%|
Complication
Dilatation (15)
40(161
31
Stenosis
Gastrogastrostomy (14)
Reversal (2)
Laparotomy and drainage (12)
18(7.2)
18
Gastric leak
Percutaneous drainage (6)
2
Wound infection
21 (8.3)
17(6.7)
Incisional hernia
5(2.0)
It
Bleeding requiring splenectomy
1
1 (0.4)
Evisceration
Miscellaneous
1
Gastrocutaneous fistula
1 (0.4)
1
1 10.4)
Small bowel obstruction
*2 patients died.
tReoperation required because of Marlex erosion of the splenic artery.

of staples and Prolene reinforcement of
the greater curvature stoma (group 2). In
group 2, major complications included a
gastric leak or subphrenic abscess, or
both, in 18 patients (7.2%) and delay in
pouch emptying requiring reoperation in
25 patients (10%). We had better success
in this group; 8 of 26 patients followed
up for 3 years sustained weight loss of
30% or more. Maximal weight loss oc
curred at 12 months, being 32% ± 13.1%
of preoperative weight (73 patients) and
there was a gradual weight gain, so that
at 3 years the mean weight decrease was
only 19.7% ± 13.6% of preoperative
weight (26 patients). This weight gain was
thought to be caused by enlargement of
the stoma as well as adaptation o f pouch
size and disruption of the staple line.
Since November 1982, transverse
gastroplasty has been abandoned in
favour of the vertical banded gastroplas
ty. Thirteen patients have undergone the
procedure and although follow-up is
short, the results are encouraging. Only
one patient suffered a complication
(minor gastrointestinal bleeding) and
there have been no leaks or obstructions.
Postoperative recovery is rapid and
3-month weight loss is comparable to that
seen in our group 2. A satisfactory
operative procedure for morbid obesity
has yet to be found and will require con
tinued, careful monitoring of results of
any future procedures or modifications.
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23. Weight Loss following Horizontal Gastroplasty
with Rigid Stoma and Variable Pouch Size:
Comparison with Intestinal Bypass
Between October 1979 and November
1981, 126 gastroplasties were performed.
Pouches and stomas were constructed as
described previously.1 Stomas were con
structed by a standard technique and
pouch volumes ranged from 60 mL to 25
mL. All patients were followed up for at
least 500 days. Follow-up was longest for
the patients having 60-mL pouches and
shortest for those having 25-mL pouches
(Table I), because the larger pouches were
constructed in the first patients operated
upon and pouch size was decreased in
subsequent groups.
The mean final weight loss was
approximately 60% of excess weight for
all pouch sizes (Table II). Weight loss
varied extensively, indicating that some
patients lost a minimal amount of weight
while others lost enough to reach their
ideal weight. Unfortunately, in almost all
instances, final mean weight loss was less
notable, being almost 10% less than the
lowest weights recorded and in some,
weight returned to preoperative levels.
Nevertheless, a substantial number of pa

From the Department o f Surgery,
University o f Alberta, Edmonton, Alta.

tients achieved and maintained satisfac
tory weight loss throughout the follow
up period. Table III shows the results if
all patients who lost less than 40% of ex
cess weight are excluded. These patients
are failures. The mean greatest weight loss
in the remaining patients is nearly 70%
of excess weight. The tendency for these
patients to regain weight is appreciably
smaller than for patients in the failure
group. Unfortunately, the failure rate
(Table IV) must be accepted as represen
tative of the results of the horizontal
gastroplasty procedure. Certainly, the
failure rate for the 60-, 50- and 40-mL
pouch volumes is unacceptable and may

Table II--Gastroplasty: Overall Excess Weight Loss (%)
Pouch size, mL
Excess
weight loss
Greatest loss
Mean
Range
Final loss
Mean
Range

Correspondence to: Dr. P.A. Salmon,
Department o f Surgery, Clinical Sciences
Building, University o f Alberta, Edmonton,
Alta. T6G2G3

Table -Gastroplasty: Follow-up
Pouch
Postoperative
volume, mL
days, range
60
747-1272
50
921-1215
40
753-969
30
624-811
25
502-739

Table IV--Gastroplasty Failure Rate
Pouch
Failure, %
volume, mL
43
60
33
50
44
40
27
30
25
23
234

indicate that smaller pouches are more ef
ficacious. However, patients with
pouches of 30- and 25-mL volumes have
not been followed up for sufficient time
and a definitive statement of the efficacy
of smaller pouches is still pending.
In this institution, the only other weight
loss procedure routinely used at the time
of this study was intestinal bypass.2
Table V shows mean excess weight loss
in 106 such patients. The mean greatest
and final losses of excess weight for the
overall group are much better than for
horizontal gastroplasty. There is still some
tendency for slight weight gain after
lowest weight is achieved; nevertheless, a

60
(n = 15)

50
(n = 27)

40
(n = 32)

30
In - 22)

25
(n = 30)

59
16-100

61
22-86

59
29-93

64
34-105

65
28-104

50
11-94

51
9-81

42
-1-93

56
26-93

59
10-101

Table III—Gastroplasty: Excess Weight Loss (%) Results,
Excluding Failures (Less Than 40% Final Excess Weight Loss)
Pouch size, mL
Excess
weight loss
Greatest loss
Mean
Range
Final loss
Mean
Range

Weight loss
Mean greatest
weight loss
Mean final
weight loss

60
(n - 8)

50
In - 18)

40
(n = 18)

30
In - 16)

25
In - 23)

76
52-100

69
50-86

64
40-93

70
44-105

71
45-104

70
42-94

63
40-88

57
40-93

64
44-93

69
40-101

Table V-Intestinal Bypass: Mean Excess Weight Loss (%)
Year of operation
1976-77
1978
1979
In - 28)
In - 23)
In = 34)

1980-82
In - 21)

78

87

86

84

65

77

79

79
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much greater loss of weight is maintained
over a much longer time. Only 1 of the
^ 106 patients was a weight-loss failure.
Horizontal gastroplasty has not provf ed to be entirely satisfactory. Overall
weight loss has not been uniform or as
^ profound as that achieved after intestinal

bypass and the failure rate is unacceptably
high. Patients with pouch volumes rang
ing from 60 mL to 25 mL did not have
appreciably different mean losses of ex
cess weight. However, the failure rate in
patients with 30- and 25-mL pouches was
much lower.
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24. Surgery for Morbid Obesity: the Size of the
Gastric Pouch versus the Size of the G astric Stom a
Controversy exists as to whether the size
of the gastric pouch or the gastric stoma
is the important factor in successful
4 weight loss after gastroplasty.1’3
We studied gastric stoma size in pa
tients who had undergone a gastrogastrot stomy for morbid obesity.

q

Patients and Methods

;
,

Fifteen patients with morbid obesity
underwent a gastroplasty and gastrogastrostomy with a pouch volume of 150 to
;
200 mL. The gastroplasty was done by
y applying the TA-90 stapler twice so that
i v four rows of staples separated the proxi
imal gastric pouch from the distal
,,
stomach. Then, a gastrogastrostomy was
l,
fashioned in two layers over a no. 16
f nasogastric tube. A gastrostomy was also
done in all patients. Follow-up was at
k least 8 months. All patients were seen at
» least once a month. Weight loss was
j * measured, dietary intake recorded and
esophagogastroscopy carried out to assess
ii
the stoma size. Initially, an Olympus Q
* gastroscope (Olympus Corp. of America,
!
New Hyde Park, NY) with a tip diamer ter of 11 mm was used, but in the last
j
seven patients an Olympus XQ gastro4 scope with a tip size of 9.5 mm was used.

Results

Discussion

In 10 patients the diameter of the stoma
was between 4 and 6 mm and remained
so throughout the 8-month assessment
period (Fig. 1). Two patients initially had
a satisfactory stoma size of about 5 mm,
but the stoma size increased so that at 8
months it was greater than 10 mm. Three
patients had a stoma size greater than 10
mm in the immediate postoperative
period and this increased so that at 8
months it was between 12 and 14 mm.
Fig. 2 correlates weight loss with stoma
size. In the patients who had a stoma size
between 4 and 6 mm, weight loss was
satisfactory and was at least 25% of the
preoperative weight at the 8-month
follow-up. However, in the patients who
had a stoma size of 10 mm or more,
weight loss was unsatisfactory.

Although this is a small series, it does
demonstrate the importance of stoma size
in maintaining adequate weight loss. The
patients whose stoma was between 4 and
6 mm in diameter and did not increase
throughout the follow-up had adequate
weight loss. Once the stoma was 10 mm
or more, weight loss became unsatisfac
tory.

1. GOMEZ CA: Gastroplasty in the surgical treatment o f mor
bid obesity. A m J Clin N utr 1980; 33(2 suppl): 406-15
2. Mason EE, P rinten KJ, Blom m ers T J, L ew is JW,
SCOTT DH: Gastric bypass in morbid obesity. Ibid:
395-405
3. Kirkpatrick JR, Siegel T: Critical determinants o f a
successful gastric bypass: reservoir versus stoma. A m J
Gastroenterol 1982; 77: 464-6

FIG. I—Stoma size in 15 patients with
gastroplasty and gastrogastrostomy.

FIG. 2—Relation between stoma size and
weight loss.
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25. Results of Horizontal Gastroplasty
Over a 4-year period, 172 patients under
went horizontal gastroplasty, 7 patients
in 1979, 50 in 1980, 41 in 1981 and 74 in
1982.
Comparison was made by year with
respect to success or failure. The failures
included those with unsatisfactory weight
loss (less than 20% of preoperative
weight) and those lost to follow-up. The
percentage of successful cases rose from
36% in 1980 to 83.7% in 1982.
Complications of the procedure con
sisted of incisional hernia, bleeding re
quiring splenectomy, fistula, stomal
obstruction and wound disruption.
The improvement in our success rate
was due primarily to two factors: (a) a
From the Department o f Surgery,
Scarborough Centenary Hospital,
Westhill, Ont.
Correspondence to: Dr. J.D. Salmon,
Department o f Surgery, Scarborough
Centenary Hospital, 2867 Ellesmere Rd.,
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change in surgical technique and (b) the
formation of a gastroplasty clinic.
From 1979 to the middle of 1981, the
stoma on the greater curvature side of the
stomach was unsupported. Then we
modified the procedure as follows: (a) 2-0
silk was used as a seromuscular stoma
suture, (b) 2-0 silk was used to oversew
the staple line and (c) we inserted a no.
20 Foley catheter through the stoma,
which was 9 mm in diameter, thus
preventing stenosis.
The gastroplasty clinic was formed to
provide directed, supportive group discus
sions that would enable patients having
undergone gastroplasty surgery to achieve
the desired weight reduction. To that end,
we help patients to attain and maintain
long-term weight loss goals by providing
emotional support and information that
will assist them in making a change in life
style and attitude towards food. An up
dated progress record is kept on each pa
tient. We try to expand the patient’s

knowledge regarding gastroplasty and
provide written information to help the,
patient understand the surgery and thel
diet.
All patients are required to attend tha
clinic before operation. The public healtl'
nurse visits the patient at home and com
pletes an assessment. The dietitian ex
plains the various stages of the postsurgical diet that the patient must adhere to
for life to ensure success of the surgery.
The physiotherapist introduces patients to l.
the “ incentive spirometer” and deep
breathing exercises that they must per
form postoperatively. The surgical nurse
provides the patient with literature ex
plaining the surgical procedure and the
,
diet.
After operation, the patient attends the
clinic four times a month, twice to receive
dietary instructions and education on nu
trition, once for exercise classes and once
for an educational class that includes
movies, lectures and fashion shows.

1

1
SESAP IV Critique
ITEM 16
The serious complications of gastric bypass are perioperative, and of these, leakage from the
gastrojejunal anastomosis has been the worst. The diagnosis has proved elusive, and may be
heralded only by early unexplained tachycardia. Failure to establish the diagnosis and to in
stitute proper management has been almost uniformly lethal. Hepatic failure, urolithiasis, in
testinal pseudo-obstruction, and hypocalcemia are all well-known complications of jejunoileal
rather than gastric bypass.

m
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26. Selection of Patients for Gastric Partitioning
[The criteria for selection of patients for
gastric partitioning consists of four parts:
jirst, a history, which documents the
lilure of exhaustive conservative regij o m the St. Joseph’s Health Centre,
foronto, Ont.
Correspondence to: Dr. M. Deitel,
Associate Professor o f Surgery, University
\ f Toronto, St. Joseph’s Health Centre
Research Foundation, 30 The Queensway,
Toronto, Ont. M6R 1B5

mens over many years and includes infor
mation from the referring doctor(s); se
cond, a thorough outline of the patient’s
complaints (both physical and
psychological) regarding obesity; third, a
physical examination, verifying the degree
of obesity and related physical effects,
supplemented by assessment of surgical
risk, indicated blood work and further
consultations; finally, an explanation of
the procedure, including discussion of the
hazards, as informed consent, with the

spouse or close relatives present. The pa
tient fills out a form (Fig. 1) before enter
ing the consulting room. The form is
clarified and enlarged further by discus
sion with the surgeon. The form serves
as a medicolegal document, in the pa
tient’s own handwriting. A diagram of
the procedure is drawn on the form while
the procedure is explained to the patient,
and again serves as a record. The form
evokes and covers intricately the criteria
for operation.

4
OBESITY HISTORY

♦

' long overweight? _

4 •*
sig h t lo*» c lin ic s Attended
Other problems - d ie t

folds; between thighs
tended for weight

Fig. la

Fig. lb

FIG. 1—(a) First page of form, which facilitates interview and documents all modalities of weight loss tried, (b) Second page, on which
rpatient describes effects of obesity, (c) Explanatory diagram drawn on back of second page (upside-down, because surgeon comes around desk,
so diagram will face patient).
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27. Horizontal Gastric Partitioning for Morbid Obesity
, After performing jejunoileal bypass

V ^operations with satisfactory results in 65
■ patients,1 we switched to the horizontal
,/
■
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gastroplasty with a tiny upper gastric
pouch. It was carried out on 202 patients.
The first 56 patients had a nonreinforced
channel, in 6 others the channel was later
reinforced, and 140 patients had rein
forcement of the greater curvature chan
nel at time of gastroplasty, by a cir
cumferential imbricating Prolene suture
about a no. 36 French Maloney bougie.
With nonreinforced horizontal gas

troplasty, mean weight loss at 12 months
was 21.1% of the preoperative weight, at
24 months 22.0% and at 36 months
23.2%. Mean body mass index (kg/m2)
fell from 44.2 to 33.9; eight patients have
been lost to follow-up.
In the six additional patients with a
nonreinforced channel who were failures,
reinforcement with Prolene suture was
performed 18 to 24 months later. These
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patients had had a mean weight loss at 12
months o f 16.5% and at 18 months three
patients weighed the same as they did
preoperatively. Mean weight loss (com
pared to the preoperative weight) at 36
months after the reinforcement was
20.0%, the body mass index falling from
44.5 to 32.3 (two patients lost to follow
up). The weight loss following the later
reinforcement was not satisfactory, ex
cept in one patient who had reinforce
ment by a Marlex-mesh collar.
In the 140 patients who had reinforce
ment of the channel with circumferential
Prolene suture, the weight loss at 12
months was 34.5%, at 24 months 40.7%,
and at 36 months 40.1 %. The body mass
index fell from 45.9 to 27.4 (six patients
lost to follow-up).
At 36 months, 36.1 % o f patients with
a nonreinforced horizontal gastroplasty
and 82.1% o f those with a reinforced
horizontal gastroplasty had lost 25% or
more weight.
Early complications included channel
obstruction requiring reoperation less
than 8 weeks postoperatively in 6 patients,
leakage in 2 requiring emergency reopera
tion, pulmonary embolism in 1, throm
botic thrombocytopenic purpura in 1, col
ostomy in 1, wound infection in 3 and
wound seroma in 16. Late complications
were channel obstruction, requiring
operation after 8 weeks in 5 patients (2
required a third operation to attain an
adequate outlet) and ventral hernia in 12.
Thirteen subsequent operations were per
formed for obstruction in 11 patients —
gastrogastrostomy in 8 patients and
enlargement o f the outlet in 5 (2 patients
underwent both procedures). Other sub
sequent operations were: cholecystectomy
in 5 patients, ventral hernia repair in 12
and a hiatal hernia repair in 1.
Since Nov. 1, 1982, 191 vertical band
ed gastroplasties have been performed.
The results o f this simpler, safer opera
tion must await analysis. We have had no
deaths with any weight loss operation.
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Because hypotension induced by the ad
ministration of hypertonic sodium bicar
bonate is more severe when cardiac
4 performance is impaired, the authors
evaluated the hemodynamic conse1 quences of peroperative myocardial
ischemia upon the response of conscious
‘ dogs to an intravenous bolus of sodium
bicarbonate. Twenty-two control dogs
(group 1) were equipped with an elec
tromagnetic flow probe positioned
around the ascending aorta. Seventeen
►-dogs (group 2), equipped in the same
manner, were subjected to 1 hour of
myocardial ischemia combined with
topical cardiac hypothermia.
r Hemodynamic studies were performed
daily for 1 month before and during the
administration of sodium bicarbonate.
^Baseline hemodynamic values in group 1
were always within normal limits. In
, group 2, cardiac failure was evident in
the immediate postoperative period but
Hiemodynamic values reached normal
limits 24 hours postoperatively. For both
groups, the peak hypotensive response
to sodium bicarbonate was combined
with a substantial reduction in all
hemodynamic values reflecting the left
ventricular performance. However, this
response is significantly (p < 0.01) more
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pronounced in group 2 during the first 4
postoperative days, being maximal 3 and
24 hours after operation. Afterwards,
the hemodynamic response to sodium
bicarbonate was similar in both groups.
These results indicated that an intra
venous bolus of sodium bicarbonate
decreases left ventricular performance
and that this decrement is greater when
cardiac performance is impaired follow
ing peroperative myocardial ischemia.
Long-term hemodynamic studies show
that this temporary myocardial ischemia
is not deleterious to cardiovascular
adaptability to hypertonic sodium bicar
bonate administration.

Parce que I’hypotension induite par le
bicarbonate de soude hypertonique est
plus prononcee en presence d'une defaillance cardiaque postoperatoire, les
auteurs ont evalue les consequences
hemodynamiques de I'isch6mie myocardique peroperatoire vis-a-vis la r6ponse a
un bolus intraveineux de bicarbonate de
soude hypertonique chez le chien eveille.
Vingt-deux animaux (groupe 1) munis
d'une bague electromagnetique autour de
I'aorte ascendante ont servi de controle.
Dix-sept animaux (groupe 2) ont en plus
ete soumis a 1 heure d'ischemie myocardique combinee a de I'hypothermie car
diaque de surface.
Pendant 1 mois des etudes h^modynamiques quotidiennes sont realisees avant
et pendant ('administration de bicarbo
nate de soude hypertonique. Pour le
groupe 1 des donnees de base sont toujours dans les limites normales alors que
pour le groupe 2 la d£faillance cardiaque
est 6vidente dans la p£riode postopera
toire immediate pour disparaftre 24 heures plus tard. Dans les deux groupes, la
reponse hypotensive maximale aprfes
I'administration de bicarbonate de soude
hypertonique est associ6e a une reduc
tion significative (p < 0.01) de tous les
parametres hemodynamiques refietant la

performance ventriculaire gauche. Cette
reponse est cependant significativement
plus prononcee dans le groupe 2 pour les
4 premiers jours postoperatoires, avec
une difference maximale & 3 et 24 heures apres la chirurgie. Par la suite, la
reponse h I'administration de bicarbonate
de soude hypertonique est similaire dans
les deux groupes d'animaux.
Ces resultats indiquent qu'un bolus
intraveineux du bicarbonate de soude
hypertonique diminue la performance car
diaque et que cet effet est plus prononce
en presence de la defaillance cardiaque
associee a une ischemie myocardique
peroperatoire. A long terme, les etudes
hemodynamiques indiquent que cette
ischemie myocardique temporaire n'a pas
de consequences negatives sur I'adaptabilite de systeme cardio-vasculaire a I'ad
ministration de bicarbonate de soude
hypertonique.

Hypertonic sodium bicarbonate has been
widely used clinically because it is effec
tive in correcting metabolic acidosis.1,2
Increasing concern over the hem o
dynamic effects o f this treatment has led
to numerous studies; systemic hypoten
sion associated with rapid intravenous in
jection o f hypertonic sodium bicarbonate
was a constant feature o f those reports,
while its effects on left ventricular perfor
mance yielded conflicting results.3-9
We became interested in this problem
when we noticed that patients recovering
from cardiac surgery had a more severe
hypotensive response to hypertonic
sodium bicarbonate when cardiac per
formance was depressed. The purpose o f
this study was, therefore, to quantitate
the hemodynamic effects o f hypertonic
sodium bicarbonate given to dogs with
normal or depressed cardiovascular func
tion. We also evaluated the long-term
consequences o f peroperative myocardial
ischemia upon the hemodynamic response
to hypertonic sodium bicarbonate given
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intravenously. These measurements were
obtained in unanesthetized dogs by
carrying out left ventricular performance
tests during the early postoperative hours
and daily during the following month.

Methods

anesthesia with sodium pentobarbital (25
mg/kg, intravenously), they were in
tubated and ventilated with a volume
respirator (Harvard, model 607; Harvard
Apparatus Co. Inc., S. Natick, Mass.).
The animals were divided into two
groups.

Healthy mongrel dogs, weighing 16 to
22 kg, were selected on the basis of their
normal clinical, hematologic and bio
chemical status.10 After induction of

costal space and the pericardium opened.
The aortic root was encircled with a
Teflon band over which an electro- *
magnetic flow probe (Statham SP 2200
blood flow transducer; Statham Instru
ments, Oxnard, Calif.) of appropriate ^
diameter was placed. Polyvinyl catheters
were positioned in the descending thoracic'*' •
aorta through the left subclavian artery
Group 1
and at the cavoatrial junction through the -«
In 22 control dogs, a left thoracotomy left external jugular vein. The distal ends
was performed through the fourth inter of the catheters and of the flow-probe *
«

Table 1--Baseline Hemodynamic Data from Control (Group 1) and Experimental (Group 2) Dogs
Postoperative day
Measurement
HR
Group 1
Group 2
AP syst
Group 1
Group 2
AP dias
Group 1
Group 2
AP mean
Group 1
Group 2
SV
Group 1
Group 2
Cl
Group 1
Group 2
PR
Group 1
Group 2

1

2

3

4

165 ± 2 9 *
174 ± 23

129 ± 16
152 ± 36

135 ± 19
140 ± 22

144 ± 36
134 ± 13

141 ± 20
147 ± 15

121 ± 26
139 + 27

112 ± 20
106 ± 10

149 ± 18
147 ± 23

159 ± 24
155 ± 23

153 ± 11
156 ± 27

147 ± 18
152 ± 25

154 ± 20
155 ± 19

149 ± 26
140 ± 18

148 ± 2 0
142 ± 28

102 ± 22
108 ± 14

95 ± 16
93 ± 18

95 ± 13
99 ± 16

91 ± 10
89 ± 24

97 ± 14
91 ± 9

88 ± 14
89 ± 15

87 ± 13
94 ± 19

118 ± 19
121 ± 17

116 ± 17
114 ± 18

114 ± 12
118 ± 18

110 + 12
110 ± 23

116 ± 15
112 ± 11

108 ± 17
106 ± 16

107 ± 14
110 ± 2 2

31.6 ± 5.9
18.7 ± 5 .4 t

4 3 .3 ± 12.2
37 .0 ± 14.3

51.5 ± 9.1
42.0 ± 12.3

53.2 ± 17.9
42.3 ± 12.4

53.7 ± 12.9
52.8 ± 14.8

58.7 ± 13.8
49.7 ± 6.8+

58.5 ± 28.6
56.0 ± 6.1

5.2 ± 1.2
3.2 ± 0 .7 t

5.5 ± 1.3
5.4 ± 2.0

6.9 ±
5.9 ±

7.4 ± 2.0
5.6 ± 1.4

7.6 ± 2.1
7.8 ± 2.7

7.1 ± 2.3
6.7 + 1.3

6.2 ± 2.3
5.9 ± 0.6

32 ± 7
53 ± 2 4 t

34 ± 13
32 ± 14

24 ± 7
30 + 11

22 ± 11
28 ± 9

23 + 6
21 ± 11

23 ± 9
19 ± 6

24 ± 9
25 ± 11

1.3
1.9

5

6 -1 0

Long term

*

k

%

V

HR = heart rate (beats/min), AP syst - systolic arterial pressure (mm Hg), AP dias = diastolic arterial pressure (mm Hq), AP mean = mean arterial pressure
(mm Hg), SV - stroke volume (mL/stroke • m -2), Cl - cardiac index (L/min m 2), PR = total peripheral resistance (units).
‘ Mean ± standard deviation (SD).
tp < 0.01 unpaired comparison,
t p < 0.05 unpaired comparison.

Table II—Baseline Data Reflecting Left Ventricular Function of Control (Group 1) and Experimental (Group 2) Dogs
Postoperative day
1

2

3

4

5

6 -1 0

Long term

1
2

6.3 ± 1.5*
3.6 ± 1 .2 t

9.1 ± 2.3
7.7 ± 3.1

10.5 ± 1.8
8.8 ± 3.3

10.6 ± 4.4
8.6 ± 2.7

11.0 ± 2.9
10.7 ± 1.9

11.7 ± 3.7
9.2 ± 2.1 +

12.0 ± 7.3
10.7 ± 2.6

1
2

375 ± 38
26 5 ± 3 8 t

4 5 9 ± 72
501 ± 135

530 ± 97
517 ± 128

549 ± 144
487 ± 143

511 ± 1 1 6
580 ± 125

696 ± 437
593 ± 193

581 ± 256
49 2 ± 72

1
2

237 ± 48
142 ± 30+

31 2 ± 98
2 7 5 ± 91

315 ± 70
290 ± 84

292 ± 69
278 ± 82

33 4 ± 110
32 4 ± 71

401 ± 220
294 ± 102

283 ± 96
223 ± 54

1
2

74.9 ± 14.9
52.0 ± 10.5+

97 .9 ± 23.5
104.3 ± 33.9

108.2 ± 21.3
107.9 ± 32.4

107.7 ± 32.0
97.3 ± 23.1

105.0 ± 25 .8
118.1 ± 15.4

109 ± 32
106 + 39

119.0 ± 68.4
94.9 ± 30.0

1
2

5.1 ± 1.5
3.0 ± 0.7 +

6.3 ± 2.4
6.8 ± 3.0

6.1 ± 2.4
6.1 ± 2.9

5.4 ± 2.0
6.7 ± 2.7

7.4 ± 2.1
6.7 ± 2.7

Measurement
SW
Group
Group
MSF
Group
Group
Vel
Group
Group
Power
Group
Group
Acc
Group
Group

8.8 ± 5.6
5.0 ± 2.2+

5.8 ± 1.9
4.9 ± 1.7

maximum systolic flo w (mUs -m"2), Vel - peak velocity (cm/s ■m 2), Power - stroke power (10 8 erg/s • n r
SW - stroke w ork (10 6 gcmls • rrr2), MSF
Acc - maximum acceleration (1 0 3 cmls2 ■m - 2 |
‘ Mean ± SD.
t p < 0.01 unpaired comparison.
+p < 0.05 unpaired comparison.
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cable were exteriorized dorsally for long
term use. The arterial and central venous
^ pressures were monitored continuously
and the animal’s rectal temperature was
^ kept at 37°C. Sequential determinations
of hemoglobin level, hematocrit, leuko
c y t e count, serum electrolyte levels,
blood gas concentrations and acid base
r ^balance were done before, during and

FIG. 1—Changes in hemodynamic measure
ments at peak hypotensive phase, following ad
ministration of hypertonic sodium bicarbonate,
* - expressed as percentage change ( A Vo) from
baseline measurements (mean ± standard
y.
deviation). Group 1 = black columns; group
2 = hatched columns. Open squares = p <
0.05, closed squares = p < 0.01 by paired
comparison within each group; open circle =
p < 0.05, closed circles = p < 0.01 by un’’paired comparison between groups 1 and 2.
HR = heart rate, AP syst = systolic arterial
v pressure, AP dias = diastolic arterial pressure,
AP mean = mean arterial pressure, SV =
y.
stroke volume, Cl = cardiac index, PR =
peripheral resistance.

FIG. 2—Changes in left ventricular perform
ance following administration of hypertonic so
dium bicarbonate, expressed as percentage
*■ change (A% ) from baseline measurements
(mean ± SD). Group 1 = black columns,
,
group 2 = hatched columns. SW = stroke
work, MSF = maximum systolic flow, Vel =
^ peak velocity, Power = stroke power, Acc =
maximum acceleration. Squares and circles =
p values as in Fig. 1

after the operation to confirm that the cli
nical condition of the animal was satis
factory. The thorax was left open for 4
hours and then closed using conventional
methods.
Group 2
The 17 animals in this group were
selected, prepared and monitored in the
same way as those in group 1. In addi
tion, they were put on cardiopulmonary
bypass, the aorta was cross-clamped for
1 hour and topical hypothermia was us
ed to protect the myocardium. The details
of those techniques have been reported
previously.1112 Briefly, cardiopulmonary
bypass is effected with a vertical-screen
pump oxygenator (Med Science Elec
tronics, Inc., St. Louis, Mo.). Perfusion
pressure was 80 to 110 mm Hg, blood
flow was 75 to 115 mL/kg»min‘‘.
Myocardial protection included the
following steps: the heart is left in the
pericardial crater; cold physiologic saline
(4°C) is used as the irrigating solution; the
initial flow of irrigating solution is 150 to
200 m L/m in, which, upon satisfactory
cooling, is reduced to 10 to 50 mL/min
and cardiac submersion is total in order
to obtain and maintain rapid uniform
myocardial cooling. With this method of
myocardial protection, we have previous
ly d em onstrated13 that tem porary
myocardial depression occurs. Since con
trolled postoperative myocardial impair
ment was necessary to verify our hypo
thesis, this technique was used in the
present work.
Both Groups
Hemodynamic studies were performed
3 hours after operation and then daily for
1 month in the unanesthetized, nonacidotic, resting animal. Following control
hemodynamic measurements, 18.5 mmol
of a 1786 mOsm/L hypertonic solution
of sodium bicarbonate was administered
as a rapid intravenous bolus (in less than
5 seconds by hand). Hemodynamic para
meters were measured continuously until
they had stabilized. Control experiments
were also performed using 20 mL of nor
mal saline.
During each study, the following were
recorded; electrocardiographic data, heart
rate, systolic and diastolic arterial
pressures, stroke volume, cardiac output,
total peripheral resistance, left ventricular
power and work, the maximum systolic
flow, peak velocity and maximum ac
celeration. All data were processed ac
cording to methods of recording, conver
sion, calculation, indexing and analysis
reported elsewhere.14,15
Statistical Analysis
Hemodynamic data obtained at the

peak hypotensive effect of sodium bicar
bonate were compared to baseline values
using the Student’s /-test for paired data
when comparisons were within each
group and using the Student’s /-test for
unpaired data when comparisons were
between g roups. H om ogeneity o f
variance was verified using the ShapiroWilk’s test and Bartlett’s test.16
Results
The hemodynamic data obtained at
rest, in both groups, before each experi
ment, are presented in Tables I and II. In
group 1, baseline values were always
within normal limits. In group 2, cardiac
failure was evident in the immediate
postoperative period but hemodynamic
values returned to normal by postopera
tive day 2.
A t 3 Hours
Figs. 1 and 2 illustrate the hemody
namic events at the peak of hypotension
in both groups. Three hours postoperatively, the hypotension observed
in control animals was associated with
a significant decrease (p < 0.01) in stroke
power and work, maximum systolic flow,
peak velocity and maximum acceleration.
In group 2, hypotension was more pro
nounced and was associated with a
significant (p < 0.01) decrement in all
hemodynamic parameters. Also, in group
2, the left ventricular performance was
significantly (p < 0.01) more affected by
the administration of sodium bicar
bonate.
A t 24 Hours
The hemodynamic response to sodium
bicarbonate in group 1 animals was
similar to th at observed 3 hours
postoperatively and remained the same
for the duration of the study. In group
2, a response similar to that observed 3
hours postoperatively occurred except
that the hypotensive phase was less severe;
again, the response seen in group 2 at this
time was more pronounced than that in
the control group. At postoperative days
3 and 4, the negative inotropic response
to sodium bicarbonate administration in
group 2 was still more pronounced than
in group 1 but diminished progressively
to become similar by postoperative day
5. From days 6 to 30, the patterns of
hemodynamic response were similar in
both groups.
Discussion
This study extends the previously
known information about the cardiovas
cular effects o f hypertonic sodium bicar-
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bonate in norm al subjects.3'9'17,ls
Previous studies related to the hemody
namic consequences of administering
hypertonic sodium bicarbonate were con
ducted in anesthetized dogs, with the
chest o pen.
Since
anesthesia,
thoracotomy and artificial ventilation
have profound, detrimental effects on
cardiovascular function and autonomic
reflexes, they make it difficult to
recognize the true hemodynamic conse
quences associated with administration of
hypertonic sodium bicarbonate.19'21 Our
hemodynamic investigation could relay
more valid data since our results were ob
tained
from
h ealthy,
resting,
unanesthetized animals. In the experimen
tal group, 1 hour of aortic cross-clamping
along with selective myocardial protection
was carried out to elicit temporary
myocardial failure comparable to that
seen in the clinical setting. With respect
to total cardiopulmonary bypassing,
previous studies have demonstrated that
it does not have deleterious effects on
myocardial performance.22'24 Therefore,
comparing the hemodynamic response to
hypertonic sodium bicarbonate observed
in control and experimental groups can
be considered valid and any differences
between results can only be related to the
consequences of peroperative myocardial
ischemia.25
In the c o n tro l gro u p , baseline
hemodynamic data were normal for the
duration o f the study while in the ex
perimental group, cardiac failure was evi
dent in the immediate postoperative
period only. The hypotension observed
with administration of hypertonic sodium
bicarbonate was combined with a signifi
cant decrement in all hemodynamic
parameters. From a previous study26 we
were able to show that this hemodynamic
impairment following rapid administra
tion of sodium bicarbonate was cardiac
in nature (i.e., when the solution reach
ed the coronary bed), that neither the
volume injected nor the hyperosmolarity
of the solution played a role in this
response while the high sodium content
of the solution explained part of the
decrement in myocardial function. Tran
sient ionic as well as acid-base distur
bances are other mechanisms that have to
be considered along with coronary
vasoconstriction. This hemodynamic
response was more pronounced in the ex
perimental group during the first 4
postoperative days. The negative in
otropic response in this group was max
imal 3 hours after operation when
baseline hemodynamic values were
already depressed. Thus, our results
demonstrate that the response to sodium
bicarbonate administration is more severe
in the presence of cardiac failure. Dur
ing the next 3 postoperative days, even if
baseline hemodynamic values were within
244

normal limits, the fact that in the ex
perimental group the response to sodium
bicarbonate was still more pronounced in
dicates residual myocardial impairment
which can only be detected by this phar
macologically stressful stimulus. Since the
response to sodium bicarbonate was
similar in the control and experimental
groups from 5 to 30 days after operation,
the hemodynamic consequences of per
operative myocardial ischemia are no
longer apparent.
Conclusions
The hypotensive phase induced by
hypertonic sodium bicarbonate is com
bined with a decrease of left ventricular
performance in both normal and ischemic
myocardium. This hemodynamic re
sponse is more severe in the presence of
evident cardiac failure, 3 hours postoperatively and during the following 3
days when baseline hemodynamic data
have reached normal limits. Long-term
studies show that peroperative myocardial
ischemia does not impair cardiovascular
adaptability to hypertonic sodium bicar
bonate administration.
We thank Mrs. Suzanne Chartrand, Miss
Lise Langevin, Mr. Gaetan Lagace, Mr. Robert
Parent and Mr. Normand Trepanier for
technical assistance, and Mrs. Sylvie Tasse for
secretarial assistance.
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^

occasional constipation

1^ geriatric patients
^

post-op patients

Popular m arshm allow flavour for greater patient acceptance!
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The Lithotomy-Trendelenburg Position for Restorative Resection ,
by Stapling and Abdominoperineal Excision of the Rectum •
The introduction of stapling for anterior
resection of the rectum has made the
use of the lithotomy-Trendelenburg posi
tion almost mandatory in the surgical
treatment of cancer of the rectum. Use
of this position allows the surgeon to
choose, after initial dissection, which of
the two principal procedures (abdomino
perineal excision or restorative resection)
to perform, regardless of the procedure
originally planned. This can be done
without altering or modifying the chosen
procedure in any way. The authors de
scribe the proper placement of all special
equipment used and the sequence of
steps for correct positioning and draping
of the patient.
L'adoption des agrafes pour la resection
anterieure du rectum a rendu presque
obligatoire le recours a la position de la
taille-Trendelenburg dans la chirurgie du
cancer du rectum. L'utilisation de cette
position permet au chirurgien de choisir,
apres dissection initiale, entre les deux
principales interventions offertes (exci
sion abdomino-perineale ou resection
reconstituante) quelle que soit celle qui
avait ete planifiee au debut. Ceci peut
etre fait sans changer d'aucune facon de
('intervention choisis. Les auteurs decrivent la disposition appropriee de I'equipement special utilise et la sequence des
etapes utilisees pour corriger la position
du patient et decouvrir le champ
operatoire.

The two principal operations performed
for carcinoma of the rectum are ab
dominoperineal excision and restorative
resection.
Lloyd-Davies1 of St. M ark’s Hospital
in London, England, introduced the
From the Department o f Surgery,
University of Manitoba, and Health Sciences
Centre, Winnipeg, Man.
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lithotomy-Trendelenburg position in 1939
to permit combined excision of the rec
tum by two surgeons working simultane
ously. This technique enables the ab
dominal and perineal stages to be com
pleted without changing the patient’s
position on the table. It increases the
resectability rate, facilitates the recogni
tion of correct tissue planes, ensures safe
ty of vital structures and allows more
complete hemostasis,
A single surgical team will find this
position well suited for excision of the rec
tum. If technical difficulties are en
countered during perineal dissection,
especially in separating the rectum from
the anterior pelvic structures, the
surgeon’s orientation may be improved
with the help of an assistant working in
the abdominal field.
Ideally, these patients should have con
tinuity restored, the anal canal and its im
portant musculature retained, and even
a small portion of rectum left to provide
normal reflex response and continence.
Restoration of continuity may be con
sidered when the tumour is situated 10 cm
or more from the anal verge, measured
sigmoidoscopically, and is of average
grade and size. These guidelines vary with
the size and sex of the patient. Transec
tion of the bowel 4 to 5 cm distal to the
tumour is considered adequate in most
cases.

tion, regardless of the procedure original-'*
ly planned.

■*

-i

We describe the special sequence of
steps required to place the patient proper- -*
ly in the lithotomy-Trendelenburg posi1
tion; this will facilitate the subsequent "* 1
surgical procedures.
I
■*

1

Lloyd-Davies advocated a special table
j
and accessories for use with the litho- r j|
tomy-Trendelenburg position
(Fig. 1). 1
A

The operating room is arranged into
three separate areas around the operating A j
table — abdominal, perineal and anesj
thesia (Fig. 2). Each surgical team con- * ^
sists of surgeon, assistant and nurse.
j

FIG. 1—Operating table with special ac
cessories in Trendelenburg position. (1) A t
tached Mayo table, (2) shoulder rests, (3) in- 7 Y
datable back support, (4) sacral rest of
Goligher, (5) Lloyd-Davies padded stirrups, (6) <
low Mayo table and (7) stools for perineal
surgeon and assistant.
^

Goligher2 noted that an anterior resec
tion may be performed if the tumour is
found to be further from the anus once
full mobilization and straightening of the
rectum have been achieved at operation.
The advent of the Russian SPTU staple
gun as used by Goligher2 in England and
the EEA stapler as modified in the United
States3 for anterior resection of the rec
tum has increased the application of the
lithotomy-Trendelenburg position. It has
become almost mandatory for this
procedure.
By placing patients in the lithotomyTrendelenburg position, the surgeon can,
after trial dissection, choose either ab
dominoperineal excision or restorative
resection without alteration or modifica

BIG. 2—Arrangement of equipment and
personnel around patient forms three distinct
areas (perineal, abdominal and anesthesia) with
borders within which each team works. Each
surgical team consists of surgeon, assistant and
nurse.
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Separate sponges, swabs, packs and in
struments are used in each area and are
► counted separately.

F

Abdominal Field

The patient is placed on the operating
(Fig. 3) with the buttocks near the
break of the table. The patient’s legs are
elevated, placed on the padded LloydDavies stirrups and fastened by straps.
The caudal end of the table is removed
or lowered to its limit. The Goligher
sacral rest is inserted under the buttocks.
The perineal surgeon ensures that the pa
tient’s sacrum rests on the cantilevered
rubber pad so that the buttocks are free
and not compressed by the sacral rest.
Shoulder rests are now placed against the
point of each shoulder (not base of neck)
to fix the patient on the table. The LloydV f Davies stirrups are adjustable for size and
position. The legs should be abducted and
slightly flexed at the hips. The arms are
padded and placed on the table (Fig. 3).
4
The perineum and abdomen are washed
A and painted separately and simultaneous
ly. The fixed overhead Mayo table is tilted
•i A so that it will be horizontal when the table
is placed in the Trendelenburg position.
The caudal edge of the tray is placed at
about nipple line. A large elevated cranial
surgery table is now brought into position
near the fixed Mayo stand.
V
The patient is draped by the abdominal
team. An adherent transparent sheet is
first applied to the abdomen, excluding
the genitalia from both abdominal and

►

)

* table

perineal fields. A sheet of sterile plastic
is placed over the guard of the unsterile
fixed Mayo table frame. A sterile tray is
fitted into the bracket. Triangular leg
drapes are applied. An abdominal drape
is placed over the patient and the Mayo
table and clipped to intravenous poles to
exclude the anesthesia area (Fig. 4) or it
may be fastened to the drapes along the
edge of the cranial table by towel clips.
Leg drapes and the caudal edge o f the ab
dominal drape are joined by towel clips.
The opening in the abdominal drape is
positioned over the incision site and fix
ed to the skin of the pubis by towel clips.
A stainless steel instrument rack (Fig.
5) is attached to the guard of the fixed
Mayo stand. Double pegs are arranged so
that instruments for the abdominal part
of the operation are situated on one side
of the rack and common hemostatic for
ceps are placed in the centre. Larger

miscellaneous instruments or retractors
are placed on the Mayo table when re
quired as the procedure progresses.
When the large elevated cranial table
is used there must be sufficient slack in
the drape attached to the cranial table to
allow the patient to be placed later into
the Trendelenburg position. The ham 
mock of excess draping serves as a buf
fer between the raised table and the Mayo
stand and is a convenient place for
cautery and suction-tip attachments. The
distance between the cranial table and
Mayo stand should be 30 to 45 cm. Later,
as the operating table is tilted into the
Trendelenburg position, the Mayo stand
and instrument rack will rotate until the
latter abuts against the edge of the cranial
table.
The abdominal area is separated from
the anesthesia area by a sterile sheet
spread and fastened to the edge of the
cranial table and abdominal drape and to
an intravenous pole.
The operative field is now ready for the
abdominal operation.
Perineal Field

FIG. 5—Complete set-up. (1) Overhead
draped Mayo table, (2) instrument rack, (3)
large elevated cranial surgery table Note plat
form for abdominal nurse to stand on.

The perineal draping is completed after
the abdominal surgeon finds that the
tumour is resectable and he is ready either
for perineal dissection or to use the staple
gun for anastomosis. Two transverse
drapes, a sterile plastic and a cloth sheet
across the posterior perineum to exclude
the sacral rest, are applied (Fig. 6).
The low Mayo stand should fit easily
over the surgeon’s knees. The surgeon,
and his assistant to his right, are seated
on low stools with wheels.
Summary
The lithotomy-Trendelenburg position
is recommended for the surgical manage
ment of carcinoma of the rectum. The
position is applicable to the synchronous
two-team or the single surgical team ap
proach in abdominoperineal excision or
in anterior resection of the rectum using
stapling methods.
These surgical techniques are enhanced
by careful theatre preparation, correct se
quence of patient positioning and the use
o f special equipment and instruments.

References

FIG. 4—Draping. (1) Triangular leg drapes;
4 (2) overall abdominal drape. Excess abdominal
drape tucked under edge of attached Mayo
table (arrow).

FIG. 6—Perineal draping. Low Mayo stand
and stool(s) in position. (1 and 2) Towel clips
attach transverse drapes to skin behind anus
and to triangular leg drapes, (3) transverse
drape fastened to stirrup frames by pole clips.
Lower edges of transverse drapes placed in
floor bucket.
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Recent Research Suggests...

(clindamycin phosphate)

3.

clindamycin-laden PMN moving
toward the site of infection

► v

Phosphate S.S.
enhances
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2^3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144( 5)
2) Johnson JD, et al (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
(eds. J Nelson, C Grassi) Am Soc Microbiol Vol 2

5.

phagocytosis of the bacterium
by antibiotic-enhanced PMN

6. degranulation and killing
of engulfed bacterium
I
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Dalacin C Phosphate Phosphate S.S.
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C P ho sp h a t?

b y causin g a reduction in the rate of synthesis of nucleic acids.

(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology,
urinalysis and liver a nd kidney function tests. Som e of these tests were abnormal initially and r e tu r n - #
ed to normal during therapy with Dalacin C Phosphate, while others were normal initially and becam e
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients doe s n&{
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, h epatic or renf?
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase # d ^
there have not been clinical signs of drug-induced hepatic toxicity.

Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec
tions where the oral route is not indicated or feasible.
D alacin C Phosphate is indicated in the treatment of serious infections d ue to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species a nd m icroaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections d ue to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when
th e patient is intolerant of. or the organism resistant to other appropriate antibiotics.

Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. N fl

Contraindications: The use of Dalacin C Phosphate (clindam ycin phosphate) is contraindicated

specific antidote is known. Doses as high as 1200 m g every six hours (4800 mg/day) by infusion for
five days have been given without adverse effects.
^

in patients previously found to be hypersensitive to this com p ou nd , the parent com pound, clinda
mycin, or clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride)
has not been dem onstrated, it is re com m ended that Dalacin C Phosphate not be used in patients
w h o have dem onstrated lincomycin sensitivity.

Adults

Until further clinical experience is obtained, Dalacin C P hosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women

DOSAGE A N D ADMINISTRATION

-4

Intramuscular Injection: 600 m g/day in 2 equal doses.

m

Moderately severe infections. 600 to 1200 m g/day in 2 or 3 equal doses.

Warnings: Some cases of severe and persistent diarrhea have been reported during or after ther
apy with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally asso
ciated with blood a nd m ucus in the stools a nd has at tim es resulted in acute colitis. W hen e nd os
c o p y has been perform ed, som e of these cases have shown pseudom em brane formation.
If significant diarrhea occurs during therapy, this d ru g should be discontinued or, if necessary, c o n 
tin ue d o nly with close observation. Significant diarrhea occurrin g up to several weeks post-therapy
sh ou ld be m anaged as if antibiotic-associated.

Severe infections: 1200 to 2400 m g/day in 2 ,3 o r 4 equal doses. Intramuscular injections of m of$
than 600 m g into a single site are not recom m ended.

Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted p rio r*
to I.V. administration to a dilution of 300 m g in 50 ml of diluent (6 mg/ml) or more, and infused in not
less than 10 minutes. Administration of m ore than 1200 m g in a single 1 hour infusion is not recom 
m ended. Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.

If colitis is suspected, endoscopy is recom m ended. Mild cases showing m inim al mucosal changes
m ay respond to sim ple d rug discontinuance. Moderate to severe cases, in clu din g those showing
ulceration or pseudom em brane formation, should be m an ag ed with fluid, electrolyte, and protein
supplem entation as indicated. C orticoid retention enemas a nd systemic corticoids may be of help
in persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes
of colitis should b e considered.

M oderately severe infections: 9 00 to 1800 m g/day by continuous drip or in 2 or 3 equal doses,
infused over 20 minutes o r longer.

Studies indicate a toxin(s) p roduced by Clostridia (especially Clostridium difficile) may be a princi
pal c a use of clindam ycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. W hen 125 m g to 500 m g of vanco
m ycin were adm inistered orally four times a day for 5 -1 0 o r m ore days, there was a rapid observed
d isappearance of the toxin from faecal sam ples a nd a coincidental recovery from the diarrhea.

Dilution and infusion rates:

It should be noted that serious relapses have occurred u p to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recom m ended.

Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed
w ith caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organism s - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the clin
ical situation.
A s with all antibiotics, perform culture and sensitivity studies in conjunction w ith d rug therapy.
S ince abnorm alities of liver function tests have been noted occasionally in anim als and man, peri
o d ic liver function tests should be perform ed d uring prolonged therapy. B lood counts should also
b e m onitored d uring extended therapy.
D alacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindam ycin in
patients with im paired hepatic function is greater than that found in normal patients, the dose of
D alacin C P hosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are
not effective means of removing the com pound from the blood. Periodic serum levels should be deter
m ine d in patients with severe hepatic a nd renal insufficiency.

A d verse

R e action s: L ocal.

(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin phosphate)
intramuscularly (with a solution containing 150 mg/mL), six (1.5%) dem onstrated local reactions as
follows: Two com plained of pain at the injection site, two dem onstrated induration at the injection site
a nd tw o developed sterile abscesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3% ) demonstrated local reactions. Eleven patients developed superficial throm bophlebitis and
o ne patient developed both superficial and deep throm bophlebitis. The majority of these cases
developed in conjunction with the use of indwelling I.V. catheters and it is difficult to know how m uch
the d ru g contributed to the irritation. Two patients developed localized erythema, swelling a nd pain
at the site of the infusion.

Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as follows:
N um ber o f Patients
R a s h ...................................................................................................................................................................7
U rtic a ria ..............................................................................................................................................................1
P r u r it u s .............................................................................................................................................................. 1
Fever, Leucocytosis.......................................................................................................................................... 1
Nausea, with or without vo m itin g ................................................................................................................. 1
D iarrhea (See also under “W a rn in g s").........................................................................................................4
H yp ote nsion ...................................................................................................................................................... 1
H y p e rte n s io n .................................................................................................................................................... 1
Shortness of Breath ....................................................................................................................................... 1
S upe rin fe ctio n*................................................................................................................................................. 4
C a rd ia c arrest* ’ ............................................................................................................................................... 1
B ad o r bitter taste in m o u th ...........................................................................................................................5
*Superinfection is a complication of antibiotic therapy in general and is not necessarily a true
side effect of clindam ycin phosphate.
**D u e to underlying myocarditis in this patient.
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Severe infections: 1800 to 2700 m g/day by continuous d rip or in 3 or 4 equal doses, each infused
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 m g/day by continuous
d rip or in 3 or 4 equal doses each infused over 20 minutes or lo nger may be given.

Dose

Diluent

Time

300 m g
600 m g
900 m g

50 ml
100 ml
150 ml
200 ml

10 min.
20 min.
30 min.
45 min.

1200 m g

k

4

Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed
by continuous I.V. infusion as follows:
To maintain serum
clindamycin levels

Rapid
infusion rate

Maintenance
infusion rate

Above 4 mcg/ml
Above 5 m cg/m l
Above 6 m cg/m l

10m g/m in. for 30 min.
15m g/m in. for 3 0 min.
2 0m g/m in . for 3 0 min.

0.75m g/m in.
1.00mg/m in.
1.25 mg/m in.

±4

Children: (Over one month of age)
Intramuscular injection: 10 to 15m g/kg/day in 2 ,3 o r 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 m g/kg/day in 3 or 4 equal doses.

Intravenous Administration:
Moderately severe infections: 15 to 25 m g/kg/day by continuous drip or in 3 or 4 equal doses, e a c b ^
infused over 20 minutes o r longer. In severe infections, it is recom m ended that children be given no
less than 300 m g/day regardless of b o d y weight. (Dilute Dalacin C Phosphate Sterile Solution in the
same manner as for adults.)
^

Dilution and Compatibility:

y

^

4 ml (600 mg) Dalacin C Phosphate w hen diluted with 1000 ml of the following com m only used in
fusion solutions was found to be physically com patible and demonstrated no significant ch an ge in
pH or antim icrobial potency over a period of 24 hours:
*
Sodium chloride injection
Dextrose 5 % in water
Dextrose 5 % in saline
Dextrose 5 % in Ringer's S olution
Dextrose 5 % in half-strength saline plus 40 mEq potassium chloride
Dextrose 2 1/2 % in Lactated Ringer’s S olution (Hartm ann’s Solution).

4
v
j

Dalacin C Phosphate was not stable w hen a dd ed to Dextrose 5 % in water plus vitamins. Therefore
it is not recom m ended that Dalacin C Phosphate be mixed with any infusion solution containing B
vitamins.
*

Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindam ycin base 150 mg
Benzyl alcohol 5 m g
Disodium edetate 0.5 m g
Water for injection q.s.

m

When necessary the pH is adjusted with sodium hydroxide a nd/or hydrochloric a cid to maintain a
pH range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.

NOTE: Do not store below 15°C.
Product Monograph available upon request,
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Delayed Hemorrhage following Conservative Surgery for Tubal
Ectopic Pregnancy: Prevention and Early Detection

*-

SThere is growing acceptance of conser
vative surgery for ectopic (tubal)
r pregnancy. An uncommon, yet potential
ly fatal, complication is delayed hemory rhage due to persistence of gestational
tissue. An illustrative case is presented.
Routine postoperative determination of
/- (.serum human chorionic gonadotropin
levels and the use of frozen sections
4 when a partial salpingectomy is carried
out are recommended to identify and
A prevent this condition.

viable pregnancy among women who
have had a conservative procedure on the
single remaining tube. These results are
especially important in the light of the ap
parent increase in the absolute rate of ec
topic pregnancies in the general popula
tion.9,10 The case reported demonstrates
a serious and possibly fatal complication
of such surgery, and methods that are
available to prevent and identify such a
complication are discussed.
Case Report

* La chirurgie conservatrice est de plus en
tplus accept6e dans les cas de grossesse
ectopique (tubaire). L'hemorragie retardee causee par la persistance de tissu de
gestation est une complication rare, bien
*^que potentiellement mortelle. L'article
decrit un cas qui illustre ce danger. Afin
v d'identifier et de prSvenir ce probleme,
on recommande la determination post* operatoire systematique des taux seriques de la gonadotropine chorionique
humaine et ('utilisation des coupes en
r congelation apres toute salpingectomie
partielle.

j

V

Conservative surgical procedures are be
ing carried out frequently for ectopic
^ Jtubal) pregnancy.1 This is because the
contralateral tube is abnormal in more
> than 50% of women and, subsequently,
an appreciable proportion will experience
► either another ectopic pregnancy or per
manent, involuntary infertility.2 Lawson
■Tait3 was the first to advocate laparo
tomy in the presence of bleeding in an ec* topic pregnancy; his series of five patients
included one woman who underwent a
conservative procedure and subsequenty ly died. Early reports4,5 indicated that
conservative procedures could be follow►ed by successful pregnancies, while recent
reports6'8 indicate a very high rate of

A 31-year-old woman (G,T,P,A,L 3,1,0,2,1)
complained of vaginal bleeding and pain in the
right lower quadrant. She had had two
previous ectopic pregnancies; the first had
resulted in a left salpingectomy 4 years
previously and the second in removal of an ec
topic pregnancy from the right tube at another
centre, 23 days before the present admission,
through a midsegment salpingotomy with
primary closure. The patient was well
postoperatively with the exception of daily
vaginal spotting. Pain had begun in the right
lower quadrant 3 days before the present ad
mission. She appeared healthy and her vital
signs were stable. On pelvic examination, a
tender firm mass was found in the right
adnexa. The uterus was of normal size. The
serum human chorionic gonadotropin (/3HCG) level was 65 IU /L.
At laparotomy the right fallopian tube was
distended. Tissue extruded from the fimbriated
end of the tube and from a dehiscence in the
salpingotomy incision (Fig. 1). As a result of
previous discussions with the patient regarding
her future wishes for fertility, a partial sal
pingectomy was done in such a way that a

X '—
From the Department o f Obstetrics and
A Gynecology, McMaster University,
Hamilton, Ont.

Discussion

This case is similar to previously
reported cases of delayed hemorrhage
following a conservative procedure for
tubal pregnancy.11,12 The symptoms
developed 2 to 5 weeks after the initial
operation. Delayed hemorrhage occurred
after both linear salpingostomy and am
pullary expression of gestational tissue.
The serum levels of /3-HCG were not
serially measured to zero although in all
cases in which the assay was done, ap
preciable levels were found. There was
histologic evidence of invasion of the
fallopian tube by gestational tissue in
all but one case which demonstrated
decidual tissue.
The major concerns with respect to
delayed hemorrhage are, first, prevention
and second, early diagnosis, before tubal
rupture and intraperitoneal hemorrhage
occur. Ligation of the vessels in the
mesosalpinx adjacent to the implantation
site has been advocated.13 Frozen sec
tions o f the resection line may be par
ticularly helpful if a partial salpingectomy
is performed, as it is of benefit to main
tain as much of the normal tube as possi
ble. This condition can be identified ear
ly by serial measurement of serum /3-HCG
levels. This should be done to ensure that
the level becomes undetectable. In the
management of tubal gestation with either
salpingotomy or partial salpingectomy,
the patient should be made aware of the
possibility of residual gestational tissue,
as part of the informed consent.
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reanastomosis could be performed later. To en
sure that all of the gestational tissue was re
moved, frozen sections were done of the lines
proximally and distally. Three days postopera
tively, the serum level of /3-HCG was 9 IU /L
and at 19 days the serum /3-HCG level was no
longer detectable. There are no immediate
plans to do the ampullary isthmic reanastomo
sis.

FIG. 1— Ectopic pregnancy involving am
pulla of right tube. Tissue extrudes through
dehiscence in salpingotomy incision (A) and
distal end of tube (B).
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Cyclosporine in Cardiac Transplantation
Since 1981 the authors have performed
14 orthotopic heart transplantations and
one heart-lung transplantation, using
cyclosporine and prednisone as immuno
suppressants. Eight of the recipients had
terminal congestive cardiomyopathy and
six had ischemic cardiac dysfunction.
The combined heart-lung transplantation
was performed on a patient with a con
genital ventricular septal defect with
Eisenmenger's syndrome. Twelve of the
patients were alive and well at follow-up
9 to 34 months (mean 17.4 months)
after transplantation. One patient died of
acute rejection and one of acute pan
creatitis and secondary peritonitis. The
third death, due to acute right ventricular
failure, occurred immediately after
transplantation. Rejection was diagnosed
histologically on seven other occasions
in four patients and was treated suc
cessfully. Infection was not a major pro
blem. Cyclosporine-induced reversible
nephrotoxicity was evident in 12 pa
tients, 2 of whom required dialysis.
Other side effects of cyclosporine seen
in these patients included hypertension,
gastrointestinal upset, headaches and
hirsutism.
This experience suggests that cyclo
sporine is a potent immunosuppressive
agent that has greatly reduced the
hazards of rejection and infection.
However, the frequency of nephro-
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toxicity is high; careful monitoring of
cyclosporine blood levels and renal func
tion is essential.
Depuis 1981, les auteurs ont effectue
14 transplantations cardiaques en posi
tion normale et une greffe coeur-poumon, utilisant comme immunosuppresseurs la cyclosporine et la prednisone.
Huit receveurs souffraient de cardiomyopathie congestive terminale et six d'ischemie cardiaque. La transplantation
coeur-poumon a ete pratiquee chez un
patient ayant une communication interventriculaire congenitale et presentant un
syndrome de Eisenmenger. Douze pa
tients vivent encore et sont en bonne
sante de 9 a 34 mois (moyenne de 17.4
mois) apres la greffe. Un patient est
mort apres un rejet aigu et un deuxidme
d'une pancreatite aigue avec peritonite
secondaire. Le troisieme deces, du a une
insuffisance ventriculaire droite aigue,
est survenu immediatement apres la
greffe. Un rejet a ete diagnostique histologiquement en sept autres occasions
chez quatre patients et traite avec succes. L’infection n'a pas ete un probieme
majeur. Chez 12 patients, la cyclosporine
a provoque une nephrotoxicity reversible
qui, dans 2 cas, a necessity la dialyse.
Les autres reactions indesirables observees chez ces patients comprennent
hypertension, malaises gastrointestinaux, cephalees et hirsutisme.
Cette experience montre que la cyclos
porine est un immunosuppresseur puis
sant qui reduit considerablement les risques de rejet et d'infection. Toutefois, la
frequence des reactions de nephrotoxi
city est yievee; la surveillance des taux
sanguins de cyclosporine et de la fonction renale est primordiale.
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The success of most cadaveric transplant
operations depends on good surgical
technique, safe and effective immunosup
pressive therapy and reliable methods for

the early diagnosis of rejection. The
technique of orthotopic heart transplant s
tation has changed little since the first suej
cessful operation in 1967. The principal *
problem with cardiac transplantation in t ■
its first decade was inefficient im
munosuppression, with the majority of *
the patients dying of rejection or infec
tion. The poor survival rates dampened* jj
the initial enthusiasm shown at many
centres.
In the last 5 years there has been a
;
resurgence o f interest in c a rd ia c ’"*
transplantation, primarily owing to the
introduction of cyclosporine as an im- J
munosuppressant and to a better under- _
standing of the immunology of rejection.
The beneficial effect of cyclosporine in'
enhancing graft survival in experimental
and clinical renal and cardiac allografting * ;
is well established.1-5
This study reflects our experience us- "*
ing cyclosporine and prednisone in 14
heart transplantations and one combined ’
heart-lung transplantation.
y ^
Patients

Since April 1981, 14 patients (12 men,
2 women) have received orthotopic car- ,
diac allografts at University Hospital in
London, Ontario. Eight of these had ter- 4
minal congestive cardiomyopathy and six
j
had ischemic cardiac failure. Patients ranged in age from 18 to 52 years. A
36-year-old man with Eisenmenger’s syn- '*
drome due to a congenital ventricular septal defect received a heart-lung transplant. "
At follow-up between 9 and 34 months, 4
(mean 17.4 months), 12 of the 15 reci
pients were alive and well. All the 11 sur- *
viving heart-transplant patients were in
functional class I or II (New York Heart -*
Association classification). The progress
in hospital of the heart-lung recipient was *"
complicated by acute pancreatitis and ^ i
pancreatic fistula. At 9-month follow-up '
he was in functional class II.
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Three patients died. One died on post
operative day 40 of acute pancreatitis and
*■secondary fulminating peritonitis. One
patient died on day 46 of acute rejection.
^ The third death occurred immediately
. after transplantation and was due to acute
right ventricular failure.

►>
Immunosuppression
y

Cyclosporine and prednisone were
used in all the patients. The first five pa
tien ts received a loading dose of 20 mg/kg
body weight of cyclosporine orally 4
■- ►hours before operation. Subsequently, the
loading dose was reduced to between 5
t" and 10 mg/kg body weight, depending on
the patient’s renal and hepatic functions.
y Methylprednisone, 500 mg, was given
y intraoperatively following revasculariza
tion of the graft.
/ t Postoperatively, cyclosporine was given
by slow intravenous infusion for the first
4 few days and then orally every 12 hours
to maintain serum trough levels between
A 150 and 250 ng/mL. To maintain optimal
^ blood concentration, the daily dose is be* tween 5 and 7 mg/kg body weight.
i k Prednisone, 1 mg/kg body weight, was
given postoperatively for 1 week and
gradually decreased to a maintenance
dose of 0.15 to 0.2 mg/kg body weight
H-at 4 weeks.
Episodes of graft rejection, confirmed
v by cardiac histologic examination, were
treated with intravenous pulses of
methylprednisolone in a total dose of 40
vmg/kg body weight over 5 days. Serum
levels of cyclosporine were brought to opr timal values and the response to therapy
was assessed by cardiac biopsy.
Immunologic Monitoring
r

In addition to ABO grouping, the reac
tivity of the recipient’s serum (in a search
' for cytotoxic antibodies) is tested before
transplantation against a randomly
selected panel of lymphocytes from nor
mal persons. If it is reactive against more
than 10% of the panel, a direct crossmatch between the recipient’s lympho
cytes and the potential donor’s serum is
«• performed.
Following transplantation, antibody
dependent cell-mediated cytotoxicity,
complement-dependent cytotoxicity and
y lymphocyte-mediated cytotoxicity are
.measured, once a week for the first 3
months, by chromium-51 release assays.
a, The patient’s serum and peripheral
lymphocytes are used against the donor’s
phytohemagglutinin-transformed, cryopreserved splenic lymphocytes and third* party (indifferent) lymphocytes. The reac
tivity of antigen nonspecific lymphocytes
A is assessed by spontaneous blastogenesis.
Serum cyclosporine levels are monitored

twice a week by radioimmunoassay. The
mean spontaneous blastogenesis value
was maximally elevated during the second
week after transplantation, subsequent
ly returning to baseline values. Com
plement-dependent cytotoxicity, antibody
dependent cell-mediated cytotoxicity and
lymphocyte-mediated cytotoxicity were
most prevalent between 2 and 8 weeks
after tran sp lan tation. Spontaneous
blastogenesis was notably elevated on 63
occasions (of 211 tests performed) but ac
companied a histologic diagnosis of re
jection only twice. Similarly, the tests for
complement-dependent cytotoxicity, anti
body dependent cell-mediated cytotoxi
city and lymphocyte-mediated cyto
toxicity were reactive on 40, 77 and 50 oc
casions, respectively, but did not show
any individual relation to rejection. Each
type of toxicity occurred together on eight
occasions and on three of these there was
histologic evidence of rejection.
Rejection was diagnosed histological
ly on endomyocardial biopsy specimens.
Eight rejection episodes were defined in
five patients. The serum trough cyclo
sporine levels were greater than 150
ng/mL on all occasions (range from 152
to 296 ng/mL) and did not correlate with
rejection. Immunofluorescence studies us
ing monoclonal antibodies showed myo
cardial infiltration with T-cell subsets in
15 instances but this was accompanied by
a reactive lymphocyte-mediated cytotoxi
city test only twice.
The ability of the recipient to respond
to donor antigen was examined in vitro
using mixed-lymphocyte culture and cellmediated lympholysis assays. Recipient
lymphocytes obtained before and at
weekly intervals after transplantation
were incubated in microtitre wells with
cryopreserved donor or third-party (indif
ferent) lymphocytes. Lymphocyte pro
liferation was measured by 3H-thymidine
incorporation, and killer-cell generation
by lysis of target cells labelled with 51Cr.
The stimulation index was calculated as
the ratio of the patient’s response to
donor and indifferent lymphocytes in
mixed-lymphocyte culture to response to
the patient’s own lymphocytes. This has
been studied in seven patients, from 3 to
12 months after transplantation. All pa
tients remained fully responsive to the in
different lymphocytes in both assays. In
contrast, there was a diminished response
to the specific donor lymphocytes in four
of the seven patients studied.
Diagnosis of Rejection
Endomyocardial biopsy is the only
reliable method of diagnosing graft rejec
tion; the diagnostic value of currently
used immunologic tests and noninvasive
cardiac investigations is uncertain.2 A
right ventricular biopsy is obtained at

weekly intervals during the first 6 weeks
after transplantation, using the technique
described by Caves and coworkers.6 The
histologic features are interpreted and
graded according to the criteria described
by Billingham.7 To warrant a diagnosis
of rejection, evidence of myocytolysis
or heavy infiltration of proliferating T
lymphocytes, which take up U nnaPappenheim stain, or both, is essential.
A weak-staining lymphocytic interstitial
infiltrate is normally seen in most
cyclosporine-treated grafts.
The myocardial histology has been
shown8 to reflect pulmonary paren
chymal histology in patients who have
undergone heart-lung transplantation.
Complications of Immunosuppression
The most important complication of
cyclosporine treatment is nephrotoxicity.
Six of our patients had renal failure; two
of these required dialysis. Six other pa
tients had oliguria with biochemical
evidence of renal damage. The sequence
of events leading to renal failure appears
to be consistent. The loading dose of
cyclosporine is given orally 4 hours before
operation. Before and during the opera
tion, adequate diuresis is ensured and this
persists for 4 to 6 hours after operation.
Thereafter, the urine output decreases
despite optimal hydration and hemody
namic status. The response to diuretics is
minimal. The serum cyclosporine levels
have ranged between 50 and 400 ng/m L.
Serum levels o f renin, urinary Nacetyl-0-glucose am inidase, gam m aglutamyl transferase and /3-2-micro
globulin were all elevated and remained
so for 2 to 4 weeks. With conservative
treatment the diuretic phase starts in 48
to 72 hours and the serum levels of elec
trolytes, creatinine and urea rapidly
return to normal. The severity of these
changes has been reduced by using con
trolled intravenous infusion of cyclo
sporine postoperatively until renal func
tion has become stable.
Acute pancreatitis occurred in two pa
tients, both during the third week after
transplantation. One patient died on day
40 with secondary peritonitis. The second,
the patient who received a heart-lung
transplant, convalesced slowly with a
draining pancreatic fistula and was in
hospital for more than 6 months.
Although the serum bilirubin value
rises with high cyclosporine levels, hepatotoxicity has not been a problem
clinically.
There have been no cases of bacterial
or fungal infection. Rising cytomegalo
virus titres were seen in three patients but
there were no symptoms clinically. One
patient had a herpes simplex infection of
the mouth which resolved w ithout
treatment.
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Hypertension, predominantly systolic,
was seen in eight patients. Headaches and
abdominal discomfort have been asso
ciated with high cyclosporine levels
(greater than 400 ng/mL). Hirsutism is
common but was troublesome only in the
two women.
Convulsions occurred in the first week
after transplantation in three patients and
resolved without sequelae. The cause of
this complication is unclear.
Discussion
An increasing number of transplanta
tion centres are using cyclosporine as the
major immunosuppressant. During the
last 5 years, the 1-year survival following
cardiac transplantation has improved to
more than 80% and the expected survival
at 5 years to more than 50%. Our ex
perience shows the advantage cyclo
sporine has over conventional immuno
suppressants. The incidence of rejection
has been low (one episode per 400 pa
tient-days at risk) compared with
conventionally treated patients in whom
the rate has been 5 to 10 times greater.9
None of the patients had clinically evident
infection, compared with a figure of 51 %
in a group o f patients for whom conven
tional immunosuppressants were used.
We have not seen any lymphomas and we
have not used antithymocyte globulin.
The dose of prednisone is rapidly reduced
to a maintenance dose of 0.15 to 0.2
m g/kg body weight, thereby mitigating
many of its side effects.
In contrast to conventional im 
munosuppression, the peripheral lympho
cyte count remains near normal (24% ±
7%) with adequate cyclosporine therapy
and does not reflect the degree of
immunosuppression.
Nephrotoxicity has been a major prob
lem with cyclosporine therapy. Lowering
the loading dose of the immunosuppres
sant, ensuring adequate urine output
before, during and after operation, and
maintaining safe serum cyclosporine
levels (150 to 250 ng/mL) by controlled
intravenous infusion postoperatively
(starting with 0.75 to 1 mg/kg body
weight over 12 hours) should reduce the
renal problems.
M easuring and com paring im 
munologic indices such as the antibody
dependent cell-mediated cytotoxicity and
lymphocyte-mediated cytotoxicity, and
spontaneous blastogenesis, and using
mixed-lymphocyte culture and cellmediated lympholysis assays were thought
to be valuable in predicting graft
rejection.10 However, recent studies do
not support this contention. In our own
series, the correlation between these im
munologic tests and graft histology re
mains to be determined.
In cyclosporine-treated patients who
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have undergone cardiac transplantation,
noninvasive tests for diagnosing rejection
have been o f little value. Echocar
diography revealed subtle volume changes
in one patient preceding a rejection
episode. It also revealed septal and left
ventricular wall thickening in six patients
and an increase in right ventricular endsystolic volume in four patients. These
findings coupled with radionuclide angio
graphic evidence of a normal left ven
tricular ejection fraction that does not in
crease with exercise suggest a change in
myocardial compliance and emphasize
the need for long-term histologic follow
up. Two of our patients have shown in
creasing fibrosis of their myocardium. A
kidney biopsy specimen from one of these
patients 18 months after transplantation
showed extensive interstitial fibrosis,
tubular basement membrane thickening
and tubular atrophy. These effects of
cyclosporine will need long-term assess
ment.
Our observations on the use of cyclo
sporine in this small group of patients
suggest that it is a safe and effective im
munosuppressant at serum trough levels
between 150 and 250 ng/m L, the risk of
rejection and infection are greatly reduc
ed and the results of cardiac transplanta
tion in terms of survival, palliation and
functional rehabilitation are encouraging.
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Postanal Repair to Restore Fecal Continence after
Failed Sphincteroplasty
The traditional procedure of delayed
repair of the sphincters and perineor
rhaphy failed to restore continence to a
3 1 -year-old woman who had fecal incon
tinence following obstetric trauma. Suc
cessful control was achieved by postanal
surgical repair. This case report shows
that good results are possible by
reconstruction of the anorectal angle
even after failed sphincteroplasty.
L'intervention classique comprenant
reparation retardge des sphincters et
perineorraphie n'a pu retablir le fonctionnement normal du sphincter anal chez
une femme de 31 ans souffrant d'incontinence des matures fecales a la suite
d'un traumatisme obstetrical. Un bon
contrdle a ete obtenu par reparation chirurgicale postanale. Cette observation
demontre que de bons resultats sont
possibles quant on a recours a la recons
truction de I'angle anorectal meme aprfes
I’echec de la sphincteroplastie.

Fecal continence is partially maintained
by efferent spinal motor fibres that keep
a constant tone in the striated puborectalis muscle. This muscular sling creates
the flap-like valve o f the anorectal angle,
which is responsible for gross continence
o f solid stool but cannot control gas or
prevent mucous soiling.1
Disruption o f the sphincters during
childbirth is by far the most common
cause of incontinence. When this hap
pens, the recommended treatment is
sphincteroplasty with direct suture o f the
damaged muscles.2
Incontinence may not be associated
with trauma. Parks1 has suggested that
From the Department o f Surgery,
McMaster University, Hamilton, Ont.
*Research Fellow, tAssociate Professor,
Department o f Surgery, McMaster
University

idiopathic incontinence occurs in subjects
who habitually strain and lose the anorec
tal angle. In such circumstances, good
results have been achieved with postanal
repair.3
We recently treated a patient in whom
fecal incontinence developed following
obstetric trauma. Sphincteroplasty
resulted in little improvement. Con
tinence, however, was achieved after
postanal repair, which has not previous
ly been recommended for persistent in
continence after sphincteroplasty.

Case Report
A 31-year-old woman had incontinence o f
gas and stool. Four years earlier labour had
been complicated by a fourth degree tear in
volving the vagina and rectum. A primary
repair resulted in no residual sphincter dysfunc
tion. Two years later during labour, she sus
tained a second tear involving the vagina, rec
tum and anal sphincters. Immediate repair was
unsuccessful. Although there was complete in
continence o f gas and stool, urinary continence
was unaffected.
Six months later she underwent anal sphinc
teroplasty with overlapping o f the external
sphincter muscles. There was improvement for
3 months, then her symptoms returned. She
suffered from urgency o f defecation and any
rise in intra-abdominal pressure caused soiling.
Examination o f the perineum revealed a lax
sphincter with a grossly increased anorectal
angle.
Postanal repair was carried out. Through a
postanal incision and intersphincteric ap
proach, Waldeyer’ s fascia was divided to ex
pose the mesorectal fat. The rectum was then
angled forward by successive plication o f the
pubococcygeus, puborectalis and external
sphincter from above downwards. Skin closure
with vacuum suction drainage resulted in
primary healing.
Eighteen months after her repair she had
control o f solid stool but not o f gas. She was
delighted with the result, had no soiling and
no longer had urgency o f defecation. Examina
tion revealed a lax sphincter with decreased
squeeze pressure but a normal anorectal angle.
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the condition occurs with impaction,
aperients may be all that is necessary.
Even healthy subjects may have soiling
with severe diarrhea and this will usually
respond to constipating agents. Once muscle or nerve damage has occurred,
other measures are necessary. Medical 4
treatment includes exercise o f pelvic
musculature using implanted electrodes or
an external anal plug stimulator.4'5 This
usually gives disappointing results but,
more recently, some success has been a
reported using biofeedback to retrain the
anal sphincter.6 Operation is indicated if *
these measures fail and the patient does
not wish to resort to daily rectal irriga
tions.
For incontinence with no ob v iou sM
cause, several procedures have been
recom m ended,7’9 including postanal
repair.1 This operation restores con- .
tinence in 85% o f patients.10 If incon
tinence is caused by surgical or obstetric trauma, sphincteroplasty is the procedure
o f choice.2 Direct repair o f the sphincter ■*
in such cases has a success rate o f about
85 % ,3 but what operation should be o f
fered the failures?
Parks and associates11 demonstrated
that traction on the pudendal nerves from ,
repeated depression o f the perineum in
patients who habitually strain to evacuate stool results in atrophy and loss o f tone
in the puborectalis. Postanal repair at
tempts to restore this tone and reconsti
tute the anorectal angle. Although
obstetric trauma usually damages muscles
rather than nerves, either may be injured.
It seems probable that both these factors „
were present in our patient since sphinc
teroplasty alone did not restore conti
nence.
No conclusions can be drawn from one ”
case but we believe that if sphinctero
plasty fails to restore continence, good '
results are possible with postanal repair.

Discussion
The treatment o f fecal incontinence
depends on its cause and severity. When
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, Effects of Crystalloid and Blood Cardioplegic Solutions on
- Myocardial Cooling during Myocardial Revascularization
V ■

____________________________________________________________________________________________________

'

^Cardioplegic protection during ischemic
arrest is impaired in patients with serious
coronary artery disease, resulting in large
4 regional temperature gradients and im
paired myocardial cooling. Recent data
4 have suggested that the viscosity of car
dioplegic solutions may affect their
i ^distribution beyond coronary artery
stenosis. This study compared the ef
fects of asanguineous and blood car
dioplegic solutions on myocardial cooling
*An 26 such patients who underwent elec
tive myocardial revascularization; 15
were subjected to blood cardioplegia and
y 11 to crystalloid cardioplegia. One litre
of blood or asanguineous cardioplegic
- solution was infused into the aortic root
at a constant infusion pressure. Samples
rfo r viscosity determination were taken
from both cardioplegic solutions during
v their infusion. Regional myocardial
temperature was measured distal to
coronary artery obstructions following
i._ administration of the cardioplegic agent.
Although the viscosity of the blood
►
solution was 250% greater than the
asanguineous solution, regional myocarr dial temperatures were not significantly
different beyond the coronary artery
' stenosis. Regional temperature was
reduced to less than 15°C after infusion
of the cardioplegic agent in regional
^myocardium with a normal coronary cir
culation. Marked temperature gradients
f. were observed distal to a critical
stenosis, with temperatures ranging be
tw e e n 18°C and 2 0 °C for stenosis, and
about 23°C for obstruction. The authors
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conclude that the marked difference in
viscosity between crystalloid and blood
cardioplegic solutions does not
significantly affect their distribution
beyond a coronary artery stenosis.
Chez les patients qui souffrent de maladie coronarienne grave, la protection du
myocarde par la technique de cardioplegie est affectee, ce qui entraine localement un large gradient de temperature et
une diminution du refroidissement du
myocarde. Des donnees recentes indiquent que la viscosity des solutions utilisees pour la cardioplegie peut affecter
leur distribution au-dela de la stenose
coronarienne. La prgsente etude compare
les effets de solutions sanguine et non
sanguine de cardioplegie sur le refroidis
sement myocardique de 26 patients
coronariens qui ont subi une revasculari
sation myocardique non urgente; 15 ont
ete soumis a une cardioplegie sanguine
et 11 a une cardioplegie a I’aide d'un
cristalloTde. Un litre de solution sanguine
ou non sanguine de cardioplegie a ete
perfuse a la racine de I'aorte a pression
constante. Des echantillons des deux
solutions de cardioplegie ont ete preieves
en cours de perfusion afin d'en determi
ner la viscosite. Apres I'administration de
I'agent de cardioplegie, la temperature
myocardique regionale a ete mesuree en
position distale par rapport aux obstruc
tions des arteres coronaires.
Bien que la viscosite de la solution
sanguine ait ete 250% plus grande de
celle de la solution non sanguine, les
temperatures myocardiques regionales
obtenues au-dela de la stenose avec
I'une ou I'autre n'etaient pas significativement differentes. Dans la region du
myocarde irrigue par une circulation
coronarienne normale, la temperature
s'est abaissee a moins de 15°C apres la
perfusion cardiopiegique. De nets gra
dients de temperature ont ete observes

dans les cas de stenoses importantes, la
temperature distale variant entre 18°C et
20 °C pour une stenose et atteignant
pres de 23°C pour une obstruction. Les
auteurs concluent que les differences de
viscosite marquees entre les solutions de
sang et de cristalloide utilisees pour fins
de cardioplegie n'influencent pas de
maniere importante leur distribution audela des stenoses des coronaires.

Asanguineous and blood cardioplegic
solutions are now used routinely to pro
vide myocardial protection during
ischemic arrest.1 However, the effec
tiveness of these solutions is limited in pa
tients with serious coronary artery
disease2’3 because coronary artery
stenosis prevents the uniform distribution
of cardioplegic solution to regional
myocardium, resulting in large tem
perature gradients and impaired cool
ing.45 A recent report, comparing the
delivery of asanguineous and blood car
dioplegic solutions beyond coronary
artery stenosis, has suggested that the
blood with its greater viscosity provides
better poststenotic delivery of cardiople
gia to regional myocardium than do asan
guineous solutions.6
This study was designed to compare
regional myocardial cooling during infu
sion of blood and asanguineous car
dioplegic solutions in patients with severe
coronary artery disease who underwent
elective myocardial revascularization.
Patients and Methods
Coronary angiography, using the
Seldinger technique, was performed in 26
patients before they underwent coronary
artery bypass. The results of angiography
divided the coronary arteries into three
separate groups: the normal arteries,
those with important stenosis indicated by
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a reduction of intraluminal diameter
greater than 70% and occluded arteries.
The protocol for anesthesia and in
traoperative monitoring techniques were
as described previously.5 A fter ad
ministering heparin (3 mg/kg) systemically, we cannulated the ascending aorta
with a no. 20 French USCI cannula
(USCI Surgical Products, Billerica,
Mass.) and venous return was provided
by a 51 two-stage Sams cannula (Sams
Inc., Ann Arbor, Mich.). Cardiopul
monary bypass was established and the
patient was cooled to 28°C. The aorta
was then clamped and the heart arrested
with 1 L of asanguineous crystalloid (11
patients) or blood cardioplegic (15 pa
tients) agent (potassium 20 mmol/L)
(Table I), which was injected directly in
to the ascending aorta through a 14-gauge
angiocatheter delivered by a Sams lowflow pump. Perfusion pressure was main
tained within the range of 90 to 110 mm
Hg by adjusting flow and was monitored
with a second 14-gauge angiocatheter.
Myocardial temperature was measured
over the left anterior descending, cir
cumflex and right coronary artery areas
with the Shiley digital temperature
probe (Shiley Corp., Irvine, Calif.).
Regional myocardial temperature was
recorded following potassium cardiople
gia (infusion of 1L of solution) and after
the use of topical hypothermia (4 L of
plasmalyte solution at a mean tempera
ture of 4°C).
The coronary artery bypass was con
ducted in a similar manner in each pa
tient. The distal anastomoses were com
pleted using a single cross-clamping with
the proximal anastomosis being per
formed during rewarming. After each
distal anastomosis was completed, more
cardioplegic solution was injected directly
through the vein graft and more topical
hypothermic agent was used to maintain
myocardial temperature below 15°C.
Samples were taken from both blood
and crystalloid cardioplegic solutions dur
ing their administration for later measure
ment of viscosity with a Fann rotating
viscometer (Fann Inc., Houston, Tex.).
Viscosity was measured at 6°C (the
temperature of the cardioplegic solution
during its administration), 28°C (core
temperature of the patient during car
diopulmonary bypass) and at 37°C for
comparison.

Results have been reported as the
arithmetic mean ± standard error. The
unpaired Student’s /-test was used where
appropriate to determine statistical sig
nificance.
Results
The mean age, number of grafts per pa
tient and cardiac disability, using the New
York Heart Association classification,
were similar in both patient groups (Table
II).
The results of the viscosity determina
tions are represented in Table III. The
viscosity of both solutions was measured
at three temperature ranges to demon
strate the difference in viscosity between
blood and crystalloid solutions with
change in temperature. The difference in
viscosity between blood and crystalloid

solutions was striking at 6°C (the
temperature of the cardioplegic solutions
during their infusion). The viscosity of the
blood solution was 250% greater than the *
asanguineous solution (p < 0.01). Similar ^
results were obtained for the solutions
when measured at 28°C and 37°C.
4
Regional myocardial temperatures fol
lowing the infusion of 1 L of crystalloid^ <
or blood cardioplegic solutions (6° to
8°C) indicated that the solutions had *
similar effects on myocardial cooling
regardless of the severity of coronary
artery disease. Myocardial temperature^,
was reduced to less than 15°C following
the infusion of either cardioplegic solu-« tion in regional myocardium supplied by
a normal coronary artery (Fig. 1).
Significantly (p < 0.01) warmer tempera
tures, ranging between 18° and 20°C, '
were measured distal to severe coronary
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FIG. 1—Myocardial cooling with varying degrees of coronary artery obstruction. Shaded 1
area represents myocardial temperature in safe operative range. Figures are means ± standard" *
error.

VOLUME 27, NO. 3, M A Y 1984 / THE CANADIAN JOURNAL OF SURGERY

artery stenosis following the infusion of
cardioplegic solution but were similar for
* blood and asanguineous solutions.
Myocardial temperature was about 23 °C
A for both cardioplegic solutions in regional
myocardium supplied by a completely oc^ eluded coronary artery; this temperature
.was significantly (p < 0.01) higher than
* that of myocardium with a normal cirk culation. Despite the presence of severe
coronary artery disease, the regional
v temperature was reduced to less than
15°C after the use of topical cooling.

-

^Discussion

*

Cardioplegic preservation is now a
well-established technique for protecting
K the myocardium during ischemic arrest.
The infusion of cold potassium solution
directly into the coronary circulation not
►only results in a rapid diastolic arrest,
preserving high-energy phosphates, but
A also reduces myocardial temperature,
thereby lowering metabolic demands.7
*
The optimal vehicle for delivering
the potassium is controversial, although
* more data are accumulating to indicate
Athat blood may provide better myocardial
preservation than an asanguineous solu
tion, because of its oxygen-carrying
capabilities.811 However, regardless of
►
.the type of cardioplegic agent used dur
ing cardiac surgery, cardiac preservation
v is limited in the presence of severe coro
nary artery disease. Coronary stenosis
prevents the uniform distribution of car
dioplegic solutions to regional myocar
dium, resulting in large myocardial
temperature gradients and impaired
cooling.4 Recently, Robertson and
v colleagues6 have suggested that blood
solutions may be superior to
-asanguineous solutions because of their
greater viscosity. Using an animal model,
^ they infused both blood and asanguine
ous solutions into the aortic root at a con' stant rate with simulated left anterior descending coronary artery stenosis.
Although their data demonstrated
►
significantly higher poststenotic flow of
blood solutions, mean aortic infusion
► pressure (82 mm Hg) in these animals was
significantly higher than in those receivMng the asanguineous solution (48 mm
Hg). The interpretation of these data is,
^ therefore, subject to some criticism be
cause of the large differences in aortic in
fusion pressure between the blood and
► crystalloid solutions. The aortic infusion
pressure during the administration of carAdioplegic solutions may significantly in
fluence the distribution of solution to
* regional myocardium in patients with cor
onary artery disease, as indicated by
tngelman and colleagues.12
. ^ Our study was designed to determine
* whether viscosity would affect myocardial
cooling during the administration of car

dioplegic solutions in patients with severe
coronary artery disease. Mean cardiople
gic infusion pressure was kept in a cons
tant range for blood and asanguineous
solutions by adjusting the rate of infu
sion. Despite the large difference in
viscosity between blood and asanguineous
cardioplegic solutions, we failed to
demonstrate any difference in regional
myocardial temperatures. Regional
myocardial temperatures recorded after
the delivery of cardioplegic solutions did
not differ significantly between the
two patient groups regardless of the
degree of coronary artery disease. These
data indicate that the viscosity of car
dioplegic solutions has relatively little in
fluence on their poststenotic distribution
and confirm our previous observations
that large temperature gradients and
uneven myocardial cooling are routinely
observed following the administration of
cardioplegic solutions in patients with
severe coronary artery disease.4
Our attempts to modify the distribution
of cardioplegic solutions in patients with
coronary artery stenosis have been unsuc
cessful. Encouraged by previous reports
indicating that intracoronary administra
tion of nitroglycerin may redistribute
blood flow to areas of regional ischemia,
we attempted to improve the delivery of
cardioplegic solution beyond coronary
artery obstructions by adding nitrogly
cerin to standard blood cardioplegic
solutions.5 However, therapeutic doses
of nitroglycerin did not result in any
significant difference in regional myocar
dial cooling and large temperature gra
dients persisted in areas of regional
ischemia, despite the use of this
vasodilator.
The risk of intraoperative ischemic in
jury is greatest in poststenotic regional
myocardium, because these areas
paradoxically receive the least effective
regional cardioplegic preservation. This
critical situation may be modified to some
extent by using the following guidelines,
which attempt to individualize the preser
vation techniques used during ischemic
arrest: the judicious use of topical cool
ing during the initial arrest combined with
continuous temperature monitoring can
ensure myocardial temperatures of less
than 15°C throughout the ischemic
period,4 the most ischemic region should
be revascularized first since this area of
myocardium has received the least effi
cient myocardial preservation during the
initial arrest; following completion of
each distal anastomosis, cardioplegic
solution should be injected directly into
the vein graft, thereby bypassing the
proximal coronary obstruction and pro
viding more effective distribution of car
dioplegic solution. All of these techniques
cannot completely overcome the maldis
tribution of cardioplegic solution in pa

tients with coronary artery disease but
should decrease the risk of intraoperative
injury by providing improved cold
potassium cardioplegic delivery to areas
of regional ischemia.
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jf infectious mononucleosis. PIPRACIL* should be used with caution in the treatment of patients with infeclononucleosis.
eracfconsJhe mixing of PIPRACIL* with an aminoglycoside in vitro can result in substantial inactivation of the
llycosides.
luring Pregancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined. Because
•reproduction studies are not always predictive of human response, this drug should be used during pregnancy
clearly needed. It has been found to cross the placenta in rats. Caution should be exercised when PIPRACIL*
nistered to nursing mothers. It is excreted in low concentrations in milk.
' Usfr Dosages for children under the age of 12 have not been established.
- REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been local in
following intravenous or intramuscular injection. The following adverse reactions may occur:
T\ Reactions - In clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or indurathe injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis and
imas^
ypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less frequent findings; pruitis,
ar eruptions, positive Coombs tests.
gtrolnfpstinal- Diarrhea and loose stools were noted in 2.8% of patients. Less frequent reactions: vomiting,
, bloody diarrhea.
patic- Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
mat ^Elevations of creatinine or BUN.
ntral Nervous System - Headache, dizziness, fatigue.
imic and Lymphatic - Reversible leukopenia, neutropenia, thrombocytopenia and/or eosinophilia, bleeding and
ses>in prothrombin time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in
s receiving prolonged therapy at high dosages or in association with drugs known to cause this reaction,
rum Electrolytes - Individuals with liver disease or individuals receiving cytotoxic therapy or diuretics, were
d rarely to demonstrate a decrease in serum potassium concentrations with high doses of PIPRACIL*
Jsculo-Skeletal - Rarely, prolonged muscle relaxation.
jjer-Ruperinfection, including candidiasis.
*ND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injecinfusion. Dosage and route of administration should be determined by the severity of the infection and
m of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
infusion administered intravenously.
e maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

h

DOSAGE
Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intra
abdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

Usual Total
Daily Dosage
12-18 gl.V.
(200-300 mg/kg)

Frequency of
Administration
Every 4 to
6 hours

8-16 gl.V.
(125-200 mg/kg)
6-8 g I.M. or I.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 to
12 hours
Single dose

*One gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Creatinine
Urinary Tract
Urinary Tract
Clearance
Infection
Infection
mL/min.
(uncomplicated)
(complicated)
>40
No dosage adjustment necessary
20-40
No dosage adjustment necessary 9 g/day 3 g every 8 hrs.
<20
6 g/day 3 g every 12 hrs.
6 g/day 3 g every 12hrs.
Patients on
Hemodialysis*

Serious Systemic
Infection
12 g/day 4 g every 8 hrs.

8 g/day 4 g every 12 hrs.
“Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs.
1 g additional dose should be administered following each dialysis period.

For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provide
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient’s clinical and bacteriological progress. For most
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asympto
matic.Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. daily
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for m ainte
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium
treatment. Administration should not exceed 2 g. per injection at any one site. This route has been used primarily in
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12Years of Age: The reconstituted solution is given by deep intramuscular injection. The
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given in the
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only with caution
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein irritation.
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent infusion
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to discontinue
the primary intravenous solution. Any unused portion must be discarded. For continuous infusion the solution may
be administered over a longer period of time.
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
“Bacteriostatic Water for Injection,
**Lidocaine HC1 0.5 or 1%(without epinephrine)-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required,
“Bacteriostatic Water for Injection.
‘ Either parabens or benzyl alcohol.
**Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetics of
the amide type.
RECONSTITUTION TABLE
Product
VOLUME OF
Approximate
Approximate
Size
Diluent to be added
Available Volume
Average Concentration
Vials 2 g
4.0 mL
5.0 mL
1 g/2.5 mL
3g
6.0 mL
7.5 mL
1 g/2.5 mL
7.8 mL
48
10.0 mL
1 g/2.5 mL
Infusion Bottles
3g
15 mL
17 mL
4g
20 mL
23 mL
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
Intravenous Admixtures:
5% Dextrose in Water [D5W]
Normal Saline (+KCL 40 mEq).
0.9% Sodium Chloride (Normal Saline) [NS],
5% Dextrose/Water [D5W] (+KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride [D5NS],
5% Dextrose/Normal Saline [D5NS] (+KCL 40 mEq).
Lactated Ringer’s Injection, U.S.P.
Ringer’s Injection, U.S.P. (+KCL 40 mEq).
Dextran 6 % in 0.9% Sodium Chloride.
Lactated Ringer’s Injection, U.S.P. (+KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with recom
mended diluents and further diluted with the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at room
temperature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recom
mends discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated If used
as a multi-dose container, the vials must be reconstituted only with the bacteriostatic diluents noted above.
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous administration with
solutions containing sodium bicarbonate
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently with aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation of the aminoglycoside.
DOSAGE FORMS: PIPRACIL*(sterile, lyophilized piperacillin sodium) is available in vials containing amounts of pipera
cillin sodium equivalent to 2,3 and 4 grams of piperacillin. Available in boxes of 12 vials
Product Numbers: 2 g /v ia l- 3879-48 3 g/vial-3882-49 4 g /v ia l-3880-50
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium
powder equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles
Product Numbers: 3 g /b o ttle s-3882-41 4 g/bottles - 3880-42
Piperacillin Sensitivity Discs impregnated with 100 ug of piperacillin are also available
Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C (59-86°F)
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
“PIPRACIL is a trade mark of Lederle Piperacillin, Inc.

Cyanamid Canada Inc.
Toronto
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Asynchronous Pheochromocytoma in Childhood
A case of asynchronous pheochromocy
toma in a 13-year-old boy is reported.
Two years elapsed between excision of
the right adrenal gland and the ap
pearance of another tumour in the con
tralateral gland. Selective central venous
sampling for plasma catecholamine
measurement and adrenal phlebography
were of diagnostic value. Excision of the
tumour with partial adrenalectomy was
the preferred surgical treatment in the re
maining contralateral adrenal; no clinical
or biochemical abnormalities were
observed 2 years after removal of the
second pheochromocytoma. This case
stresses the importance of a closer
follow-up in children for early detection
of a second pheochromocytoma.
Un cas de pheochromocytome asynchrone est rapporte chez un garpon de
13 ans. Une periode de 2 ans s'est
ecoulee entre I'ablation de la glande surrenale droite et I'apparition d'une autre
tumeur dans la glande contralaterale.
Des prelfevements dtagds dans la veine
cave pour mesure des catecholamines
plasmatiques et une venographie surrenalienne se sont averes utiles pour dtablir
le diagnostic. L'excision de la tumeur
avec une surrenalectomie partielle a ete
choisie comme approche chirurgicale au
niveau de la surrenale restante contrala
terale; 2 ans apres I'ablation du second
pheochromocytome. Nous n'avons
observe aucune anomalie clinique ou biochimique. Ce cas souligne I'importance
d'un suivi plus assidu chez I'enfant afin
de detecter precocement un deuxidme
pheochromocytome.

pathetic ganglia, the organ of Zuckerkandl, the bladder and, rarely, the thorax.
Although usually unilateral, bilateral
tumours have been reported in 5% to
10% of adult cases1 and 25% of
childhood cases.2 Moreover, in roughly
30% of children the tumours are found
at both adrenal and extra-adrenal sites,
or only at an extra-adrenal site.3 The
rate of recurrence in pheochromocytoma
is not well established because
documented cases are rare; one group has
reported a 10% recurrence rate4 and in
a series of 100 children with pheochromo
cytoma,3 5 had recurrent tumour. Ac
cording to several reports, clinically
malignant disease occurs in about 10% of
adult cases,5 whereas the frequency in
children has been reported to be as low
as 2.4%.2
This report describes the medical and
surgical management of a boy who first
presented with a pheochromocytoma in
the right adrenal gland; almost 2
years after operation, a second tumour in
the remaining adrenal was discovered.
Special emphasis is placed on the need to
rule out other ectopically located
tumours, and on the surgical approach to
tumour in a single remaining adrenal.

elevated, but urinary and plasma epinephrine
values were normal (Table I). Normal values*
were also obtained for serum electrolytes, acidbase balance, urinary sediment, urinary 17-keto y
and 17-hydroxysteroids, plasma cortisol (0800
hours, 690 nmol/L [normal 193 to 690 -x
nm ol/L] and 1500 hours, 215
nmol/L [normal 55 to 248 nmol/L]) and x
plasma calcitonin. Subsequent selective renal ;
arteriography disclosed a well-defined, highly* \
vascular mass, most probably a pheochromocytoma, in the right adrenal (Fig. 1). There was A
no evidence of a similar tumour on the left side. j
Preoperative preparation was initiated by k
giving phenoxybenzamine 20 to 30 mg daily in
three to four divided doses. After 6 days, blood* j
pressure was reduced to 150/100 mm Hg. Pro
pranolol was administered only during the* I
operation by intravenous infusion (0.75 mg/h),
beginning at the time of induction. Right 1
adrenalectomy was performed through an
anterior transverse abdominal incision.*.,
Peroperative manipulation of the tumour j
resulted in substantial increases in blood y
pressure, which fell markedly when the principal vein of drainage was clamped. Intra—,
abdominal palpation did not elicit any suggestion of remaining tumours. The tumouF
measured 2.5 x 2.8 x 3.9 cm; light and electron microscopy confirmed that it was a^
pheochromocytoma. On day 4 postoperative- J
ly, the urinary norepinephrine and vanillyl- y

Case Report

A normally developed 13-year-old boy, the
youngest of seven children, experienced
episodes of profuse sweating, headaches and
blurring of vision. Weight loss and pallor were
also noted. Because of his visual problem, he
was seen by an ophthalmologist. Fundoscopic
examination disclosed bilateral hemorrhages,
exudates and papilledema, that is, grade 4
Keith-Wagener-Barker classification of hyper
tension. The blood pressure was 180/120 mm
Pheochromocytoma, a functional tumour Fig; none of his brothers or sisters were similar
affected, all being normotensive. The elec
of chromaffin tissue, is usually found in lytrocardiogram
showed left ventricular hyper
the adrenal glands, but can also be located trophy; the chest
film was normal.
in a number of ectopic sites including
The
findings
on
laboratory investigation
para-aortic sympathetic and parasym- were as follows; the blood
creatinine value was
61.9 /rmol/L; blood sugar values were 5.9
From the *Department o f Nephrology and mmol/L (fasting) and 6.1 mmol/L (2 hours
t Department o f Surgery, Flotel-Dieu de
postprandial); plasma aldosterone and plasma
Quebec and University Laval, Quebec City, renin activities, measured with the patient
PQ
supine, were elevated at 371.1 pmol/L (nor
mal 66.6 to 288.5 pmol/L) and 2.67 ng/L*s_1
Accepted fo r publication May 2, 1983
(normal 0.30 ± 0.21 ng/L«s'') respectively.
Urinary and plasma norepinephrine levels were
FIG. 1—Arteriogram, late phase, showsReprint requests to: Dr. M. Lebel, Centre
markedly elevated and the urinary tumour (arrows) that measured 3.9 cm in
de Recherche, I’Hotel-Dieu de Quebec,
II Cote du Palais, Quebec, PQ G1R 2J6
vanillylmandelic acid level was slightly diameter in right adrenal.
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gain of 3 kg. Operation was performed through
a transverse abdominal incision. As there was
no evidence of a malignant tumour, we strove
to, and succeeded in, extirpating the tumour
while leaving the normal tissue of the adrenal
intact. The tumour was well encapsulated and
was in no way ruptured during the operation.
The tumour measured 2.2 x 2.0 x 1.2 cm.
Pheochromocytoma was confirmed by light
and electron microscopy.
Because of the likelihood of temporarily per
turbed adrenal function postoperatively,
steroid supplements were given on the day of
operation. The dosage was reduced over the
following 3 weeks and then discontinued with
no untoward effects, indicating autonomous
adrenal function.
The boy did well postoperatively; 7 days
after o p e ra tio n , u rin ary and plasma
norepinephrine as well as blood pressure had
returned to normal levels. After a 2-year
follow-up, blood pressure and catecholamine
levels were normal (Table I).

mandelic acid levels were within normal limits
and there was concomitant, progressive reduc
tion in the blood pressure (Table I). At follow*■ up 1 and 5 months after operation, the urinary
catecholamine and vanillylmandelic acid levels
k were normal, blood pressure was 130/70 mm
Hg and 135/70 mm Hg respectively, and the
►boy had gained 4 kg. We had every reason to
believe he was cured.
► To our surprise, almost 2 years after the ini
tial operation, the boy’s pressure was noted to
be slightly but persistently elevated (150/90 mm
Hg), but there were no clinical signs or sympv toms. Again, plasma and urinary norepi
nephrine and urinary vanillylmandelic acid
►-levels were elevated, whereas plasma and
urinary epinephrine levels were normal (Table
*{). Renal arteriography was repeated, this time
revealing a tumour in the left adrenal (Fig. 2).
v
In order to rule out the presence of other
ectopically located tumours or metastatic
v disease, the inferior vena cava was catheterized
and multiple central venous sampling carried
vout for plasma catecholamine measurement.
As illustrated in Fig. 3, the plasm a
►norepinephrine level was markedly elevated in
the left adrenal and renal vein compared with
A other sites. Peripheral blood samples for
plasma catecholamine measurements were ob4 tained from the patient through a butterfly nee
dle previously inserted into an antecubital vein
kafter 30 minutes of bed rest and after 10
minutes in the upright position. Vena caval
kblood sam ples were o b tain ed under
fluoroscopic control from multiple'sites (Fig.
3) through a catheter introduced by the stand
ard Seldinger technique. Plasma catecholmamine levels were determined by radioenzymatic assay.® The normal values established in
y
our laboratory for norepinephrine, epinephrine
and dopamine are 176 ± 17 pg/m L (SHM)
►-(1.04 ± 0.1 nmol/L), 8.7 ± 3.5 pg/m L (47.5
± 19.1 pmol/L) and 8.6 ± 3.2 pg/m L, res
pectively, after 30 minutes of recumbency, and
457 ± 65 pg/m L (2.7 ± 0.38 nmol/L), 25.6
►± 6.4 pg/mL (139.7 ± 34.9 pmol/L) and 15.5
± 4.6 pg/mL, respectively, after standing for
10 minutes. After venous samplings, phlebo
graphy of the left adrenal outlined the tumour
stnore clearly (Fig. 4).
Phenoxybenzamine treatment was again ini
tiated preoperatively. Plasma volume was in
creased as evidenced by a decrease in
hematocrit from 49.4% to 43.4% and a weight

adult is relatively straightforward. In
children, however, the higher incidence o f
bilateral, multiple and extra-adrenal
tumours makes it imperative for the

The diagnosis and treatment o f solitary
pheochromocytoma o f the adrenal in the

FIG. 3—Plasma norepinephrine (NE), epi
nephrine (E) and dopamine (DA) levels at dif
ferent sites in central venous system before ex
cision of second pheochromocytoma in left
adrenal.

FIG. 2—Arteriogram, late phase, shows
small tumour (arrows) in left adrenal.

FIG. 4—Left adrenal venogram demon
strates mass (arrow) measuring 2 cm in dia
meter within left adrenal gland.

Discussion

T a b l e l - U r i n a r y a n d P la s m a C a t e c h o l a m i n e L e v e l s a n d B l o o d P r e s s u r e b e f o r e a n d a f t e r R e m o v a l o f t h e
R i g h t A d r e n a l P h e o c h r o m o c y t o m a a n d t h e S e c o n d T u m o u r in t h e L e ft A d r e n a l 2 Y e a r s L a t e r
U ri n a r y

P la sm a *
B loo d

T im e

VMA,

NE,

E,

NE,

E,

DA,

pressure,

p im o li d

nm o l/d

n m o l/d

pg/m L

pg/m L

pg/m L

m m Hg

0

3500

20

_

1 9 0 /1 3 0

—

—

—

1 4 0 /9 0
1 3 0 /7 0

R igh t adrenal tu m o u r
P re o p

78.2

4894

4 d postop

3 8 .4

376

2 .2

1 m o postop

2 7 .8

177

1 6.4

—

—

_

5 mo postop

3 0.8

-

-

—

—

—

1 3 5 /7 0
1 5 0 /9 0

Left adrenal tum our
P re o p

6 2.1

1878

7 3 .7

8 96 (1 40 7 )

2 3(3 3 )

016)

7 d postop

3 7 .3

134

0

75(3 2 4)

0 (6 )

14(1 6 )

1 2 0 /7 0

1 m o postop

4 1 .4

45

2 6 .2

1 1 0 (27 0 )

9191

2 0 (14)

1 2 0 /7 0

8 mo postop
2 0 mo postop
VMA

-

van illylm andelic acid, N E

—

-

—

1 58 (2 87 )

0 (8 )

0 (0 )

1 3 4 /8 0

3 9 .9

-

~

120 (2 68 )

1 9 (2 3 )

3 0(2 2 )

1 3 0 /8 0

=

n o r e p i n e p h r in e , E -

ep in ep h rin e, D A

*

d o p a m in e .

* A s m e a s u r e d in r e c u m b e n t a n d ( u p r i g h t ) p o s it io n s .

VOLUME 27, NO. 3, MA Y 1984 / THE CANADIAN JOURNAL OF SURGERY

263

physician to eliminate such possibilities
once the diagnosis has been made.
In the light of biochemical data, the
angiographic image and the operative
findings, it appears fully justified in the
present case to conclude that the left
adrenal tumour was not present at the
time of the initial operation or, if present,
was not clinically or biochemically detect
able. Such late recurrence of pheochromocytoma (2 years) has been reported
previously.3’7 This emphasizes that long
term follow-up is mandatory in children
for the early detection of recurrence or
asynchronous tumour.
After the tumour had been located in
the remaining left adrenal gland, vena
caval catheterization was performed with
blood samples taken from different levels
for assay of plasma catecholamines. As
can be seen in Fig. 3, the results were con
clusive in attesting that no other tumours
were present. This technique, in addition
to confirming the presence and localiza
tion of the pheochromocytoma, is useful
in detecting or eliminating the presence
of other ectopically located tumours or
of metastatic disease.810 This is par
ticularly indicated in children since in
almost one third of the cases the tumours
are either bilateral, multiple or extra
adrenal. Furthermore, it has been pointed
out that the majority of deaths from

pheochromocytoma in children resulted
from the presence of a second tumour,
which had been missed when the first was
removed.2
Whether or not to perform selective
venography is controversial. The ex
perience of the Mayo Clinic1 with this
technique has been very favourable and
without complications; however, some
radiologists tend not to favour the ap
proach because of possible infarction of
adrenal gland . 11 We have had no com
plications using the technique and the
preoperative information on venous
drainage can be very useful to the surgeon
in his dissection.
Regarding the surgical approach to the
patient presenting bilateral pheochromo
cytoma or asynchronous pheochromocy
toma in a single remaining adrenal gland,
ReMine and associates1 recommend that
a small portion of the normal tissue be
left behind in the adrenal with the smaller
tumour, whereas others prefer to perform
total bilateral adrenalectomy when con
fronted with bilateral tumours. 12 The ra
tionale of the latter approach is that rup
ture of an apparently benign tumour dur
ing dissection may result in spread and
recurrence. We chose to preserve the re
maining normal adrenal tissue because in
vestigation revealed no evidence that the
tumour was malignant and it was small

and easily dissected during the operation.
After a 2-year follow-up clinical and
biochemical parameters were within nor- ^
mal limits and there was autonomous
adrenal function. It should be pointed out 4
that had preservation of the normal
adrenal tissue in situ been impossible due^
to devascularization or other technical
difficulty, autotransplantation of the nor-’
mal adrenal tissue in the sartorius or rec
tus abdominis muscle would have been at- "
tempted. The results of this technique in
the surgical management of Cushing’s
disease are encouraging. 13
4
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Sum m ary of product information
DEXON * “S”

DEXON* PLUS

POLYGLYCOLIC ACID SUTURE POLYGLYCOLIC ACID SUTURE
SYNTHETIC. ABSORBABLE COATED WITH POLOXAMER 188
USP
SYNTHETIC, ABSORBABLE
USP
DESCRIPTION: DEXON “S" polyglycolic acid Suture —Synthetic
Absorbable. USP and DEXON PLUS polyglycolic acid Suture —Syn
thetic. Absorbable. USP are homopolymers of glycolic acid, con
structed of filaments finer than in an original DEXON Suture to
provide optimal handling properties. DEXON PLUS Suture, in addi
tion, is coated with poloxamer 188, a surfactant. The coating material
is inert, non-collagenous, non-antigenic and non-pyrogenic.
The sutures are sterile, inert, non-collagenous, non-antigenic, nonpyrogenic, and flexible. The braided and monofilament sutures are
colored green to enhance visibility in tissue. DEXON “S” and
DEXON PLUS braided sutures are also available undyed with a nat
ural beige color. They are uniform in size and tensile strength, but are
smaller in diameter than other absorbable surgical sutures of equiva
lent tensile strength.
ACTIONS: When DEXON “S” Sutures or DEXON PLUS Sutures are
placed in tissues, a minimal tissue reaction occurs which is followed by
a microscopic layer of fibrous connective tissue which grows into the
suture material.
Absorption studies in animals show DEXON “S" Sutures and
DEXON PLUS Sutures to be equivalent to original DEXON Sutures.
Studies in rabbits revealed minimal absorption at 7 to 15 days, signifi
cant absorption at 30 days and maximum resorption after 60-90 days.
With DEXON PLUS Sutures. 80% to 97% of the coating was excreted
in the urine during the first 3 days following implantation in rabbits.
The remainder was excreted within 40 days.
Tensile strength, not being a function of the absorption rate, may vary
from tissue to tissue depending in part on the rate of hydrolysis. The
early tensile strength of DEXON “S” Sutures and DEXON PLUS
Sutures is reported to be greater than that of comparable chromic cat
gut. In animal studies (subcutaneous tissue in rats) it has been shown
that at two weeks post-implantation approximately 55% of the original
tensile strength of a DEXON “S” or DEXON PLUS Suture remains,
while at three weeks approximately 20% of its original strength is
retained.

INDICATIONS: DEXON "S" Sutures and DEXON PLUS Sutures are
indicated whenever absorbable sutures and ligatures are employed.
CONTRAINDICATIONS: DEXON “S" Sutures and DEXON PLUS
Sutures are contraindicated where extended approximation of tissues
under strain must be maintained.
WARNINGS: The safe use of this suture in neural tissue and in car
diovascular surgery has not been established.
Under certain circumstances, notably orthopedic procedures, im
mobilization by external support may be employed at the discretion of
the surgeon.
Do not resterilize. Discard opened, unused sutures.
PRECAUTIONS: Acceptable surgical practice should be followed
with respect to drainage and closure of infected wounds.
The knot with DEXON “S" polyglycolic acid Suture must be properly
placed to be secure. Therefore, place the first throw in precise position
for the final knot using a double loop; tie the second throw square
using horizontal tension; additional throws may be used as desired.
DEXON PLUS Sutures, which are treated to enhance handling char
acteristics, require the standard surgical technique of flat and square
ties with additional throws if indicated by surgical circumstances and
the experience of the surgeon.
Skin sutures which remain in place for periods of longer than seven
days may cause localized topical irritation and the extended portion of
the suture may be snipped off after five to seven days, as indicated.
ADVERSE REACTIONS: Those reactions that have been reported
include tissue reaction or inflammation, fibrous or granulation tissue,
bleeding, wound separation in the eye, and accumulation of fluid
around subcuticular stitches.
DOSAGE AND ADMINISTRATION: Use as required
HOW SUPPLIED: DEXON “S” and DEXON PLUS Sutures sizes 8-0
braided through 2 braided (metric size 0.4—5) dyed gre6n. and 7-0
braided through 2 braided (metric size 0.5—5) natural beige.
Supplied in cut lengths or ligating reels, non-needled or affixed to the
various Davis + Geek ATRAUMATIC® needles or D-TACH® remova
ble needles USP in one, two and three dozen packages. DEXON“S"
Suture, monofilament, dyed green, is available in size 9-0 (metric size
0.3) in a variety of lengths with needles in one dozen packages.
1 data on file

DAVIS+GECK
Cyanamid Canada Inc.

2 data available on request

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5

^

•Registered Trademark of Cyanamid Canada Inc

264

VOLUME 27, NO. 3, M A Y 1984 / THE CANADIAN JOURNAL OF SURGERY

DAVIS+GECK

INTRODUCES
We started with a
superior core
(Dexon* ‘S’)...

The finer, tighter braid is smooth and
strong. This produces the suppleness
and flexibility necessary for easier
tying as well as superior knot
security — high standards
which have been proven
over years of use.

...and
added
a superior
surface
treatment
M

The
Poloxamer
188 treatment is
thinner and noticeably
smoother than other coatings.
Smoother tissue passage allows for
' simplified closings and reduced tissue
trauma which in turn helps
speed healing.

\nd the surface treatment is rapidly absorbed^
--o n ce the job is done, it’s gone. This
jpeans better in vivo knot security than with comparable products.1

NEW DEXON* PLUS
Excellent knot security2plus superior handling
and sm oother tissue p assage.
►A
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Recurrent or Residual Shunt following Repair of
Acute Postinfarctional Ventricular Septal Defect
Recurrent o r residual v e n tric u la r septal
d e fe c t fo llo w in g operative repair o f
po stm yo ca rdial in fa rc tio n v e n tricu la r sep
ta l de fect has been reported in m any
series. M ost c o m m o n ly, th is is noted
in cid e n tally on p o stop e ra tive cardiac
ca th ete riza tio n or as a m u rm u r in
relative ly a s y m p to m a tic p a tie n ts in
w h o m no fu rth e r ope ra tio n is required.
Less fre q u e n tly, its on se t is a
ca ta stro p h ic e ve n t leading to th e pa
tie n t’ s death. On th e o th e r hand, th e
sh u n t may be s u ffic ie n tly sm all to a llo w
tim e for reoperation.
W ith recent im p ro ve m en t in surgical
techniques, m ore pa tie nts w ith th is c o m 
p lica tio n o f m yocardial in fa rc tio n have
been saved. Recurrent or residual ve n 
tric u la r septal d e fects have becom e less
freq u e n t, decreasing fro m a rate o f 4 6 %
b efore 1 9 7 0 to an overall 1 5 % to d ay.
F ew details have been published ab o ut
recurrence o r persistence o f v e n tricu la r
septal d e fe c t fo llo w in g o p e ra tive repair.
The authors rep o rt on a p a tie n t w ith a
persistent v e n tric u la r septal d e fe ct
fo llo w in g ope ra tio n and n e ce ssitatin g
reoperation. T he y describe th e op e ra tive
repair and re v ie w o f th e lite ra tu re on th is
co n d itio n since 1 9 7 3.
Dans plusieurs etudes p o rta n t sur de
grands nom bres de m alades on a rapp o rte une r6cidive ou la fe rm e tu re in co m 
p le te d 'un e co m m u n ica tio n in te rv e n tric u laire apres une ch irurgie c o rre ctrice d 'u n e
co m m u n ica tio n in te rv e n tricu la ire conse
c u tiv e ci un in fa rc tu s du m yocarde. Le
p lu s frequem m ent, cela e st co n sta te a
I'occa sio n d 'u n ca th ete rism e cardiaque
postop e ra toire ou par I'a p p a ritio n d 'u n
s o u ffle chez un p a tie nt, par ailleurs
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asym p to m a tiqu e , qui n 'e s t pas ca ndidat
a une autre chirurgie. Plus rarem ent, le
problem e se m an ife ste de fa co n ca ta stro phique qui m&ne a la m o rt du patient,
par co n tre , la d e riva tio n p e u t etre su ffisam m ent p e tite afin d 'a llo u e r plus de
te m p s pour la re inte rve n tion .
A ve c les dernieres a m eliorations des
techniques chirurgicales, davantage de
victim e s des co m p lica tio n s de I'in fa rc tu s
du m yocarde so n t sauvees. Les recidives
ou les ferm etures in co m p ld te s des co m 
m unications in te rve n tricu la ire s sont
m oins frequentes, leur ta u x e ta n t passe
de 4 6 % ava n t 1 9 7 0 a, globalem ent,
1 5 % a u jo u rd 'h ui. Peu de d etails o n t ete
publics concernant la recidive ou la persistance des co m m u n ica tio n s in te rv e n tri
culaires apres une ch irurg ie de repara
tio n . Les auteurs fo n t e ta t d 'u n pa tie nt
chez qui il y e u t persistance p o stopera
to ire d 'u n e co m m u n ica tio n in te rv e n tric u 
laire qui necessita une nouvelle in te rve n 
tio n . Ils d e crive n t la ch irurg ie de repara
tio n e t resum ent les p u b lica tio n s parues
sur ce sujet depuis 1 9 7 3 .

Ventricular septal defect complicating
acute myocardial infarction is rare but
carries a dismal prognosis unless it is cor
rected surgically. Sanders and associates1
found that at least 50% o f these patients
do not survive 1 week and that 80% die
within 2 months if the condition is uncor
rected. Since the first case report in 1957
by Cooley and associates,2 many reports,
including some large series,3’5 have been
published concerning the timing and
nature of operative intervention for cor
recting this lesion.
Earlier reports2,6"12 advocated waiting
a minimum o f 3 to 6 weeks to allow scar
to form, providing better tissue margins
for suturing. However, many patients
would not survive that long, and those
who did often suffered from intractable
congestive heart failure, pulmonary
edema and multiple organ system failure.
Thus, many authors have advocated ear
ly surgical repair.4,13,14 Improved meth
ods o f preoperative support, such as use
o f the intra-aortic balloon pump,
peripheral vasodilators to reduce after
load and inotropic agents and improve-

■4

ment in the cardiac index have allowed
many patients to undergo early corrective
procedures.
Because o f the shift towards earlier
operation, sutures must often be placed
through friable or necrotic tissue,
sometimes under conditions o f difficult
exposure, in hearts with poor contractility *
and electrical irritability, so it is not sur
prising that wound dehiscence is com
mon. The review o f Kitamura and
associates15 noted a cumulative rate of
residual or recurrent ventricular septal
defect o f 46% and a patient who was
reported to have had a defect 5 mm in
diameter at autopsy.2
Improved surgical techniques carried
out since about 1970 have resulted in a
lower recurrence rate and salvage o f pa
tients who would otherwise have died.
However, few details have generally been
published on recurrent ventricular septal
defect and patients in whom reoperation
was required. To illustrate the problems
of managing patients with a ventricular
septal defect following myocardial infarc
tion, we report on a patient who required
two operations with placement o f an ad
ditional patch to close a residual defect.

Case Report
A 66-year-old woman was admitted with a
documented anteroseptal myocardial infarc
tion. She had a 10-year history of hyperten
sion and maturity-onset diabetes, but no other
cardiac problems. A pansystolic apical mur
mur was heard the day after her myocardial
infarction. Over the next 9 days, her condition
gradually deteriorated with increasing con
gestive heart failure, rising blood urea nitrogen
and serum creatinine levels, and confusion. On
examination, she was noted to be dyspneic, her
blood pressure was 104/60 mm Hg, pulse rate
102 beats/min, respiratory rate 30/min. Rales
were heard in the lower third of both lung
fields. Neck veins were full at 10 cm at 45° with
hepatojugular reflux. The cardiac apex was dif
fuse and dyskinetic 2 cm to the left of the
midclavicular line in the fifth intercostal space.
The first heart sound was decreased and a third
heart sound was present. There was a grade 4/6
holosystolic murmur at the left sternal border
and apex, associated with a palpable thrill.
The hemoglobin level was 146 g /L ,
leukocyte count 16.3 x 109/L and serum elec-
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trolyte levels were normal. The blood urea
nitrogen level was 22.13 mmol/L urea, serum
^ creatinine value was 159.1 /tmol/L and blood
glucose 17.82 mmol/L. Electrocardiographic
v findings were consistent with a previous
anteroseptal myocardial infarction. Cardiac
^ catheterization on the day of arrival revealed
a large ventricular septal defect and a calculated
t
shunt of 4:1. On coronary angiography, the left
anterior descending artery was found to be
^ completely occluded, but the right coronary
artery and the circumflex artery were normal.
v At operation, 10 days after the myocardial in
farction, a large anterior ventricular septal
^ defect was closed through a ventriculotomy
over the infarcted left ventricle with a Dacron
(
patch, using the free wall of the right ventri
cle as a buttress, as described by Hill and
associates.3 The patient was weaned off
bypass easily but the blood pressure slowly
y decreased and intra-aortic balloon pumping
was necessary. In the recovery room, a residual
v thrill was noted with oxygen saturations in
dicating a shunt of 1.5:1 to 1.9:1. The patient
k improved hemodynamically over the next few
days and was weaned from the intra-aortic
^ balloon pump. She continued to be confused
and her renal function steadily deteriorated.
^ Four days after operation, a continuous oxygen
saturation catheter (Oximetric Shaw Catheter

Oximeter System; Oximetrix Inc., Mountain
View, Calif.) indicated that the shunt had in
creased to 4.4:1. The blood urea nitrogen level
was 64.3 mm ol/L urea and the serum
creatinine 371.3 /tmol/L. Clearly, this patient’s
only hope for survival was operative closure
of the residual ventricular septal defect. At
reoperation 5 days after the first procedure, a
posterosuperior dehiscence of the patch was
noted. It was repaired using an additional
Dacron patch (Fig. 1). The original patch was
not removed. After the patient was weaned
from bypass and the heparin effect reversed
with protamine sulfate, there was severe
hemorrhage from the lateral wall o f the left
ventricle. Bypass was reinstituted after
reheparinization. A dissecting hematoma had
perforated the free wall of the left ventricle,
between two obtuse marginal branches of the
circumflex coronary artery. This was sutured
using Teflon pledgets and several deep horizon
tal mattress sutures placed lateral to the ob
tuse marginal branches. Again, the patient re
quired support with the intra-aortic balloon
pump. Postoperatively she did well. Her con
fusion cleared and renal function returned to
normal. She was discharged from hospital 21
days after the second closure. A single pass ra
dionuclide scan showed no evidence of shunt
ing. She is alive and well 12 months

FIG. 1—Cross-sections of heart at level of ventricular septal defect. (A) Infarcted area
anteriorly (hatched) and direction of shunt from left ventricle (LV) to right ventricle (RV). (B)
Initial repair of ventricular septal defect with Dacron patch, buttressing septum against right
ventricle free wall. (C) Ventriculotomy closed. (D) Recurrence of shunt from left ventricle to
right ventricle associated with further septal necrosis. (E) Second Dacron patch sutured to first.
Pledgeted sutures brought through posterior septum from right ventricle through second patch.
► (F) Septal sutures tied and ventriculotomy closed.

T a b le 1-- P o s t m y o c a r d ia l In f a r c t io n P a t ie n t s O p e r a t e d o n f o r
V e n t r ic u la r S e p ta l D e f e c t ( V S D )
P a t ie n t s
A u th o rs

T o ta l no.

o p e ra te d o n ,

o f p a t ie n t s

n o . (% )

O u tc o m e o f p a t ie n t s
n o t o p e ra te d o n

H ill a n d a s s o c ia te s 3

23

D a g g e tt a n d a s s o c ia te s 4

43

3 6 (8 4 )

A ll d ie d

M o n t o y a a n d a s s o c ia te s 5

27

2 0 (7 4 )

A ll d ie d w it h in

L o is a n c e a n d a s s o c ia t e s 14

57

3 8 (6 7 )

A ll d ie d

150

1 1 3 (7 5 )

T o ta l

1 9 (8 3 )

2 d ie d , 2 w i t h a s y m p t o m a t ic V S D

23%

13 d

d ie d , 2 a liv e

postoperatively, with heart function in class 1
(New York Heart Association).
D iscu ssio n

Ventricular septal defect complicating
acute myocardial infarction continues to
be lethal if it is not corrected surgically.
When the largest series since 1973 are con
sidered, approximately 25% o f patients
were not offered or did not undergo
operation; o f these patients, only 5% sur
vived without operation (Table I). These
deaths often occur during investigation,
despite the trend towards early aggressive
investigation and operation.3,5>13’14'16'18
Unfortunately, little detailed information
is available about patients who have
recurrence after repair o f the ventricular
septal defect.
Kitamura and associates15 noted a
46% rate o f recurrent or residual ven
tricular septal defect in a review o f the
published reports to 1970. They noted
that the majority o f the repairs had been
performed through a right ventriculo
tomy. Brandt and associates in 197919
analysed the recurrence o f ventricular sep
tal defects from the viewpoint o f surgical
approach and found that the recurrence
rate for the right ventricular approach
was 41.2% (7/17), for the left ventricular
approach was 11.3% (7/62) and for the
posterior approach was 20% (3/15). The
cumulative recurrence rate for the series
reviewed after 1973 is approximately 15%
(35/228 cases). This figure must be con
sidered approximate, as often recurrence
was assumed on the basis o f a residual
heart murmur; in one series, only docu
mented recurrences were m entioned.3
This low recurrence rate most likely
reflects the improved surgical approaches
to this lesion, using left ventriculotomy
or an approach through the infarct.
It is also impossible to compare ac
curately recurrence rates o f patch as op
posed to suture repair, owing to lack o f
recent information. In the series o f D ag
gett and associates,4 4 o f 25 (16%) pa
tients who had suture closure o f the ven
tricular septal defect had recurrence, com
pared with 2 o f 11 (18%) in the patch
group. O f five patients operated upon at
5 or less days after repair o f the ven
tricular septal d efect, K illen and
associates16 had two recurrences using a
left ventriculotomy with single or double
patch. In a series o f 16 patients operated
on an average o f 5.3 months after repair
o f the ventricular septal defect, Giuliani
and associates20 reported only a single
recurrence, at 3 years, in a patient whose
defect was closed with sutures from a
right ventriculotomy. Yet, 11 o f his other
patients had only suture closure.
It would appear that using a patch
when operating on a very recent ven
tricular septal defect is no guard against
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recurrence. Sutures placed through friable
or ischemic muscle cannot be counted on
to hold as well as those placed through
the scar tissue forming around the defect
weeks or months after a myocardial in
farction. Thus, the timing of the initial
surgery after septal rupture is important.
Of patients reviewed in large series since
1973,3-5,8,13,m , 16-18,20-22 74% were operated
on within 4 weeks of rupture. If one ex
cludes the Mayo Clinic series20 whose pa
tients were operated on an average of 5.3
months after ventricular septal rupture,
this figure increases to 80%. The lower
incidence of recurrence (15% after 1973,
46% before 1970) over the last 10 years
reflects a remarkable improvement in the
surgical approach to this lesion.
The clinical course following a recur
rent or residual ventricular septal defect
after surgical repair tends to fall into three
main categories4’16,17'20’21,23’24 as follows:
a catastrophic event, usually intraoperatively or in the early postoperative period
leading to the patient’s death (although
Daggett and colleagues4 reported one
case occurring 7 weeks postoperatively);
a residual defect with a sufficiently small
shunt to allow a second operation or to
lead to the patient’s death after several
days or weeks; and, most commonly, an
asymptomatic shunt found incidentally at
cardiac catheterization or suspected
through the persistence of a pansystolic
murmur postoperatively; alternatively,
the shunt may be symptomatic but
medically controllable.
Recurrent shunting appears to occur
most commonly during operation or in
the early postoperative period, possibly
because sutures placed through friable
tissue in the flaccid, arrested heart are
subjected to considerable forces as the
heart begins to beat following bypass. If
sutures begin tearing out under the strain,
the net effect is a recurrent shunt. In the
series of Daggett and colleagues,4 five of
the six recurrences occurred in this
fashion; the last one was a catastrophic
rupture 7 weeks postoperatively. Other
series5,13 report similar findings. In our
case the defect appeared to be residual.
It is possible that the severity of some
of these postoperative shunts may in
crease, as noted in the present patient
where the shunt increased from 1.5:1 im
mediately after operation to 4.4:1,5 days
later. One patient in Daggett’s group4
made a smooth recovery and had good
cardiac function despite the persistence of
a murmur. Three years later, progressive
heart failure developed and the patient
was noted to have a 2.5:1 shunt on car
diac catheterization 1 year after that. It
is unlikely that the patient could have
tolerated this degree of shunting
postoperatively and have had good car
diac function for 3 years.
To detect the postoperative appearance
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or increase of shunting, we recommend
frequent determinations of right atrial,
pulmonary arterial and systemic arterial
oxygen saturations for the first few days
after closure of the ventricular septal
defect or as the clinical situation warrants.
This aspect of monitoring could be
facilitated by the insertion of a spectrophotometric oxygen saturation cathe
ter (as in our case) in the same fashion
as a Swan-Ganz catheter, allowing con
tinuous monitoring of pulmonary arterial
saturations and intermittent monitoring
of right atrial oxygen saturations (the lat
ter simply by temporarily retracting the
catheter).
As most shunts appear to be residual,
it is conceivable that shunt determinations
could be done immediately after the
repair is completed and the heart is
beating (before removal of the aortic can
nula), either with the spectrophotometric
oxygen saturation Swan-Ganz catheter or
by obtaining blood from the right atrium,
pulmonary trunk and systemic circula
tion. The shunt (Qp:Qs) may be quickly
calculated using the formula:
Qp
Qs

—

Sao2 — Rao2
Sao2 - Pao 2

where Sao 2 is the systemic oxygen
saturation, Rao 2 is the right atrial
oxygen saturation, Pa 02 is the
pulmonary arterial oxygen saturation,
Qp is the right heart output and Qs is the
left heart output.
At what level of shunt one should re
open the heart is unclear and, of course,
depends on the clinical situation. Most
survivors who have residual defects have
shunts equal to or less than 1.5:1,3,13,21
although Moss and colleagues23 reported
a survivor with a 1.7:1 shunt who was
asymptomatic after 9 months. Certainly
these patients with small shunts should be
carefully followed in the early post
operative period and operated upon again
if the shunt increases appreciably, before
the complications of acute left to right
shunting develop.
The presence of acute renal failure or
congestive heart failure, or both, perhaps
should not contraindicate operation as
Daggett and associates4 have seemingly
indicated. Our patient was in increasing
renal failure with a blood urea nitrogen
level of 22.13 mmol/L urea before the
first operation and 64.3 mmol/L urea by
the time of the second operation 5 days
later. With correction of the residual ven
tricular septal defect, the blood urea
nitrogen value returned to normal after
6 days. She had been receiving low doses
of dopamine (4 /ig/kg min ’) preoperatively to ensure a low but continuous
urine output.
The use of an additional patch (Fig. 1)
offers several advantages during reopera-
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NOW TREAT
POST-OPERATIVE
PAIN BEFORE YOU
LEAVE THE O.R.

MARCAINE* NERVE BLOCK OR INFILTRATION
BEFORE CLOSURE GIVES UP TO 15 HOURS OF
POST-OPERATIVE PAIN RELIEF1
PO ST -O PER A T IV E S T R E S S can be
substantially reduced by preventing
post-operative pain in those critical
first hours after surgery2

Marcaine blocks this pain, giving an
easier, quicker recovery; often w ithout
the need for narcotic analgesics.3

MARCAINE

FOR PAIN RELIEF THAT
STARTS IN THE O.R.
Winthrop Laboratories
Division o f Sterling Drug Ltd.**
Aurora, Ontario L4G 3H 6
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Prescribing Information

Marcaine*
(bupivacaine hydrochloride injection U.S.P.).
Indications:
Peripheral nerve block including retrobulbar block, infiltration, sympa
thetic blockade, caudal, epidural, and pudendal blocks.
Contraindications:
Bupivacaine is contraindicated in persons with known sensitivity to
local anesthetics of the amide type.
The use of bupivacaine is contraindicated in the presence of sepsis
near the site of proposed injection, in severe shock and in heart block.
Warnings:
Usage in Pregnancy: There are no adequate and well-controlled studies
in pregnant women of the effect of bupivacaine on the developing
fetus. Decreased pup survival in rats and an embryocidal effect in rab
bits have been observed when bupivacaine hydrochloride was adminis
tered to these species in doses comparable to nine and five times
respectively the maximum recommended daily human dose (400 mg).
Bupivacaine hydrochloride should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. This does not
exclude the use of Marcaine 0.25% or 0.50% at term for obstetrical
anesthesia or analgesia.
Obstetrics: The highest (0.75%) concentration is not recommended for
obstetrical anesthesia. There have been reports of cardiac arrest with
difficult resuscitation or death following its use for epidural anesthesia
in obstetrical patients.
Due to the high risk to the fetus, paracervical block is no longer recom
mended.
The obstetrician is warned that severe persistent hypertension may
occur after administration of certain oxytocic drugs, if vasopressors
have already been used during labor (e.g. in the local anesthetic solu
tion or to correct hypotension).
Until further experience is gained in children younger than 12 years,
administration of bupivacaine in this age group is not recommended.
Precautions:
Marcaine (bupivacaine) should be used cautiously in persons with
known drug allergies or sensitivities, particularly to the amide-type local
anesthetics.
Caution is advised in administration of repeat doses of bupivacaine to
patients with severe liver disease.
The lowest dosage that gives effective anesthesia should be used, to
avoid high plasma levels and serious systemic side effects. Injection of
repeated doses of bupivacaine may cause a significant increase in
blood levels due to accumulation of the drug or its metabolites or slow
metabolic degradation.
Tolerance varies with the status of the patient. Debilitated, elderly and
acutely ill patients may require reduced doses commensurate with age
and physical condition.
It should be remembered that solutions containing a vasopressor
agent, e.g. epinephrine, should be used with caution, if at all, in patients
who are receiving monoamine oxidase inhibitors or anti-depressants
of the triptyline or imipramme type, because severe, prolonged hyper
tension may result. Dose-related cardiac arrhythmias may occur if
preparations containing epinephrine are employed in patients during or
immediately following the administration of chloroform, halothane,
cyclopropane, trichloroethylene or other related agents. In deciding
whether to use these products concurrently in the same patient,
the combined action of both agents upon the myocardium, the concen
tration and volume of vasoconstrictor used, and the time since injec
tion, when applicable, should be taken into account.
The decision to use a local anesthetic containing a vasoconstrictor in
areas with a limited blood supply or in patients with peripheral vascular
disease, will depend on the physician’s appraisal of the relative advan
tages and risks.
Local anesthetics which contain preservatives, i.e. those supplied in mul
tiple dose vials, should not be used for caudal or epidural anesthesia.
Epidural Use: It is advised that a test dose, generally 2-3 mL of 0.5%
Bupivacaine (or other amide anesthetic) containing 1:200,000 epine
phrine (10-15 micrograms) be administered to check that the spinal
canal or a blood vessel has not been entered while locating the epidural
needle or catheter.
In the event of spinal injection clinical signs of spinal block would
become evident in a few minutes.
In the event of intravascular injection a transient increase in pulse rate
and possibly momentary increase in systolic blood pressure are
usually detectable with a monitor. The other symptoms and signs of
“epinephrine response” are less dependable. The effects of other medi
cation the patient has received may modify this response.
When reinforcing doses are required the test dose should be used
again to check the catheter location.
Use in Ophthalmic Surgery: When Marcaine 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clini
cally acceptable external ocular muscle akinesia. Therefore, presence
of akinesia rather than anesthesia alone should determine readiness of
the patient for surgery.
Adverse Reactions:
Reactions to bupivacaine are characteristic of those associated with
amide-type local anesthetics. A major cause of adverse reactions to
this group of drugs is excessive plasma levels, which may be due to
over-dosage, inadvertent intravascular injection, or slow metabolic
degradation. Other causes of reactions to these local anesthetics may
be hypersensitivity, idiosyncrasy, or diminished tolerance.
Excessive plasma levels cause systemic reactions involving the central

nervous system and the cardiovascular system. The central nervous
system effects are characterized by excitation or depression. The first
manifestation may be nervousness, dizziness, blurred vision, or tre
mors, followed by drowsiness, convulsions, unconsciousness, and pos
sibly respiratory arrest. Since excitement may be transient or absent,
the first manifestation may be drowsiness, sometimes merging into
unconsciousness and respiratory arrest.
Other central nervous system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The cardiovascular manifesta
tions of excessive plasma levels may include depression of the myocar
dium, blood pressure changes (usually hypotension), and cardiac
arrest. Recent clinical reports and animal studies suggest this may be
more likely to occur with the long acting amide local anesthetics such
as bupivacaine.
Allergic reactions are characterized by cutaneous lesions (e.g. urticaria,
edema) and other manifestations of allergy.
Reactions following epidural or caudal anesthesia may include: high or
total spinal block, urinary retention; fecal incontinence, loss of perineal
sensation and sexual function; persistent analgesia, paresthesia, and
paralysis of the lower extremities; headache and backache; and slow
ing of labor and increased incidence of forceps delivery.
It should be noted that reactions due to systemic absorption may be
slow or rapid in onset. Those of rapid onset include respiratory depres
sion, cardiovascular collapse and cardiac arrest. This type of reaction
necessitates a high degree of preparedness since it can occur with little
warning.
In co-ordinated studies of 3200 procedures carried out by 15 investiga
tors, there were 2 severe systemic reactions. Both patients experienced
convulsions as a result of inadvertent vascular injection.
Fetal bradycardia has been observed with the use of bupivacaine. Most
cases, including a few fatalities, occurred when the paracervical route
was used (see “Warnings").
In some subjects bupivacaine may produce marked peripheral vaso
constriction in unanesthetized areas which may last for several hours.
Treatment of Overdose and Severe Reactions:
Toxic effects of local anesthetics require symptomatic treatment; there
is no specific cure. The physician should be prepared to maintain an
airway and to support ventilation with oxygen and assisted or con
trolled respiration as required. Supportive treatment of the cardiovas
cular system includes intravenous fluids and, when appropriate, vaso
pressors (preferably those that stimulate the myocardium).
Convulsions may be controlled with oxygen and intravenous adminis
tration, in small increments, of a barbiturate or muscle relaxant, as
follows: preferably, an ultra short-acting barbiturate such as thiopental
or thiamylal; if this is not available, a short-acting barbiturate (e.g. seco
barbital or pentobarbital) or a short-acting muscle relaxant (succinylcholine). Intravenous muscle relaxants and barbiturates should only be
administered by those familiar with their use.
Dosage and Administration:
The duration of anesthesia with bupivacaine is such that, for most pro
cedures, a single dose is sufficient. Maximum dosage limit must be indi
vidualized in each case after evaluating the size and physical status of
the patient, as well as the usual rate of systemic absorption from a par
ticular injection site. Most experience to date is with single doses of
bupivacaine up to 225 mg with epinephrine 1:200,000, and 175 mg
without epinephrine; more or less drug may be used depending on indi
vidualization of each case.
At present there is insufficient clinical evidence with multiple dosage or
intermittent dose techniques to permit precise recommendations for
such procedures to be given. However, limited clinical experience in this
area of use indicates that bupivacaine may be repeated in 3 to 6 hours
up to a maximum dose of 400 mg in 24 hours. In most cases the dura
tion of anesthetic effect is prolonged by the addition of epinephrine.
The following doses have generally proved satisfactory for the average
adult. They may require adjustment in relation to age and the physical
condition of the patient.
Local infiltration: up to a maximum dosage of 0.25% solution.
Peripheral nerve block: 5 to 30 mL of 0.50% or 5 to 60 mL of 0.25%
solution.
Sympathetic: 20 to 50 mL of a 0.25% solution.
Epidural: 10 to 20 mL of a 0.25%, 0.50%, or 0.75%t solution.
Caudal: 15 to 30 mL of a 0.25% or 0.50% solution.
t0.75% not recommended for obstetric use.
Supplied:
Each 20 mL single dose vial contains: bupivacaine 0.25%, 0.50% or
0. 7 5 . with or without epinephrine 1:200,000. Boxes of 5 vials.
Each 50 mL multiple dose vial contains: bupivacaine 0.25% or 0.50%.
Boxes of 1 vial.
Note: Bupivacaine solutions without epinephrine may be autoclaved.
Product Monograph available on request.
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tion. No time is wasted removing the
original patch and suturing a larger one,
leading to more operative trauma from ^
a greater number o f sutures. There is, o f
course, no guarantee that the remaining <
initial sutures will not fail, but, as
previously noted, dehiscence after the first i
few days is uncommon especially when
the free wall of the right ventricle is used ^ 1
as a buttress. A second advantage is that _
the volume of the right ventricle is not
further compromised; the posterior edge <
o f the patch in the area o f the dehiscence
is the only portion o f the second patch not i
buttressed to the free wall o f the right ven
tricle. The technique should also be"'
applicable to anterior dehiscences of
previously patched posterior ventricular N
septal defects.
We thank Mrs. Susan Anderson for her help y
in preparing this manuscript.
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Cystic dilatation of the biliary tree is an
uncommon congenital condition, most
often discovered in infancy. It should be
suspected in an adult who has a history,
over a long period, of intermittent pain in
the right upper quadrant, episodes of
jaundice or cholangitis, or both, and has
a palpable mass in the right hypochondrium. Ultrasonography and especially
endoscopic retrograde cholangiopancreatography allow the biliary cyst to be
diagnosed preoperatively more often
than previously. The authors describe
the case of a 60-year-old woman with
congenital cystic dilatation of extra- and
intrahepatic bile ducts with cystlithiasis
that followed an unusual course. Of the
various theories of causation. Babbitt's is
now the most widely accepted, especially since the advent of endoscopic
retrograde cholangiopancreatography.
The presence of stones is an uncommon
and late complication. The treatment is
surgical, excision of the biliary cysts be
ing the treatment of choice; however,
Roux-en-Y choledochocystojejunostomy
is performed when excision is technically
impossible.

La dilatation kystique des voies biliaires
re st une maladie congenitale peu frequente, surtout decouverte durant I'enfance. Le diagnostic devrait etre soupponne chez I'aduite presentant une histoire chronique de douleur intermittente a
I'hypochondre droit, des Episodes d'ictere ou de cholangite, ou les deux, et
, - une masse palpable d I'hypochondre
droit. La venue de I'dchographie mais
r surtout de la cholangio-pancreatographie
retrograde a permis de porter un diagnostic preoperatoire de kyste biliaire plus
souvent que par le passe. Les auteurs
decrivent un cas de malformation kysti, que congenitale des voies biliaires extra-
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et intra-hepatiques contenant des calculs
avec une evolution inhabituelle chez une
femme de 60 ans. Des diff6rentes theo
ries citees, la theorie de Babbitt est
actuellement la plus acceptee, surtout
depuis I'arrivee de la cholangiopancreatographie retrograde. La presence
de calculs dans les kystes biliaires est
une complication rare et tardive. Le traitement est uniquement chirurgical. L'excision du kyste biliaire est considgree de
plus en plus comme le traitement de
choix; cependant, la derivation choledochokystojejunostomie Roux-en-Y
demeure I'autre forme de traitement si
I'excision est techniquement impossible.
Bile-duct cysts are a relatively uncommon
condition in western countries; approx
imately 70% o f all the reported cases have
been described in the Japanese
literature.1 The classification proposed
by Alonso-Lej and associates2 is widely
known, but Todani and associates3 ex
panded it to include both extra- and in
trahepatic cystic dilatations.4,5 Although
lithiasis is the commonest complication of
biliary cysts,1 its incidence is low .6-8 The
best surgical treatment is still controver
sial — excision o f the cyst or an internal
drainage procedure.
We report a patient with both extraand intrahepatic biliary cyst containing
numerous stones. This patient’s disease
had an unusual course since she survived
frequent episodes o f acute cholangitis
over 23 years without suffering from
biliary cirrhosis, liver abscess or any other
complication reported in the English
literature. Endoscopic retrograde cholan
giopancreatography (ERCP) revealed the
malformation o f the pancreatobiliary
system described by Babbitt.9,10
Case Report
A 60-year-old woman had had recurrent pain
in right upper quadrant with rare episodes of
fever and chills since she had undergone
cholecystotomy during a pregnancy 23 years
previously. The cholecystotomy was followed
by an uncomplicated cholecystectomy a few
months after delivery. The operative report of
the cholecystectomy described a choledochal
cysts 5 cm in dimension with choledocholi-

thiasis; a common-bile-duct exploration only
was performed.
One year before admission, she began to
have more frequent episodes of pain, fever
and chills. However, she was never jaundiced.
Despite several medical consultations, an ap
propriate investigation was never performed.
On admission she was noted to be a thin
woman in no acute distress. Her vital signs were
normal. There were no signs of cirrhosis. She
was not jaundiced. The findings on chest and
cardiovascular examinations were normal.
There were no palpable abdominal masses; the
liver was palpable two fingerbreadths below the
right costal margin. It was firm and tender;
there was no splenomegaly. Rectal examina
tion showed coloured stools.
Her hemoglobin level was 119 g/L,
hematocrit 35%, leukocyte count 6.5 x
109/L , erythrocyte sedimentation rate
(Westergren) 80 mm/h. The serum alkaline
phosphatase level was 1005 U/L (normal less
than 100 U/L), gamma glutamyltransferase
1260 U/L (normal less than 18 U/L), total
bilirubin 15.4 /rmol/L, direct bilirubin 8.6
/rmol/L, glutamic oxaloacetic transaminase 43
U/L and glutamic pyruvic transaminase 48
U/L. The total serum protein and serum
albumin levels, prothrombin time and partial
thromboplastin time were normal.
A liver scan showed hypertrophy of the left
hepatic lobe and uptake was not uniform.
Intravenous cholangiography combined with
laminography showed faint visualization of the
common bile duct. Endoscopic retrograde
cholangiopancreatography demonstrated an
abnormally long common channel with inser
tion into the common bile duct at an acute
angle (Fig. 1). Above a short and normal-sized
segment of common bile duct was a cystic
dilatation measuring 5.1 cm in diameter (Fig.
2). The cystic remnant as well as the extrahepatic and the main intrahepatic bile ducts
(principally on the left) were also dilated (Figs.
2 and 3). Numerous bile-duct stones were noted
in the cyst (Fig. 3). The pancreatic duct was
normal.
At laparotomy, biliary cirrhosis, hepatic
abscess and portal hypertension were absent.
Excision of the cyst was judged to be too risky
because of extensive fibrosis and inflammation
around it. A small choledochocystoduodenal fistula was identified and closed.
Numerous stasis stones were found in the
biliary cyst. A Roux-en-Y choledochocystoje
junostomy was then performed. The diameter
of the stoma was about 5 cm.
After a satisfactory course, the woman was
discharged 10 days after operation with a lowoutput biliary-cutaneous fistula. One year
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later, the fistula was excised and a new Rouxen-Y choledochocystojejunostomy was per
formed. She was admitted again 1Vi years later
for an episode of cholangitis, which respond
ed rapidly to medical treatment. Since then, she
has been completely asymptomatic.

Discussion
Todani and colleagues4 reported 17
patients with multiple cysts of the extraand intrahepatic bile duct such as ours.
They believed that the incidence of this
form of biliary cyst is much higher than
has previously been thought. Since the
classification o f A lonso-L ej and
associates2 is applicable only to cysts of
the common bile duct, Todani and
colleagues3 proposed a more complete
classification as follows: type I, cystic
dilatation of the common bile duct; type
II, diverticular dilatation of the common
bile duct; type III, choledochocele; type
IVa, multiple cysts of the extra- and in
trahepatic bile ducts; type IVb, multiple
cysts in the extrahepatic bile duct; type
V, single or multiple cysts of the in
trahepatic bile ducts (Caroli’s disease).
The most common type is type I. Our case
was type IVa.
Many theories of the etiology of biliary
cysts have been proposed. The major con
troversy is between the congenital and
acquired origins o f the cysts.
Yotuyanagi11 suggested that the cellular
proliferation of the common bile duct is
more active at the proximal end than in
the distal portion during the solid stage
of embryonic development; then, as
canalization occurs, the proximal part is
abnormally dilated while the distal part
is normal or somewhat stenotic. Glenn and
McSherry12 proposed that there is a con
genital weakness in the fibromuscular
components of the submucosal and
subserosal layers of the ductal system.
However, Kozloff and Joseph13 believed
that there is an acquired structural
weakness o f the wall of the common bile
duct because they found some cases of
biliary cyst at reoperation on patients
whose previous common-bile-duct ex
plorations had yielded negative findings.
According to Saito and Ishida14 and
many others,2,15‘17 Yotuyanagi’s theory
was the most favoured, until recently.
Since the advent of ERCP, the new
etiologic concept of B abbitt9 and
associates10 is now the most acceptable.
They suggest that an anomalous pancreaticobiliary ductal relation with an ab
normally long common channel outside
the duodenum precludes the development
of a sphincter at the junction of the pan
creatic and common bile ducts. Free pan
creatic reflux to the biliary system then
produces recurrent bouts of cholangitis,
which cause a bile-duct cyst to develop.9
Endoscopic retrograde cholangiopan
creatography has been of great help in
demonstrating malformation of the
272

pancreaticobiliary ductal system (Figs. 1
and 2) — the shortness and small calibre
of the distal common bile duct and its in
sertion into the pancreatic duct at a right
angle, forming an unusually long common
channel from the ampulla of Vater. Ono
and colleagues18 supported the sugges
tion of Babbitt and associates.10 Kimura
and associates19 reminded us that Bab
bitt’s theory does not account for those
biliary cysts without a common channel
and does not explain the purely in
trahepatic bile-duct dilatation.
About 60% of patients with bile-duct
cysts are less than 10 years old at the time
of diagnosis.6 The classic triad of pain
with a mass in the right upper quadrant
and jaundice is not as common as
previously thought,6'15,20 but the inter
mittent nature of these symptoms and
signs, occasionally extending over a
period of years, should suggest possible
bile-duct cyst.6 Various diagnostic
methods have been used but since the in
troduction of ERCP, ultrasonography
and computerized tomography, biliary
cysts will be diagnosed before operation
more frequently.1'17,20
There are many complications of
biliary cyst: spontaneous rupture with bile
peritonitis,1,15,21 severe cholangitis,22,23
biliary cirrhosis,23 liver abscess,24 portal
hypertension,24,25 pancreatitis,24 cyst
lithiasis1'6'8 and cancer.1'3,6,26'27 How
ever, although our patient’s symptoms
were of long duration, the only compli
cation was cystlithiasis found at lapa
rotomy.
Only 19 cases of biliary cyst with

cystlithiasis were reported up to 1975.6
Since then, Matsumoto and colleagues7
described 66 identical cases and Harris a
and colleagues8 described 1. Although
Yamaguchi1 stated that the presence of '
stones is the most common complication
of bile-duct cyst, only 8% of more than *
1500 patients reported with biliary cyst^
had cystlithiasis. M atsum oto and
colleagues7 noted that the older the patient, the higher was the frequency of
calculi, and of those older than 30 years,
90% had cystlithiasis.
Our patient had primary duct stones "
(stasis pigmented stones). These form
secondarily to bile stasis and bile"1
infection.28,29 Longmire and Mandiola22
suggested that congenital cystic dilatation
of the common bile duct may be respon
sible for stasis stone formation and
repeated episodes of obstruction and v

FIG. 2—Anteroposterior view shows cystic
dilatation of common bile duct (A), cystic duct
remnant (B) and left intrahepatic bile duct (C).
Numerous stones are in dilated common bile
duct. Diameter of cyst is 5.1 cm.

FIG. 1—Endoscopic retrograde cholangio
pancreatography (ERCP), lateral view. Abnor
mally long common channel (large arrow) with
insertion into common duct at acute angle.
Cannula of ERCP is in short distal common
bile duct. Pancreatic duct (small arrow) is
normal.

FIG. 3—Anteroposterior view shows cystic
dilatation of common bile duct, cystic duct/*remnant, extrahepatic and main intrahepatic
bile ducts (principally left). Note cystlithiasis.
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cholangitis. Matsumoto and colleagues7
said that not only congenital cystic dilata^ tion o f the biliary tree but also the distal
narrow segment below the enlargement
> may cause bile stasis and infection.
t
Surgery for biliary cysts is the only ac” ceptable form o f management. Medical
, ^ treatment has no place because it is
associated with high mortality.6'15 The
► condition o f the patient, the type of cyst,
the operative risk and the increased in►
- cidence o f carcinoma determine the
operation of choice — either surgical excision or biliary-enteric bypass.30 When
^technically possible, excision o f the bileduct cyst is preferred.17
r

Many authors15'31,32 advocate biliaryintestinal bypass procedures because they
are easier to perform and carry a low
y mortality; however, they are associated
with a higher incidence o f postoperative
rcom plications such as recurrent
cholangitis, biliary stasis with possible
* formation of cystlithiasis, anastomotic
stricture and malignant tumours o f the
4 bile duct.1'2’14'20'33'34 The main cause o f
4 these complications is the failure to create
a mucosa-to-mucosa anastomosis because
, 4. of the incomplete epithelial lining o f the
cyst.20,33
Excision o f the bile-duct cyst is the
operation of choice to diminish the risk
of anastomotic strictures and the developv ment o f carcinoma.1'6'33,35'37 However,
the type of biliary cyst, the increased dif- ficulty in dissection, the prolonged
operating time and the risk o f injury to
- 'porta hepatis or pancreatic duct are disad
vantages of excision.38
r

Since our patient had a type IVa cyst
and appreciable fibrosis from two
previous biliary operations, it was judg*• ed technically impossible to excise the
cyst. We did a Roux-en-Y choledochocys' r tojejunostomy. She is still being follow
ed up periodically since an increased in
cidence of carcinoma has been reported
,
recently in association with biliary
cysts.1,6,39 It developed in 50% o f pay tients a mean o f 4 years after an initial
internal drainage procedure.6,20,39
v
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Salvage of a Severely Ischemic Limb
by Arteriovenous Revascularization: a Case Report
Severe ischemia in a limb that cannot be
revascularized almost inevitably leads to
gangrene and eventual amputation. For
decades, surgeons have considered utiliz
ing the venous system to revascularize
ischemic tissue in numerous areas, in
cluding the lower limb, but with very
limited success. This report documents
the successful revascularization of a
severely ischemic pregangrenous limb
with a bypass graft from the femoral
artery to a tibial vein. The authors
believe this is the first clinical report of
salvage of an ischemic limb by this
approach.
L'ischemie severe d'un membre auquel la
revascularisation n'est plus possible,
mbne presqu'inevitablement a la gan
grene et a I'amputation. Durant plusieurs
decennies, les chirurgiens ont envisage
d'utiliser le systeme veineux pour revasculariser les tissus ischemiques tel que
les membres inferieurs, mais avec des
succes tres limites. Ce rapport documente la reussite d’une revascularisation
d'un membre infdrieur severement ischemique et pr6-gangreneux en utilisant un
pontage de I'artere femorale a une veine
tibiale. A connaissance des auteurs, ceci
est le premier rapport clinique dans la l i 
terature de la recuperation d’un membre
ischemique en utilisant une telle
approche.

Distal arterial obliteration by arterio
sclerosis generally produces intractable
rest pain or gangrene, or both, and leads
to m ajor am putation because conven
tional arterial revascularization is not
feasible. Because the venous system is
unaffected by the m ost diffuse athero
sclerotic process, num erous investigators,
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since the start o f the century, have tried
to use it for revascularizing ischemic
tissue.1 These attem pts generally were
not successful, so this approach was
abandoned. In recent experimental work,
H iertonn2 and Johansen and Bernstein3
develop ed th e co n cep t o f staged
arteriovenous reversal. Using this ap
proach at the popliteal level, we were able
to prevent necrosis in severely ischemic
limbs in an experim ental canine m odel.4
We now report w hat is to our knowledge
the first attem pt w ith this procedure to
salvage a severely ischemic limb in man.

Case Report

bosed once more and the patient’s leg again
became severely ischemic. As the limb was
viable and the patient still refused amputation,
he was discharged. He was readmitted 1 month
later with continuing severe ischemic rest pain
and paresthesia in the left leg. Repeat
angiography demonstrated a patent aorto
femoral graft filling the deep femoral artery
in the left leg with no reconstitution of the
superficial femoral, popliteal or any of the
tibial arteries below the knee (Fig. 1). At this
point, the possibility of using the venous system
for revascularization was explained to the pa
tient and he accepted this on the understanding
that if it failed amputation would probably be
necessary. A venogram was done to be certain
that the deep venous system was intact. A
6-mm PTFE graft was anastomosed end-toside to the aortofemoral graft at the groin and
the distal end was anastomosed end-to-side to
the peroneal vein approximately 2 to 3 cm distal
to the point where the tibial veins formed the
popliteal vein. An intraoperative angiogram
(Fig. 2) demonstrated a patent anastomosis
with rapid flow into the venous system. An at
tempt was made at the time of the distal

A 72-year-old man presented with severe
claudication of the right leg. The angiogram
revealed complete occlusion of the right com
mon iliac artery, stenosis of the left common
iliac artery and an aneurysm of the abdominal
aorta, 5 cm in diameter. The patient underwent
resection of the aneurysm and a bilateral aortofemoral bypass to restore normal perfusion
to both limbs. He remained well for 4 years,
then he again had rest pain in his left leg.
Angiography revealed that the aortofemoral
bypass graft was patent but there was occlu
sion of the superficial femoral artery on the
left side and reconstitution of the popliteal
artery below the knee with two-vessel outflow.
The patient then underwent a left
femoropopliteal bypass below the knee. A
polytetrafluoroethylene (PTFE) graft, 6 mm
in diameter, was used because the saphenous
vein was inadequate. Following this procedure,
the patient once more had normal perfusion
of both lower limbs and was asymptomatic for
a further 6 months when he presented with sud
den onset of severe ischemia in the left leg. An
angiogram showed that the femoropopliteal
graft on the left was occluded; thrombectomy
of this graft was attempted but was unsuc
cessful in restoring flow to the limb. Amputa
tion was recommended but the patient refused
to undergo the operation.
The patient was readmitted 10 days later
because of severe, unremitting, intractable rest
pain and paresthesia in the left foot. Another
attempt at femoropopliteal thromboendarterectomy with revision of the distal limb of the
graft was made, but intraoperative
angiography demonstrated that only the
posterior tibial vessel was patent down to the
FIG. 1—Preoperative arteriogram shows
foot and it had extensive atherosclerotic in obliteration of superficial femoral, popliteal
volvement. Postoperatively, the graft throm and tibial arteries.
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FIG. 2—Intraoperative arteriogram demon
strates patent polytetrafluoroethylene (PTFE)
graft to peroneal vein anastomosis and reversed
flow in vein distaily.

A

V
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A
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FIG. 3—Segmental pressures and pulse
volume tracings at thigh (T), calf (C) and ankle
(A). A = before operation, B = 1 week after
operation. A /B = ankle-brachial index.

F'g- 4c

Fig. 4d

FIG. 4—Arteriogram 4 months postoperatively. (a) 2.5 seconds, showing patent PTFE graft
and rapid filling of popliteal vein, (b) 5 seconds, (c) 6 seconds, showing extensive neovasculari
zation extending to foot, (d) 7 seconds, showing venous return from foot.
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anastomosis to break down several o f the
venous valves distal to it in order to establish
reversed flow in the distal venous tree, but this
was only partially successful (Fig. 2).
Postoperatively, the patient continued to
have a painful, ischemic foot but the leg in the
region of the calf down to about the ankle was
extremely warm. Doppler studies 1 week later
(Fig. 3) demonstrated a markedly increased
pulse volume at the calf and thigh compared
with the preoperative state, indicating a wide
ly patent arteriovenous anastomosis. There
was, however, little change in perfusion distal
to the ankle. Repeat angiography was carried
out 10 days after operation and demonstrated
the formation of collateral vessels in the region
o f the fistula but no notable perfusion o f the
more distal vessels. Clinically, the patient im
proved slowly over the next 2 to 3 months with
some relief o f rest pain and he was discharged
from hospital. Follow-up vascular studies done
monthly demonstrated gradual improvement
in perfusion to the ankle; at 4 months (Fig.
4) there was a measurable pressure of 90 mm
Hg in the posterior tibia! artery and con
siderable increase in pulse volume at that level
(Fig. 5A).
To differentiate the native circulation from
that originating from the revascularization pro
cedure, an antegrade femoral artery puncture
was performed and the catheter situated direct
ly in the femorotibial graft. At 2.5 seconds, the
patency of the fistula is demonstrated with
rapid venous return (Fig. 4). At 5 and 6
seconds, retrograde venous flow to the foot is
demonstrated with extensive neovascularization
of both large- and small-calibre vessels. By 7
seconds, venous return can be seen from the

foot. Clinically, the patient was free of rest pain
and limb swelling was negligible. At 7 months
after operation (Fig. 5B), vascular studies
demonstrated a virtually normal response to
exercise in both ankle pressure and pulse
volume. The patient was entirely free of symp
toms in his left leg 20 months after operation.

Discussion
Despite aggressive efforts on the part
of vascular surgeons over the past 20
years to salvage severely ischemic limbs
by extending revascularization to the most
distal tibial vessels, there remains a group
of patients who require amputation be
cause such a surgical approach is impos
sible or unsuccessful. As far back as the
late 19th century, surgeons attempted to
use the venous circulation to deliver blood
to the ischemic extremity both by rever
sal of flow in the venous system itself and
by creating an arteriovenous fistula.1
Although there have been sporadic
reports of limb salvage, unfavourable
clinical results such as those reported by
Szilagyi and associates5 in 1951
discouraged the use of this approach.
Most such attempts were at the femoral
level where the presence of distal valves
prevented revascularization of the distal
limb and the high flow rate in the
arteriovenous communication resulted in
severe venous insufficiency, with a sub
stantial risk of cardiac failure as well.

Widespread arterial revascularization to
the popliteal and tibial vessels led us to
believe that this might be a more suitable ±
level for arteriovenous revascularization.
Investigations in our laboratory over V
the past 2 years clearly demonstrated the
ability of staged arteriovenous revascu- 4
larization at the popliteal level to salvage
an extremity that would otherwise rapid- 4 ly develop severe ischemic necrosis.4
Bernstein’s group, utilizing a somewhat

FIG. 5—Segmental pressures and pulse
volume at thigh, calf and ankle. A = 4 months
after operation, B = 7 months after operation,
with pre- and postexercise ankle tracings. 5V
A /B = ankle-brachial index.
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different model and a similar procedure,
demonstrated success in revascularizing
^ otherwise irreversibly ischemic canine
limbs.3 Our experimental studies also
/
clearly showed that the mechanism of
I
revascularization was primarily the fork mation of numerous arteriovenous com
munications rather than reversal of flow
^ in the venous system itself.
v
Our patient was aware of our investiga
tion in the laboratory and, because of his
K
strong desire to avoid amputation, re
quested that we try this procedure. The
► surgical procedure itself varies little from
a conventional femorotibial arterial
*■ bypass. The high flow rate through the
graft resulting from the arteriovenous
K fistula should lead, as in this case, to a
higher patency rate than might be ex
pected on the arterial side. We were also
, gratified to learn that the degree of
venous insufficiency was relatively mild
*- and did not preclude successful
revascularization of the distal tissue.
A Perhaps the most striking feature of this
case is the gradual improvement in tissue
■ perfusion that evolved over several
4 months — improvement documented
both by serial noninvasive studies and by
( < angiography. Clearly, this procedure
would not help a patient with extensive
gangrene where immediate revasculariza
tion or am putation is necessary.
However, in the patient with severe and

unremitting rest pain, with or without
limited dry gangrene or ulceration, where
there is time for distal collaterals to form,
the procedure may offer an opportunity
for limb salvage.
Summary

This report documents our first attempt
at femorotibial arteriovenous revasculari
zation for salvage of an otherwise irrever
sibly ischemic limb in man. Although the
success of the procedure in this patient is
gratifying, further experimental and
clinical trials are essential to establish its
value and to delineate better the exact
mechanism by which tissue perfusion is
improved.
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Chronic Traumatic Aneurysm
of the Descending Thoracic Aorta with
Compression of the Tracheobronchial Tree
A 60-year-old man was admitted to the
emergency department in severe
respiratory distress. He had been involv
ed in a major motorcycle accident, 43
years earlier. A plain chest film showed
a calcified mediastinal mass close to the
aortic knob and displacement of the
trachea and the opaque nasogastric tube
to the right. The aortogram showed a
9-cm saccular aneurysm situated at the
isthmus. At thoracotomy, the descending
thoracic aorta was found to be
transected through 60% of its cir
cumference. The ends of the transected
intimal and medial layers of the aortic
wall were 6 cm apart and a false
aneurysm, which was calcified and full
of old and new clot, was compressing
the left main bronchus and the
pulmonary artery. With protection from a
Gott shunt inserted between the ascend
ing and the descending portions, the aor
ta was successfully repaired with an in
terposition Dacron graft.
Un homme de 60 ans a ete hospitalise
souffrant d'insuffisance respiratoire profonde. Quarante-trois ans auparavant, il
avait ete impliqud dans un grave acci
dent de motocyclette. Une plaque simple
a revele une masse mediastinale calcifiee
proche du bouton aortique et le deplace
ment vers la droite de la trachee et d’une
sonde nasogastrique opaque. L'aortogramme a montrd la presence d'un anevrisme sacciforme de 9 cm localise d
I'isthme. A la thoracotomie on dgcouvrit
une dissection transversale de I'aorte
thoracique descendante, a 60% de sa
circonference. Les extrdmit6s de I'intima
et de la media de la paroi aortique dissequ6e etaient ecartees de 6 cm et un faux
anevrisme comprimait la bronche supe-
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rieure gauche et I'art&re pulmonaire;
I'anevrisme etait calcifie et rempli de caillots recents et anciens. Sous le couvert
d’une derivation de Gott inseree entre les
portions ascendante et descendante,
I'aorte a ete reparee par interposition
d'une plaque en Dacron.

Since the first successful excision of a
traumatic thoracic aneurysm was reported
by Stranahan and associates1 in 1955,
many authors have treated the subject
with increasing interest. It has long been
admitted by many that only 2°lo to 5%
of patients surviving a traumatic rupture
of the thoracic aorta live long enough for
a chronic false aneurysm to develop.2
We report such a case in which the
aneurysm caused life-threatening com
pression o f the tracheobronchial tree.

confirmed. A transection of the intima and
media of the descending thoracic aorta in
volved 60% of the aortic circumference. The
adventitia was intact and both aortic ends were
retracted over a distance of 6 cm. The false
aneurysm was full of old and fresh clots and
was bulging towards the mediastinum. A
26-mm diameter woven Dacron prosthesis was
used for the aortic repair.
The postoperative period was smooth except
for expected respiratory insufficiency that
necessitated a tracheotomy for prolonged ven
tilatory support. Bronchoscopy was repeated
and showed tracheomalacia due to the long
standing pressure of the aneurysm against the
tracheal wall. We decided to perform a
tracheostomy on the 10th postoperative day to
avoid further damage to the tracheal mucosa
and permit better healing o f the tracheal wall.
The patient was weaned off the respirator on

Case Report
A 60-year-old man complained for 1 year of
dyspnea that had worsened in the previous 3
months. He was admitted in severe respiratory
distress. Marked wheezing could be heard dur
ing both the inspiratory and expiratory phases
of respiration. He had been involved at the age
of 17 years in a major motorcycle accident in
which his passenger was killed; our patient was
undoubtedly subjected to high deceleration and
ejection forces since he was thrown a good
distance away from the impact area.
A chest roentgenogram revealed a calcified
mediastinal shadow close to the aortic knob,
suggestive of a descending thoracic aortic
aneurysm (Fig. 1). Bronchoscopy showed
marked compression of the lower third of the
trachea and the left main bronchus by a highly
pulsatile structure.
Aortography confirmed that there was a
descending thoracic aortic aneurysm (9 cm in
dimension) at the isthmus; its general saccular
configuration suggested a traumatic origin (Fig.

FIG. 1—Roentgenogram showing medi
astinal mass close to aortic knob.

2).

The surgical approach to the aneurysm was
through the bed of the fifth left rib. As in repair
of all lesions o f the descending thoracic aor
ta, a 9-mm Gott external shunt (Sherwood
Medical Industries, St. Louis, Mo.) was in
serted proximally in the ascending aorta and
distally in the descending thoracic aorta.3 This
assured proximal aortic decompression and op
timal distal aortic perfusion during the 28
minutes o f aortic cross-clamping. When the
aneurysm was opened, its traumatic origin was

FIG. 2—Aortogram shows descending
thoracic aneurysm at isthmus.
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the 30th postoperative day and the tracheos
tomy cannula removed on the 33rd day. Three
months after his discharge from the hospital,
the patient was readmitted because o f marked
dyspnea. Bronchoscopy showed notable
improvement o f the tracheomalacia but there
was severe tracheal stenosis at the previous
tracheostomy site. A new tracheotomy was car
ried out to permit full healing of the
^ tracheomalacia so that a limited tracheal resec
tion could be done under the best conditions.
Fifteen months after the thoracic aneurysm
resection, the patient breaths easily through a
temporary tracheostomy tube. The definitive
tracheal reconstruction will be carried out later.

Discussion
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Although it has been thought that less
than 5% of patients with traumatic rup
ture of the aorta live long enough for a
false aneurysm to develop, the increasing
number of reports4 suggest that this
percentage is probably too low. The
average long-term survival after such a le
sion could be higher than ever suspected.
This emphasizes that every patient who
has suffered multiple traumatic injuries
and who did not undergo aortography at
the time of injury should undergo chest
roentgenography annually.
A chronic traumatic aneurysm is lifethreatening because it tends to dilate pro
gressively and eventually rupture. Bennett
and Cherry,2 Finkelmeier and associates4
and McCollum and colleagues5 have
demonstrated the unstable character of a
traumatic aneurysm even after a “ silent”
period of 5 years.
Symptoms or signs of expansion of
these aneurysms have developed in about
42% of cases at 5 years and 85% at 20
years after the original injury.4 In a
series of 10 patients of our own reported
in 1980,6 90% had signs of mediastinal
compression within 5 years of the accident. In five patients who had had chest
roentgenograms, progressive dilatation of
the thoracic aorta was evident. Rupture
is obviously the major threat of this
lesion.
Peripheral embolization has also been
reported by Roon and Sauvage7 and
Soyer and associates.8 This is not sur
prising, as the calcium deposits and the
laminated old and fresh thrombi cover
ing the inner surface of the aneurysms
predispose to embolization.
Compression of mediastinal structures
is frequently caused by luetic and
arteriosclerotic aneurysms9 but not em
phasized in the case of traumatic
aneurysms. In our 1980 series,6 50% of
patients had a combination of bronchial
and esophageal compression manifested
by dyspnea, chronic cough and
dysphagia. Our patient who required an
emergency resection to relieve the lifethreatening tracheobronchial compres
sion 43 years after the initial injury is one
of the oldest reported in the literature.

Eiseman and Rainer10 reported a
traumatic aneurysm that was stable for
43 years and then showed progressive
enlargement on chest roentgenography
for the next 4 years. These two cases em
phasize that it cannot be taken for granted
that chronic traumatic thoracic aneur
ysms remain stable even after a long
symptomless period.
From other reported data2,4 there ap
pears little place for observation of these
lesions. In our view, the aneurysm should
be repaired surgically as soon as the
diagnosis has been established. This at
titude is highly supported by our surgical
results. In 20 consecutive cases of chronic
traumatic aneurysms of the descending
thoracic aorta, surgical treatment was
performed 4 months to 43 years after the
injury. An external Gott shunt was in
serted between the ascending and
descending aorta in all cases. All surviv
ed with no cardiac or renal failure and no
paraplegia after a follow-up ranging from
4 months to 10 years.
Conclusions

A chronic post-traumatic aortic
aneurysm represents a constant threat to
life. It should be repaired surgically as
soon as the diagnosis is established
without waiting for complications to
develop, such as rupture, peripheral
embolization, compression of medi
astinal structures and increasing size.
They can complicate or compromise an
otherwise simple and safe surgical
procedure.
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FLAGYL 5 0 0

can dramatically reduce
the risk o f antibiotic failure
in anaerobic infections
consistently bactericidal
against virtually all clinically
important anaerobes. In fact, Flagyl
500 Inj. is “ the only compound...
with consistent bactericidal activity
against anaerobic bacteria, including
B. fragilis.'”

Comparative efficacy o f 4 antimicrobial agents
against isolates o f Bacteroides in a mouse model
o f sc abscesses
Decrease vs.
controlst
(log cfu)

Statistical
analysis*

> 6 ,7 ± 0 .6

1

Clindamycin

5.0± 0.6

2

Moxalactam

3 .8 ± 0 .6

2,3

Cefoxitin

3.5±0.5

3

penetrates
rapidly into colonic tissue, achieving a
significant reduction in Bacteroides
content of the colon within one hour.2
Flagyl 500 Inj. is distributed in all
body tissues and fluids, including
abscesses.3,4

t Mice given no antibiotic had mean (± SEM) counts of

concentrates
at bactericidal levels in wound tissue.
In an animal study comparing Flagyl
500 Inj. with clindamycin and
cefoxitin, only Flagyl 500 Inj.
achieved therapeutic concentrations in
both fresh and healing colonic tissue.5

eradicates
pathogens from within the abscess
cavity, achieving significantly greater
reductions in Bacteroides count than
clindamycin or cefoxitin.4

1q 9.9± 0.3cft, pg,. abscess at five days.

*Results for drugs with the same numerical designation were
not significantly different (P >0.05) by Student’s t- test of
independent means.

Excellent safety profile
Flagyl 500 Inj. is well tolerated, with a
low incidence of side effects.6
Pseudomembranous colitis is unlikely
to occur, as Flagyl 500 Inj. is highly
effective against C. d ifficile?’8 which is
usually associated with this disease5
Clindamycin and cefoxitin, on the
other hand, show little activity against
C. difficile .7,s
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A selective anaerobicide
ACTIONS
Flagyl (m etronidazole) is bactericidal against
anaerobic bacteria, it exerts trichom onacidal activity
and is also active against Giardia lamblia and
Entamoeba histolytica. Its exact m echanism o f action
has not been entirely determined as yet. It has been
proposed that an interm ediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infections: The treatment o f serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroldes fragilis (and
oth er species of Bacteroides), Clostridium,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
perform ed to determine the causative organisms and
their susceptibility to m etronidazole. Based on clinical
judgm ent and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration o f an antibiotic appropriate for the
treatm ent o f the aerobic com ponent o f the infection.
(S ee Warnings).
Flagyl (m etronidazole) has also been used in the
treatm ent o f a small number o f cases o f brain or lung
infections (some with abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history o f hypersensitivity to
m etronidazole or oth er nitroim idazole derivatives.
F lagyl should not be administered to patients with
active neurological disorders or a history o f blood
dyscrasia, hypothyroidism and hypoadrenalism.

WARNINGS
Flagyl (m etronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria. In
patients with mixed aerobic/anaerobic infections,
appropriate concomitant antibiotics active against the
aerobic component should be considered.
Know n or previously unrecognized moniliasis m ay
present more prominent symptoms after treatment
with Flagyl.
Studies in rats and m ice have provided some
evidence that metronidazole m ay cause tumors in
these species when administered orally for a long
period at high doses. T h e relevance o f these findings
in humans is not known.
S evere neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flagyl (administered
orally o r intravenously). These have oeen observed
very infrequently.

PRECAUTIONS
Patients taking F lagyl (m etronidazole) should be
warned against consuming alcohol, because o f a
possible disulfiram-like reaction. For the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatm ent with Flagyl. Regular total
and differential leukocyte counts are advised if
administration for m ' " 2 than 10 days or a second
course o f therapy is considered to be necessary.
Metronidazole crosses the placental barrier.
A lth ou gh Flagyl has been given to pregnant women
without apparent com plication, it is advisable that
oral administration be avoided in pregnant patients
and F lagyl be withheld during the first trimester o f
pregnancy. In serious anaerobic infections, if the
administration of F lagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be w eighed against the possible
risks to the fetus.

<
M etronidazole is secreted in breast m ilk in
concentrations similar to those found in plasma.
Intravenous or oral administration o f Flagyl should be
avoided in the nursing mother.
M etronidazole has been reported to potentiate the
anticoagulant effect o f warfarin resulting in a
prolongation o f prothrombin tim e. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type o f anticoagulant
therapy. Clinical experience in children is very limited.
The monitoring o f this group o f patients is particularly
important. The safety and effectiveness o f intravenous
Flagyl in children has not been established.
A rare case o f reversible but profound neurological
deterioration has been reported following a single oral
dose o f Flagyl; it is therefore advisable that a patient
taking Flagyl for the first time not be left unattended
for a period o f tw o hours. The appearance o f abnormal
neurologic signs demands prompt discontinuation o f
Flagyl therapy and, when severe, im m ediate medical
attention. Gastric lavage m ay be considered if no
more than two or three hours have elapsed since
administration o f the drug.
Treatment with Flagyl should be discontinued if
ataxia o r any other symptom o f C N S involvement
occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant accumulation of
metronidazole and its metabolites in the plasma.
Accordingly, for such patients, doses o f Flagyl below
those usually recom m ended should be administered
and with caution. Th e determination o f serum
glutamic oxaloacetic transaminase (S G O T ) by the
Technicon S M A 12/60 system in blood samples from
patients receiving Flagyl may give abnorm ally low
values. This abnormality is artifactual and caused by
the absorption o f metronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophotometrically.

ADVERSE REACTIONS
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
m etallic taste.
Hematopoietic: transient eosinophilia or
leucopenia.
Dermatologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on m oderately high to high-dose prolonged
oral treatment with metronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation o f oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
Metabolic: An antithyroid effect has been reported
by som e investigators but three different clinical
studies failed to confirm this.
Local Reactions: Throm bophlebitis has occurred
with I.V. administration.
Other: Proliferation o f Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion o f alcohol; altered taste o f
alcoholic beverages. Darkening o f the urine has been
reported. This is probably due to a metabolite o f
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion m ay produce vomiting and slight ■*
disorientation.

Treatment
There is no specific antidote. Early gastric lavage
m ay rem ove a large amount o f the drug; otherwise,
symptomatic treatment.

DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS

-x

Treatment should be initiated by the I.V. route. Oral
medication may be substituted when it is feasible
and/or practical. Duration o f therapy depends upon
clinical and bacteriological assessment. Treatment for
seven days should be satisfactory for most patients.
However in cases where infection sites cannot be
v
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
treatment may be required.
*

I.V. ADMINISTRATION:
100 mL (500 m g) by intravenous infusion every 8
hours. The injection should be infused intravenously
*'
at the rate o f 5 m L per minute.
H agyl injection is com patible in a volume ratio o f
.
1:5 with normal saline, dextrose-saline, dextrose 5 per *
cent w/v or potassium chloride injections (20 mmol
and 40 m m ol). It should not be mixed with sodium
^
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY
Injection 0.5% w/v in V iaflex* plastic bags of
100 m L (500 m g) for intravenous infusion.
FU LL P R O D U C T M O N O G R A P H AVAILABLE O N ,
REQUEST.

References:
i
v
l.F in e g o ld SM. Metronidazole: Selected proceedings
o f the international m etronidazole conference.
Excerpta M edica 1979; 141-6. 2 . Hinchey EJ et al.
Ann Surg 1980; 192(2): 221-6. S . Product
monograph. 4 . Joiner K et al. J Infect Dis 1982;
145(4): 561-8. 5 . Chou S et al. Can J Surg 1982;
■*
25(5): 527-31. 6 . W illis A T . Metronidazole: Selected
proceedings o f the international metronidazole
conference. Excerpta M edica 1979; 209-15. 7 . Dzink 4
J, Bartlett JG. Antim icrob Agents Chemother 1980;
17(4): 695-8. 8. Rolfe RD, Finegold SM. Antimicrob
Agents Chem other 1981; 20(5): 600-9.
f
^

RHONE-POULENC PHARMA Inc.
8580 Esplanade
Montreal, Quebec
•authorized user

GEE) I PAABJ,
iiiii

RHONE-POULENC

*

______ _

►K
►
M

o e

K

h a n

,

m d

,

f r c s ic j ;

R

o ber t

G

r ie b e l

,

m d

►
*•

Subdural Empyema: a Retrospective Study of 15 Patients
Su bdu ral em pyem a is a surg ical
^emergency, w h ic h , if not recognized and
m anaged prom ptly, is rapidly fa ta l. The
Y v-clinical fe a tu re s, d iagno sis, infecting
o rg an ism s, treatm ent and resu lts in 15
► p atients w ith subdural em pyem a adm it
ted to the U n ive rsity and Sa sk ato o n C ity
T ho sp itals b etw een 1 9 5 6 and 1 9 8 2 are
.evaluated . T h e re w ere 11 m ales and 4
4 t
fe m a le s; 8 0 % w ere under 5 0 ye ars of
*ag e. Paranasal sin u sitis in s ix patients
w a s th e m o st comm on cau se o f the con4 dition. T h e m o st frequent presenting
fe atu re s w e re fe v e r, head ache, vom iting,
4 se izu res and m otor d e ficit. Preoperative
d iagno stic m ethods included skull roent
geno grap hy, cerebrospinal fluid stu d ie s,
electro encep halo g raphy, cerebral
angiography and com puterized tom o
g r a p h y . C u ltu res of the pus w ere
p o sitive fo r bacteria in 13 o f the 15 pa, tie n ts. D rainage of the em pyem a w a s a c 
com plished through m ultiple burr holes,
*■cranio to m y and craniecto m y. Follow-up
ranged from 1 month to 15 y e a rs.
► 'E leven patients recovered w ith m inimal
or no neurologic d eficit, 2 patients had
v ^permanent m ajor de ficits and 2 died.
S u c c e s s fu l m anagem ent of subdural
em pyem a depends on early d iagnosis,
y. prom pt evacuatio n of the pus and ap
propriate antibiotic therapy.
► V

y

^La presence d'un em pyem e sous-dural
c o n stitu e une urgence chiru rg icale. Tou t
, delai dans le diagnostic ou le traitem ent
e st rapidem ent fata l. C ette com m unica*■ tion e s t basee su r I’ analyse de 15 pa
tie n ts adm is au Centre H ospitalier Unir versitaire de l'U n ive rsit6 de la S a sk a tc h e 
w a n et au Saskato o n C ity Hospital entre
1 9 5 6 et 1 9 8 2 ave c ce d iagnostic.
'
L e s auteurs fo nt I'a n alyse de la presen
tation clin ique, des etudes diagnostiques,
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du profil m icrobiologique et du traitem ent
et de s e s re su lta ts. Q uatre-vingt pour
cent d es p atients avaient m oins de 50
an s, 11 etaient des hom m es et 4 des
fe m m e s. Le site in fe ctie u x prim aire fut
une sin u site paranasale dans s ix c a s. La
presentation clinique la plus frequente
fu t une fie vre accom pagnee de cephalees, v o m isse m e n ts, c o n vu lsio n s et defi
c it m o teu r. L'evalu atio n paraclinique
preoperatoire inclua I'etude radiologique
cla ssiq u e du cra n e , I'angiographie cerebrale, la tom odensiom etrie a x ia le , le le ctroencephalographie et I'etud e du liquide
cephalo-rachid ien. Une culture positive
de I'em py&m e fu t retrouv6e d a n s 13 des
1 5 c a s . Le drainage de I'em pyfcm e fut
e ffe c tu e so it par trep anation, so it par
craniotom ie ou craniecto m ie. Le suivie
des p a tien ts s'6 tale d'un m ois a 15 ans.
O nze d e s patients ont gueri sa n s
seq uelle neurologique ou ave c des
se q u e lie s m in eures. 2 so n t dem eures

Table 1-D istribution of
Patien ts by Age and Sex
Sex
Age,

a v e c des se q ue lie s perm anen tes m ajeure s alors que 2 so n t de ce d es.
Le succ& s du traitem ent e s t d irectem en t lie au d ia g n o stic, et k I'e v a c u a tio n
p reco ce de la co llectio n et k I'antib io therapie sp ecifiq u e.

Subdural empyema accounts for 13% to
20% of all intracranial suppurations.1'4
The most common cause of this condi
tion is paranasal sinusitis, followed by
otitis.5'7 Less common causes include
postoperative infection, traum a,
leptom eningitis, osteomyelitis and
hematogenous spread from an infected
focus elsewhere in the body.4,8 Mortali
ty from subdural empyema ranges from
15% to 43%.3-5,9,10 -phe major prognostic
sign is the patient’s level of consciousness
on admission.1,2,5
Patients

In this retrospective study were 15 pa
tients admitted to the University and
Saskatoon City hospitals between 1956
and 1982. There were 11 males and 4
females, the youngest patient being 6
months and the oldest 72 years (mean 27
years) (Table I).

M

F

0 .5 - 1 0

1

2

1 1 -3 0
3 1-5 0

6

1
1

Findings

1

5 1-7 2

3

0

11

4

In all 15 cases the subdural empyema
was located in the supratentorial compart
ment. Paranasal sinusitis was found in six

yr

Total

Table II- -C a u se of Infection and Organisms Cultured
Cause
P aran asal sinusitis
Frontal
Multiple

No.
6
3
3

Organisms
a-hem olytic streptococci
Anaerobic streptococci
Non hemolytic streptococci

Staphylococcus aureus
O titis media
M eningitis
Traum a
Postoperative
Hematogenous spread from

1
1
3
1

Pharynx
Lungs

1
1

Unknown

1
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No growth
a hemolytic streptococci

Pneumococcus sp
S. aureus
Proteus mirabilis
Staphylococcus epidermidis
Pasteurella multocida
Klebsiella pneumoniae
Enterococcus sp

No.
1
1
1
1
2
1
1
2
1
1
1
1
1
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patients; three had frontal sinusitis
and three had multiple sinus invol
vement. The next most trequent cause
was trauma (three patients). Other causes
include otitis media, meningitis, post
operative and hematogenous spread
(Table II). Hemolytic and anaerobic
streptococci and Staphylococcus aureus
were the m ost frequent offending
organisms (Table II). The pus was sterile
in two cases. The usual clinical course was
acute, beginning with headache, vomiting
and fever followed by mental confusion
and neck stiffness. Later signs were
cerebral dysfunction including drowsi
ness, hemiparesis, focal or generalized
seizures and dysphasia (Table III). These
progressed rapidly resulting in stupor,
coma and finally death unless early ag
gressive therapeutic measures were taken.
The neurologic state of each patient at the
time of admission was graded I to IV,
according to the level of consciousness,
as described by Carey and associates11
and Morgan and associates12 (Table IV).
Preoperative diagnostic studies were
limited to those procedures that were
available at the time of the patient’s
presentation. Peripheral leukocytosis with
a shift to the left was noted in all patients
and the erythrocyte sedimention rate was
elevated in 10. Skull and sinus roent
genograms demonstrated opacification of
the sinuses in six patients and pineal shift
in two. Lumbar puncture was perform
ed in nine patients, but the opening
pressure was only recorded in one, at 240
mm HzO. Pleocytosis of 25 to 500
cells/mm3 with 70% to 90% polymor
phonuclear neutrophils was found in all
nine patients. The cerebrospinal fluid pro
tein was elevated in seven patients while
the glucose level was more than 1.9
mmol/L in all. No organism was seen on
G ram staining and culture of the
cerebrospinal fluid grew Pneumococcus
sp. in only one patient who had associated
leptomeningitis. Electroencephalography
was carried out on 12 patients; in 10 there
was generalized or unilateral slow wave
activity or unilateral suppression of
voltage. Cerebral angiography was done
on eight patients and avascular ex
tracerebral collections were noted in
seven. Only one patient had parafalcine
pus collection. Computerized tomogra
phy, performed in one recent case,13
revealed the subdural fluid collection
(Fig. 1).
The pus was evacuated in 10 patients
through multiple burr holes, 4 had
craniotomy and 1 a craniectomy (Table
V). Following evacuation of the pus, the
subdural space was irrigated copiously
with Elliot’s solution and 1 or 2 subdural
drains were left in situ. These were re
moved 2 to 4 days later. We did not en
counter any particular difficulty in drain
ing the pus and no patient required multi
284

ple procedures. Each patient received ap
propriate antibiotics and bacitracin was
used locally in eight cases.
Follow-up extended from 1 month to
15 years (mean 4.5 years). Eleven patients
recovered with minimal or no neurologic
deficit, 2 patients died, 1 with an asso
ciated intraparenchymal abscess and the
other with leptomeningitis. Two patients
had permanent major residual neurologic
deficit. Six patients experienced focal or
generalized seizures during the first 6
months after their illness. The seizures
were all controlled by Dilantin or phenobarbital, or both, except in one 21-yearold man who required cortical cicatrix ex
cision 2 years later to control his seizures.
D iscu ssion

abscess,14 pachymeningitis in tern a,15
purulent pachymeningitis16 and subdural
abscess.17 Kubik and Adams17 adopted* -«
the term subdural empyema which has
been widely accepted. In 1699, De La« <
Peyronie18 performed the first successful
operation for subdural empyema and *
reported that case in 1709. In 1910, ^
Blevad14 reported on 44 such cases and
25 years later Courville15 described 42^
cases of subdural empyema secondary to
purulent frontal sinusitis, verified aU <
autopsy. In 1948, Schiller and
colleagues16 reported 33 cases, of which -*
23 were caused by paranasal sinusitis and
6 by otitis media or mastoiditis. They also *
demonstrated the importance of penicillin
in treating this condition; 23 patients who* ’
received little or no penicillin died, while.,
7 of the remaining 10 survived with ade*

The term subdural empyema designates
pus collection between the dura and the
arachnoid layers. This has been described
under different names including cortical

Table Ill-Signs and Symptoms
Associated with Subdural Empyema
Signlsymptom
Fever
Headache
Seizures
Hemiparesis
Vomiting
Neck stiffness
Speech impairment
Papilledema
Cranial nerve palsy
III
V
VI
VII
Sensory deficit

No.
15
10
10
10
9
7
4
3
3
2
2
2
2
FIG. 1—Computerized tomogram shows left*
subdural empyema.

Grade
1

II
III
IV

Table IV—Level of Consciousness According to Carey and
Associates11 and Morgan and Associates12
Neurologic state
Alert, minimal neurologic symptoms
Drowsy or moderate to severe
neurologic symptoms, or both
Semicomatose, responsive to painful
stimuli
Unresponsive to pain with disturbance
of vital functions

No.
2
8
4
1
------------------ 4

Table V--Results According to Treatment
Neurologic deficit*
Treatment
None
Minimal
Severe
Died
Total 1
Multiple burr holes and antibiotics
7
1
1
1
10
Craniotomy and antibiotics
2
1
1
4
Craniectomy and antibiotics
1
1
Total
7
4
2
2
15
"Minimal = return to normal activities, severe - assistance needed for daily living activities.
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quate penicillin therapy. Subsequently,
many reports have appeared in the
^ ^literature.1'4,7' 12,19'27
An acute pyogenic infection may reach
y * the subdural space by direct extension of
infection or septic thrombophlebitis5,15
* from an adjacent sinusitis, otitis,
^ osteomyelitis or extradural abscess. The
mechanism of empyema formation fol, flowing contaminated compound skull
fractures and cranial surgery is easily
> , understood.19 Subdural empyema may
be a sequel to or a concomitant feature
of purulent leptomeningitis, especially in
infants.20 Infection of the subdural space
*■ secondary to hematogenous spread from
a distant focus is less common.8,10
Y ' f
The clinical onset in patients with suby ^dural empyema is characteristically acute
with rapid deterioration. Fever, head► ache, vomiting, seizures, hemiparesis and
cranial nerve disturbances were noted in
r the majority of our patients on admission
(Table III) and in five, signs of major
A cerebral dysfunction (grade III or IV)
were present. Two of the five progressive71 ly deteriorated and died in spite of
^ prompt, aggressive therapy. The duration
of symptoms before diagnosis ranged
i from 2 to 27 days. The three patients
whose subdural empyemas developed as
a result of head injury were symptomatic
for 27, 22 and 18 days respectively before
v ‘ The clinical diagnosis was made. They also
received antibiotics following their head
trauma for 14 to 16 days. In the remainr ing 12 patients, the clinical diagnosis was
made 3 to 5 days after the onset of symp►toms. These patients deteriorated rapid
ly, becoming drowsy, lethargic or
y 'semiconscious 24 to 48 hours after admis
sion. In this group of patients, there was
V *no notable relation between the type of
organism or source of infection and the
rapidity with which symptoms evolved.
,
However, the prophylactic use of an
tibiotics in the head injured group of pa►►tients may have modified the clinical
response.
^ f Streptococcus was the most common
organism isolated in published
7 reports,1'3,5 accounting for over 50% of
all cases reported and was most often
secondary to paranasal sinusitis and otitis.
>In subdural empyema secondary to
trauma or neurosurgical wound infection,
► FS. aureus is m ost com m only
i found.3'4,10,21 Negative cultures from
+ subdural empyema are due largely to re
cent antibiotic therapy, failure to isolate
fastidious anaerobes because of inade4quate specimen transport or culture
technique.21'23
/ « Peripheral leukocytosis, with or
w ithout a left shift or increased
erythrocyte sedimentation rate, or both,
are typical hematologic findings of pa
tients with subdural empyema. The ab
normal findings on plain skull roent

genograms include pineal shift, sclerosis
or erosion of the mastoid, or both, osteo
myelitis, opacification of sinuses and
diastasis of sutures in infants. Although
cerebrospinal fluid studies are valuable to
diagnose and differentiate various in
tracranial infections, lumbar puncture re
mains a hazardous procedure in the
presence of increased intracranial
pressure. Several deaths reported in the
literatu re were related to lum bar
puncture2,21,23,24 and several recorded
cases showed signs of transtentorial
hern iatio n shortly after the p ro 
cedure.2,5,9,22,24 A bnorm alities o f
cerebrospinal fluid associated with sub
dural empyema include high opening
pressure, pleocytosis and a variable
glucose level in the cerebrospinal fluid.
Gram staining and cerebrospinal fluid
culture are usually negative.7,10,17
In infants, transillumination is a sim
ple and useful diagnostic tool,8 although
lack of transillumination may be due to
the density of pus.22 Percutaneous
diagnostic tapping through the anterior
fontanelle is often valuable.1,8,10,25
Electroencephalographic findings in the
presence of subdural empyema are
variable. When abnormal, they may in
clude generalized or unilateral slowing or
voltage suppression.8,9,22 Focal delta
waves and spikes, with or without
unilateral slowing and of localizing value,
are seen in less than 50% of cases.4,8,9,22
Before the advent of computerized
tomography, cerebral angiography was
considered the diagnostic procedure of
choice for subdural empyema.4,5,7,22
Angiographic findings specific for con
vexity subdural empyema include the
following:
• A crescentic avascular area over the
surface of the cerebral hemisphere on
anteroposterior projection with scallop
ing of the medial portion. This is due to
irregular medial displacement of the bran
ches of the middle cerebral artery from
the inner table of the skull.9
• A thickened dural vascular wall.7
• Contralateral shift of the anterior
cerebral artery or internal cerebral
vein.21
• Avascular semilunar zone sur
rounded by a vascular stain in the lateral
projection.21

Grade
1
II
III
IV
Total

• An S-shaped pattern, characteristic
of parafalcine subdural empyema, seen
on the anteroposterior projection. The
pattern is formed by contralateral
displacement of the pericallosal branch
and ipsilateral displacement o f the
callosomarginal branch o f the anterior
cerebral artery together with the avascular
area over the convexity and alongside the
falx.22
Computerized tomography now offers
a quick, accurate and noninvasive method
of diagnosing a subdural empyema.26'28
Contrast enhancement demonstrates a
characteristic rim-like crescent adjacent
to the cortex.21,26
Proper management of subdural em
pyema requires prompt surgical evacua
tion of the pus and appropriate parenteral
antim icrobial th erap y .22 Surgical
drainage is most commonly achieved by
making multiple burr holes, or by
craniotom y or craniectom y.21 Each
technique has advantages and limitations.
We prefer to make multiple burr holes
positioned so that craniotomy can be per
formed if required to drain thick pus. The
issue of local antibiotic usage is not set
tled. Ideally, appropriate antibiotics
should be continued parenterally for at
least 3 weeks in the presence of resistant
organisms or osteomyelitis. Removal of
the primary source of infection, such as
a sinus, should be performed shortly after
recovery from the subdural empyema.
Prophylactic anticonvulsant therapy is
important.5,7,10,15 Immediate postopera
tive seizures were encountered in 17 of the
19 patients who survived in the series
reported by Hitchcock and Andreadis.7
There is a close correlation between
m orbidity and m o rtality and the
preoperative level of consciousness.2,3,5,26
Of the 15 patients reviewed, 2 died; on
admission the neurologic state of 1 was
grade III and the other grade IV. Similar
ly, morbidity was greater in patients ad
mitted with a depressed level of con
sciousness than those in a less drowsy
state (Table VI).
In reviewing the available literature, the
mortality from subdural empyema re
mains alarmingly high, ranging from 15%
to 43%.3'5,9,10 It is hoped that with an in
creased awareness of this condition
and the advent of computerized tom o
graphy the diagnosis can be made early

Table VI—Results According to Grading on Admission
Neurologic deficit
None
Minimal
Severe
Died
—
—
—
2
—
4
3
1
1
1
1
1
1
7
4
2
2
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Total
2
8
4
1
15
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From cells
to organ system s...

Solu-Medrol
protects against
the inroads of
shock and improves
the patient’s
chance for survival*

Inadequate tissue perfusion, which
occurs during shock, changes the
metabolic function of vital organs,
leading to multiple organ failure.
® Particularly insidious is the effect
on the lung. Polysaccharides
released in shock cause chaotic
activation of complement. This
affects granulocytes, which
migrate to the lung, plug the
pulmonary micro vasculature, and
trigger the release of toxic oxygen
radicals that damage the
epithelium and permit capillary
leakage. The result is the acute
adult respiratory distress
syndrome (ARDS).

• Pharmacologic doses of SoluMedrol Sterile Powder (methy
prednisolone sodium succinate;
given early in the course of the
illness can be lifesaving.
• In the lungs of patients with sB
tic and hemorrhagic shock, sjk
doses have reduced the perme
ability defect and increased Sui
vival rates.1"*
»A
• Solu-Medrol inhibits compleme
induced granulocyte aggregatic
and formation of leukostatic*
plugs, decreases arteriovenous
shunting, and increases oxyger
consumption.56
*adjunctively with standard methods of ,
combating shock
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•osage
In early or impending shock, a
pharmacologic dose of 30 mg/kg
Soju-Medrol intravenously over
a period of 10 to 20 minutes
'Additional doses at four-hour
intervals until patient’s condition
has stabilized (up to 48-72 hours)
A *

A

A

Timing
Immediate stabilization of the pa
tient with respiratory support,
fluids and vasoactive drugs is of
primary concern. Solu-Medrol
may tip the balance toward
survival.78
• Early treatment with steroid
appeared to be “ a critically
important prerequisite for
successful recovery” of animals
subjected to experimental
shock.910
• Large doses of Solu-Medrol did
not depress phagocytic activity
or delay time of recovery in
dogs or baboons.
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and appropriate therapy carried out be
fore irreversible neurologic deficit or
death supervenes.

Solu-Medrol

<r 4

protects the chain
of organ systems in shock
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Action:
Solu-Medrol, like other corticosteroids, exerts its action by its
anti-inflammatory effect.
Indications and Clinical Uses:
Intravenous administration of Solu-Medrol is indicated in situa
tions in which a rapid and intense hormonal effect is required.
Shock:
In severe shock adjunctive use of intravenous methylpredni
solone sodium succinate (Solu-Medrol) may aid in achieving
hemodynamic restoration. Corticoid therapy should not replace
standard methods of combating shock, but present evidence
indicates that concurrent use of large doses of corticoids with
other measures may improve survival rates. In particular, large
pharmacological doses of Solu-Medrol have been proven useful
in bacteremic or endotoxin shock, hemorrhagic shock, traumatic
shock, and cardiogenic shock.
Contraindications:
Except when used for short-term or emergency therapy as in
acute sensitivity reactions, Solu-Medrol is contraindicated in
patients with arrested tuberculosis, herpes simplex keratitis,
acute psychoses, Cushing’s syndrome, peptic ulcer, vaccina and
varicella.
Precautions:
Existence of diabetes, osteoporosis, chronic psychoses, active
tuberculosis, renal insufficiency or predisposition to thrombo
phlebitis requires that Solu-Medrol be administered with
extreme caution. In the presence of infection, the causative
organism must be brought under control with appropriate anti
bacterials, or therapy with Solu-Medrol should be discontinued.
While therapy with corticoids does not appear to be contraindi
cated in pregnancy, caution is recommended, particularly during
the first trimester. Also, newborn infants of mothers who
received such therapy during pregnancy should be observed for
signs o f hypoadrenalism and appropriate measures instituted if
such signs are present. Since Medrol, like prednisolone, suppres
ses endogenous adrenocortical activity, it is highly important
that the patient receiving Solu-Medrol be under careful observa
tion, not only during the course of treatment but for some time
after treatment is terminated. Adequate adrenocortical suppor
tive therapy including ACTH, must be employed promptly if the
patient is subjected to any unusual stress such as surgery,
traum a, or severe infection. Patients should be advised to
inform subsequent physicians of the prior use of Solu-Medrol.
There have been a few reports of cardiovascular collapse asso
ciated with the rapid intravenous administration of large doses
of Solu-Medrol (greater than 0.5 grams) in organ transplant reci
pients. The cause and relation to other medications (i.e.,
diuretics) is not known at this time, but physicians should be
alert to this possibility.
Adverse Reactions:
Adverse reactions are not likely to result from short-term intra
venous administration of Solu-Medrol, but may be anticipated if
continued therapy with oral or intra-muscular corticosteroid
preparations is to follow. Medrol has less tendency than pred
nisolone to induce retention of sodium and water, and in some
cases has been observed to produce diuresis and an increased
excretion o f sodium. Likewise, therapy with Medrol appears to
produce less nervousness and psychic stimulation than that
produced by prednisolone. While epigastric distress has not been
totally lacking in patients receiving Medrol, the incidence and se
verity o f this side reaction to date suggest that although Medrol
has an enhanced anti-inflammatory potency when compared
with prednisolone on a weight basis, the so-called ulcerogenic
potential o f this corticosteroid is no greater, and may even be
less, than that o f prednisolone.
With the exception of the differences noted in the preceding
paragraph, Medrol is similar to hydrocortisone and prednisolone
in regard to the kinds of adverse reactions and metabolic altera
tions to be anticipated when treatment is intensive or prolonged.
Negative nitrogen balance is usually counteracted by a high

protein intake. In patients with diabetes mellitus, Solu-Medrol
may increase insulin requirements during the period of adminis
tration. Ecchymotic manifestations, while noted only rarely
during the clinical evaluation o f Medrol may occur. Excessive
loss of potassium is not likely to be induced by effective mainte
nance doses of Medrol. If such reactions are serious or distres
sing to the patient, reduction in dosage or discontinuance of
corticoid therapy may be indicated. While a retardant effect on
wound healing is seldom encountered, except in high doses, it
should be a matter of consideration when Solu-Medrol is ad
ministered in conjunction with surgery.
Symptoms and Treatment of Overdosage:
Single large doses of Solu-Medrol do not have any apparent
toxic effect and require no specific therapy. Continuous over
dosage would require careful gradual reduction of dosage in
order to prevent the occurrence of acute adrenal insufficiency.
Dosage and Administration:
In treating severe shock there is a tendency in current medical
practice to use massive (pharmacological) doses of corticoste
roids. The following are Solu-Medrol doses suggested by various
authors:
Author

Dose

Repeat

Oaks
Weil
Melby
Cavanagh
Dietzman

100 mg
200 mg
250 mg
15 mg /kg
30 mg /kg

Every 2-6 hours
100 mg every 4-6 hours
Every 4-6 hours
Every 24 hours
In 4 hours if needed

Therapy is initiated by administering Solu-Medrol intravenously
over a period of at least 10 minutes. In general high dose corti
costeroid therapy should be continued only until the patient’s
condition has stabilized, usually not beyond 48 to 72 hours.
Although adverse effects associated with high dose short term
corticoid therapy are uncommon, peptic ulceration may occur.
In other indications initial dosage will vary from 10 to 500 mg
depending on the clinical problem being treated. The larger
doses may be required for short-term management of severe,
acute conditions. The initial dose usually should be given intra
venously over a period of at least 10 minutes. Subsequent doses
may be given intravenously or intramuscularly at intervals dic
tated by the patient’s response and clinical condition.
Solu-Medrol may be given by intravenous infusion using as the
infusion solution either 5% dextrose in water, isotonic saline
solution or 5% dextrose in isotonic saline solution. Solu-Medrol
is also compatible with most other commonly used infusion
solutions and plasma or whole blood.

Solu-Medrol, 500 mg:
Reconstitute with 7.8 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
Solu-Medrol, 1 gram:
Reconstitute with 15.6 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
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Management of Acute Spinal Cord Injuries

!

This report describes the results achievr * ed in 144 patients with spinal cord injury
admitted during the period 1974 to
^ r 1979 to the Acute Spinal Cord Injury
Unit of Sunnybrook Medical Centre in
r Toronto. Several innovations have been
r made. These are based on a systems
analysis approach to care and docu» i mentation. It includes epidemiologic
studies of, and programs for, urologic
-* * and respiratory management and the use
of halo devices. The unit has achieved a
1
marked reduction in both mortality and
( morbidity. Patients have been transferred
i
to the unit earlier after trauma and have
J
been discharged earlier to rehabilitation
hospitals partly because of the coordina,
tion of the acute and rehabilitation
.
phases of care. There has been a marked
y
► reduction in the cost of care, because of
f
fewer complications and a shorter stay
*" in the acute hospital. The study confirms
I
the advantages of regionalization and
|
specialization in the field of acute spinal
, cord injury.
t Cet article decrit les resultats obtenus
chez 144 patients souffrant de lesion
r
medullaire qui, entre 1974 et 1979, ont
£te hospitalises dans le Service de soins
V aux victimes de lesion medullaire aigu,
;
du Sunnybrook Medical Centre a
*■ ’ Toronto. Cette periode a ete marquee de
1
plusieurs innovations. Les changements
ont ete apportes & la suite d'une analyse
j
de systemes portant sur les soins urologiques et respiratoires ainsi que sur I'utilisation d’appareils servant a immobiliser
■
et a stabiliser la colonne vertebrate (halo
*- > devices). Le service a reussi a reduire
nettement la mortalite et la morbidity
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Les patients ont ete achemines plus rapidement vers le service de soins apr£s un
traumatisme, et ils ont ete diriges plus
tot vers des hopitaux de readaptation, en
partie grace a une meilleure coordination
de la phase aigue de traitement avec la
phase de readaptation. On a assiste a
une diminution importante des couts de
traitement due £ une diminution des
complications et £ une reduction du
sejour en hdpital pour malade aigu.
L'etude confirme les avantages de la
regionalisation et de la specialisation
dans le domaine des traumatismes de la
moelle epiniere.

The Acute Spinal Cord Injury Unit at
Sunnybrook Medical Centre in Toronto
was opened in 1974. It comprises a
multidisciplinary team of medical, nurs
ing, paramedical and administrative staff.
Although such units have existed for
many years in the United Kingdom, the
United States, Australia and several Euro
pean countries, the Sunnybrook unit was
the first in Canada. A similar unit was
opened at Shaughnessy Hospital in Van
couver in 19751 and others are in the
planning stages in at least two other
provinces.
The impetus for the Sunnybrook effort
was provided by the findings o f Botterell
and colleagues,2 who analysed the 224
acute spinal cord injuries reported in On
tario in 1969 and 1970. They found that
the initial treatment was given in too
many hospitals where staff had variable
experience and resources, and that the
results of such management could have
been better. They strongly recommend
ed the formation of acute spinal cord in
jury units, a concept supported by emi
nent workers in this field such as
Gingras3 in Canada and Bucy4 in the
United States. It was anticipated that
regionalizing and concentrating the treat
ment of patients with cord injuries would
improve the standard of care and reduce
the co st.5 It was recognized that
although the annual rate of spinal cord
injuries per million population in Ontario
was only 15, the cost of care was extreme
ly high because of the length of stay in
acute-care hospitals and the high rate of

m ajor complications, often requiring
lifelong care.
The project team on the management
o f spinal cord injuries, designated by the
O ntario Ministry of Health to evaluate
the Botterell report, strongly endorsed the
recommendation to establish several
regional units for the management of
acute spinal cord injuries in the Province
o f O ntario.6 To date, the Sunnybrook
unit is the only Ontario unit and current
ly treats approximately 30% of all spinal
cord injuries in the province.
This report reviews the results of the
unit’s coordinated programs in the areas
o f diagnosis and treatment of acute cord
injury, with emphasis on three important
aspects: the halo program, the urologic
management program and the reduction
in cost. Comparisons are made between
the patients treated in the unit and other
groups of spinal cord-injured patients in
Ontario including those reported by Bot
terell and colleagues,2 and the study of
358 patients with cord injury admitted to
Sunnybrook or Toronto General hos
pitals from 1948 to 1973 reported by
T ator and Edmonds.7
Patients and Methods
Detailed information, collected on a
systems analysis basis, was available for
the 144 patients (113 male, 31 female) ad
m itted to the unit from 1974 to the end
o f 1979 (Table I). Data collection and
methods of analysis were organized by
CSF Consultants, Ltd. of Ann A rbor,
Michigan. The information was derived
by computer processing of information
from the patient’s charts with the
assistance of the Department of Statistics,
University of Toronto. The minimum
follow-up was 6 months for complete
cord injuries and 12 months for in
complete injuries. The 144 patients rang
ed in age from 12 to 83 years (mean 34
years, median 27 years).
Results and Discussion
Spinal Cord Injury and Multiple Trauma
O f the 144 cord-injured patients, 104
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(72%) had no other major injuries. Of the
remaining 40 patients (28%), some had
only minor additional injuries, but several
had major injuries to other body systems.
Some of the patients with multiple trauma
were referred either to the Acute Spinal
Cord Injury Unit or to the Regional
Trauma Unit, which opened at Sunnybrook in 1976. We recently analysed the
effect of multiple trauma on the outcome
of these patients and found that they had
significantly higher mortality and
morbidity .8 In addition, those with
multiple trauma showed less neurologic
recovery.
Admission
Early admission is one of the major ad
vantages of an organized unit. The unit
staff assist the referring physician in
achieving rapid transfer of patients either
by air or land. Early referral provides the
opportunity to begin active treatment
soon after injury and to avoid complica
tions such as pressure sores and urinary
tract infection. In most instances steroids
are administered en route and advice is
given regarding treatment of hypotension
and respiratory failure. We believe that
avoiding hypotension is one of the most
important aspects in the immediate
management of acute cord injury,
especially cervical injury. In the 144 pa
tients, the median interval from the time
of injury to admission at Sunnybrook was
4.9 hours. This represents a marked im
provement over the median interval of
more than 12 hours in the period 1948 to
1973.7Also, more patients were transfer
red either directly to the unit or with on
ly one intermediate off-loading in a near
by hospital than was the case in the
1969/1970 study of Botterell and
colleagues.2 The use of the heliport at
Sunnybrook Medical Centre is a major
reason for the shortened referral intervals.

juries10 and sports-recreational inju
ries11’12 have been carried out by the
unit staff. Because of the high rate of
sports-recreational spinal injury, we have
carried out two detailed epidemiologic
studies of these injuries. The first was a
study conducted jointly with the Royal
Life Saving Society of Canada of all
aquatic accidents causing spinal injury in
Ontario in 1979. It identified 54 spinal
injuries . 13,14 The second study was
prompted by an alarming increase in
spinal injuries due to ice hockey.15 The
unit is presently conducting a national
epidemiologic study of all spinal injuries
associated with hockey in Canada since
1976. Up to Jan. 31, 1983, there were
42 cases.16
Severity o f the Neurologic Injury
Table II shows the severity of the
neurologic deficit graded according to the
new Sunnybrook scale17 in which grade
1 denotes a complete spinal cord lesion,
and grades 2 to 9 denote varying degrees
of partial cord injury. Grade 10 indicates
no neurologic deficit. This scale is
an expansion of the one developed by
Frankel and associates;18 it is an im
provement because it allows more precise
quantitation and comparison between
groups. On admission, 57 patients

(39.6%) had grade 1 (complete) spinal
cord injuries and 87 (60.4%) had grades
2 to 10 injuries. Although the percentage^
of grade 1 cases did not change
significantly, the grades 2 to 7 patients* ^
showed some improvement, as indicated
by lower percentages in these grades and *
higher percentages in grades 8 , 9 and 10 4
at follow-up. There were striking dif
ferences between the current group of pa-*
tients and the 358 patients in the 1948 to
1973 study. For example, in the latter* ■*
group there were 232 (64.8%) patients in
grade 1 and 126 (35.2%) patients in **
grades 2 to 10, indicating that there is now
a much lower percentage of complete "*
cord injury. Possible reasons for this in-*
elude better first aid treatment at the
scene of the accident and more skilfuN 4
transport, which will prevent the patient’s
condition from deteriorating.5 Another 1
explanation is earlier referral of patients
in the incomplete stage; in the earlier *
study many patients were transferred only4
after their condition had deteriorated. It *
is possible that seat belts may have reduc- 1 ,
ed the severity of the injuries in traffic
accidents.
*
Neurologic Recovery
Based on the Sunnybrook scale,17 we
have developed three methods for
documenting neurologic change. One *4

Table 1-Number of Patients Admitted to the Acute Spinal Cord Injury Unit

Year

No. with spinal
cord injury

No. with spinal
injury but no
cord injury

Total no.

19 74
1975
1976
1977
1978
1979

5
11
25
35
37
31

0
1
8
26
28
25

5
12
33
61
65
56

Total

144

88

23 2

Cause o f Injury
Traffic accidents in 59 patients (41.0%)
caused most injuries, followed by sports
and recreational activities 33 patients
(22.9%), work mishaps 25 patients
(17.4%), falls at home 15 patients
(10.4%) and others 12 (8.3%). In com
parison, the 1948 to 1973 review of 358
patients with acute cord injuries admit
ted to two Toronto hospitals showed that
although traffic accidents were responsi
ble for most injuries, work injuries ex
ceeded the sports and recreational
injuries.7 Indeed, our impression is that
there has been both an increase in the ac
tual numbers in the sports-recreational
group and a decrease in the number of
work-related accidents to account for
these relative differences. Specific studies
of traffic injuries ,9 work-related in
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Table It—Sunnybrook Scale of Neurologic Deficit
Residual neurologic function
below level of lesion

No. (%) of patients

Sunnybrook
grade

Motor
function*

Sensory
function

On admission
In - 1441

At discharge
(n - 144)

At follow up
(n - 9 5 t)

1
2
3
4
5
6
7
8
9
10

0
0
Useless
Useless
Useless
Useful
Useful
Useful
Normal
Normal

0
Partial
0
Partial
Normal
0
Partial
Normal
Partial
Normal

57139.6)
2 0 (1 3 .9 )
0
11 17.6)
0
1 (0.7)
4 2 (2 9 .2 )
7 (4.9)
2 (1 .4 )
4 (2 .8 )

5 5 (3 8 .2 )
1 6 (1 1 .1 )
0
11 (7.6)
0
1 (0.7)
43 (29.9)
1 0 (6 .9 )
2 (1 .4 )
6 (4 .2 )

33 (34.7)
1 0 (1 0 .5 )
0
2 (2 .1 )
0
1 (1.1)
2 4 (2 5 .3 )
9 (9 .5 )
4 (4 .2 )
1 2 (1 2 .6 !

'Useless - insufficient strength for walking, useful - sufficient strength for walking (generally
Medical Research Council grades 3 to 51.
tin 49 cases, a follow up grade could not be assigned because of early death, incomplete follow up or
loss to follow up.
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method is shown in Fig. 1. Two patients
showed neurologic deterioration while 41
^•♦improved and 52 did not change. Six pa
tients improved from grade 4 on admis►sion to grade 7 at follow-up and eight pa
tients improved from grade 7 on admission to grade 10 at follow-up.
^ Mortality
There has been a considerable reduct.tion in the early mortality. In the present
series, 10 of the 144 patients (6. 9%) died
► in hospital compared with 50 of the 358
patients (14.0%) in the earlier study.7
Improved respiratory management is one
o f the principal facto rs in this
improvement.19,20 Other factors include
, reduced frequency of pulmonary em
bolism and septicemia from urinary tract
*. infection.
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FIG. 1—Neurologic grade at admission and
j follow-up in 95 patients with adequate follow
up. Shaded squares = no change in neurologic
grade, below the line = deterioration, above
the line = improvement.
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Level o f Injury
The level of bony injury was as follows:
cervical (C l-T l) 82 patients (56.9%),
thoracic injury (T l-T ll) 23 patients
(16.0%), thoracolumbar (T11-12-L1-2)
34 patients (23.6%) and lumbosacral
(L2-S5) 5 patients (3.5%). These percen
tages are approximately the same as those
reported in the 1948 to 1973 study.7
Length o f Stay in the Unit
Factors influencing the length of stay
include the level of injury, severity of
neurologic deficit, age of the patient and
presence of other injuries. In the unit,
those with complete cord injuries had a
longer mean stay (54.1 days) than those
with incomplete injuries (47.7 days) (ex
cluding the 10 patients who died) (Table
III). During the period 1948 to 19737 at
Sunnybrook and the Toronto General
hospitals (excluding the 50 patients who
died in hospital), the respective figures
were 111.4 days and 83.2 days. Thus, the
unit has halved the length of stay in the
acute-care hospital.
Another method of computing the
reduction of acute hospital stay is to com
pare the length of stay of 49 Sunnybrook
patients treated during 1978 and 1979
with a matched series of 49 patients from
other hospitals in Ontario, mainly Toron
to, treated during the same period. All 98
patients were referred to Lyndhurst
Hospital in Toronto for rehabilitation
and the matching was done by an in
dependent observer. The patients were
matched on the basis of time of admis
sion, level of cord injury, severity of in
jury, age and sex. In each group 20 pa
tients had complete cord injuries and 29
incomplete injuries. Sunnybrook patients
had a markedly reduced length of stay

v-

f

■v
A,

Table Ill-Length of Hospital Stay for Patients with Acute Spinal Cord Injuries
Sunnybrook and Toronto
Sunnybrook unit.
General hospitals,
1 9 7 4 -1 97 9
1 9 4 8 -1 9 7 3 7
Mean reduction in
No. of
No. of
hospitalization, d
Mean stay, d
Type of injury
patients
Mean stay, d
patients
57.3
192
Complete cord
51
54.1
111.4
83.2
35.5
Incomplete cord
47.7
116
83
50.6
308
100.8
Total/mean
134
50.2

Table IV--Length of Hospital Stay of Matched Cases for 1978 and 1979 from
Sunnybrook and Other Hospitals in Ontario
Mean hosoital stav. d
No. of
Mean reduction in
Type of injury
patients
Sunnybrook
Other hospitals
hospitalization, d
Complete cord
20
46.7
81.1
34.4
Incomplete cord
29
38.7
71.0
32.3
Total/mean
49
42.0
75.1
33.1

compared with patients from other
hospitals (Table IV).
Cost o f Care
Duration of hospitalization is one of
the most important factors in determin
ing the cost of caring for patients with
spinal cord injuries. If the average daily
cost of acute hospitalization at Sun
nybrook for the 1974 to 1979 period is ar
bitrarily set at $225., then for the 134 pa
tients who were discharged from hospital,
there was a saving of $1 525 590. This
figure may be high because there were
more patients with incomplete lesions in
the period 1974 to 1979 than in the period
1948 to 1973. For patients with complete
lesions, the saved days equalled 2922.3 (51
x 57.3) and for the incomplete injuries,
2946.5 (83 x 35.5) giving a total of
5868.8 for a saving of $1 320 480. Similar
results were obtained when the 1978 and
1979 patients treated at Sunnybrook were
compared with those treated elsewhere.
For the 20 patients with complete injuries,
there were 688 saved days (20 x 34.4),
and for the 29 with incomplete injuries
the figure was 936.7 (29 X 32.3) for a
to tal o f 1624.7 and a saving of
$365 557.50 for these 49 cases.
Many Sunnybrook patients were trans
ferred to Lyndhurst H ospital for
rehabilitation. However, the cost per day
in this rehabilitation hospital is much less
than in the acute-care setting. Moreover,
there is no evidence that the stay in a
rehabilitation unit is prolonged because
of early referral from an acute-care unit.
Indeed, the reverse is probably the case
because the incidence of complications
such as pressure sores is reduced.2 Thus,
the saving in cost would probably be even
greater if the duration of hospitalization
in both the acute and rehabilitation
phases of care is considered. Other
aspects of cost reduction are described
below.
The Halo Program
The halo program is one of the major
therapeutic innovations introduced by our
unit for the treatment of patients with cer
vical fractures or dislocations. Although
halos have been used elsewhere for other
conditions, Sunnybrook Medical Centre
was the first in Canada to develop a halo
program for cord injuries. To date, we
have used halos in more than 300 patients
with cervical spine injuries, approximately
half of whom had cord injuries.21 24
For complete or incomplete cervical
cord injuries, one of the primary aims of
immediate management is to prevent fur
ther damage to the cord and nerve roots
by restoring vertebral alignment and early
rigid immobilization of the vertebral col
umn. Since 1933, when Crutchfield25 in-
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troduced skeletal traction with tongs, this
has been the principal method for restor
ing and maintaining alignment. The main
disadvantage of this method is the need
to confine patients to bed for 8 to 12
weeks, until bony fusion or ligamentous
repair occurs. The prolonged bed rest
may lead to complications such as
pressure sores and pneumonia and has a
negative effect on the patient’s morale.
Although halo devices were first used
in 195926 for nontraumatic instability of
the cervical spine and shortly after for
traumatic lesions of the cervical spine,
they were used mainly for patients
without cord injury. Indeed, one study
even reported that the halo ring and vest
were contraindicated in patients with
complete cord injuries and anesthetic
skin.27 Our experience clearly indicates
the advantages of halo devices for both
incomplete and complete cord injuries.
From 1974 to 1979, we used halo devices
in 113 patients with acute cervical spine
traum a (Table V). The ages of patients
in this group ranged from 12 to 86 years,
and a variety of bony injuries were treated
including dislocations, fractures and
fracture-dislocations. Fifty cord-injured
patients were followed up for at least 6
months to determine the results of bony
fusion and neurologic improvement (ex
cluding 7 who died mainly from
respiratory causes and 2 lost to follow
up). Successful healing with stability at
the fracture site was achieved in 43 (86%)
as a result of the initial treatment, which
included early operative fusion in several
cases. In the remaining seven patients,
stability was achieved only after late
operative fusion. Improvement in the
overall neurologic status was noted in 44
and none deteriorated neurologically be
cause of the halo device. Complications
related directly to the halo devices were
few and minor. They included scalp in
fections, pressure sores and loosening of
halo pins, and did not force us to discon
tinue the halo treatment.
The halo program was an important
factor in reducing hospital stay for pa
tients with acute cord injury and for those
with cervical spine injuries without
neurologic deficit. Indeed, the latter were
often discharged home within 2 weeks of

injury and many were able to return to
work in their halo vests. The unit main
tains a stock of halo devices of varying
sizes, each of which is reused repeated
ly.23 Table VI summarizes the numerous
advantages of halo devices.
The Urologic Management Program
The most important aspect of the
urologic management program is inter
mittent catheterization. Although this
method of managing the neurogenic blad
der in acute cord injuries had been used
for decades in other countries, Sunnybrook developed the first organized
program in Canada for intermittent
catheterization of patients with acute cord
injuries. Our program emphasizes the in
tegration of the acute and rehabilitation
phases of care, and urodynamic assess
ment. This coordinated approach allow
ed more accurate follow-up; patients were
cared for by the same urologic staff
throughout the acute and rehabilitation
phases. Sterile intermittent catheterization
reduced morbidity during the acute phase,
eased bladder rehabilitation and markedly
improved the course over the long term.
Our program was organized and super
vised by the two urologists who are
members of the unit. In general, intermit
tent catheterization was begun within 24
to 48 hours of admission. In males, the
catheterizations were performed by
urology technicians, and in females, by
the nursing staff. The frequency of
catheterization was individually determin
ed for each patient with the urine volume
and frequency were recorded on a special
ly designed record attached to the pa
tient’s chart. Before discharge, every
cord-injured patient underwent in
travenous pyelography, and cystoscopy
and urodynamic studies were carried out
on an outpatient basis approximately 2
months after injury. Urodynamic assess
ment provided an accurate determination
of the function of the lower urinary tract.
A low-pressure system was produced by
drugs and procedures that reduce outflow
resistance.
The results of the urologic management
program were excellent in terms of reduc
ing morbidity from urologic causes.28-31

Table V -A c u te Cervical Spinal Injuries Treated with
Halo Devices, 1 9 7 4 to 1 9 7 9
Method of treatment
Neurologic deficit
on admission
None (grade 10)
Root injury alone (grade 10)
Complete cord injury (grade 1)
Incomplete cord injury (grades 2 - 9 )
Total

292

Halo ring
and vest

Halo ring
alone

Total

43
6
23
29

4
1
2
5

47
7
25
34

101

12

113

In 101 patients with cord injuries, half of
which were complete, and followed up for
an average of 25 months, the complica- *-<
tion rate was low and the incidence of in
dependent, catheter-free voiding was ^ ^
high. It should be noted that clean inter
mittent catheterization as a form of long- *
term management evolved from the use ^
of sterile intermittent catheterization in
the acute phase and was a successful alter- -< „
native. At follow-up, clean intermittent
catheterization was being used by 17 pa—* -i
tients, most of whom had low-pressure
systems and good use of their hands, 43 "
were voiding with no appliance and were
continent and 29 had reflex or spon- "*
taneous voiding with incontinence, which t
was managed in males by a condom ap- 1
pliance. A number of patients in this , ^
group required a transurethral sphinc
terotomy to achieve a low-pressure -t
system. The 12 patients with indwelling
catheters included 5 incontinent females, ’
3 quadriplegic males who did not respond
j
to sphincterotomy and 4 patients who A i
preferred an indwelling catheter to in- ^
termittent catheterization. No patient reh
quired urinary diversion or cystotomy. *
Infection was not a major problem. In
\
general, each patient had positive urine >
cultures once or twice a year; there have
j
been no deaths from urosepsis. The
relatively low rate of stones (bladder four,
j
kidney two) was owing to the fact that
most patients became catheter-free after
less than 3 months of sterile intermittent "*
catheterization. Indeed, the six patients „
with stones had reverted to management
by indwelling catheter. Hydronephrosis ■*

Table VI—Advantages of Halo Devices for
Acute Cervical Cord Injuries
Early ambulation of patients w ith minor
neurologic deficits
Early sitting and wheelchair use for patients
with major neurologic deficits, leading to
earlier participation in rehabilitation programs
Reduce complications of prolonged bed rest
Pneumonia
Pressure sores
Thrombophlebitis and pulmonary embolism
Muscle wasting
Loss of morale
Avoid turning frames
Patient comfort
Easier nursing care
Reduce length of hospitalization
Cost reduction
Adjunct to other spinal surgery
Easy access for anterigr or posterior operations
Immobilization
Increase safety of surgery
Increase likelihood of fusion without deformity
Allow 4-way adjustment of fracture or dislocation
Anteroposterior
Lateral
Rotation
Traction
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occurred in four and epididymitis in seven
patients. There were no instances of
^ u re th ral fistula or stricture.
To assess these urologic results, com*■ >parison was made with the control group
consisting of patients admitted to Lyndy hurst Hospital from other hospitals in
Ontario during 1978 and 1979.28,31 The
* control group took twice as long to be
w ^transferred to the rehabilitation hospital,
suffered approximately eight times the
h oirologic complication rate and seven
times the infection rate of the Sun►nybrook patients. Urologic causes were
responsible for the deaths of two patients
*■in the control group.
r » It is estimated that the urologic
management program for 140 patients
y r'.vith spinal cord injuries during the 5-year
period saved more than $2 million. The
►major saving was due to the reduction of
acute urologic complications. Although
r the cost of developing and maintaining a
^urologic management program was sub
stantial, especially in terms of staff, the
t «cost was more than offset by the savings.
Indeed, both the reduction in urologic
* morbidity and the attendant cost savings
are cogent reasons for establishing a
* spinal cord injury unit.
Diagnostic Techniques
The unit developed organized programs
y Tor the neurophysiologic32,33 and
neuroradiologic34,35 diagnosis of acute
spinal and spinal cord injuries. Neurov physiologic testing of cord function in our
unit was achieved by serial recording of
y The somatosensory evoked potential. Pa
tients with complete cord injuries conV tsistently showed an absence of this poten
tial from sites distal to the injury while
f those with incomplete lesions showed
varying degrees of alteration of the
y somatosensory evoked potential.32 In the
^ ^incomplete cases, serial somatosensory
evoked potentials were helpful in
► ^establishing prognosis at an earlier stage
than by clinical examination alone.33
y Currently under development is a system
for continuously monitoring the somato’ sensory evoked potential in the acute
^phase.

A broad range of neuroradiologic prorcedures was used for initial diagnosis and
subsequent management. Although
” conventional tomography continued to be
used, computerized axial tomography
became essential. In most patients both
K conventional tomography and computer
ized axial tomography were carried out
\ ^as soon as possible after admission to
evaluate the vertebral injury. They were
4 also frequently used subsequently for
assessing bony healing. A full range of
4 myelographic techniques was used for
detecting spinal cord compression, with

computerized tomography-myelography
becoming increasingly useful.
Medical and Surgical Treatment
The unit adopted vigorous methods to
relieve persisting spinal cord compression
in incomplete neurologic injuries and to
reduce spinal deformity and provide im
mobilization as soon as possible after
trauma. Whenever possible, an attempt
was made to achieve these goals nonoperatively, as with halo devices. When
persisting cord compression was iden
tified in incomplete injuries, early
operative treatment was often carried out,
using one or more operative approaches.
Although the cord was decompressed
from posterior, anterior or lateral ap
proaches, anterior approaches were
preferred. For thoracic and lumbar in
juries requiring operative fusion, Har
rington rod instrum entation was
employed frequently.36,37
Steroids were used in the acute phase
in almost all patients. In patients with
complete neurologic deficits, steroids
were rapidly reduced after 1 week, but
maintained at high doses for 2 weeks in
those with incomplete injuries. Diuretics
were also used in patients with suspected
or demonstrated cord swelling who were
not hypotensive. Hypotension was treated
vigorously, mainly by transfusion of
whole blood or plasma for volume expan
sion, or by infusion of crystalloid.
Spinal Cord Nursing Program
A new intensive-care facility, con
structed for acute spinal cord injury and
acute neurosurgical cases, was where
almost all cord-injured patients were
nursed initially, although some were nurs
ed on the trauma ward, the orthopedic
ward or in the respiratory failure unit as
required. The marked seasonal incidence
of acute spinal injury in Ontario made it
economically unsound to have a fixed
number of beds for spinal injuries alone.
As the nursing service gained expertise,
rotational frames and circle beds were
eliminated. With standard beds and the
log-rolling technique, the staff virtually
eliminated pressure sores, but deep
venous thrombosis remained a continu
ing problem. All patients wore thighlength elastic stockings from the first day.
A clinical nurse specialist was responsi
ble for nursing education at the bedside
for staff, patients and relatives.
Rehabilitation Program
The rehabilitation program began
almost immediately after the patient’s
admission.38 The physiotherapists and
occupational therapists were guided by a
physiatrist with a particular interest in

paraplegia and specifically involved in the
care of the patients with spinal cord in
juries from the day of admission. Con
tinuity of care from the acute to the con
tinuing rehabilitation phases was ensured
by the physiatrist’s appointment also at
Lyndhurst Hospital to which most of the
patients with major cord injuries were
transferred as early as possible. The close
cooperation between the two hospitals
allowed coordination of the acute and
rehabilitation phases of care. This coor
dination was facilitated by the many
cross-appointments of medical staff.
Readmission to Sunnybrook as required
for any acute complications, such as
pulmonary embolism, was thus facili
tated. Coordination of the various phases
of care was one of the important recom
mendations of the project team on the
management of spinal cord injuries.6

Conclusions
This report describes the results of
management of the first 144 patients ad
mitted to the Acute Spinal Cord Injury
Unit, Sunnybrook Medical Centre from
1974 to 1979. In general, there was an im
provement in results — the overall mor
tality was reduced and the morbidity,
especially that related to urinary tract
dysfunction, decreased. Approximately
28% of the patients had additional in
juries and these patients were at added
risk of morbidity and mortality.
Patients were referred much earlier
than in previous years, with a median in
terval of 4.9 hours between trauma and
adniission to the unit. The length of stay
in the acute-care hospital was also re
duced, and this is one of the chief reasons
for the marked reduction in the cost of
care.
Epidemiologic analysis showed impor
tant differences between current and past
series of patients with spinal cord injury.
Traffic injuries remain the commonest
cause, but sports and recreational injuries
have replaced work-related injuries as the
second commonest cause. The percentage
of patients with incomplete injury to the
cord has increased.
A multidisciplinary approach to early
management has allowed numerous in
novations including neurophysiologic
methods of diagnosis and spinal manage
ment by halo devices and spinal in
strumentation. Patients entered the
rehabilitation program early and in most
instances long periods of bed rest with its
attendant morbidity were avoided.
Regionalization and specialization in
the field of acute cord injury has resulted
in improved patient management and re
duced costs.
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The Orthopedic Approach in Infected Median Sternotomy
A retrospective review of 10 infected
median sternotomies revealed that the
management may be difficult and several
procedures may be required to obtain a
satisfactory result. Repeated curettage
was successful in four patients. The
cavity created by debridement was
treated by the temporary insertion of
gentamicin beads in one patient and by
the Papineau bone grafting procedure in
two. In two patients the thoracic cage
became unstable as a result of extensive
debridement and was stabilized success
fully by inserting Harrington compression
rods. One patient died of mediastinitis.
Une etude retrospective de 10 sternoto
mies infect6es montre que le traitement
est difficile, necessitant plusieurs inter
ventions chirurgicales. Quatre patients
furent gueris aprfes plusieurs curettages.
L'espace mort cree par le curettage a
necessity I'insertion de billes de gentamycine pour un patient et la greffe de
Papineau pour deux. Chez deux patients,
('instability thoracique residuelle a ete
traitee par des tiges de Harrington. Un
patient est mort des suites de mediastinite.

In the three patients with chronic in
with the cooperation of the staff from the
orthopedic and infectious diseases fection, Staphylococcus aureus was the
causative organism; three of the acute
departments.
cases were caused by S. aureus, two by
Serratia sp, one by Candida organisms
Patient Data
and one had a mixed flora. All patients
From 1979 to 1983, staff in the or required from one to six procedures each
thopedic and cardiovascular departments to eradicate the osteitis.
There were no differences in the
at the University of Sherbrooke treated
10 patients (6 men, 4 women) with resis management of the acute and chronic
tant osteomyelitis following median ster conditions but the acute Serratia and
notomy, 1.5Wo of the sternotomies per Candida infections were notably difficult
formed during that period. The patients to eradicate and one patient with Serratia
ranged in age from 32 to 71 years (mean infection subsequently died of
mediastinitis. Repeated curettage and in
55 years).
Seven patients had elective aorto travenous antibiotic therapy were suc
coronary procedures and three had cessful in two patients and gave lasting
emergency procedures. No patient had an relief to two others. Because of extensive
associated condition predisposing to in curettage and creation of a large dead
fection and all had postoperative suction space, one patient had gentamicin beads
inserted for 2 weeks and two underwent
drainage.
Seven patients had acute infection in bone grafting by the Papineau technique
the immediate postoperative period and (Fig. 1).
Two patients had extensive sternal
three had chronic infections lasting more
than 3 months. The diagnosis was resection and the thoracic cage had to be
clinically obvious in six patients and in stabilized with Harrington compression
four patients, radionuclide scanning with rods (Fig. 2) inserted at the chondrocostal
gallium citrate was useful in identifying junctions.
Follow-up after the last procedure
the site of infection.

Median sternotomy is the approach of
choice for the majority of cardiac surgical
procedures. Wound infection occurs in
less than 2% of the patients’ but when it
does, the morbidity and mortality are very
high.1,2
Most of these infections are recog
nized and treated early with intravenous
antibiotic therapy and surgical debride
ment.3,4 In resistant cases, several addi
tional procedures may be required before
the infection becomes quiescent.
Treatment must be carefully planned,
From the Department o f Orthopedic
Surgery, University o f Sherbrooke,
Sherbrooke, PQ
Accepted for publication Sept. 20, 1983
Reprint requests to: Dr. P. Kinnard,
Department o f Orthopedic Surgery,
Centre Hospitalier Universitaire,
University de Sherbrooke, Sherbrooke,
PQ J1H 5N4

FIG. 1—Bone graft in sternal cavity using
Papineau technique.

FIG. 2—Stability of thoracic cage by Harr
ington compression rods.
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ranged from 4 months to 2 years. One pa
tient died o f infection, two became
asymptomatic despite positive gallium
scans and in seven patients the sternotomy
healed well (gallium scans negative in two
and scanning not done in the other five).
Discussion
The basic principles for preventing and
treating bone infection apply to the ster
nal bone. Prevention of sternal infection
includes clean surgery, antibiotic cover
age,3'5 short-term drainage postoperatively6 and sternal stabilization.
Sternal cerclage with wires is a standard
procedure3 but is not biomechanically
sound7 because the wire may cut through
the thin cortical bone, thus favouring in
stability and dehiscence. Parham bands
may distribute the compression forces
more evenly8 and their use is encour
aged.
As soon as an infection becomes clini
cally evident, aggressive treatment is
mandatory3,4'9-10 because, in Pasteur’s
words, “ the germ is nothing; it is the ter
rain in which it grows which is every
thing” .

It has been said that most cases of ster
nal infection diagnosed early will respond
to proper antibiotic treatment and wound
debridement,4'9 but this was not our ex
perience — only repeated curettage
eradicated the infection. Additional prob
lems may be created if a large defect is
left after curettage.
A sternal defect cannot be left open to
obtain healing by secondary intention2
because of the fear of mediastinitis. All
efforts m ust be directed towards
obliterating dead spaces created, so it is
essential, after removing all necrotic
tissue, to fill the cavity either by a pectoralis major flap11 or by staged ortho
pedic procedures using bone graft or
gentamicin beads, or both.
The cavity may be successfully
obliterated by the temporary use of
methylmethacrylate beads, which release
high concentrations of gentamicin, pro
viding the skin can be closed,1214 or by
the staged procedure of Papineau, which
includes initial curettage followed by in
sertion of bone graft and later coverage
by a skin g raft.15
Should the thoracic cage become
unstable because of extensive debride

ment, the defect must be obliterated and
the thoracic cage stabilized. This can be
done by wide pectoralis major m u s c le ^
transfer1 or by inserting Harrington
compression rods which allow the wound 1 margins to be approximated and provide
stability to the thoracic cage.
*
In view of the morbidity caused by this
complication, all efforts must be directed
towards prevention and early aggressive A M
treatment.
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Editor's note.—The application of orthopedic
principles to sternal infections is of interest and A A
undoubtedly is useful from time to time. Cau
tion should be used in instituting these ^
measures early since most infections clear with
continuous irrigation with an antibacterial solu- k
tion (such as dilute povidone-iodine). A small
tube is used for instillation and a sump drain ^
for removal. The treatment has usually been
effective when applied for 7 to 10 days.
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‘ “ Malignant Leiomyoblastoma (Epithelioid Leiomyosarcoma)
of the Duodenum

Leiomyoblastoma of the stomach is exv ceedingly rare. The authors report the
case of a 69-year-old woman who
presented with acute epigastric pain,
anemia and weight loss. She was found
to have a malignant leiomyoblastoma
> (epithelioid leiomyosarcoma) of the
duodenum with lymph-node involvement.
4 * The clinical and pathological aspects of
leiomyoblastoma of the gastrointestinal
* * tract are reviewed, with emphasis on the
distinctive, diagnostic histologic features.
To the authors' knowledge, this is only
K the fourth reported case of leiomyo
blastoma of the duodenum and the only
case in which the tumour was malignant.
r

MA

Le leiomyoblastome de I’estomac est ex* cessivement rare. Les auteurs decrivent
le cas d'une femme de 69 ans qui
presentait de la douleur epigastrique
„ aigue, de I'anemie et une perte de poids.
On decouvrit chez elle un leiomyoy » blastome matin (Igiomyosarcome
epithelioide) du duodenum avec atteinte
- ►ganglionnaire. Dans cet article, les
aspects cliniques et pathologiques du
leiomyoblastome des voies digestives
sont passes en revue, et on en souligne
les caracteristiques histologiques distincr , tives servant au diagnostic. Selon les
auteurs, c'est seulement le quatrieme
L * cas de leiomyoblastome du duodenum a
etre signale et le premier cas de tumeur
*
maligne.

> In 1960, M artin and associates1
described an unusual smooth muscle
i y tumour of the stomach which they called
myoid tumour. Stout2 in 1962 applied
a the term leiomyoblastoma to this group

a,4 From the Department o f Surgery II,
University o f Coimbra Hospital and
^ Medical School o f Coimbra, Coimbra,
Portugal
K
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of neoplasms. In the recent classification
of tumours of soft tissue proposed by the
W orld H ealth O rganization,3 these
tumours are called epithelioid leiomyo
mas and leiomyosarcomas.
This type of tumour has distinctive
microscopic features and the appearance
under light microscopy is characteristic
and diagnostic. Although the tumour is
usually benign, some are malignant or
potentially malignant. Leiomyoblastoma
is found chiefly in the stomach,4'6 but
may occasionally be seen in other portions
of the intestinal tract,6'7 as well as the
retroperitoneum,8 uterus6 and vulva.6
However, in the duodenum, colon and
rectum, they are so rare as to be
curiosities.4
The purpose of this report is to present
a case of malignant leiomyoblastoma of
the duodenum. To our knowledge, only
three cases6,9'10 of leimyoblastoma have
been reported previously in this location
and none was malignant.
Case Report
A 69-year-old woman was admitted with
severe epigastric pain and anemia. She was
anorexic and nauseated but she had not
vomited.
During the previous 5 months, she had suf
fered from nonspecific, recurrent abdominal
pain and weight loss. There had been no ab
dominal trauma.
The patient was an asthenic, lethargic
woman. There was occult blood in her feces,
but no abdominal mass or tenderness. Findings
from laboratory tests were normal except for
a hemoglobin level o f 80 g/L .
Gastroscopy showed no evidence of disease
in the stomach or duodenum. A conventional
barium meal examination was also performed
but no abnormality was noted. A liver scan was
normal.
Exploration o f the abdomen through a
midline incision showed a mass 5 X 5 cm aris
ing from the posterior wall of the first portion
o f the duodenum, 4 cm distal to the pylorus
(Fig. 1). The tumour, which was soft and
round, was intramural and appeared cir
cumscribed but was adherent to the pancreas.
No tumour necrosis or mucosal ulceration was
present. A metastatic node, 5 mm in diameter,
was found near the celiac trunk. A sarcoma

was strongly suspected. A Whipple resection
was performed. The metastatic node was also
resected. The postoperative course was com 
plicated by a mild urinary infection.
The patient was discharged from the hospital
21 days after operation. However, she became
progressively worse and died at home 3 months
later.
The histologic diagnosis was malignant
leiomyoblastoma with lymph-node involve
ment (Fig. 2).

Discussion
The m ost com m on lo catio n o f
leiomyoblastoma is the stomach. In
cluding three patients of ours (unpublish
ed data), the total number of gastric
leiomyoblastomas reported to date is ap
proximately 420. In contrast, this tumour
is exceedingly rare in the duodenum. Only
three cases have been reported previous
ly in this location.
Our case was a malignant form of
leiom yoblastom a with evidence o f
metastases to the lymph nodes.
On light microscopy, the characteristic
cell of leiomyoblastoma ranges in size
from 15 to 25 pm in diameter and is
round or polyhedral. The cytoplasm is
finely granular and acidophilic. The
nucleus can be central or eccentric and is

FIG. 1—Tumour in posterior wall of
duodenum, opened.
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surrounded by a clear zone that does not
stain for mucus, glycogen or lipids. This
clear zone has been shown to be an ar
tifact of formalin fixation .11,12 Although
these round cells with clear cytoplasm
(epithelioid cells) have been considered
the characteristic cell of epithelioid leio
myoma, many such tumours contain a
mixture of round epithelioid and spindle
cells.4
The cell composition of malignant
leiomyoblastoma is similar to that of the
benign type. The distinguishing features
are the small size of the cells and occa
sionally higher mitotic counts .4
Although the origin of the tumour may
be in question from the light microscopic
studies, the findings at the ultrastructural
level support its origin from smooth mus
cle. Some investigators 9,11,12 have
recognized by electron microscopic ex
amination that scattered cells in the
leiomyoblastoma have ultrastructural
features in common with mature smooth
muscle cells. These include typical
myofibrils, 60 to 80 A in diameter,
pinocitic vesicles, convoluted nuclei and
segments o f basement membrane-like
material. However, Appelman and
Helwig4 believe that the leiomyoblasto
ma is not composed of normal smooth
muscle elements, but that it contains cells
that seem capable of partial, although im
perfect, differentiation towards smooth
muscle.
The biologic behaviour of leiomyoblastom as has been controversial.
Typically, th e tum our is benign.
However, o f the malignant variants aris
ing in the stomach, 63*% metastasize .4
The malignant leiomyoblastoma is a
highly aggressive neoplasm that spreads

rapidly to peritoneal surfaces and the liver
usually within 2 years of diagnosis .4
Because the metastatic growth is usually
nodular and bulky, it is difficult to ascer
tain how frequently lymph nodes are in
volved. Extra-abdom inal spread is
uncommon .5
There are several clinical and mor
phologic features which suggest that a
given leiomyoblastoma is malignant.
Weight loss and abdominal pain are more
likely to be manifestations of malignant
neoplasms .4 Microscopic evidence of in
filtration and the presence of infarcted
lobules of neoplasm are often associated
with sarcoma .4 The size of the tumour
can also be correlated with metastases.
Tumours less than 6 cm in diameter rarely
metastasize.4 However, Abramson 5 con
cluded that there is no direct correlation
between the larger masses and malignant
disease and that malignant degeneration
is even rarer in pedunculated growths.
The mitotic count from 50 high-power
fields has been suggested by Stout2 to be
a guide for malignancy. Nevertheless,
some investigators4,5 believe that the
mitotic count is not a completely satisfac
tory criterion of malignancy unless it is
related to the histologic appearance of the
tumour. On the other hand, Lavin and
associates6 attach importance to mitotic
counts greater than one per high-power
field as an indication of malignant
disease.
According to Appelman and Helwig,4
the best approach in determining the
malignant nature of these tumours is to
use all the criteria (symptoms, gross mor
phologic features, mitotic counts and
microscopic features) with special em
phasis on the histologic features.

Abram son 5 takes an opposite view,
believing that no definite correlation be
tween size or mitotic rate and malignancy can be established.
4 A
The most common symptoms and signs
produced by leiomyoblastomas are ^
similar to those of other smooth muscle
tumours of the gastrointestinal tract — 4
gastrointestinal hemorrhage, recurrent
abdominal pain and an abdominal mass. ■< «
Several patients with smooth muscle
tumours of the small intestine h a d ' *
previous investigation for upper gastro
intestinal bleeding, including laparotomy,
before the diagnosis of the tum our .5 In
most instances, no abnormality is noted
on the barium contrast studies or on en -. i
doscopy. In these cases selective
arterio g rap h y may supply useful -> „
information.
Malignant leiomyoblastomas of the <
stomach have a more favourable course
than the other gastric sarcom as . 13 4
Because similar tumours rarely occur in k
extragastric sites, it is not possible to come *
to any conclusion about the 5-year sur- » t
vival rate. Nevertheless, Lavin and
associates 6 believe that extragastric *
origin of the tumour is indicative of a
poor prognosis.
*
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dosing regimen. In other instances, renal function improved following increased hydration,
dosage adjustment, or discontinuation o f ZOVIRAX therapy.
* <
When dosage adjustments are required they should be based on estimated creatinine
clearance (See DOSAGE AND ADMINISTRATION).
It is not known whether acyclovir is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised when ZOVIRAX is administered to a
nursing mother.
All animal studies carried out to date on reproduction and teratology have been negative.
4
However, since animal reproduction studies are not always predictive o f human response,
ZOVIRAX should be used during pregnancy only if the physician feels the benefit will outweigh
the possible harm to the fetus.
There exists no data, at this time, which demonstrates that the use o f ZOVIRAX will
prevent transmission o f herpes simplex infection to other persons.
Consideration should be given to an alternative treatment regimen if after 5 days o f treat
ment there is no expected clinical improvement in the signs and symptoms o f the infection.
Strains o f herpes simplex virus which are less susceptible to ZOVIRAX have been isolated
from herpes lesions and have also emerged during intravenous treatment with ZOVIRAX.

* ^

(ACYCLOVIR SODIUM)

LV INFUSION
Now, the first effective anti-herpes therapy is
available in an I.V. infusion form: Indicated for immuno
comprom ised adults and children with initial or recur
rent mucosal or cutaneous herpes simplex infections
...and for norm al patients with severe initial episodes
o f herpes sim plex infections.
ZOVIRAX
(ACYCLOVIR SODIUM)
I.V. INFUSION
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ADVERSE REACTIONS

The m ost frequent adverse reactions reported during controlled clinical trials o f acyclovir
were inflammation or phlebitis (14%) at the injection site following infiltration o f the I.V. fluid,
A
and rash or hives (4.7%). O f the patients receiving placebo, 4.8% experienced the same reactions
(inflammation/phlebitis, rash or itching).
Less frequent adverse reactions were diaphoresis, hematuria, hypotension, headache and
nausea, each o f which occurred in 1.6% o f the patients. Hematuria and nausea were experienced
«
by placebo recipients at the same frequency. These reactions were observed in severely
immunocompromised patients who often have multisystem diseases unrelated to herpes
infections and, therefore, it is difficult to state conclusively that these reactions were caused
by ZOVIRAX therapy.
Additional adverse reactions were reported in uncontrolled trials. The most frequent
»
k
adverse reaction was elevated serum creatinine. This occurred in 9.8% o f patients, usually
but not always following rapid (less than 10 minutes) intravenous infusion. It is not known
whether this phenomenon is drug related but in view o f the fact that the drug is known to
k
crystallize in urine there exists a possibility that this occurred due to inadequate hydration of
the patients. Less frequent adverse experiences were thrombocytosis (0.4%) and jitters (0.4%).

SYMPTOMS AND TREATMENT OF OVERDOSAGE

ACTIONS
ZOVIRAX (acyclovir), an acyclic nucleoside analog, is a substrate specific for herpesvirusspecified thymidine kinase. It inhibits replication o f these viruses. Normal cellular thymidine
kinase does not effectively utilize acyclovir as a substrate. Herpesvirus-specified thymidine
kinase transforms acyclovir to its monophosphate which is then transformed by cellular
enzym es to acyclovir diphosphate and acyclovir triphosphate. Acyclovir triphosphate is both
an inhibitor of, and a substrate for, herpesvirus-specified DNA polymerase. Although the cellular
oc-DNA polymerase in infected cells may also be inhibited by acyclovir triphosphate, this occurs
only at concentrations o f acyclovir triphosphate which are higher than those which inhibit the
herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and selectively
converted to its active form by herpesvirus-infected cells. Thus, acyclovir has a very much lower
toxic potential for normal uninfected cells because: 1) less is taken up; 2) less is converted to
the active form; 3) cellular oc-DNA polymerase has a lower affinity for the active form o f the drug

INDICATIONS AND CLINICAL USE
ZOVIRAX Sterile Pow der is indicated for treatment o f initial and recurrent mucosal and
cutaneous herpes simplex infections in immunocompromised adults and children. It is also
indicated for severe initial episodes o f herpes simplex infections in patients who m ay not be
immunocompromised. It is not recommended for use in herpes encephalitis or other herpes
group infections all o f which are still the subject o f ongoing investigations.
The indications are based on the results o f a number o f double-blind, placebo-controlled
studies which examined changes in virus excretion, total healing o f lesions, and relief o f pain.
Because o f the wide biological variations inherent in herpes simplex infections, the following
summary is presented m erely to illustrate the spectrum o f responses observed to date. As in
the treatment o f any infectious disease, the best response m ay be expected when the therapy
is begun at the earliest possible moment.
In patients experiencing initial episodes o f herpes genitalis, virus excretion had ceased
in 100% o f initial lesions within 3 days after the start o f a 5-day course o f intravenous ZOVIRAX
therapy. Only 20% of placebo recipients were virus-free at this time, as well as when therapy
was discontinued. ZOVIRAX therapy arrested virus excretion in over 90% o f immunocompromised
patients with mucocutaneous disease at the end o f 7 days o f therapy, while only 26% o f placebotreated patients were virus negative at the same time.
Because complete re-epithelialization o f herpes-disrupted integument necessitates recruit
ment o f several complex repair mechanisms, the physician should b e aware that the dis
appearance o f visible lesions is somewhat variable and will occur later than the cessation o f
virus excretion. In spite o f these limitations, 100% o f ZOVIRAX-treated patients with initial
episodes o f herpes genitalis healed within 15 days after initiation o f treatment. Only 50% o f
placebo recipients were healed at this same interval. The lesions of61% ofimmunocompromised
patients w ho received ZOVIRAX were healed within 15 days after the initiation o f a 7-day course
o f therapy; only 38% o f placebo patients had healed their lesions at that point.
Pain associated with herpes infections is highly variable in frequency and intensity. These
clinical studies, however, demonstrated that ZOVIRAX therapy plays a significant role in reduc
tion o f pain in cutaneous herpes infections in immunocompromised patients. For example.
61% o f ZOVIRAX-treated immunocompromised patients were pain-free by day 10, whereas
44% o f placebo-treated patients were pain-free in the same period o f time.
Whereas cutaneous lesions associated with herpes simplex infections are often pathogno
monic, Tzanck smears prepared from lesion exudate or scrapings may assist in diagnosis.
Positive cultures for herpes simplex virus offer the only absolute means for confirmation o f
the diagnosis.

CONTRAINDICATIONS
ZOVIRAX Sterile Pow der is contraindicated for patients w h o develop hypersensitivity to
the drug.

WARNINGS
ZOVIRAX Sterile Pow der should not be administered by any route [i.e. topically (skin or
eye), intramuscularly, orally or subcutaneously] other than by intravenous infusion

PRECAUTIONS
Precipitation of ZOVIRAX crystals in renal tubules can occur if maximum solubility (1.3 mg/mL
in w ater) is exceeded. This phenomenon is reflected by a rise in serum creatinine and blood
urea nitrogen and a decrease in creatinine clearance. With sufficient renal tubular compromise,
urine output decreases
Acute increases in serum creatinine and decreased creatinine clearance have been observed
in humans receiving ZOVIRAX and: (1) who were poorly hydrated; (2 ) who were receiving
concomitant nephrotoxic drugs (e.g., amphotericin B, and aminoglycoside antibiotics); (3 ) who
had pre-existing renal compromise or damage-, and (4 ) in w hom the dose was administered
by rapid intravenous injection (less than 10 minutes). Observed alterations in renal function
have been transient, in som e instances resolving spontaneously without change in ZOVIRAX

-Trade Mark

W-2055
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No acute massive overdosage o f the intravenous form has been reported.
Doses administered to humans have been as high as 1200 mg/m2 (28 mg/kg) three
times daily for up to two weeks. Peak plasma concentrations have reached 80 ^g/mL. Possible
evidence o f central nervous system (CNS) toxicity (coarse tremors, confusion and agitation)
and/or bone marrow toxicity were seen in four patients at 2100 and 2700 mg/mVday. The
CNS side effects resolved upon lowering the dosage or discontinuing ZOVIRAX therapy. Pre
cipitation o f acyclovir in renal tubules may occur when the solubility (1.3 mg/mL) in the intratubular fluid is exceeded. Precipitation may be avoided or overcome by adequate hydration of
the patient. Acyclovir is dialyzable. In the event o f acute renal failure and anuria, hemodialysis
should be initiated until renal function is restored.

DOSAGE AND ADMINISTRATION
CAUTION - RAPID OR BOLUS INTRAVENOUS AND INTRAMUSCULAR OR SUBCUTANEOUS
INJECTION ARE TO BE AVOIDED.
Therapy is recommended for at least 5 days for immunocompetent patients and for at
least 7 days for immunocompromised patients.
Adults: 5 mg/kg infused at a constant rate over a 1-hour period, every 8 hours (15 mg/kg/day)
in patients with normal renal function.
Children Under 12 Years: In children under 12 years o f age, more accurate dosing can be
* 1
attained by administering 250 m g/m2 infused at a constant rate over a 1-hour period, every
8 hours (750 mg/m2/day).
Patients with Acute or Chronic Renal Impairment: Use the recommended doses and
*4
-*
methods o f administration; and adjust the dosing interval as indicated in the following table.
Creatinine Clearance
Dose
Dosing Interval
(mL/min/1.73m2)
(mg/kg)
(hours)
>5 0
5
8
25-50
5
12
10-25f
5
24
0-10+
2.5
24-48
t Hemodialysis: For patients who require hemodialysis, the mean plasma half-life o f
acyclovir during dialysis is approximately 5 hours, which results in a 60% decrease in plasma
concentrations following a 6-hour dialysis period. Recommended doses should be administered
every 24-48 hours, and after hemodialysis.
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PHARMACEUTICAL INFORMATION
Reconstitution
Reconstitute as follows:

Vial Size
500 m g

Volume to be
Added to Vial
10 m L

Solutions for Reconstitution
Sterile Water for Injection
Reconstitution Table
Approximate Available
_______ Volume_______
10 mL

.

Approximate Average
Concentration
50 mg/mL

SHAKE WELL UNTIL DISSOLVED. ASSURE COMPLETE DISSOLUTION BEFORE MEASURING
AND TRANSFERRING EACH INDIVIDUAL DOSE.
Intravenous Infusion: The calculated dose o f the reconstituted solution should be removed
and added to an appropriate intravenous solution listed below at a volume selected for ad
ministration during each 1-hour infusion. Infusion concentrations exceeding 10 mg/mL are
not recommended. Since the vials do not contain any preservatives any unused portion of
the reconstituted solution should be discarded.
Solutions for I.V. Infusion
5% Dextrose Injection
Ringer's Injection
5% Dextrose and 0.9% Sodium Chloride Injection
Normal Saline Injection
5% Dextrose and 0.2% Sodium Chloride Injection
Lactated Ringer's Injection
Stability o f Solution
Storage: Reconstituted solutions at a concentration o f 50 mg/mL should be used within
12 hours if kept at room temperature. Refrigeration may result in the formation o f a precipitate
which will redissolve at room temperature.
Once diluted, the admixtures are to be administered within 24 hours o f the preparation.
The admixtures are not to be refrigerated.
Incompatibility: ZOVIRAX should not be added to biologic or colloidal fluids (e.g. blood
products, protein hydrolysates or amino acids, fat emulsions, etc.).

DOSAGE FORMS
Availability: ZOVIRAX is available as sterile powder in 10 mL vials, each containing acyclovir
sodium equivalent to 500 mg o f acyclovir.
Storage: ZOVIRAX should be stored at 15°-30°C.
Product Monograph available on request.
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Role of Plasmapheresis in Preparing Myasthenic Patients
for Thymectomy: Initial Results
Between 1976 and 1981, one of the
authors operated on 16 patients for
myasthenia gravis. Plasmapheresis was
carried out preoperatively on seven pa
tients, while nine patients were operated
upon without previous plasmapheresis.
The seven patients who underwent
plasmapheresis had a smooth course
pre- and postoperatively. In the
other group, there were two
postoperative myasthenic complications.
Both patients improved with medication
and plasmapheresis. Also, the degree of
myasthenia gravis was slightly more
severe in this group.
From their experience, the authors
conclude that plasmapheresis is a worth
while and safe adjuvant in the prepara
tion of myasthenic patients for thymec
tomy, especially those in Osserman class
IV.
Entre 1976 et 1981, I'un des auteurs a
op6re 16 patients pour myasth6nie
grave. Sept patients ont subi la plasmapherese avant I'operation et neuf n’ont
pas et£ prepare de cette facon.
Les sept patients ayant subi la
plasmaph£r&se furent operas sans
complication. Parmi les neuf autres
patients, deux ont souffert de
complications myasth^niques durant la
pgriode postoperatoire. Tous deux ont
6te ameliores par la medication et la
plasmaphgrese. Le degre de myasthgnie
grave etait leggrement plus avanc£ chez
les patients n'ayant pas subi la
plasmaphgrdse.
Les auteurs concluent que la plasmapherese est avantageuse pour preparer
les patients g la thymectomie, principale-
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ment ceux de classe Osserman IV. La
plasmaphgrgse prgsente peu
d'inconvenients.

The value of thymectomy in the manage
ment of patients suffering from myas
thenia gravis is now well recognized.
Blalock performed this procedure first in
1936 and by 1944 was able to report en
couraging results in 20 patients.1'2 In
G reat B ritain, this operation was
pioneered by Geoffrey Keynes who had
performed 281 thymectomies by 1956.3
Many reports support the use of thy
mectomy.4-7 In one retrospective study,8
patients treated by thymectomy showed
better clinical improvement and survival
than their matched control patients who
did not undergo operation.
Considerable evidence supports an
autoimmune cause for myasthenia gravis.
With the use of refined techniques, anti
bodies to acetylcholine receptor can be de
tected in 87% of myasthenic patients.9 A
myasthenic syndrome can be produced in
mice by serial injections of immuno
globulin derived from myasthenic
patients.10 It is suggested that the anti
body binds on or near the acetylcholine
receptor and accelerates degradation of
the receptor leading to the typical
muscular weakness.11*12
Plasmapheresis was introduced into the
treatment of myasthenia gravis to reduce
the amount of circulating antibody. In
1976, Pinching and colleagues13 reported
clinical improvement in two of three pa
tients who failed to respond to anti
cholinesterases, steroids and thymectomy.
One year later, Dau and associates14
reported success in all five patients who
had not responded to anticholinesterases,
steroids, thymectomy and immunosup
pressive therapy. Plasmapheresis is now
widely used in the treatment of myasthe
nia gravis when traditional measures are
unsuccessful or when a myasthenic crisis
occurs.
In an effort to optimize the condition
of patients being prepared for thymec
tomy, plasmapheresis was carried out
preoperatively. This study examines the

results using this procedure in seven pa
tients. Their outcome is compared with
that of nine patients who had undergone
thymectomy without plasmapheresis.
Patients and Methods
We reviewed the charts of all 16 pa
tients who underwent thymectomy from
1976 to 1981. All suffered from myasthe
nia gravis and had been referred to the
cardiovascular and thoracic surgery ser
vice by neurologists at the Montreal
Neurological Hospital. Beginning in
February 1980, all seven patients who
underwent thymectomy were treated by
plasmapheresis preoperatively (group 1).
Each patient underwent four 3-L ex
changes during the week before opera
tion. Exchange was possible through a
brachial vein in all cases. The 3 L of blood
were replaced by 3 L of a solution of 5%
albumin in normal saline.
Thymectomy was performed by one
surgeon (J.E.M .). A midline sternotomy
was always used and care was taken to en
sure complete excision of the thymus. The
mediastinum and, if necessary, the pleural
spaces, were drained by tubes. All pa
tients received 500 mg of cefazolin in one
dose preoperatively and 1 g postopera
tively every 8 hours for 48 hours. The pa
tients were observed postoperatively in
the intensive care unit until their condi
tion was stable, then transferred back to
the Montreal Neurological Hospital.
Results
Data on the 16 patients are summarized
in Table I .15
Group 1
The postoperative course of all group
1 patients was uncomplicated. The re
sected thymus was hyperplastic in six
cases and normal in one. All patients were
extubated within 24 hours of operation,
and were moved from the intensive care
unit within 3 days. All were discharged
home within 13 days of the operation. No
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patient required transfusion and there
were no infections.

episodes of weakness. Both patients sub
sequently responded to plasmapheresis.

Group 2

Plasmapheresis was introduced in an
attempt to reduce postoperative respira
tory complications caused by an exacerba
tion of myasthenic weakness. Despite
modern anesthesia, pulmonary complica
tions are still common postopera
tively.16' 18 Mulder and associates5 com
pared the m axim um pre- and
postoperative vital capacity in a group of
patients who underwent thymectomy.
They found an average decrease of 73%.
Other objective evidence of decreased
strength postoperatively comes from
nerve stimulation data. Horowitz and
colleagues19 compared muscle stimula
tion before and in the first 4 days after
thymectomy. They found that 36% were
unchanged but that 12% were worse.

In the nine patients of group 2, who did
not undergo plasmapheresis, there was
one major and one minor complication.
One 26-year-old woman required ventila
tion for 10 days. Despite giving her anti
cholinesterases and steroids, we could not
extubate her until after she had undergone
a course of plasmapheresis. A laryngeal
stricture subsequently developed. It was
managed successfully later. A 30-year-old
man had repeated episodes of severe
weakness postoperatively. Reintubation
was not necessary. He was much im
proved by plasmapheresis. All patients ex
cept one were ventilated for 24 hours or
less and all were discharged from the in
tensive care unit within 4 days. There were
no infections, no bleeding problems and
no deaths in this group.

Discussion
This initial experience with plasma
pheresis is encouraging. The plasmapher
esis was done easily and without com
plication. In the postoperative period,
none of the patients had any problems.
In particular, there was no bleeding or in
fection, although the plasmapheresis was
carried out during the week before opera
tion. However, group 2 patients were
older and the myasthenia was more
serious, an d three o f them had
thymomas. In this group there was one
serious complication in a young woman
with a thymoma. One man had frequent

What is the role of plasmapheresis?
The excellent response of two patients
who underwent plasmapheresis when they
became weak after operation suggests that
the procedure should be done early in the
postoperative period if weakness does not
respond rapidly to the administration of
anticholinesterases and steroids. If
plasmapheresis is instituted early in pa
tients who cannot be weaned from the
ventilator, the duration of intubation and
possible laryngotracheal complications
should be reduced. W hether plas
mapheresis should be used in all patients
in preparation for thymectomy is not
clear from this small series. It should be
considered preoperatively for all patients,
particularly if there are indications that
symptoms are worsening, and for patients
who are more severely affected as sug
gested by the Osserman classification.15

In this series all those who had weakness
postoperatively were in Osserman class IV
and plasmapheresis was beneficial during
the postoperative period — it could have
been o f greater benefit if used
preoperatively. Plasmapheresis is a safe
procedure in myasthenic patients. None
of the patients who underwent plasma
pheresis suffered from bleeding or infec
tion. Although we could not document a
clear benefit in the mildly myasthenic pa
tients (Osserman class IIA and IIB), we
believe that plasmapheresis should be us
ed more frequently preoperatively.
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Table 1-Data on 16 Patients Suffering from Myasthenia Gravis
Patient
no.

Age,
Osserman*
Sex
classification15
yr
Group 1 (plasmapheresis)
1
F
21
IIB
2
M
IIA
15
3
F
IIA
33
4
F
16
IIA
5
F
23
IIA
6
F
19
IIB
7
F
23
IIB
Group 2 (no plasmapheresis)
8
F
34
IIA
9
F
52
IIB
10
M
30
IV
11
F
23
IIB
M
12
38
IIA
13
F
51
III
14
F
26
IV
15
52
F
IIB
41
16
F
IIB
'Before plasmapheresis and operation.
tPlasmapheresis postoperatively.
N - normal, H - hyperplastic, T - thymoma.
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Status
of thymus

Time spent
in ICU, d

Time ventilation
required
postop, d

Duration of
hospital stay
postop, d

Complications

H
N
H
H
H
H
H

2
1
1
3
2
2
2

0
0
0
1
1
0
0

9
9
7
11
13
8
11

None
None
None
None
None
None
None

H
T
N
H
H
T
T
H
N

1
1
2
1
1
4
12
3
1

0
1
0
0
1
1
10
0
0

8
30
16
8
8
10
21
17
7

None
Radiated
Repeated attacks of weakness!
None
None
None
Laryngeal stricture!
None
None
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Preoperative Administration of
High-Dose Methotrexate for Osteosarcoma

* * Nine p a tie n ts , aged 9 to 27 years (m e
dian 16 years), w ith osteosarcom a w ere
'
given high-dose m eth o trexa te fo llo w e d
^ by fo lin ic acid rescue before a m p u ta tio n .
The dose o f m eth o trexa te w a s 12 g /m 2
A fo r ch ild ren under 12 years o f age and 8
g /m 2 fo r th o se over 12 years. A m p u ta 
tio n w a s done a fte r tw o to fiv e (median
fo u r) courses o f th e drug. Between 5 %
V-* and 6 0 % o f tu m o u r cells w ere nonviable
on h is to lo g ic exam ination. No renal or
'
h e m a to lo g ic to x ic ity w as encountered.
M ild m uc o sitis and abnorm al liver
c h e m is try w e re present, usually a fte r the
th ird dose o f m eth o trexa te . Patients w h o
achieved higher serum m ethotrexate
, levels a t 2 4 hours a fte r a dm inistration
also had greater tu m o u r necrosis.
k *•
P o sto p e ra tive ly, chem otherapy w as
changed to cis-p la tinu m , d oxorubicin,
cyclo p h o sph a m id e , a ctin o m ycin and
ble o m ycin . Seven patients finished th e ir
m ed ica tio n 17 to 3 5 m onths a fte r diag, nosis. One p a tie n t died a fte r refusing
ch e m o th e ra p y p o stop e ra tive ly and
*■ a n o th e r is alive w ith pulm onary
m etastases. Preoperative chem otherapy
*- is a novel approach to the tre a tm e n t o f
osteosarcom a and fu rth e r m o d ifica tio n o f
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th e tre a tm e n t p ro to co l m ay im prove
results.

N euf p a tie n ts ages de 9 a 2 7 ans
(m edian: 16 ans), s o u ffra n t d'osteosarcom e o n t repu, avant I’a m p u ta tio n , du
m e th o tre xa te a fo rte dose s u iv i d'un tra ite m e n t de relais a I'acide fo lin iq u e . La
dose de m eth o tre xa te a ete de 12 g/m 2
chez les e n fa n ts de m oins de 1 2 ans et
de 8 g /m 2 pour les plus ag6s. L'am putatio n a ete pratiqu£e apres de d e u x & cinq
(m ediane: quatre) tra ite m e n ts. Entre 5%
et S 0% des cellules tum orales etaient
non viables
I'exam en histologique.
A u cu n e to x ic ite renale ou hem atologique
n 'e s t survenue. Une legfcre infla m m a tio n
des m uqueuses e t des te sts anorm aux
de la fo n c tio n hepatique o n t e te obser
ves, h a b itu e lle m e n t apres la troisiem e
dose de m e th o tre xa te . Les p a tie n ts chez
qui les co n ce n tra tio n s seriques de
m e th o tre xa te e ta ie nt plus eievees 24
heures apres ('a d m in istra tio n du medica
m en t m o n tra ie n t egalem ent une n6crose
tu m o ra le plus im portante.
En p o stop e ra toire , la ch im iotherapie a
ete changee pour cis-platine, doxorubicine, cyclo p h o sph a m id e , a ctin o m ycin e et
b ieom ycine. Chez sept pa tie nts, la medi
ca tio n a ete in te rro m p u e de 17
35
m ois apres le d ia g n ostic. Un p a tie n t est
decede apres a voir refuse la ch im io th e ra 
pie p o sto p e ra to ire et un autre v it encore
mais e st a tte in t de m etastases pulm onaires. La ch im io th e ra p ie p reoperatoire est
une no u velle approche au tra ite m e n t de
I'oste o sa rcom e ; les fu tu re s m od ifica tio n s
du p ro to co le de tra ite m e n t so n t susceptibles d 'a m e iio re r les resultats.

b

b

metastases often develop shortly after
amputation.1 Since metastatic osteosar
com a has responded to various
chemotherapeutic agents, including highdose methotrexate follow ed by
citrovorum factor rescue,2 doxorubicin
(Adriamycin) and cis-platinum,3 Rosen
and associates4 proposed that induction
chemotherapy for a 4- to 16-week period
before definitive surgery would help to
eradicate systemic micrometastases and
thus improve disease-free survival. Of
their patients, 80% showed partial or
com plete tumour destruction on
histologic examination at the time the
primary tumour was resected. Post
operative chemotherapy was selected ac
cording to the extent of tumour necrosis
after preoperative administration of highdose methotrexate. A 93% disease-free
survival of their patient population at a
median follow-up of 20 months is the best
ever reported for osteosarcoma. In July
1980, we adopted the same principle and
treated nine patients with osteosarcoma
by preoperative chemotherapy and de
layed operation. We report our prelimi
nary results.

Patients and Methods
Patients
Between July 1980 and December 1982,
nine previously untreated patients (seven
males, two females) with high-grade
osteosarcoma were given high-dose
methotrexate before definitive surgery.
The median age at diagnosis was 16 years
(range from 9 to 27 years).

Diagnostic Studies
Patients with osteosarcoma treated by
operation alone seldom have local recurAll patients were evaluated by chest
rence, but distant (usually pulmonary) roentgenography, technetium-99m bone
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scanning and biochemical profile in
cluding measurement of the serum
alkaline phosphatase level. Computerized
tomography o f the chest and of the
prim ary tum our was done before
diagnostic biopsy if possible. Baseline
creatinine clearance values, audiogram,
pulmonary function values and echocar
diogram were also obtained. Before each
course of chemotherapy, a complete
blood count, biochemical profile and
chest roentgenography were repeated.
During therapy, serum creatinine and
methotrexate levels were monitored dai
ly. When the treatment was complete,
chest roentgenography was carried out
monthly and 99raTc bone scanning every
3 months for the first year of follow-up.
Preoperative Therapy (Fig. 1)
Chemotherapy was started 5 to 7 days
after biopsy. All patients received highdose methotrexate as a 4-hour infusion at
a dose of 8 g /m 2 for those over 12 years
o f age and at 12 g/m 2 for patients under
12 years. Twenty-four hours from the
start of methotrexate infusion, citrovorum factor, 15 mg, was given orally
every 6 hours for a total of 12 doses. In
travenous fluid hydration, 3 L /m 2 daily,
and alkalinization to keep urine pH above
7 were maintained for 72 hours. Treat
ment was repeated weekly up to six doses,
provided th e hem atologic and
biochemical profiles returned to normal
before the following treatment. Vin
cristine, 1.5 m g/m 2, was given 30
minutes after the start of methotrexate,
but was omitted if peripheral neuropathy
might impair the mobility of the patient.
Patients were monitored clinically as well
as by serum alkaline phosphatase deter
mination if it was initially elevated. When
the disease was suspected to have pro
gressed clinically, bone scanning and
roentgenography of the tumour were re
peated. Alternative chemotherapy was

tried before surgical resection was carried
out.
Operation and Histologic Grading
One week after completion of the last
course of high-dose methotrexate, wide
surgical resection (usually amputation)
was performed. Limb salvage was not at
tempted. Multiple histologic sections
from all areas of the resected specimen
were examined and the effect of pre
operative chemotherapy was assessed ac
cording to the grading system proposed
by Huvos and associates:5 grade I, little
or no effect from chemotherapy; grade
II, partial response to chemotherapy with
greater than 50% tumour necrosis; grade
III, more than 90% of tumour necrosis
with foci of viable tumour in some sec
tions and grade IV, no viable-appearing
tumour cells.
Postoperative Therapy
Maintenance chemotherapy was started
2 weeks after operation, provided wound
healing was adequate. Adriamycin (30
mg/m2) was given intravenously daily
for 3 consecutive days. Three weeks later,
when myelosuppression had resolved and
histologic response had been determined,
patients received specific maintenance
chemotherapy. Good responders (grades
III and IV) continued to receive high-dose
methotrexate. Poor responders (Fig. 2)
received three 63-day cycles of chemo
therapy. Each cycle consisted o f
Adriamycin (30 mg/m2 intravenously)
on days 1, 2, 22 and 23, cis-platinum (120
mg/m2 intravenously) on days 1 and 22
and bleomycin (15 mg/m2), cyclophos
phamide (600 mg/m2) and actinomycin
D (600 jtg/m2) intravenously on days 43
and 44. Serum electrolyte, calcium,
magnesium and creatinine levels were
monitored and audiograms and echocar
diograms used to assess toxicity.

Results
Preoperative Chemotherapy
A total of 35 courses of high-dose ^ 4
methotrexate were administered (median
4, range from 2 to 5 courses). During the 4
infusion of his fourth dose of metho
trexate, one patient asked that chemo- 4
therapy be discontinued. He received
approximately 50% of that dose. Two"' *
other patients were considered to have
radiologic evidence of disease progression "
after two and four courses of methotrexate respectively, and each received one
course of bleomycin-cyclophospha- ->
mide-actinomycin D before surgery. Six
of eight symptomatic patients were reliev- ■* t
ed of pain. However, computerized
tomograms (six patients) and roent- ^ ’
genograms (eight patients) of the primary
tumour after high-dose methotrexate fail- 5
ed to reveal any reduction in the size of ^
the lesion. One patient showed bone scan
and radiologic evidence of deterioration * >
after two courses of high-dose methotrex
ate and required alternative therapy.
* >
Histologic Response and
Methotrexate Level
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No patient had greater than grade II
response after therapy with high-dose
*
methotrexate. Four patients demonstrated more than 50% of tumour
"
necrosis attributable to preoperative treat- < ment (Table I). There was no correlation
between the histologic response and the «
pathologic subtypes or the anatomical site
of the tumour. There might be a correla- ’
tion between the response to high-dose
methotrexate and the level of the drug at- 1 '
tained. All patients with mean 24-hour
methotrexate levels of less than 2.0 x
10‘6M showed less than 10% tumour .
necrosis. Two patients with grade II
j
response recorded the highest mean -*

FIG. 2—Postoperative chemotherapy for
poor responders. ADR = Adriamycin, CPDD
= cis-platinum, BCD = combination of
bleomycin, cyclophosphamide and actinomycin
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24-hour methotrexate levels of 4.75 and
5.5 x 10‘6M respectively. The other two
^ ^ responders received the most preoperative
T chemotherapy: one had a fifth course of
l y high-dose methotrexate and the other an
additional course of bleomycin-cyclot phosphamide-actinomycin D before sur
gery.
►

Disease-Free Survival
►

y

At the time of writing, seven patients
were alive, without disease, 17 to 35
^ months from the time of diagnosis (Table
I). They had completed all therapy for 10
► to 25 months. One patient refused chemo
therapy after operation and died of
v-'r pulmonary metastases 8 months after
diagnosis. Another patient had local
' r recurrence and pulmonary metastases 6
months after diagnosis. It was thought
y that a skip lesion might have existed at
y the time of amputation. He is currently
alive, with pulmonary disease, 24 months
a i. after diagnosis (Table I).
> A Toxicity
*

All patients tolerated high-dose methotrexate well and none required additional
citrovorum factor rescue because of
elevated serum methotrexate levels. Also,
no notable change in peripheral blood
M> count and serum creatinine levels was
observed after high-dose methotrexate
- *■was given. Four patients had oral
mucositis but did not require specific
* therapy or postponement of chemo
therapy. All patients had elevated serum
h transaminase levels after each course of
high-dose methotrexate. The abnormalir ty was mild in the majority of cases and
r the enzyme levels returned to normal
F before the next treatment. In 5 of the 35
y- courses, transaminase levels remained
greater than 10 times the normal value for
more than 1 week, necessitating delay of
chemotherapy. In one patient, a sixth inv k fusion of high-dose methotrexate was
y cancelled because of abnormal enzyme

levels and operation was performed in
stead. No patient had hyperbilirubinemia.
In general, hepatic dysfunction did not
correlate with the number of doses of
methotrexate or the drug level at 24 and
48 hours.
Myelosuppression was common during
postoperative chemotherapy, occurring
after the administration of Adriamycin
and cis-platinum as well as bleomycin-cyclophosphamide-actinomycin D. Treat
ment was delayed and dosage had to be
reduced in every patient during the 6
months of treatment. However, only
three episodes of severe leukopenia and
fever occurred and the patients were ad
mitted to hospital for intravenous anti
biotic therapy. No important hemor
rhagic problems were encountered.
Nausea and vomiting were universal and
were severe after cis-platinum therapy.
Mild and reversible azotemia and hypo
magnesemia were encountered, especially
during the last two courses of cisplatinum therapy, but there was no
clinically detectable ototoxicity or
peripheral neuropathy. Pulmonary and
cardiac function remained normal
throughout the period of chemotherapy.
Discussion

Preoperative chemotherapy is useful in
the early treatment of systemic micrometastases; it is important to determine the
optimal dosage of chemotherapy for in
dividual patients and select chemother
apeutic agents for subsequent therapy.6
If such an approach is successful, fewer
distant metastases will appear on follow
up but it is successful only when the local
tumour does not progress during chem
otherapy (so that immediate surgical
resection can be postponed). High-dose
methotrexate was chosen for preoperative
chemotherapy in our patients because it
could be administered repeatedly at short
intervals without serious myelosuppres
sion or other cumulative toxic manifesta
tions. This is thought to be essential in

treating a rapidly progressing tumour.
With close m onitoring o f serum
methotrexate levels and biochemical pro
file, no appreciable morbidity was en
countered and no additional citrovorum
factor rescue was required for any
patient.
None of our patients showed favour
able (grade III and IV) response after four
courses of high-dose methotrexate. This
is in contrast to the results reported by
other investigators. Jaffe and associates7
observed three complete clinical remis
sions in four patients with nonmetastatic
osteosarcoma. Using the histologic grad
ing system, Rosen and associates4
reported that 22 of their 57 patients had
a grade III or IV chemotherapeutic
effect. There are differences in treatment
protocol between these studies and ours.
Rosen and colleagues added bleomycincyclophosphamide-actinomycin D to
methotrexate in their preoperative chemo
therapy regimen and their treatment
extended longer than ours. Jaffe and
associates7 included Adriamycin in their
study and gave up to eight courses of
high-dose methotrexate before operation.
They did not quantitate the response by
histologic examination. It is therefore
possible to improve our results by modi
fying our protocol. Cis-platinum ,
Adriamycin and the combination of bleomycin-cyclophosphamide-actinomycin
D8 have all been shown to be of value in
treating osteosarcoma and may be used
up to the preoperative period. In view
of the relatively mild side effects of highdose methotrexate, the number of courses
may be increased provided the disease
does not progress. On the other hand,
Rosen and Nirenberg9 suggested that
m aintaining a satisfactory serum
methotrexate level might be most impor
tant for achieving a favourable
therapeutic response. The mean 24-hour
methotrexate levels obtained in our pa
tients were lower than those reported by
Rosen and Nirenberg and may be the
result of the vigorous hydration of our

Table 1-Preoperative Chemotherapy Response and Results

>

k^A

Mean 24-h
Response
Local
Outcome
methotrexate
No. of
Age,
Grade
treatment
(mo)
Necrosis, %
courses
level, X 10"6M
Histology
Tumour site
Sex
Patient
yr
HTA
NED (20 +
2
4
4.75
60
Distal femur
C
F
17
1
AKA
NED (35 +
60
2
5.5
4
Proximal tibia
0
M
9
2*
AKA
1
NED (30 +
5
4
1.5
Proximal tibia
0
M
15
3
AKA
1
NED (30 +
5
1.6
4
Distal femur
0
M
13
4
NED (34 +
2
HD
60
2.2
Proximal femur
0
5
M
15
5
AWD (24 +
HTA
1
35
2.2
4
Distal femur
0
M
12
6
DOD (8)
AKA
1
10
1.5
P
3.5
M
Distal femur
17
7
AKA
NED (17 +
1
1.7
5
Fibula
A
2t
F
19
8
Resection
NED (17 +
2
2.0
4t
0
M
Rib
27
9
0 = osteoblastic, C = chondroblastic, A - anaplastic, P = pleomorphic, HTA - high thigh amputation, AKA - above knee amputation, HD - hip disarticula
tion, NED - no evidence of disease, AWD = alive with disease (lung metastases), DOD = died of disease (lung metastases).
‘ Received methotrexate at 12 g/m2.
tAlso received one course of bleomycin-cyclophosphamide-actinomycin D.
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(^Mefoxin
ANTIBIOTIC
ACTION
In vitro studies dem onstrate that the
bactericidal action of cefoxitin, a cephamycin
derived from cephamycin C, results from the
inhibition of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
the 7crposition is responsible for the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as
peritonitis and intra-abdominal abscess
2 - G ynecological in fe ctio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo int infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms p a rticularly appropriate for
therapy with MEFOXIN’ are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)

E. coli
Kl e b s i e l l a s p e c ie s ( in c lu d in g
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

K.

Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN’ can be administered to patients
who are also receiving c a rb e n ic illin ,
gentamicin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for
p a tie n ts w ith b a cte re m ia , b a c te ria l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
from such d e b ilita tin g co n d itio n s as
malnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
postoperatively) to patients undergoing
vaginal or abdominal hysterectomy and
abdominal surgery when there is a significant
risk of postoperative infection or where the
occurrence of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
administration of any antibiotic beyond
*®Trademark

24 hours following surgery increases the
possibility of adverse reactions but, in the
majority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hypers e n s itiv ity re a c tio n s to MEFOXIN*,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
of partial cross-a lle rge nicity between
cephamycins and the other beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been reported with most beta-lactam
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to consider a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. While studies indicate that a toxin
produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularlytodrugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in istra tion of the drug should be
discontinued. Serious hypersensitivity
reactions may require treatm ent with
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling's solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum
concentrations of cefoxitin exceed 100 pg/mL.
Serum samples from patients treated with
MEFOXIN* should not be analyzed for
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
following concomitant administration of
c e p h a lo s p o rin s and am in o g lyco sid e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
established. If the ad m in istra tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100mg/kg/day and
above) have been associated with an
increased incidence of eosinophilia and
elevated SGOT.

The safety and efficacy of MEFOXIN* for the
treatment of infections in infants from birth to
three months of age have not yet been
established.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. A dverts
reactions rarely required cessation of
treatment and usually have been mild aad j
transient
Local Reactions

T h ro m b o p h le b itis has occu rred w itffintravenous administration. Some degree of
pain and tenderness is usually experienced
after intramuscular injections using water.
Induration has occasionally been reported
Allergic

Maculopapular rash, urticaria, pruritus,
eosinophilia, feverand other allergic reactions have been noted.
Gastrointestinal

j

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
BlOOd

.

y

T ra n s ie n t e o s in o p h ilia , le u ko p e n ia ,
neutropenia, hemolytic anemia, and thrombocytop enia have been reported. Sonte *
individuals, particularly those with azotemia,
may develop positive direct Coombs tests,
during therapy with MEFOXIN*.
Liver Function

!

Transient elevations in SGOT, SGPT, serurft
LDH, and serum alkaline phosphatase have
been reported.
x „
Kidney

j

Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As 1
with the cephalosporins, acute renal failure
has been reported rarely. The role otk
MEFOXIN* in changes in renal function tests
is d iff ic u lt to assess, since fa c to rs
predisposing to prerenal azotemia or tS
impaired renal function have often been
present.

TREATMENT OF OVERDOSE

!

Other than general supportive treatment, r>o_(
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.
-

DOSAGE AND ADMINISTRATION

j

TREATMENT DOSAGE

"

MEFOXIN* may be administered intra
venously or intramuscularly when requiredf
(See monograph for Preparation of Solution.)
Adult Dosage

* ,

The usual adult dosage is 1 g or 2g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined "
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
of infection

Daily
Dosage

Frequency 4 '
and Route
-<
1 g every 6-8 h
I.V. or I.M.

Uncomplicated
forms* of in
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

Moderately
severe or severe
infections

6-8 g

1 g every 4 h 4 ^
or
2 g every 6-8 h I.V.

Infections
commonly
needing anti
biotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

‘ Inclu d in g patients in whom bacteremia
absent o r unlikely

h A

----------------------------------- k -

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infectionsshould be maintained
for at least 10 days to guard against the risk offrheumatic fever or glomerulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.

-i

Dosage in Adult Patients with Impaired Renal
Function

MEFOXIN* may be used in patients with
r ► reduced renal function but a reduced dosage
should be employed and it is advisable to
^ . monitor serum levels in patients with severe
impairment.
i
In adults with renal insufficiency, an initial
r
loading dose of 1 g to 2 g should be given.
A fte r a lo a d in g dose, the fo llo w in g
> recommendations for maintenance dosage
may be used as a guide:
RENAL
FU N C TIO N

CREATININE
CLEARANCE
m L /m in

DOSE

5 0 -3 0

1 -2 g

e v e r y 8 -1 2 h

2 9 -1 0

1 -2 g

e v e r y 1 2 -2 4 h

M ild
im p a ir m e n t
M o d e ra te
im p a ir m e n t
S e v e re
im p a ir m e n t
E s s e n t ia lly
n o fu n c t io n

FREQ UENCY

9 -5

0 .5 -1 g

e v e r y 1 2 -2 4 h

<5

0 .5 -1 g

e v e ry 2 4 -4 8 h

In the patient undergoing hemodialysis, the

r loading dose of 1 -2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.

f

Infants and Children

The recommended dosage in children three
'* months of age and older is 80 to 160 mg/kg of
body weight per day divided into four to six
, equal doses. The higher dosages should be
*• used for more severe or serious infections.
The total daily dosage should not exceed 12 g.
k A At this time no recommendation is made for
children from birth to three months of age (see
PRECAUTIONS).
A At present there is insufficient data to
recommend a specific dosage for children
with impaired renal function. However, if the
A administration of MEFOXIN* is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE

.

For prophylactic use, a three-dose regimen of
MEFOxiN* is recommended as follows:
r-

^
l-

Vaginal or abdominal hysterectomy and
abdominal surgery

2 g a d m in iste re d in tra m u s c u la rly or
in tra v e n o u s ly ju s t p rio r to su rg e ry
(approximately one-halt to one hour before
initial incision).
The second and third 2g doses should be
administered at 2-6hour intervals after the
initial dose.

patients after giving methotrexate. We
have modified this policy now to aim at
a specific volume of urine output in the
first 24 hours after methotrexate infusion.
We achieved methotrexate levels two to
five times higher, using the same dosage,
without increased toxicity. This approach
will be included in the future treatment
of patients with osteosarcoma.
Although the follow-up is relatively
short and recurrence may be delayed but
not prevented by chemotherapy,10 our
results are better than those of patients
treated before 1980 with immediate
operation and postoperative adjuvant
chemotherapy for a longer period (18
months) and with similar follow-up (un
published data). The inclusion of cisplatinum, Adriamycin and bleomycin-cyclophosphamide-actinomycin D postoperatively may have helped to destroy,
or reduce the emergence of, methotrexateresistant tumour cells. This is in accord
ance with the pharmacokinetic model
proposed by Goldie and colleagues,11 us
ing alternating nonresistant chemo
therapy to reduce mutation of neoplastic
cells, and may account for the improved
survival of grades I and II responders
observed by Rosen and associates.4
Although the response of osteosarcoma
to operation alone has been reported to
have improved in the past decade (50%
of patients so treated survived 3 years or
m ore),12 it is still inferior to that obtain
ed with preoperative chemotherapy. We
believe that aggressive combination

chemotherapy given before and after
operation is essential for the treatment of
primary osteosarcoma.
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r > Cesarean Section

The first dose of 2g should be administered
intravenously as soon as the umbilical cord
*" has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
x after the first dose.
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NOTICES

AVAILABILITY
a-

Sterile MEFOXIN* is a dry white to off-white
powder supplied in vials containing cefoxitin
k sodium as follows:
No. 3356 1 g cefoxitin equivalent in boxes of
10 vials
» No. 3357 2 g cefoxitin equivalent in boxes of
10 vials.

-

.

r ►

v

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
1. Quintiliani, R.: Overview of cephalosporin
a n tib io tics in the 1980's, in "C o n 
siderations in the selection of anti
microbial chemotherapy, a round-table
discussion on treatment concepts”, Merck
& Co. Inc., 1982, pp 6-25.
2. Trunkey, D.D.: Cephalosporin in the
management of trauma, Ibid, pp 44-52.

Canadian Lung Association
The annual meeting of the Canadian
Lung Association will be held at the Westin Hotel in Edmonton, Alta., June
10-13, 1984. It will consist of structured
and free communication sessions, dealing
with such topics as clinical care, occupa
tional and environmental health and
research activities.
For further inform ation contact:
Pamela Murray, Public Relations Direc
tor, Canadian Lung Association, Ste.
908, 75 Albert St., Ottawa, Ont. K IP
5E7.

48th Annual Surgery Course

^

p*
r
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I
I
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P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8

The 48th Annual Surgery Course, spon
sored by the Department of Surgery at the
University of Minnesota Medical School,
will be held June 13-16, 1984, on the uni
versity campus.

The major topic of this course will be
advances in hepatic, biliary and pancrea
tic surgery. The course will meet the cri
teria for 26 hours of AMA Category 1
credit. The fee is $400 for surgeons and
$200 for residents.
For more information write: Conti
nuing Medical Education, University of
Minnesota, Box 293, 420 Delaware St.
SE, Minneapolis, Minn. 55455, USA; or
call (612) 373-8012.

Symposium on Infections in the
Immunocompromised Host
The 3rd International Symposium on
Infections in the Immunocompromised
Host will be held at York University,
Toronto, Ont., June 24-28, 1984. The
number of papers presented will be
limited.
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BOOK REVIEWS
CLINICAL PROBLEMS, INJURIES, AND
COMPLICATIONS OF GYNECOLOGIC
SURGERY. Edited by David H. Nichols
and George W. Anderson. 229 pp. Illust.
Williams & Wilkins, Baltimore, 1983.
$39.50 (US). ISBN 0-683-06495-9.
This book presents a practical approach to
most of the common complications that may
occur in gynecologic surgery. The editors have
chosen a multiple-author format with 38 con
tributors, writing within their own area o f ex
pertise. Most contributors are senior gyne
cologists who have a wide range of clinical ex
perience to offer both the neophyte and the
more experienced practitioner.
The text is divided into the traditional
categories of anatomical injuries involving the
urinary tract, intestinal tract and breast.
Headings relate to the surgical procedures per
formed, including vaginal hysterectomy,
laparotomy, adnexal surgery, fertility surgery
and vulvar surgery. The format is unique in
this type of book — each chapter begins with
a case report demonstrating the particular in
jury to be discussed, followed by an anecdotal
but well-organized approach to the manage
m ent of the complication. In the latter part of
the book, consideration is given to problems
th at are seldom mentioned but are frequently
present, such as dyspareunia, psychiatric
disturbances and medicolegal complications.
The content of each chapter varies; some
present complications with a satisfactory
discussion of the underlying pathophysiology
and anatomy, whereas others are deficient in
this area and are based largely on the clinical
observations o f authors who obviously have
considerable experience in the management of
these complications. This anecdotal approach
may be clinically useful but does not offer the
reader a full understanding of the complica
tions; it does, however, provide a very
thorough, technical description of their
management. Throughout the text, most
authors have placed appropriate emphasis on
the prevention of these complications.
This book is very readable but is more like
ly to be used as a reference when encounter
ing a specific problem. With less emphasis be
ing given recently on training in gynecologic
surgery during an obstetrics and gynecology
residency program, this is a valuable text for
all senior residents. In addition, the book
should appeal to any consultant actively in
volved in surgical gynecology.
G a v in C .E. S t u a r t , m d , fr c s (C)
Director, Gynecologic Oncology,
University of Calgary,
Tom Baker Cancer Centre,
1331-29th Street NW,
Calgary, Alta.
T2N 4N2
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INTRODUCTION TO ABDOM INAL
SURGERY. Fifty Clinical Studies.
Clarence J. Schein. 521 pp. Illust. Harper
& Row Publishers, Inc., Hagerstown, Md.,
1981. $30. ISBN 0-06-142381-5.
This volume is a collection of 50 surgical case
studies for beginners in surgery, selected from
the surgical teaching rounds held at the
Montefiore Hospital Medical Center and the
Albert Einstein College of Medicine in New
York City.
Unfortunately, the book covers only a few
of the possible surgical pathologic processes in
each of the following abdominal organs:
esophagus, stomach, duodenum, small and
large intestine, biliary tract, pancreas, liver and
peritoneum. The presentation of each case
starts with the history, following with provi
sional and differential diagnoses, physical fin
dings and laboratory results. Finally, the cor
rect diagnosis and treatment are discussed in
depth.
In general, the cases and discussion of treat
ment modalities are detailed, thorough and up
to date, with relevant bibliographies. Although
the book is only a selection of interesting case
studies, it exemplifies the importance of de
tailed and thorough history-taking and physical
examination in arriving at the correct diagnosis
of abdominal surgical conditions.
I would recommend this book to medical
libraries and emergency departments for junior
physicians and students to browse through in
spare moments.
A lfred J.
FRCS[C]

S t e d m a n , m d , f r c s (I),

Ste. 603,
1081 Carling Ave.,
Ottawa, Ont.
KlY 4G2
INTENSIVE CARE OF THE SURGICAL
PATIENT. 2nd ed. Edited by Marshall D.
Goldin. 672 pp. Illust. Year Book Medical
Publishers, Inc., Chicago, 1981. Price not
stated. ISBN 0-8151-3732-X.
The authors have attempted to write a prac
tical, concise textbook for the management of
critically ill surgical patients. They state,
therefore, that they have concentrated on the
clinical aspects of intensive care, and avoided
unnecessary theoretical discussions of issues
and extensive references. Almost all of the 53
contributors are associated with the RushPresbyterian-St. Luke’s Medical Center in
Chicago. The text reflects the approach to the
management of surgical patients in that institu
tion, and the strengths and weaknesses of the
book relate to this.
Most of the book is well written. The best

V

•i

-

section is the third and final part on specific
considerations in surgical intensive care, comprising 12 chapters devoted to postoperative
care and management of complications as they ^
apply to different surgical subspecialties. These
chapters contain some pertinent and practical
reviews of patient management, which clearly
fulfil the stated objectives of the book.
The earlier part of the book, unfortunate
ly, contains a few weak chapters. The con
tributors describe techniques and principles of
management that may be appropriate in their
own particular intensive care u nit in
Chicago but do not reflect more widely ac- A
cepted standards of practice. The subject of the
first chapter is invasive hemodynamic monitor- ^
ing but the part in it devoted to catheteriza
tion of the pulmonary artery is superficial, ^
poorly written and has several inaccuracies and
irritating typographical errors.
.
Postoperative respiratory management is a
vitally important aspect of critical care and
must be based on a sound knowledge of
respiratory physiology and pathophysiology.
It is therefore disappointing to find out-of-date
concepts and possibly inappropriate practices
perpetuated in this book; an example of this ^
is the section on oxygen therapy. Only 15 pages
of the book are devoted to acute surgical infections. Septicemia and septic shock remain
major problems in any intensive care unit and
are associated with a persistently high mortali
ty, yet they merit only two pages of text and * 1
no references.
These are just some examples of weak chap- * >
ters that deal with important aspects of intensive
care. They detract substantially from the value y
of this book with its stated objective of being
a readily available, concise source of reference
for junior clinicians in the intensive care unit.
R u a r a id h W . M c I n t y r e , m b , c h b ,
FRCPfC]
'

'

Coordinator, Intensive Care Unit,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
KlY 4E9
POSTOPERATIVE COMPLICATIONS OF 4
INTRACRANIAL NEUROLOGICAL
SURGERY. Norman H. Horwitz and
Hugo V. Rizzoli. 472 pp. Illust. Williams
& Wilkins, Baltimore, 1982. $66. ISBN „
0-683-04158-4.
V -i

Based on their personal experiences and on an
extensive computer-assisted review of the ^ 4
neurosurgical literature, the authors have im
proved considerably on their first edition and i,
have fulfilled their original intent “ to provide
a unified analysis of the problems in management following commonly performed neuro
surgical procedures” .
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The book is divided into seven chapters. The
introductory chapter covers general and
^ specific intraoperative and postoperative com
plications and gives memorable insights into
^ ^ air embolism, hemorrhage, infection and
neurologic deficits related to intracranial
A surgery. In my opinion, this chapter should be
required reading for neurosurgical residents.
^ The following chapters discuss in great detail
complications related to surgery of intracranial
Y Y neoplasms, aneurysms and vascular malforma
tions, head injuries, pain relieving procedures,
. intracranial infections and congenital defects.
Each section is prefaced by an introductory
k review of the subject, often giving valuable
historical insight. This is followed by detailed
accounts of all reported significant complica
tions of a particular procedure and, where apY propriate, preventive and therapeutic measures
are outlined. The style is somewhat terse at
times due to frequent citations in the body of
the text; it is difficult to see how this could have
been avoided as they provide immediate refer
ence to the original article. The book is well
illustrated with a variety of computerized
tomograms, angiograms and photographs of
A ^pathological specimens.
The discussions I found most useful were
^ those related to surgery for pituitary tumours
and craniopharyngiomas, shunt procedures for
^ hydrocephalus and posterior fossa surgery in
general. The chapter on surgery for aneurysms
k and arteriovenous malformations is an ex
cellent account of a controversial and chang
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For more information contact: Dr.
Ron Feld, Department of Medicine, Prinr v cess Margaret Hospital, 500 Sherbourne
Y St., Toronto, Ont. M4X 1K9.

>

Call for Abstracts,
Second International Conference
y
on Clinical Factors and
Mechanisms Influencing
*
Bone Growth

The second international interdisciplinary
, conference, to be held at the University
of California, Los Angeles, in early
> ►January 1985, will be a follow-up to the
basic science one held in January 1982 but
* will emphasize clinical science aspects of
bone growth. Again, a primary objective
* of the conference is to update and integrate our understanding o f the growth of
bone with new knowledge and to offer
vA directions for future clinical research.
Factors and mechanisms that influence
t \ normal and abnormal prenatal and post
natal bone growth, both general and craA niofacial, will be covered, from the subcellular to the gross level. Clinical expe1 rimental approaches to bone growth will
be emphasized; limited attention will be

ing topic. The nine-page introduction to this
chapter gives a balanced analysis of vasospasm,
use of antifibrinolytic agents and timing of
aneurysmal surgery.
This book is a unique reference for neuro
surgeons in particular but will also be valuable
for neurologists and neuroanesthetists. It is
destined to become a classic and should be on
the desk o f every neurosurgeon and
neurosurgical resident. I look forward to
volume 2 on the complications of extracranial
neurosurgical procedures, which should interest
an even wider audience.

R.O. H oln ess , MD, FRCSICl
Program Director,
Neurosurgical Residency Training Program,
Department of Neurosurgery,
Victoria General Hospital,
Halifax, NS
B3H 2Y9

SURGICAL ANATOMY A ND PA
THOLOGY FOR ORTHOPAEDIC
SURGEONS. John V. Fowles. 444 pp. IIlust. Williams & Wilkins, Baltimore, 1983.
$39, paperbound. ISBN 0-683-03317-4.
This book is divided into two major sections.
It is very readable, written in point form, with
many entertaining mnemonics and side com
ments. The book is of convenient size and

given to basic science aspects. English tit
les and abstracts, 100 to 200 words long,
are being solicited from various clinical
and other biologic disciplines including,
but not limited to; anthropology; compu
ter science; genetics; metabolism; mor
phology; oral, maxillofacial and plastic
surgery; orthodontics; orthopedics;
pediatrics and pedodontics. Abstracts
should include purpose, method and
material, results and conclusions. They
should be submitted for consideration as
soon as possible, but no later than June
30, 1984. Attendance will be limited. The
proceedings o f the conference will be
published.
For more information write: Dr.
Andrew D. Dixon or Dr. Bernard G. Sarnat, Dental Research Institute, School o f
Dentristry, School o f Medicine, Center
for Health Sciences, University of Cali
fornia, Los Angeles, Los Angeles, CA
90024, USA.

The Society for Ear, Nose and
Throat Advances in Children
The annual meeting o f the Society for
Ear, Nose and Throat Advances in
Children (SENTAC) will be held Nov.
1-3, 1984 in New Orleans, La. This
meeting will be o f interest to a number
o f multidisciplinary groups including ear,
nose and throat surgeons, plastic sur

shape and can easily be stored in one’s locker
or lab-coat pocket.
The first section covers basic surgical
anatom y of the spine and limbs. It describes
some o f the more frequently used approaches.
The line drawings are quite good but a few
more could have been provided. This section
is not meant to be a complete anatomical
review but more a quick reminder between
cases or before examinations.
The second section is concerned with basic
surgical physiology and pathology. It is divid
ed into 16 subsections, which include topics
such as respiratory physiology, fluid and elec
trolyte problems, nutrition, wound healing,
hematologic problems, renal problems and in
fection. Each subsection starts with a review
of the basic physiology and ends with diagnosis
and treatment o f the more common problems.
Since this book is aimed at orthopedic
surgeons, a section on orthopedic implants
would have been appropriate.
This book will be particularly useful to
orthopedic residents before writing their
fellowship examinations. It will probably soon
be found in the lockers or briefcases o f most
orthopedic surgeons and residents.
R ic k A . O g il v ie , m d
Tne Sports Medicine Clinic,
Carleton University,
Colonel By Dr.,
Ottawa, Ont.
K1S 5B6

geons, audiologists and pediatricians.
There will be presentations o f free papers
as well as brief communications covering
this broad topic area.
For further information contact Dr.
Robert E. Macdonald, Canadian Liaison
Officer for SENTAC, Ste. 526, Medical
Arts Building, 170 St. George St., Toron
to, Ont. M5R 2M8; or Dr. William P.
Potsic, Program Chairman, Department
o f Otolaryngology and Human Com
munication, The Children’s Hospital o f
Philadelphia, 34th and Civic Center,
Philadelphia, PA 19104, USA.

Implant Surgery for the Hand
and Upper Extremity
The 15th Annual International Sym
posium on Implant Surgery for the Hand
and Upper Extremity will be held Oct.
25-27, 1984 at the Blodgett Memorial
Medical Center and Amway Grand Plaza
Hotel in Grand Rapids, Michigan, and
will be sponsored by the American Socie
ty for Surgery o f the Hand. This sym
p osium w ill also include surgical
demonstrations on closed-circuit colour
television.
For further information contact Dr.
Alfred B. Swanson, Course Chairman,
290 Blodgett Professional Building, 1900
Wealthy St. SE, Grand Rapids, Mich.
49506, USA.
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COLON & RECTAL FELLOWSHIP
Available at the
University of Toronto
COLON & RECTAL RESIDENCY
Training Program
Position available July 1, 1985
Program Director Dr. Zane Cohen

CLASSIFIED ADVERTISING

1

For more information contact:
Dr. Zane Cohen
Toronto General Hospital
Eaton Bldg., 9-211
101 College St.
Toronto, ON M5G 1L7
(416) 595-3846
-S 84-018
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surgeon and/or general and vascular surgeon re
quired immediately to join a busy group practice in
an expanding regional hospital. Must be certified or
exam eligible. Reply to: Box S104, CJS.
-S84-010
GENERAL SURGEON: AB - Required by a well
established 15-doctor group. Laboratory and x-ray
facilities in clinic. Accredited 120-bed active treat
ment hospital in community of 12 000 and servicing
the regional needs of 30 000 people. Camrose is a
beautiful place to live; close, but not too close to
Edmonton, with a Junior College and active recrea
tional, sports and cultural programs. Relocation ex
penses will be provided. Contact: M r. T.C. O frim ,
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Camrose, AB, Canada T4V 1R9. Tel: (403)
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—S83-007

250

287,

288

Winthrop Laboratories
M arcaine

The dosing date for applications is
June 1, 1984. In accordance with Cana
dian immigration requirements, this
advertisement is directed to Canadian
citizens and permanent residents.
—S84-016

209

Leo Laboratories Canada Ltd.
Fucidin

5)

Sunnybrook Medical Cen
tre, a major teaching hospital of the
University of Toronto is seeking a Chief of
Urology. Departmental strengths and in
terests include oncology, urodynamics
and microsurgery.

302

Calmic Medical Division
Burroughs Wellcome Inc.
Neosporin

CHIEF OF UROLOGY,
SUNNYBROOK MEDICAL
CENTRE,
UNIVERSITY OF TORONTO

(

Burroughs Wellcome Inc.
Zovirax

270

iA

As a further service to its readers the Canadian Journal o f Surgery is pleased to
accept suitable classified advertisements. The deadline is 1 month before issue date.
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UPDATE ON GENERAL S U R G IC A L O N 
COLOGY — The Division of General Surgery at the
Toronto General Hospital will present a Clinical Day
for Surgeons on Monday, June 4, 1984. The pro

gram will be entitled "A n Update on General
Surgical Oncology". Guest speakers will include Dr.
Murray Brennan, Chief of Gastric and Mixed v
Tumour Services, Memorial-Sloan Kettering Cancer
Centre, New York, NY and Dr. Charles Batch, Pro- y t,
fessor of Surgery, University of Alabama at Birm
ingham. Contact: Miss Ines P ontoriero, Eaton ^
Building, 8th floo r, Rm. 315, T oronto General
Hospital, 101 College S t., T o ronto, ON, Canada
M5G1L7. Tel.: (416) 595-3556.
-S84-013
"

GENERAL SURGEON
&
OTORHINOLARYNGOLOGIST
NB
Required for
accredited 90-bed
general hospital
McGill affiliation.

-

i

A
A
A

St. Joseph's Hospital
Dalhousie, NB
E0K 1B0
—S84-015

UROLOGUE DEMANDE
Le service d'urologie de I'hopital Regional Docteur
Georges-L. Dumont, situ6 & Moncton au NouveauBrunswick est a la recherche d'un sp6cialiste en
urologie. Les postulants(es) doivent d6tenir un certificat
de specialisation du College Royal du Canada ou de la
Province de Quebec.
L'hopital Dumont est un hopital regional francophone
de 330 lits avec un projet d'expansion de 88 lits dont la
construction debute a I'6t6 1984.
Les mGdecins intdressds peuvent
s'adresser a:

D octeur L6on Richard
D irecteur M edical
H opital D octeur Georges-L. D um ont
330, rue A rchibald
M o ncton , N ouveau-Brunsw ick
E1C2Z3
—S84-014

OSHAWA GENERAL HOSPITAL
GENERAL SURGEON
Oshawa General Hospital invites applications
from general surgeons interested in practice in
the community. Canadian fellowship and
special interest in trauma are required.
Oshawa General Hospital is a 640-bed
regional general hospital, located 48 km east of
Toronto and services a population of approx l> *
imately 150 000.
Please contact:

Dr. D.G. Pierson
Chairman, Department of Surgery
Oshawa General Hospital
24 Alma St.
Oshawa, ON L1G 2B9
—S84-017
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An important
surgical tool:
Ensure*
complete nutrition

i

by mouth or by tube

Av

-(

ENSURE

Protein-calorie malnutrition threatens almost 50% of
hospitalized patients'. Its consequences - slow healing,
anemia, increased susceptibility to infection, wound
dehiscence - can compromise the outcome of treatment or
surgery and even jeopardize the patient’s life.
Ensure, complete nutrition for hospitalized patients
Before surgery, to help build up the patient’s strength and
immunocompetence2.
After surgery, to help restore a positive nitrogen balance
and help speed recovery3.
References:
1. Bistrian BR et al. JAMA 1976; 235:15. 2. Chandra RK et al. Nutrition Research 1982; 2:223-232.
3. Hoover C Jetal. JPEN 1977; 14A(1).

complete liquid nutrition

Helps surgical patients
back to good health

Total commitment to nutrition
ROSS LA B O R A T O R IE S

*TM

| PAAB |

Davis + Geek Introduces
i*

FTGUT
Surgical Chromic Suture

Something
you’re used to
without
the problems
you’re used to
You told us that you liked using catgut but you didn’t like its
problems. So we took catgut and made it
•
•
•
•

soft and supple
easy to tie
less likely to curl, “pigtail” and tangle
easy to handle and control
■

In fact, we made it

SFTCiUr
Surgical Chromic Suture

Better than catgut — but still catgut

DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5
•Trademark American Cyanamid Company

